



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification:
C12N 15/12, C07K 14/72,
G01N 33/50, G01N 33/566

A1 (11) International Publication Number:
(43) International Publication Date:

WO 00/22129
20 April 2000 (20.04.2000)

(21) International Application Number: PCT/US99/23938

Published

(22) International Filing Date: 12 October 1999 (12.10.1999)

(30) Priority Data:

09/170,496 13 October 1998 (13.10.1998) US

(60) Parent Application or Grant

ARENA PHARMACEUTICALS, INC. [] () BEHAN,
Dominic, P. [] () CHALMERS, Derek, T. [] () LIAW,
Chen, W. [] () BEHAN, Dominic, P. [] () CHALMERS,
Derek, T. [] () LIAW, Chen, W. [] () MILLER, Suzanne,
E. [] ()

(54) Title: NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED HUMAN G PROTEIN-COUPLED RECEPTORS

(54) Titre: RECEPTEURS COUPLES A LA PROTEINE G HUMAINE NON ENDOGENES ET ACTIVES DE FAÇON CONSTITUTIVE

(57) Abstract

Disclosed herein are constitutively activated, non-endogenous versions of endogenous human G protein-coupled receptors comprising (a) the following amino acid sequence region (C-terminus to N-terminus orientation) and/or (b) the following nucleic acid sequence region (3' to 5' orientation) transversing the transmembrane-6 (TM6) and intracellular loop-3 (IC3) regions of the GPCR: (a) P1_Δ AA_Δ15 X and/or (b) Pcodon_Δ (AA-codon)_Δ15 X_Δcodon, respectively. In a most preferred embodiment, P1_Δ and Pcodon_Δ are endogenous proline and an endogenous nucleic acid encoding region encoding proline, respectively, located within TM6 of the non-endogenous GPCR; AA_Δ15 and (AA-codon)_Δ15 are 15 endogenous amino acid residues and 15 codons encoding endogenous amino acid residues, respectively; and X and X_Δcodon are non-endogenous lysine and a non-endogenous nucleic acid encoding region encoding lysine, respectively, located within IC3 of the non-endogenous GPCR. Because it is most preferred that the non-endogenous human GPCRs which incorporate these mutations are incorporated into mammalian cells and utilized for the screening of the candidate compounds, the non-endogenous human GPCR incorporating the mutation need not be purified and isolated per se (i.e., these are incorporated within the cellular membrane of a mammalian cell), although such purified and isolated non-endogenous human GPCRs are well within the purview of this disclosure.

(57) Abrégé

La présente invention concerne des versions non endogènes et activées de façon constitutive de récepteurs couplés à la protéine G humaine endogène (GPCR) comprenant: (a) la région de séquence d'acides aminés suivante (orientée de l'extrémité C vers l'extrémité N) et/ou (b) la région de séquence d'acides aminés suivante (orientée 3' vers 5') transversale aux régions transmembranaire 6 (TM6) et à boucle intracellulaire 3 (IC3) du GPCR: (a) P1_ΔAA_Δ15X et/ou (b) Pcodon_Δ (AA-codon)_Δ15 X_Δcodon, respectivement. Dans un mode de réalisation idéal, P1_Δ et Pcodon_Δ représentent respectivement une proline endogène et une proline codant pour une région codant pour un acide nucléique endogène, situées dans la TM6 du GPCR non endogène; AA_Δ15 et (AA-codon)_Δ15 représentent respectivement 15 résidus d'acides aminés endogènes et 15 codons codant pour les résidus d'acides aminés endogènes; et X et X_Δcodon représentent respectivement une lysine non endogène et une lysine codant pour une région codant pour un acide nucléique non endogène, situées dans IC3 du GPCR non endogène. Parce qu'idéalement les GPCR humains non endogènes comprenant ces mutations sont contenus dans des cellules mammaliennes et sont utilisés dans le criblage de composés candidats, il n'est pas nécessaire de purifier et d'isoler per se les GPCR humains non endogènes contenant la mutation (c.-à-d.) qu'ils sont contenus dans la membrane cellulaire d'une cellule mammalienne, bien que cette invention couvre bien le domaine de ces GPCR humains non endogènes purifiés et isolés.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷: C12N 15/12, C07K 14/72, G01N 33/50, 33/566	A1	(11) International Publication Number: WO 00/22129 (43) International Publication Date: 20 April 2000 (20.04.00)
(21) International Application Number: PCT/US99/23938 (22) International Filing Date: 12 October 1999 (12.10.99) (30) Priority Data: 09/170,496 13 October 1998 (13.10.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/170,496 (CIP) Filed on 13 October 1998 (13.10.98) (71) Applicant (for all designated States except US): ARENA PHARMACEUTICALS, INC. [US/US]; 6166 Nancy Ridge Drive, San Diego, CA 92121 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BEHAN, Dominic, P. [GB/US]; 11472 Roxboro Court, San Diego, CA 92131 (US). CHALMERS, Derek, T. [GB/US]; 347 Longden Lane, Solana Beach, CA 92075 (US). LIAW, Chen, W. [US/US]; 7668 Salix Place, San Diego, CA 92129 (US).	(74) Agents: MILLER, Suzanne, E. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED HUMAN G PROTEIN-COUPLED RECEPTORS		
(57) Abstract <p>Disclosed herein are constitutively activated, non-endogenous versions of endogenous human G protein-coupled receptors comprising (a) the following amino acid sequence region (C terminus to N-terminus orientation) and/or (b) the following nucleic acid sequence region (3' to 5' orientation) transverse the transmembrane-6 (TM6) and intracellular loop-3 (IC3) regions of the GPCR: (a) P¹ AA₁₅ X and/or (b) P^{codon} (AA codon)₁₅ X_{codon}, respectively. In a most preferred embodiment, P¹ and P^{codon} are endogenous proline and an endogenous nucleic acid encoding region encoding proline, respectively, located within TM6 of the non-endogenous GPCR; AA₁₅ and (AA-codon)₁₅ are 15 endogenous amino acid residues and 15 codons encoding endogenous amino acid residues, respectively; and X and X_{codon} are non-endogenous lysine and a non-endogenous nucleic acid encoding region encoding lysine, respectively, located within IC3 of the non-endogenous GPCR. Because it is most preferred that the non-endogenous human GPCRs which incorporate these mutations are incorporated into mammalian cells and utilized for the screening of the candidate compounds, the non-endogenous human GPCR incorporating the mutation need not be purified and isolated <i>per se</i> (i.e., these are incorporated within the cellular membrane of a mammalian cell), although such purified and isolated non-endogenous human GPCRs are well within the purview of this disclosure.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

10

15

20

**NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED
HUMAN G PROTEIN-COUPLED RECEPTORS**

25

The benefits of commonly owned U.S. Serial Number 09/170,496, filed October 13, 1998, U.S. Serial Number 08/839, 449 filed April 14, 1997 (now abandoned),
5 U.S. Serial Number 09/060,188, filed April 14, 1998; U.S. Provisional Number 60/090,783, filed June 26, 1998; and U.S. Provisional Number 60/095,677, filed on August 7, 1998, are hereby claimed. Each of the foregoing applications are incorporated by reference herein in their entirety.

30

35

FIELD OF THE INVENTION

10

40

The invention disclosed in this patent document relates to transmembrane receptors, and more particularly to human G protein-coupled receptors (GPCRs) which have been altered such that altered GPCRs are constitutively activated. Most preferably, the altered human GPCRs are used for the screening of therapeutic compounds.

45

50

55

- 2 -

BACKGROUND OF THE INVENTION

Although a number of receptor classes exist in humans, by far the most abundant and therapeutically relevant is represented by the G protein-coupled receptor (GPCR or GPCRs) class. It is estimated that there are some 100,000 genes within the human genome, and of these, approximately 2% or 2,000 genes, are estimated to code for GPCRs. Of these, there are approximately 100 GPCRs for which the endogenous ligand that binds to the GPCR has been identified. Because of the significant time-lag that exists between the discovery of an endogenous GPCR and its endogenous ligand, it can be presumed that the remaining 1,900 GPCRs will be identified and characterized long before the endogenous ligands for these receptors are identified. Indeed, the rapidity by which the Human Genome Project is sequencing the 100,000 human genes indicates that the remaining human GPCRs will be fully sequenced within the next few years. Nevertheless, and despite the efforts to sequence the human genome, it is still very unclear as to how scientists will be able to rapidly, effectively and efficiently exploit this information to improve and enhance the human condition. The present invention is geared towards this important objective.

Receptors, including GPCRs, for which the endogenous ligand has been identified are referred to as "known" receptors, while receptors for which the endogenous ligand has not been identified are referred to as "orphan" receptors. This distinction is not merely semantic, particularly in the case of GPCRs. GPCRs represent an important area for the development of pharmaceutical products: from approximately 20 of the 100 known GPCRs, 60% of all prescription pharmaceuticals have been developed. Thus, the orphan GPCRs are to the pharmaceutical industry what gold was to California in the late 19th century – an opportunity to drive growth, expansion, enhancement and development. A serious drawback exists, however,

- 3 -

with orphan receptors relative to the discovery of novel therapeutics. This is because the traditional approach to the discovery and development of pharmaceuticals has required access to both the receptor *and* its endogenous ligand. Thus, heretofore, orphan GPCRs have presented the art with a tantalizing and undeveloped resource for the discovery of pharmaceuticals.

Under the traditional approach to the discovery of potential therapeutics, it is generally the case that the receptor is first identified. Before drug discovery efforts can be initiated, elaborate, time consuming and expensive procedures are typically put into place in order to identify, isolate and generate the receptor's endogenous ligand - this process can require from between 3 and ten years per receptor, at a cost of about \$5million (U.S.) per receptor. These time and financial resources must be expended before the traditional approach to drug discovery can commence. This is because traditional drug discovery techniques rely upon so-called "competitive binding assays" whereby putative therapeutic agents are "screened" against the receptor in an effort to discover compounds that either block the endogenous ligand from binding to the receptor ("antagonists"), or enhance or mimic the effects of the ligand binding to the receptor ("agonists"). The overall objective is to identify compounds that prevent cellular activation when the ligand binds to the receptor (the antagonists), or that enhance or increase cellular activity that would otherwise occur if the ligand was properly binding with the receptor (the agonists). Because the endogenous ligands for orphan GPCRs are by definition not identified, the ability to discover novel and unique therapeutics to these receptors using traditional drug discovery techniques is not possible. The present invention, as will be set forth in greater detail below, overcomes these and other severe limitations created by such traditional drug discovery techniques.

GPCRs share a common structural motif. All these receptors have seven sequences of between 22 to 24 hydrophobic amino acids that form seven alpha helices, each of which spans the

- 4 -

membrane (each span is identified by number, *i.e.*, transmembrane-1 (TM-1), transmembrane-2 (TM-2), etc.). The transmembrane helices are joined by strands of amino acids between transmembrane-2 and transmembrane-3, transmembrane-4 and transmembrane-5, and transmembrane-6 and transmembrane-7 on the exterior, or "extracellular" side, of the cell membrane (these are referred to as "extracellular" regions 1, 2 and 3 (EC-1, EC-2 and EC-3), respectively). The transmembrane helices are also joined by strands of amino acids between transmembrane-1 and transmembrane-2, transmembrane-3 and transmembrane-4, and transmembrane-5 and transmembrane-6 on the interior, or "intracellular" side, of the cell membrane (these are referred to as "intracellular" regions 1, 2 and 3 (IC-1, IC-2 and IC-3), respectively). The "carboxy" ("C") terminus of the receptor lies in the intracellular space within the cell, and the "amino" ("N") terminus of the receptor lies in the extracellular space outside of the cell. The general structure of G protein-coupled receptors is depicted in Figure 1.

Generally, when an endogenous ligand binds with the receptor (often referred to as "activation" of the receptor), there is a change in the conformation of the intracellular region that allows for coupling between the intracellular region and an intracellular "G-protein." Although other G proteins exist, currently, Gq, Gs, Gi, and Go are G proteins that have been identified. Endogenous ligand-activated GPCR coupling with the G-protein begins a signaling cascade process (referred to as "signal transduction"). Under normal conditions, signal transduction ultimately results in cellular activation or cellular inhibition. It is thought that the IC-3 loop as well as the carboxy terminus of the receptor interact with the G protein. A principal focus of this invention is directed to the transmembrane-6 (TM6) region and the intracellular-3 (IC3) region of the GPCR.

Under physiological conditions, GPCRs exist in the cell membrane in equilibrium between

- 5 -

two different conformations: an "inactive" state and an "active" state. As shown schematically in Figure 2, a receptor in an inactive state is unable to link to the intracellular signaling transduction pathway to produce a biological response. Changing the receptor conformation to the active state allows linkage to the transduction pathway (via the G-protein) and produces a biological response.

5 A receptor may be stabilized in an active state by an endogenous ligand or a compound such as a drug. Recent discoveries, including but not exclusively limited to modifications to the amino acid sequence of the receptor, provide means other than endogenous ligands or drugs to promote and stabilize the receptor in the active state conformation. These means effectively stabilize the receptor in an active state by simulating the effect of an endogenous ligand binding to the receptor. Stabilization by such ligand-independent means is termed "constitutive receptor activation."

As noted above, the use of an orphan receptor for screening purposes has not been possible. This is because the traditional "dogma" regarding screening of compounds mandates that the ligand for the receptor be known. By definition, then, this approach has no applicability with respect to orphan receptors. Thus, by adhering to this dogmatic approach to the discovery of therapeutics, the art, in essence, has taught and has been taught to forsake the use of orphan receptors unless and until the endogenous ligand for the receptor is discovered. Given that there are an estimated 2,000 G protein coupled receptors, the majority of which are orphan receptors, such dogma castigates a creative, unique and distinct approach to the discovery of therapeutics.

20 Information regarding the nucleic acid and/or amino acid sequences of a variety of GPCRs is summarized below in Table A. Because an important focus of the invention disclosed herein is directed towards orphan GPCRs, many of the below-cited references are related to orphan GPCRs. However, this list is not intended to imply, nor is this list to be construed, legally or

- 6 -

otherwise, that the invention disclosed herein is only applicable to orphan GPCRs or the specific GPCRs listed below. Additionally, certain receptors that have been isolated are not the subject of publications per se: for example, reference is made to a G Protein-Coupled Receptor database on the "world-wide web" (neither the named inventors nor the assignee have any affiliation with this site) that lists GPCRs. Other GPCRs are the subject of patent applications owned by the present assignee and these are not listed below (including GPR3, GPR6 and GPR12; *see* U.S. Provisional Number 60/094879):

Table A

Receptor Name	Publication Reference
GPR1	23 Genomics 609 (1994)
GPR4	14 DNA and Cell Biology 25 (1995)
GPR5	14 DNA and Cell Biology 25 (1995)
GPR7	28 Genomics 84 (1995)
GPR8	28 Genomics 84 (1995)
GPR9	184 J. Exp. Med. 963 (1996)
GPR10	29 Genomics 335 (1995)
GPR15	32 Genomics 462 (1996)
GPR17	70 J Neurochem. 1357 (1998)
GPR18	42 Genomics 462 (1997)
GPR20	187 Gene 75 (1997)
GPR21	187 Gene 75 (1997)
GPR22	187 Gene 75 (1997)
GPR24	398 FEBS Lett. 253 (1996)
GPR30	45 Genomics 607 (1997)
GPR31	42 Genomics 519 (1997)
GPR32	50 Genomics 281 (1997)
GPR40	239 Biochem. Biophys. Res. Commun. 543 (1997)
GPR41	239 Biochem. Biophys. Res. Commun. 543 (1997)
GPR43	239 Biochem. Biophys. Res. Commun. 543 (1997)
APJ	136 Gene 355 (1993)
BLR1	22 Eur. J. Immunol. 2759 (1992)
CEPR	231 Biochem. Biophys. Res. Commun. 651 (1997)
EBI1	23 Genomics 643 (1994)
EBI2	67 J. Virol. 2209 (1993)
ETBR-LP2	424 FEBS Lett. 193 (1998)
GPCR-CNS	54 Brain Res. Mol. Brain Res. 152 (1998); 45 Genomics 68 (1997)
GPR-NGA	394 FEBS Lett. 325 (1996)
H9	386 FEBS Lett 219 (1996)

- 7 -

HBA954	1261 Biochim. Biophys. Acta 121 (1995)
HG38	247 Biochem. Biophys. Res. Commun. 266 (1998)
HM74	5 Int. Immunol. 1239 (1993)
OGR1	35 Genomics 397 (1996)
V28	163 Gene 295 (1995)

As will be set forth and disclosed in greater detail below, utilization of a mutational cassette to modify the endogenous sequence of a human GPCR leads to a constitutively activated version of the human GPCR. These non-endogenous, constitutively activated versions of human GPCRs can be utilized, *inter alia*, for the screening of candidate compounds to directly identify compounds of, e.g., therapeutic relevance.

SUMMARY OF THE INVENTION

Disclosed herein is a non-endogenous, human G protein-coupled receptor comprising (a) as a most preferred amino acid sequence region (C-terminus to N-terminus orientation) and/or (b) as a most preferred nucleic acid sequence region (3' to 5' orientation) transversing the transmembrane-6 (TM6) and intracellular loop-3 (IC3) regions of the GPCR:

(a) P¹ AA₁₅ X

wherein:

- (1) P¹ is an amino acid residue located within the TM6 region of the GPCR, where P¹ is selected from the group consisting of (i) the endogenous GPCR's proline residue, and (ii) a non-endogenous amino acid residue other than proline;
- (2) AA₁₅ are 15 amino acids selected from the group consisting of

- 8 -

(a) the endogenous GPCR's amino acids (b) non-endogenous amino acid residues, and (c) a combination of the endogenous GPCR's amino acids and non-endogenous amino acids, excepting that none of the 15 endogenous amino acid residues that are positioned within the TM6 region of the GPCR is proline; and

(3) X is a non-endogenous amino acid residue located within the IC3 region of said GPCR, preferably selected from the group consisting of lysine, histidine and arginine, and most preferably lysine, excepting that when the endogenous amino acid at position X is lysine, then X is an amino acid other than lysine, preferably alanine;

and/or

(b) $P^{\text{codon}} (AA\text{-codon})_{15} X_{\text{codon}}$

wherein:

(1) P^{codon} is a nucleic acid sequence within the TM6 region of the GPCR, where P^{codon} encodes an amino acid selected from the group consisting of (i) the endogenous GPCR's proline residue, and (ii) a non-endogenous amino acid residue other than proline;

(2) $(AA\text{-codon})_{15}$ are 15 codons encoding 15 amino acids selected from the group consisting of (a) the endogenous GPCR's amino acids (b) non-endogenous amino acid residues and (c) a combination of the endogenous GPCR's amino acids and non-

- 9 -

endogenous amino acids, excepting that none of the 15
endogenous codons within the TM6 region of the GPCR encodes
a proline amino acid residue; and

- (3) X_{codon} is a nucleic acid encoding region residue located within the
IC3 region of said GPCR, where X_{codon} encodes a non-endogenous
amino acid, preferably selected from the group consisting of
lysine, histidine and arginine, and most preferably lysine,
excepting that when the endogenous encoding region at position
 X_{codon} encodes the amino acid lysine, then X_{codon} encodes an amino
acid other than lysine, preferably alanine.

The terms endogenous and non-endogenous in reference to these sequence cassettes are relative
to the endogenous GPCR. For example, once the endogenous proline residue is located within the
TM6 region of a particular GPCR, and the 16th amino acid therefrom is identified for mutation to
constitutively activate the receptor, it is also possible to mutate the endogenous proline residue
(*i.e.*, once the marker is located and the 16th amino acid to be mutated is identified, one may mutate
the marker itself), although it is most preferred that the proline residue not be mutated. Similarly,
and while it is most preferred that AA₁₅ be maintained in their endogenous forms, these amino
acids may also be mutated. The only amino acid that must be mutated in the non-endogenous
version of the human GPCR is X *i.e.*, the endogenous amino acid that is 16 residues from P¹
cannot be maintained in its endogenous form and must be mutated, as further disclosed herein.
Stated again, while it is preferred that in the non-endogenous version of the human GPCR, P¹ and
AA₁₅ remain in their endogenous forms (*i.e.*, identical to their wild-type forms), once X is
identified and mutated, any and/or all of P¹ and AA₁₅ can be mutated. This applies to the nucleic

- 10 -

acid sequences as well. In those cases where the endogenous amino acid at position X is lysine, then in the non-endogenous version of such GPCR, X is an amino acid other than lysine, preferably alanine.

Accordingly, and as a hypothetical example, if the endogenous GPCR has the following endogenous amino acid sequence at the above-noted positions:

P-AACCTTGRRRDDDE -Q

then any of the following exemplary and hypothetical cassettes would fall within the scope of the disclosure (non-endogenous amino acids are set forth in bold):

P-AACCTTGRRRDDDE -**K**

P-AACCTT**H**IGRRRDDDE -**K**

P-A**D**EETTGGRRRDDDE -**A**

P-LLKFMSTWZLVAAPQ -**K**

A-LLKFMSTWZLVAAPQ -**K**

It is also possible to add amino acid residues within AA₁₃, but such an approach is not particularly advanced. Indeed, in the most preferred embodiments, the only amino acid that differs in the non-endogenous version of the human GPCR as compared with the endogenous version of that GPCR is the amino acid in position X; mutation of this amino acid itself leads to constitutive activation of the receptor.

Thus, in particularly preferred embodiments, P¹ and P^{codon} are endogenous proline and an endogenous nucleic acid encoding region encoding proline, respectively; and X and X_{codon} are non-endogenous lysine or alanine and a non-endogenous nucleic acid encoding region encoding lysine or alanine, respectively, with lysine being most preferred. Because it is most preferred that the non-endogenous versions of the human GPCRs which incorporate these mutations are

- 11 -

incorporated into mammalian cells and utilized for the screening of candidate compounds, the non-endogenous human GPCR incorporating the mutation need not be purified and isolated *per se* (*i.e.*, these are incorporated within the cellular membrane of a mammalian cell), although such purified and isolated non-endogenous human GPCRs are well within the purview of this disclosure. Gene-targeted and transgenic non-human mammals (preferably rats and mice) incorporating the non-endogenous human GPCRs are also within the purview of this invention; in particular, gene-targeted mammals are most preferred in that these animals will incorporate the non-endogenous versions of the human GPCRs in place of the non-human mammal's endogenous GPCR-encoding region (techniques for generating such non-human mammals to replace the non-human mammal's protein encoding region with a human encoding region are well known; see, for example, U.S. Patent No. 5,777,194.)

It has been discovered that these changes to an endogenous human GPCR render the GPCR constitutively active such that, as will be further disclosed herein, the non-endogenous, constitutively activated version of the human GPCR can be utilized for, *inter alia*, the direct screening of candidate compounds without the need for the endogenous ligand. Thus, methods for using these materials, and products identified by these methods are also within the purview of the following disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a generalized structure of a G protein-coupled receptor with the numbers assigned to the transmembrane helices, the intracellular loops, and the extracellular loops.

Figure 2 schematically shows the two states, active and inactive, for a typical G protein coupled receptor and the linkage of the active state to the second messenger transduction pathway.

- 12 -

Figure 3 is a sequence diagram of the preferred vector pCMV, including restriction enzyme site locations.

Figure 4 is a diagrammatic representation of the signal measured comparing pCMV, non-endogenous, constitutively active GPR30 inhibition of GPR6-mediated activation of CRE-Luc reporter with endogenous GPR30 inhibition of GPR6-mediated activation of CRE-Luc reporter.

Figure 5 is a diagrammatic representation of the signal measured comparing pCMV, non-endogenous, constitutively activated GPR17 inhibition of GPR3-mediated activation of CRE-Luc reporter with endogenous GPR17 inhibition of GPR3-mediated activation of CRE-Luc reporter.

Figure 6 provides diagrammatic results of the signal measured comparing control pCMV, endogenous APJ and non-endogenous APJ.

Figure 7 provides an illustration of IP₃ production from non-endogenous human 5-HT_{2A} receptor as compared to the endogenous version of this receptor.

Figure 8 are dot-blot format results for GPR1 (8A), GPR30 (8B) and APJ (8C).

DETAILED DESCRIPTION

The scientific literature that has evolved around receptors has adopted a number of terms to refer to ligands having various effects on receptors. For clarity and consistency, the following definitions will be used throughout this patent document. To the extent that these definitions conflict with other definitions for these terms, the following definitions shall control:

AGONISTS shall mean compounds that activate the intracellular response when they bind to the receptor, or enhance GTP binding to membranes.

- 13 -

AMINO ACID ABBREVIATIONS used herein are set below:

ALANINE	ALA	A
ARGININE	ARG	R
ASPARAGINE	ASN	N
ASPARTIC ACID	ASP	D
CYSTEINE	CYS	C
GLUTAMIC ACID	GLU	E
GLUTAMINE	GLN	Q
GLYCINE	GLY	G
HISTIDINE	HIS	H
ISOLEUCINE	ILE	I
LEUCINE	LEU	L
LYSINE	LYS	K
METHIONINE	MET	M
PHENYLALANINE	PHE	F
PROLINE	PRO	P
SERINE	SER	S
THREONINE	THR	T
TRYPTOPHAN	TRP	W
TYROSINE	TYR	Y
VALINE	VAL	V

PARTIAL AGONISTS shall mean compounds which activate the intracellular response when they bind to the receptor to a lesser degree/extent than do agonists, or enhance GTP binding to membranes to a lesser degree/extent than do agonists

ANTAGONIST shall mean compounds that competitively bind to the receptor at the same site as the agonists but which do not activate the intracellular response initiated by the active form of the receptor, and can thereby inhibit the intracellular responses by agonists or partial agonists. **ANTAGONISTS** do not diminish the baseline intracellular response in the absence of an agonist or partial agonist.

CANDIDATE COMPOUND shall mean a molecule (for example, and not limitation, a chemical compound) which is amenable to a screening technique. Preferably, the phrase

- 14 -

"candidate compound" does not include compounds which were publicly known to be compounds selected from the group consisting of inverse agonist, agonist or antagonist to a receptor, as previously determined by an indirect identification process ("indirectly identified compound"); more preferably, not including an indirectly identified compound which has previously been determined to have therapeutic efficacy in at least one mammal; and, most preferably, not including an indirectly identified compound which has previously been determined to have therapeutic utility in humans.

CODON shall mean a grouping of three nucleotides (or equivalents to nucleotides) which generally comprise a nucleoside (adenosine (A), guanosine (G), cytidine (C), uridine (U) and thymidine (T)) coupled to a phosphate group and which, when translated, encodes an amino acid.

COMPOUND EFFICACY shall mean a measurement of the ability of a compound to inhibit or stimulate receptor functionality, as opposed to receptor binding affinity. A preferred means of detecting compound efficacy is via measurement of, *e.g.*, [³⁵S]GTP γ S binding, as further disclosed in the Example section of this patent document.

CONSTITUTIVELY ACTIVATED RECEPTOR shall mean a receptor subject to constitutive receptor activation. In accordance with the invention disclosed herein, a non-endogenous, human constitutively activated G protein-coupled receptor is one that has been mutated to include the amino acid cassette P¹AA₁₅X, as set forth in greater detail below.

CONSTITUTIVE RECEPTOR ACTIVATION shall mean stabilization of a receptor in the active state by means other than binding of the receptor with its endogenous ligand or a chemical equivalent thereof. Preferably, a G protein-coupled receptor subjected to constitutive receptor activation in accordance with the invention disclosed herein evidences at least a 10% difference in response (increase or decrease, as the case may be) to the signal measured for

- 15 -

constitutive activation as compared with the endogenous form of that GPCR, more preferably, about a 25% difference in such comparative response, and most preferably about a 50% difference in such comparative response. When used for the purposes of directly identifying candidate compounds, it is most preferred that the signal difference be at least about 50% such that there is a sufficient difference between the endogenous signal and the non-endogenous signal to differentiate between selected candidate compounds. In most instances, the "difference" will be an increase in signal; however, with respect to Gs-coupled GPCRS, the "difference" measured is preferably a decrease, as will be set forth in greater detail below.

CONTACT or **CONTACTING** shall mean bringing at least two moieties together, whether in an in vitro system or an in vivo system.

DIRECTLY IDENTIFYING or **DIRECTLY IDENTIFIED**, in relationship to the phrase "candidate compound", shall mean the screening of a candidate compound against a constitutively activated G protein-coupled receptor, and assessing the compound efficacy of such compound. This phrase is, under no circumstances, to be interpreted or understood to be encompassed by or to encompass the phrase "indirectly identifying" or "indirectly identified."

ENDOGENOUS shall mean a material that is naturally produced by the genome of the species. **ENDOGENOUS** in reference to, for example and not limitation, GPCR, shall mean that which is naturally produced by a human, an insect, a plant, a bacterium, or a virus. By contrast, the term **NON-ENDOGENOUS** in this context shall mean that which is not naturally produced by the genome of a species. For example, and not limitation, a receptor which is not constitutively active in its endogenous form, but when mutated by using the cassettes disclosed herein and thereafter becomes constitutively active, is most preferably referred to herein as a "non-endogenous, constitutively activated receptor." Both terms can be utilized to describe both "in

- 16 -

vivo" and "in vitro" systems. For example, and not limitation, in a screening approach, the endogenous or non-endogenous receptor may be in reference to an in vitro screening system whereby the receptor is expressed on the cell-surface of a mammalian cell. As a further example and not limitation, where the genome of a mammal has been manipulated to include a non-endogenous constitutively activated receptor, screening of a candidate compound by means of an in vivo system is viable.

HOST CELL shall mean a cell capable of having a Plasmid and/or Vector incorporated therein. In the case of a prokaryotic Host Cell, a Plasmid is typically replicated as an autonomous molecule as the Host Cell replicates (generally, the Plasmid is thereafter isolated for introduction into a eukaryotic Host Cell); in the case of a eukaryotic Host Cell, a Plasmid is integrated into the cellular DNA of the Host Cell such that when the eukaryotic Host Cell replicates, the Plasmid replicates. Preferably, for the purposes of the invention disclosed herein, the Host Cell is eukaryotic, more preferably, mammalian, and most preferably selected from the group consisting of 293, 293T and COS-7 cells.

INDIRECTLY IDENTIFYING or **INDIRECTLY IDENTIFIED** means the traditional approach to the drug discovery process involving identification of an endogenous ligand specific for an endogenous receptor, screening of candidate compounds against the receptor for determination of those which interfere and/or compete with the ligand-receptor interaction, and assessing the efficacy of the compound for affecting at least one second messenger pathway associated with the activated receptor.

INHIBIT or **INHIBITING**, in relationship to the term "response" shall mean that a response is decreased or prevented in the presence of a compound as opposed to in the absence of the compound.

- 17 -

INVERSE AGONISTS shall mean compounds which bind to either the endogenous form of the receptor or to the constitutively activated form of the receptor, and which inhibit the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of agonists or partial agonists, or decrease GTP binding to membranes. Preferably, the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 30%, more preferably by at least 50%, and most preferably by at least 75%, as compared with the baseline response in the absence of the inverse agonist.

KNOWN RECEPTOR shall mean an endogenous receptor for which the endogenous ligand specific for that receptor has been identified.

LIGAND shall mean an endogenous, naturally occurring molecule specific for an endogenous, naturally occurring receptor.

MUTANT or **MUTATION** in reference to an endogenous receptor's nucleic acid and/or amino acid sequence shall mean a specified change or changes to such endogenous sequences such that a mutated form of an endogenous, non-constitutively activated receptor evidences constitutive activation of the receptor. In terms of equivalents to specific sequences, a subsequent mutated form of a human receptor is considered to be equivalent to a first mutation of the human receptor if (a) the level of constitutive activation of the subsequent mutated form of the receptor is substantially the same as that evidenced by the first mutation of the receptor; and (b) the percent sequence (amino acid and/or nucleic acid) homology between the subsequent mutated form of the receptor and the first mutation of the receptor is at least about 80%, more preferably at least about 90% and most preferably at least 95%. Ideally, and owing to the fact that the most preferred cassettes disclosed herein for achieving constitutive activation includes a single amino acid and/or codon change between the endogenous and the non-endogenous forms of the GPCR (i.e. X or

- 18 -

X_{codon}), the percent sequence homology should be at least 98%.

ORPHAN RECEPTOR shall mean an endogenous receptor for which the endogenous ligand specific for that receptor has not been identified or is not known.

PHARMACEUTICAL COMPOSITION shall mean a composition comprising at least one active ingredient, whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, and not limitation, a human). Those of ordinary skill in the art will understand and appreciate the techniques appropriate for determining whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan.

PLASMID shall mean the combination of a Vector and cDNA. Generally, a Plasmid is introduced into a Host Cell for the purpose of replication and/or expression of the cDNA as a protein.

STIMULATE or **STIMULATING**, in relationship to the term "response" shall mean that a response is increased in the presence of a compound as opposed to in the absence of the compound.

TRANSVERSE or **TRANSVERSING**, in reference to either a defined nucleic acid sequence or a defined amino acid sequence, shall mean that the sequence is located within at least two different and defined regions. For example, in an amino acid sequence that is 10 amino acid moieties in length, where 3 of the 10 moieties are in the TM6 region of a GPCR and the remaining 7 moieties are in the IC3 region of the GPCR, the 10 amino acid moiety can be described as transversing the TM6 and IC3 regions of the GPCR.

VECTOR in reference to cDNA shall mean a circular DNA capable of incorporating at least one cDNA and capable of incorporation into a Host Cell.

The order of the following sections is set forth for presentational efficiency and is not

- 19 -

intended, nor should be construed, as a limitation on the disclosure or the claims to follow.

A. Introduction

The traditional study of receptors has always proceeded from the a priori assumption (historically based) that the endogenous ligand must first be identified before discovery could proceed to find antagonists and other molecules that could affect the receptor. Even in cases where an antagonist might have been known first, the search immediately extended to looking for the endogenous ligand. This mode of thinking has persisted in receptor research even after the discovery of constitutively activated receptors. What has not been heretofore recognized is that it is the active state of the receptor that is most useful for discovering agonists, partial agonists, and inverse agonists of the receptor. For those diseases which result from an overly active receptor or an under-active receptor, what is desired in a therapeutic drug is a compound which acts to diminish the active state of a receptor or enhance the activity of the receptor, respectively, not necessarily a drug which is an antagonist to the endogenous ligand. This is because a compound that reduces or enhances the activity of the active receptor state need not bind at the same site as the endogenous ligand. Thus, as taught by a method of this invention, any search for therapeutic compounds should start by screening compounds against the ligand-independent active state.

Screening candidate compounds against non-endogenous, constitutively activated GPCRs allows for the direct identification of candidate compounds which act at these cell surface receptors, without requiring any prior knowledge or use of the receptor's endogenous ligand. By determining areas within the body where the endogenous version of such GPCRs are expressed and/or over-expressed, it is possible to determine related disease/disorder states which are associated with the expression and/or over-expression of these receptors; such an approach is disclosed in this patent document.

- 20 -

B. Disease/Disorder Identification and/or Selection

Most preferably, inverse agonists to the non-endogenous, constitutively activated GPCRs can be identified using the materials of this invention. Such inverse agonists are ideal candidates as lead compounds in drug discovery programs for treating diseases related to these receptors.

Because of the ability to directly identify inverse agonists, partial agonists or agonists to these receptors, thereby allowing for the development of pharmaceutical compositions, a search, for diseases and disorders associated with these receptors is possible. For example, scanning both diseased and normal tissue samples for the presence of these receptor now becomes more than an academic exercise or one which might be pursued along the path of identifying, in the case of an orphan receptor, an endogenous ligand. Tissue scans can be conducted across a broad range of healthy and diseased tissues. Such tissue scans provide a preferred first step in associating a specific receptor with a disease and/or disorder.

Preferably, the DNA sequence of the endogenous GPCR is used to make a probe for either radiolabeled cDNA or RT-PCR identification of the expression of the GPCR in tissue samples.

The presence of a receptor in a diseased tissue, or the presence of the receptor at elevated or decreased concentrations in diseased tissue compared to a normal tissue, can be preferably utilized to identify a correlation with that disease. Receptors can equally well be localized to regions of organs by this technique. Based on the known functions of the specific tissues to which the receptor is localized, the putative functional role of the receptor can be deduced.

C. A "Human GPCR Proline Marker" Algorithm and the Creation of Non-Endogenous, Constitutively-Active Human GPCRs

Among the many challenges facing the biotechnology arts is the unpredictability in gleanng genetic information from one species and correlating that information to another species

- 21 -

- nowhere in this art does this problem evidence more annoying exacerbation than in the genetic sequences that encode nucleic acids and proteins. Thus, for consistency and because of the highly unpredictable nature of this art, the following invention is limited, in terms of mammals, to human GPCRs - applicability of this invention to other mammalian species, while a potential possibility, is considered beyond mere rote application.

In general, when attempting to apply common "rules" from one related protein sequence to another or from one species to another, the art has typically resorted to sequence alignment, *i.e.*, sequences are linearized and attempts are then made to find regions of commonality between two or more sequences. While useful, this approach does not always prove to result in meaningful information. In the case of GPCRs, while the general structural motif is identical for all GPCRs, the variations in lengths of the TMs, ECs and ICs make such alignment approaches from one GPCR to another difficult at best. Thus, while it may be desirable to apply a consistent approach to, *e.g.*, constitutive activation from one GPCR to another, because of the great diversity in sequence length, fidelity, etc from one GPCR to the next, a generally applicable, and readily successful mutational alignment approach is in essence not possible. In an analogy, such an approach is akin to having a traveler start a journey at point A by giving the traveler dozens of different maps to point B, without any scale or distance markers on any of the maps, and then asking the traveler to find the shortest and most efficient route to destination B only by using the maps. In such a situation, the task can be readily simplified by having (a) a common "place-marker" on each map, and (b) the ability to measure the distance from the place-marker to destination B - this, then, will allow the traveler to select the most efficient from starting-point A to destination B.

In essence, a feature of the invention is to provide such coordinates within human GPCRs

- 22 -

that readily allows for creation of a constitutively active form of the human GPCRs.

As those in the art appreciate, the transmembrane region of a cell is highly hydrophobic; thus, using standard hydrophobicity plotting techniques, those in the art are readily able to determine the TM regions of a GPCR, and specifically TM6 (this same approach is also applicable to determining the EC and IC regions of the GPCR). It has been discovered that within the TM6 region of human GPCRs, a common proline residue (generally near the middle of TM6), acts as a constitutive activation "marker." By counting 15 amino acids from the proline marker, the 16th amino acid (which is located in the IC3 loop), when mutated from its endogenous form to a non-endogenous form, leads to constitutive activation of the receptor. For convenience, we refer to this as the "Human GPCR Proline Marker" Algorithm. Although the non-endogenous amino acid at this position can be any of the amino acids, most preferably, the non-endogenous amino acid is lysine. While not wishing to be bound by any theory, we believe that this position itself is unique and that the mutation at this location impacts the receptor to allow for constitutive activation.

We note that, for example, when the endogenous amino acid at the 16th position is already lysine (as is the case with GPR4 and GPR32), then in order for X to be a non-endogenous amino acid, it must be other than lysine; thus, in those situations where the endogenous GPCR has an endogenous lysine residue at the 16th position, the non-endogenous version of that GPCR preferably incorporates an amino acid other than lysine, preferably alanine, histidine and arginine, at this position. Of further note, it has been determined that GPR4 appears to be linked to Gs and active in its endogenous form (data not shown).

Because there are only 20 naturally occurring amino acids (although the use of non-naturally occurring amino acids is also viable), selection of a particular non-endogenous amino

- 23 -

acid for substitution at this 16th position is viable and allows for efficient selection of a non-endogenous amino acid that fits the needs of the investigator. However, as noted, the more preferred non-endogenous amino acids at the 16th position are lysine, histidine, arginine and alanine, with lysine being most preferred. Those of ordinary skill in the art are credited with the ability to readily determine proficient methods for changing the sequence of a codon to achieve a desired mutation.

It has also been discovered that occasionally, but not always, the proline residue marker will be preceded in TM6 by W2 (*i.e.*, W2P¹AA₁X) where W is tryptophan and 2 is any amino acid residue.

Our discovery, amongst other things, negates the need for unpredictable and complicated sequence alignment approaches commonly used by the art. Indeed, the strength of our discovery, while an algorithm in nature, is that it can be applied in a facile manner to human GPCRs, with dexterous simplicity by those in the art, to achieve a unique and highly useful end-product, *i.e.*, a constitutively activated version of a human GPCR. Because many years and significant amounts of money will be required to determine the endogenous ligands for the human GPCRs that the Human Genome project is uncovering, the disclosed invention not only reduces the time necessary to positively exploit this sequence information, but at significant cost-savings. This approach truly validates the importance of the Human Genome Project because it allows for the utilization of genetic information to not only understand the role of the GPCRs in, *e.g.*, diseases, but also provides the opportunity to improve the human condition.

D. Screening of Candidate Compounds

1. Generic GPCR screening assay techniques

When a G protein receptor becomes constitutively active, it couples to a G protein (*e.g.*,

- 24 -

Gq, Gs, Gi, Go) and stimulates release and subsequent binding of GTP to the G protein. The G protein then acts as a GTPase and slowly hydrolyzes the GTP to GDP, whereby the receptor, under normal conditions, becomes deactivated. However, constitutively activated receptors, including the non-endogenous, human constitutively active GPCRs of the present invention, continue to exchange GDP for GTP. A non-hydrolyzable analog of GTP, [³⁵S]GTPγS, can be used to monitor enhanced binding to G proteins present on membranes which express constitutively activated receptors. It is reported that [³⁵S]GTPγS can be used to monitor G protein coupling to membranes in the absence and presence of ligand. An example of this monitoring, among other examples well-known and available to those in the art, was reported by Traynor and Nahorski in 1995. The preferred use of this assay system is for initial screening of candidate compounds because the system is generically applicable to all G protein-coupled receptors regardless of the particular G protein that interacts with the intracellular domain of the receptor.

B 2. Specific GPCR screening assay techniques

C Once candidate compounds are identified using the "generic" G protein-coupled receptor assay (*i.e.*, an assay to select compounds that are agonists, partial agonists, or inverse agonists), further screening to confirm that the compounds have interacted at the receptor site is preferred. For example, a compound identified by the "generic" assay may not bind to the receptor, but may instead merely "uncouple" the G protein from the intracellular domain.

20 a. Gs and Gi.

Gs stimulates the enzyme adenylyl cyclase. Gi (and Go), on the other hand, inhibit this enzyme. Adenylyl cyclase catalyzes the conversion of ATP to cAMP; thus,

- 25 -

constitutively activated GPCRs that couple the Gs protein are associated with increased cellular levels of cAMP. On the other hand, constitutively activated GPCRs that couple the Gi (or Go) protein are associated with decreased cellular levels of cAMP. *See, generally*, "Indirect Mechanisms of Synaptic Transmission," Chpt. 8, From Neuron To Brain (3rd Ed.) Nichols, J.G. et al eds. Sinauer Associates, Inc. (1992). Thus, assays that detect cAMP can be utilized to determine if a candidate compound is, *e.g.*, an inverse agonist to the receptor (*i.e.*, such a compound would decrease the levels of cAMP). A variety of approaches known in the art for measuring cAMP can be utilized; a most preferred approach relies upon the use of anti-cAMP antibodies in an ELISA-based format. Another type of assay that can be utilized is a whole cell second messenger reporter system assay. Promoters on genes drive the expression of the proteins that a particular gene encodes. Cyclic AMP drives gene expression by promoting the binding of a cAMP-responsive DNA binding protein or transcription factor (CREB) which then binds to the promoter at specific sites called cAMP response elements and drives the expression of the gene. Reporter systems can be constructed which have a promoter containing multiple cAMP response elements before the reporter gene, *e.g.*, β -galactosidase or luciferase. Thus, a constitutively activated Gs-linked receptor causes the accumulation of cAMP that then activates the gene and expression of the reporter protein. The reporter protein such as β -galactosidase or luciferase can then be detected using standard biochemical assays (Chen et al. 1995). With respect to GPCRs that link to Gi (or Go), and thus decrease levels of cAMP, an approach to the screening of, *e.g.*, inverse agonists, based upon utilization of receptors that link to Gs (and thus increase levels of cAMP) is disclosed in the Example section with respect to GPR17 and GPR30.

- 26 -

b. Go and Gq.

Gq and Go are associated with activation of the enzyme phospholipase C, which in turn hydrolyzes the phospholipid PIP_2 , releasing two intracellular messengers: diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP_3). Increased accumulation of IP_3 is associated with activation of Gq- and Go-associated receptors. *See, generally*, "Indirect Mechanisms of Synaptic Transmission," Chpt. 8, From Neuron To Brain (3rd Ed.) Nichols, J.G. et al eds. Sinauer Associates, Inc. (1992). Assays that detect IP_3 accumulation can be utilized to determine if a candidate compound is, *e.g.*, an inverse agonist to a Gq- or Go-associated receptor (*i.e.*, such a compound would decrease the levels of IP_3). Gq-associated receptors can also be examined using an AP1 reporter assay in that Gq-dependent phospholipase C causes activation of genes containing AP1 elements; thus, activated Gq-associated receptors will evidence an increase in the expression of such genes, whereby inverse agonists thereto will evidence a decrease in such expression, and agonists will evidence an increase in such expression. Commercially available assays for such detection are available.

E. Medicinal Chemistry

Generally, but not always, direct identification of candidate compounds is preferably conducted in conjunction with compounds generated via combinatorial chemistry techniques, whereby thousands of compounds are randomly prepared for such analysis. Generally, the results of such screening will be compounds having unique core structures; thereafter, these compounds are preferably subjected to additional chemical modification around a preferred core structure(s) to further enhance the medicinal properties thereof. Such techniques are

- 27 -

known to those in the art and will not be addressed in detail in this patent document.

F. Pharmaceutical Compositions

Candidate compounds selected for further development can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically-acceptable carriers are available to those in the art; for example, *see* Remington's Pharmaceutical Sciences, 16th Edition, 1980, Mack Publishing Co., (Oslo et al., eds.)

G. Other Utility

Although a preferred use of the non-endogenous versions of the disclosed human GPCRs is for the direct identification of candidate compounds as inverse agonists, agonists or partial agonists (preferably for use as pharmaceutical agents), these receptors can also be utilized in research settings. For example, *in vitro* and *in vivo* systems incorporating these receptors can be utilized to further elucidate and understand the roles of the receptors in the human condition, both normal and diseased, as well understanding the role of constitutive activation as it applies to understanding the signaling cascade. A value in these non-endogenous receptors is that their utility as a research tool is enhanced in that, because of their unique features, the disclosed receptors can be used to understand the role of a particular receptor in the human body before the endogenous ligand therefor is identified. Other uses of the disclosed receptors will become apparent to those in the art based upon, *inter alia*, a review of this patent document.

EXAMPLES

The following examples are presented for purposes of elucidation, and not limitation, of the present invention. Following the teaching of this patent document that a mutational cassette may be utilized in the IC3 loop of human GPCRs based upon a position relative to a proline residue in TM6 to constitutively activate the receptor, and while specific nucleic acid

- 28 -

and amino acid sequences are disclosed herein, those of ordinary skill in the art are credited with the ability to make minor modifications to these sequences while achieving the same or substantially similar results reported below. Particular approaches to sequence mutations are within the purview of the artisan based upon the particular needs of the artisan.

5 Example 1
Preparation of Endogenous Human GPCRs

A variety of GPCRs were utilized in the Examples to follow. Some endogenous human GPCRs were graciously provided in expression vectors (as acknowledged below) and other endogenous human GPCRs were synthesized *de novo* using publicly-available sequence information.

1. GPR1 (GenBank Accession Number: U13666)

The human cDNA sequence for GPR1 was provided in pRcCMV by Brian O'Dowd (University of Toronto). GPR1 cDNA (1.4kB fragment) was excised from the pRcCMV vector as a NdeI-XbaI fragment and was subcloned into the NdeI-XbaI site of pCMV vector (see Figure 3). Nucleic acid (SEQ.ID.NO.: 1) and amino acid (SEQ.ID.NO.: 2) sequences for human GPR1 were thereafter determined and verified.

2. GPR4 (GenBank Accession Numbers: L36148, U35399, U21051)

The human cDNA sequence for GPR4 was provided in pRcCMV by Brian O'Dowd (University of Toronto). GPR1 cDNA (1.4kB fragment) was excised from the pRcCMV vector as an ApaI(blunted)-XbaI fragment and was subcloned (with most of the 5' untranslated region removed) into HindIII(blunted)-XbaI site of pCMV vector. Nucleic acid (SEQ.ID.NO.: 3) and amino acid (SEQ.ID.NO.: 4) sequences for human GPR4 were thereafter determined and verified.

3. GPR5 (GenBank Accession Number: L36149)

- 29 -

The cDNA for human GPR5 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 64°C for 1 min; and 72°C for 1.5 min. The 5' PCR primer contained an EcoRI site with the sequence: 5'-TATGAATTCAGATGCTCTAAACGTCCTGC-3' (SEQ.ID.NO.: 5) and the 3' primer contained BamHI site with the sequence: 5'-TCCGGATCCACCTGCACCTGCGCCTGCACC-3' (SEQ.ID.NO.: 6). The 1.1 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 7) and amino acid (SEQ.ID.NO.: 8) sequences for human GPR5 were thereafter determined and verified.

4. GPR7 (GenBank Accession Number: U22491)

The cDNA for human GPR7 was generated and cloned into pCMV expression vector as follows: PCR condition- PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 62°C for 1 min; and 72°C for 1 min and 20 sec. The 5' PCR primer contained a HindIII site with the sequence:

5'-GCAAGCTTGGGGGACGCCAGGTCGCCGGCT-3' (SEQ.ID.NO.: 9)

and the 3' primer contained a BamHI site with the sequence:

5'-GCGGATCCGGACGCTGGGGGAGTCAGGCTGC-3' (SEQ.ID.NO.: 10).

The 1.1 kb PCR fragment was digested with HindIII and BamHI and cloned into HindIII-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 11) and amino acid (SEQ.ID.NO.:

- 30 -

12) sequences for human GPR7 were thereafter determined and verified.

5. GPR8 (GenBank Accession Number: U22492)

The cDNA for human GPR8 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 62°C for 1min; and 72°C for 1min and 20 sec. The 5' PCR primer contained an EcoRI site with the sequence:

5'-CGGAATTCGTCAACGGTCCCAGCTACAATG-3' (SEQ.ID.NO.: 13).

and the 3' primer contained a BamHI site with the sequence:

5'-ATGGATCCCAGGCCCTTCAGCACCGCAATAT-3' (SEQ.ID.NO.: 14).

The 1.1 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamHI site of pCMV expression vector. All 4 cDNA clones sequenced contained a possible polymorphism involving a change of amino acid 206 from Arg to Gln. Aside from this difference, nucleic acid (SEQ.ID.NO.: 15) and amino acid (SEQ.ID.NO.: 16) sequences for human GPR8 were thereafter determined and verified.

6. GPR9 (GenBank Accession Number: X95876)

The cDNA for human GPR9 was generated and cloned into pCMV expression vector as follows: PCR was performed using a clone (provided by Brian O'Dowd) as template and pfu polymerase (Stratagene) with the buffer system provided by the manufacturer supplemented with 10% DMSO, 0.25 μ M of each primer, and 0.5 mM of each of the 4 nucleotides. The cycle condition was 25 cycles of: 94°C for 1 min; 56°C for 1min; and 72°C for 2.5 min. The 5' PCR primer contained an EcoRI site with the sequence:

- 31 -

5'-ACGAATTCAGCCATGGTCCTTGAGGTGAGTGACCACCAAGTGCTAAAT-3'
(SEQ.ID.NO.: 17)

and the 3' primer contained a BamHI site with the sequence:

5'-GAGGATCCTGGAATGCGGGGAAGTCAG-3' (SEQ.ID.NO.: 18).

5 The 1.2 kb PCR fragment was digested with EcoRI and cloned into EcoRI-SmaI site of PCMV
expression vector. Nucleic acid (SEQ.ID.NO.: 19) and amino acid (SEQ.ID.NO.: 20) sequences
for human GPR9 were thereafter determined and verified.

7. GPR9-6 (GenBank Accession Number: U45982)

The cDNA for human GPR9-6 was generated and cloned into pCMV expression
vector as follows: PCR was performed using genomic DNA as template and rTth polymerase
(Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and
0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 62°C
for 1min; and 72°C for 1 min and 20 sec. The 5' PCR primer was kinased with the sequence:
5'-TTAAGCTTGACCTAATGCCATCTTGTGTCC-3' (SEQ.ID.NO.: 21)

and the 3' primer contained a BamHI site with the sequence:

5'-TTGGATCCAAAAGAACCATGCACCTCAGAG-3' (SEQ.ID.NO.: 22).

The 1.2 kb PCR fragment was digested with BamHI and cloned into EcoRV-BamHI site of
pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 23) and amino acid (SEQ.ID.NO.: 24)
sequences for human GPR9-6 were thereafter determined and verified.

8. GPR10 (GenBank Accession Number: U32672)

The human cDNA sequence for GPR10 was provided in pRcCMV by Brian
O'Dowd (University of Toronto). GPR10 cDNA (1.3kB fragment) was excised from the
pRcCMV vector as an EcoRI-XbaI fragment and was subcloned into EcoRI-XbaI site of pCMV

- 32 -

vector. Nucleic acid (SEQ.ID.NO.: 25) and amino acid (SEQ.ID.NO.: 26) sequences for human GPR10 were thereafter determined and verified.

9. GPR15 (GenBank Accession Number: U34806)

The human cDNA sequence for GPR15 was provided in pCDNA3 by Brian O'Dowd (University of Toronto). GPR15 cDNA (1.5kB fragment) was excised from the pCDNA3 vector as a HindIII-Bam fragment and was subcloned into HindIII-Bam site of pCMV vector. Nucleic acid (SEQ.ID.NO.: 27) and amino acid (SEQ.ID.NO.: 28) sequences for human GPR15 were thereafter determined and verified.

10. GPR17 (GenBank Accession Number: Z94154)

The cDNA for human GPR17 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 56°C for 1min and 72 °C for 1 min and 20 sec. The 5' PCR primer contained an EcoRI site with the sequence:

5'-CTAGAATTCTGACTCCAGCCAAAGCATGAAT-3' (SEQ.ID.NO.: 29) and the 3' primer contained a BamHI site with the sequence:

5'-GCTGGATCCTAAACAGTCTGCGCTCGGCCT-3' (SEQ.ID.NO.: 30).

The 1.1 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 31) and amino acid (SEQ.ID.NO.: 32) sequences for human GPR17 were thereafter determined and verified.

11. GPR18 (GenBank Accession Number: L42324)

The cDNA for human GPR18 was generated and cloned into pCMV expression

- 33 -

vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 54°C for 1min; and 72°C for 1min and 20 sec. The 5' PCR primer was kinased with the sequence:

5'-ATAAGATGATCACCTGAACAATCAAGAT-3' (SEQ.ID.NO.: 33)

and the 3' primer contained an EcoRI site with the sequence:

5'-TCCGAATTCATAACATTTCACTGTTTATATTGC-3' (SEQ.ID.NO.: 34).

The 1.0 kb PCR fragment was digested with EcoRI and cloned into blunt-EcoRI site of pCMV expression vector. All 8 cDNA clones sequenced contained 4 possible polymorphisms involving changes of amino acid 12 from Thr to Pro, amino acid 86 from Ala to Glu, amino acid 97 from Ile to Leu and amino acid 310 from Leu to Met. Aside from these changes, nucleic acid (SEQ.ID.NO.: 35) and amino acid (SEQ.ID.NO.: 36) sequences for human GPR18 were thereafter determined and verified.

12. GPR20 (GenBank Accession Number: U66579)

The cDNA for human GPR20 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 62°C for 1min; and 72°C for 1 min and 20 sec. The 5' PCR primer was kinased with the sequence:

5'-CCAAGCTTCCAGGCCTGGGGTGTGCTGG-3' (SEQ.ID.NO.: 37)

and the 3' primer contained a BamHI site with the sequence:

5'-ATGGATCCTGACCTTCGGCCCCTGGCAGA-3' (SEQ.ID.NO.: 38).

The 1.2 kb PCR fragment was digested with BamHI and cloned into EcoRV-BamHI site of

- 34 -

PCMV expression vector. Nucleic acid (SEQ.ID.NO.: 39) and amino acid (SEQ.ID.NO.: 40) sequences for human GPR20 were thereafter determined and verified.

13. GPR21 (GenBank Accession Number: U66580)

The cDNA for human GPR21 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 62°C for 1min; and 72°C for 1 min and 20 sec. The 5' PCR primer was kinased with the sequence: 5'-GAGAATTCACCTCCTGAGCTCAAGATGAACT-3' (SEQ.ID.NO.: 41) and the 3' primer contained a BamHI site with the sequence: 5'-CGGGATCCCCGTAAGTCTGAGCCACTTCAGAT-3' (SEQ.ID.NO.: 42).

The 1.1 kb PCR fragment was digested with BamHI and cloned into EcoRV-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 43) and amino acid (SEQ.ID.NO.: 44) sequences for human GPR21 were thereafter determined and verified.

14. GPR22 (GenBank Accession Number: U66581)

The cDNA for human GPR22 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 50°C for 1min; and 72°C for 1.5 min. The 5' PCR primer was kinased with the sequence: 5'-TCCCCCGGGAAAAAACCCTGCTCCAAA-3' (SEQ.ID.NO.: 45) and the 3' primer contained a BamHI site with the sequence: 5'-TAGGATCCATTTGAATGTGGATTGTTGAAA-3' (SEQ.ID.NO.: 46).

- 35 -

The 1.38 kb PCR fragment was digested with BamHI and cloned into EcoRV-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 47) and amino acid (SEQ.ID.NO.: 48) sequences for human GPR22 were thereafter determined and verified.

15. GPR24 (GenBank Accession Number: U71092)

The cDNA for human GPR24 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 56°C for 1min; and 72 °C for 1 min and 20 sec. The 5' PCR primer contains a HindIII site with the sequence:

5'-GTGAAGCTTGCCTCTGGTGCCTGCAGGAGG-3' (SEQ.ID.NO.: 49)

and the 3' primer contains an EcoRI site with the sequence:

5'-GCAGAATCCCGGTGGCGTGTGTGGTGCCC-3' (SEQ.ID.NO.: 50).

The 1.3 kb PCR fragment was digested with HindIII and EcoRI and cloned into HindIII-EcoRI site of pCMV expression vector. The nucleic acid (SEQ.ID.NO.: 51) and amino acid sequence (SEQ.ID.NO.: 52) for human GPR24 were thereafter determined and verified.

16. GPR30 (GenBank Accession Number: U63917)

The cDNA for human GPR30 was generated and cloned as follows: the coding sequence of GPR30 (1128bp in length) was amplified from genomic DNA using the primers:

5'-GGCGGATCCATGGATGTGACTTCCCAA-3' (SEQ.ID.NO.: 53) and

5'-GGCGGATCCCTACACGGCACTGCTGAA-3' (SEQ.ID.NO.: 54).

The amplified product was then cloned into a commercially available vector, pCR2.1 (Invitrogen),

- 36 -

using a "TOPO-TA Cloning Kit" (Invitrogen, #K4500-01), following manufacturer instructions. The full-length GPR30 insert was liberated by digestion with BamHI, separated from the vector by agarose gel electrophoresis, and purified using a Sephaglas Bandprep™ Kit (Pharmacia, # 27-9285-01) following manufacturer instructions. The nucleic acid (SEQ.ID.NO.: 55) and amino acid sequence (SEQ.ID.NO.: 56) for human GPR30 were thereafter determined and verified.

17. GPR31 (GenBank Accession Number: U65402)

The cDNA for human GPR31 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 58°C for 1min; and 72 °C for 2 min. The 5' PCR primer contained an EcoRI site with the sequence: 5'-AAGGAATTCACGGCCGGGTGATGCCATTCCC-3' (SEQ.ID.NO.: 57) and the 3' primer contained a BamHI site with the sequence: 5'-GGTGGATCCATAAACACGGGCGTTGAGGAC -3' (SEQ.ID.NO.: 58). The 1.0 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 59) and amino acid (SEQ.ID.NO.: 60) sequences for human GPR31 were thereafter determined and verified.

18. GPR32 (GenBank Accession Number: AF045764)

The cDNA for human GPR32 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μM of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 56°C for 1min; and 72 °C for 1 min and 20 sec. The 5' PCR primer contained an EcoRI site with the

- 37 -

sequence:

5'-TAAGAATTCCATAAAAAATTATGGAATGG-3' (SEQ.ID.NO.:243)

and the 3' primer contained a BamHI site with the sequence:

5'-CCAGGATCCAGCTGAAGTCTTCCATCATTC-3' (SEQ.ID.NO.: 244).

- 5 The 1.1 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 245) and amino acid (SEQ.ID.NO.: 246) sequences for human GPR32 were thereafter determined and verified.

19. GPR40 (GenBank Accession Number: AF024687)

The cDNA for human GPR40 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min, 65°C for 1min and 72 °C for 1 min and 10 sec. The 5' PCR primer contained an EcoRI site with the sequence

15 5'-GCAGAATTCGGCGGCCCCATGGACCTGCCCCC-3' (SEQ.ID.NO.: 247)

and the 3' primer contained a BamHI site with the sequence

5'-GCTGGATCCCCCGAGCAGTGGCGTTACTTC-3' (SEQ.ID.NO.: 248).

The 1 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 249) and amino acid (SEQ.ID.NO.: 250) sequences for human GPR40 were thereafter determined and verified.

20. GPR41 (GenBank Accession Number AF024688)

The cDNA for human GPR41 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase

- 38 -

(Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of 94°C for 1 min, 65°C for 1min and 72 °C for 1 min and 10 sec. The 5' PCR primer contained an HindIII site with the sequence:

5' -CTCAAGCTTACTCTCTCTCACCAGTGGCCAC-3' (SEQ.ID.NO.: 251)

and the 3' primer was kinased with the sequence

5'-CCCTCCTCCCCCGGAGGACCTAGC-3' (SEQ.ID.NO.: 252).

The 1 kb PCR fragment was digested with HindIII and cloned into HindIII-blunt site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 253) and amino acid (SEQ.ID.NO.: 254)

sequences for human GPR41 were thereafter determined and verified.

21. GPR43 (GenBank Accession Number AF024690)

The cDNA for human GPR43 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 65°C for 1min; and 72 °C for 1 min and 10 sec. The 5' PCR primer contains an HindIII site with the sequence:

5'-TTTAAGCTTCCCCTCCAGGATGCTGCCGGAC-3' (SEQ.ID.NO.: 255)

and the 3' primer contained an EcoRI site with the sequence:

5'-GGCGAATTCTGAAGGTCCAGGGAACTGCTA-3' (SEQ.ID.NO. 256).

The 1 kb PCR fragment was digested with HindIII and EcoRI and cloned into HindIII-EcoRI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 257) and amino acid (SEQ.ID.NO.: 258) sequences for human GPR43 were thereafter determined and verified.

- 39 -

22. APJ (GenBank Accession Number: U03642)

Human APJ cDNA (in pRcCMV vector) was provided by Brian O'Dowd (University of Toronto). The human APJ cDNA was excised from the pRcCMV vector as an EcoRI-XbaI (blunted) fragment and was subcloned into EcoRI-SmaI site of pCMV vector.

- 5 Nucleic acid (SEQ.ID.NO.: 61) and amino acid (SEQ.ID.NO.: 62) sequences for human APJ were thereafter determined and verified.

23. BLR1 (GenBank Accession Number: X68149)

The cDNA for human BLR1 was generated and cloned into pCMV expression vector as follows: PCR was performed using thymus cDNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 62°C for 1min; and 72°C for 1 min and 20 sec. The 5' PCR primer contained an EcoRI site with the sequence:

5'-TGAGAATTCTGGTGACTCACAGCCGGCACAG-3' (SEQ.ID.NO.: 63);

- 15 and the 3' primer contained a BamHI site with the sequence:

5'-GCCGGATCCAAGGAAAAGCAGCAATAAAAGG-3' (SEQ.ID.NO.: 64). The 1.2 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamIII site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 65) and amino acid (SEQ.ID.NO.: 66) sequences for human BLR1 were thereafter determined and verified.

24. CEPR (GenBank Accession Number: U77827)

The cDNA for human CEPR was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and

- 40 -

0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 65°C for 1 min; and 72°C for 1 min and 20 sec. The 5' PCR primer was kinased with the sequence:

5'-CAAAGCTTGAAAGCTGCACGGTGCAGAGAC-3' (SEQ.ID.NO.: 67)

and the 3' primer contained a BamHI site with the sequence:

5'-GCGGATCCCCGAGTCACACCCTGGCTGGGCC-3' (SEQ.ID.NO.: 68).

The 1.2 kb PCR fragment was digested with BamHI and cloned into EcoRV-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 69) and amino acid (SEQ.ID.NO.: 70) sequences for human CEPR were thereafter determined and verified.

25. EBI1 (GenBank Accession Number: L31581)

The cDNA for human EBI1 was generated and cloned into pCMV expression vector as follows: PCR was performed using thymus cDNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 µM of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 62°C for 1 min; and 72°C for 1 min and 20 sec. The 5' PCR primer contained an EcoRI site with the sequence:

5'-ACAGAATTCCTGTGTGGTATTACCGCCCAG-3' (SEQ.ID.NO.: 71)

and the 3' primer contained a BamHI site with the sequence:

5'-CTCGGATCCAGGCAGAAGAGTCGCCTATGG-3' (SEQ.ID.NO.: 72).

The 1.2 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 73) and amino acid (SEQ.ID.NO.: 74) sequences for human EBI1 were thereafter determined and verified.

26. EBI2 (GenBank Accession Number: L08177)

The cDNA for human EBI2 was generated and cloned into pCMV expression

- 41 -

vector as follows: PCR was performed using cDNA clone (graciously provided by Kevin Lynch,
University of Virginia Health Sciences Center; the vector utilized was not identified by the source)
as template and pfu polymerase (Stratagene) with the buffer system provided by the manufacturer
supplemented with 10% DMSO, 0.25 μ M of each primer, and 0.5 mM of each of the 4
nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 60°C for 1min; and 72°C for
1 min and 20 sec. The 5' PCR primer contained an EcoRI site with the sequence:
5'-CTGGAATTCACCTGGACCAACCAATGGATA-3' (SEQ.ID.NO.: 75)
and the 3' primer contained a BamHI site with the sequence
5'-CTCGGATCCTGCAAAGTTTGTACATACAG TT-3' (SEQ.ID.NO.: 76).
The 1.2 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamHI
site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 77) and amino acid (SEQ.ID.NO.:
78) sequences for human EBI2 were thereafter determined and verified.

27. ETBR-LP2 (GenBank Accession Number: D38449)

The cDNA for human ETBR-LP2 was generated and cloned into pCMV
expression vector as follows: PCR was performed using brain cDNA as template and rTth
polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each
primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for
1 min; 65°C for 1min; and 72 °C for 1.5 min. The 5' PCR contained an EcoRI site with the
sequence:
5'-CTGGAATTCTCCTGCTCATCCAGCCATGCGG -3' (SEQ.ID.NO.: 79)
and the 3' primer contained a BamHI site with the sequence:
5'-CCTGGATCCCCACCCCTACTGGGGCCTCAG -3' (SEQ.ID.NO.: 80).
The 1.5 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamHI

- 42 -

site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 81) and amino acid (SEQ.ID.NO.: 82) sequences for human ETBR-LP2 were thereafter determined and verified.

28. GHSR (GenBank Accession Number: U60179)

The cDNA for human GHSR was generated and cloned into pCMV expression vector as follows: PCR was performed using hippocampus cDNA as template and TaqPlus Precision polymerase (Stratagene) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 68°C for 1min; and 72°C for 1 min and 10 sec. For first round PCR, the 5' PCR primer sequence was:

5'-ATGTGGAACGCGACGCCAGCG-3' (SEQ.ID.NO.: 83)

and the 3' primer sequence was:

5'-TCATGTATTAATACTAGATTCT-3' (SEQ.ID.NO.: 84).

Two microliters of the first round PCR was used as template for the second round PCR where the 5' primer was kinased with sequence:

5'-TACCATGTGGAACGCGACGCCAGCGAAGAGCCGGGT-3' (SEQ.ID.NO.:85)

and the 3' primer contained an EcoRI site with the sequence:

5'-CGGAATTCATGTATTAATACTAGATTCTGTCCAGGCCCG-3' (SEQ.ID.NO.:86).

The 1.1 kb PCR fragment was digested with EcoRI and cloned into blunt-EcoRI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 87) and amino acid (SEQ.ID.NO.: 88) sequences for human GHSR were thereafter determined and verified.

29. GPCR-CNS (GenBank Accession Number: AF017262)

The cDNA for human GPCR-CNS was generated and cloned into pCMV expression vector as follows: PCR was performed using brain cDNA as template and rTth

- 43 -

polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 65°C for 1 min; and 72°C for 2 min. The 5' PCR primer contained a HindIII site with the sequence:

5'-GCAAGCTTGTGCCCCTACCAAGCCATGCGAGCC-3' (SEQ.ID.NO.: 89)

and the 3' primer contained an EcoRI site with the sequence:

5'-CGGAATTCAGCAATGAGTTCCGACAGAAGC-3' (SEQ.ID.NO.: 90).

The 1.9 kb PCR fragment was digested with HindIII and EcoRI and cloned into HindIII-EcoRI site of pCMV expression vector. All nine clones sequenced contained a potential polymorphism involving a S284C change. Aside from this difference, nucleic acid (SEQ.ID.NO.: 91) and amino acid (SEQ.ID.NO.: 92) sequences for human GPCR-CNS were thereafter determined and verified.

30. GPR-NGA (GenBank Accession Number: U55312)

The cDNA for human GPR-NGA was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of 94°C for 1 min, 56°C for 1 min and 72°C for 1.5 min. The 5' PCR primer contained an EcoRI site with the sequence:

5'-CAGAATTCAGAGAAAAAAGTGAATATGGTTTTT-3' (SEQ.ID.NO.: 93)

and the 3' primer contained a BamHI site with the sequence:

5'-TTGGATCCCTGGTGCATAACAATTGAAAGAAT-3' (SEQ.ID.NO.: 94).

The 1.3 kb PCR fragment was digested with EcoRI and BamHI and cloned into EcoRI-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 95) and amino acid (SEQ.ID.NO.:

- 44 -

96) sequences for human GPR-NGA were thereafter determined and verified.

31. H9 (GenBank Accession Number: U52219)

The cDNA for human HB954 was generated and cloned into pCMV expression vector as follows: PCR was performed using pituitary cDNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min, 62°C for 1min and 72°C for 2 min. The 5' PCR primer contains a HindIII site with the sequence:

5'-GGAAAGCTTAACGATCCCAGGAGCAACAT-3' (SEQ.ID.NO.: 97)

and the 3' primer contains a BamHI site with the sequence:

5'-CTGGGATCCTACGAGAGCATTTTTCACACAG-3' (SEQ.ID.NO.: 98).

The 1.9 kb PCR fragment was digested with HindIII and BamHI and cloned into HindIII-BamHI site of pCMV expression vector. When compared to the published sequences, a different isoform with 12 bp in frame insertion in the cytoplasmic tail was also identified and designated "H9b." Both isoforms contain two potential polymorphisms involving changes of amino acid P320S and amino acid G448A. Isoform H9a contained another potential polymorphism of amino acid S493N, while isoform H9b contained two additional potential polymorphisms involving changes of amino acid I502T and amino acid A532T (corresponding to amino acid 528 of isoform H9a). Nucleic acid (SEQ.ID.NO.: 99) and amino acid (SEQ.ID.NO.: 100) sequences for human H9 were thereafter determined and verified (in the section below, both isoforms were mutated in accordance with the Human GPCR Proline Marker Algorithm).

32. HB954 (GenBank Accession Number: D38449)

The cDNA for human HB954 was generated and cloned into pCMV expression

- 45 -

vector as follows: PCR was performed using brain cDNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of 94°C for 1 min, 58°C for 1 min and 72°C for 2 min. The 5' PCR contained a HindIII site with the sequence:

5 5'-TCCAAGCTTCGCCATGGGACATAACGGGAGCT-3' (SEQ.ID.NO.: 101)

and the 3' primer contained an EcoRI site with the sequence:

20 5'-CGTGAATTCGAAGAATTTACAATCCTTGCT-3' (SEQ.ID.NO.: 102).

The 1.6 kb PCR fragment was digested with HindIII and EcoRI and cloned into HindIII-EcoRI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 103) and amino acid (SEQ.ID.NO.: 104) sequences for human HB954 were thereafter determined and verified.

33. HG38 (GenBank Accession Number: AF062006)

The cDNA for human HG38 was generated and cloned into pCMV expression vector as follows: PCR was performed using brain cDNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each 4 nucleotides. The cycle condition was 30 cycles of 94°C for 1 min, 56°C for 1 min and 72°C for 1 min and 30 sec. Two PCR reactions were performed to separately obtain the 5' and 3' fragment. For the 5' fragment, the 5' PCR primer contained an HindIII site with the sequence:

40 5'-CCCAAGCTTCGGGCACCATGGACACCTCCC-3' (SEQ.ID.NO.: 259)

and the 3' primer contained a BamHI site with the sequence:

20 5'-ACAGGATCCAAATGCACAGCACTGGTAAGC-3' (SEQ.ID.NO.: 260).

This 5' 1.5 kb PCR fragment was digested with HindIII and BamHI and cloned into an HindIII-BamHI site of pCMV. For the 3' fragment, the 5' PCR primer was kinased with the sequence:

50 5'-CTATAACTGGGTTACATGGTTTAAC-3' (SEQ.ID.NO. 261)

- 46 -

and the 3' primer contained an EcoRI site with the sequence:

5'-TTTGAATTCACATATTAATTAGAGACATGG-3' (SEQ.ID.NO.: 262).

The 1.4 kb 3' PCR fragment was digested with EcoRI and subcloned into a blunt-EcoRI site of pCMV vector. The 5' and 3' fragments were then ligated together through a common EcoRV site to generate the full length cDNA clone. Nucleic acid (SEQ.ID.NO.: 263) and amino acid (SEQ.ID.NO.: 264) sequences for human HG38 were thereafter determined and verified.

34. H1M74 (GenBank Accession Number: D10923)

The cDNA for human H1M74 was generated and cloned into pCMV expression vector as follows: PCR was performed using either genomic DNA or thymus cDNA (pooled) as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer. 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 65°C for 1min; and 72°C for 1 min and 20 sec. The 5' PCR primer contained an EcoRI site with the sequence:

5'-GGAGAATTCAGTGGCGAGGCGCTCCATC-3' (SEQ.ID.NO.: 105)

and the 3' primer was kinased with the sequence:

5'-GGAGGATCCAGGAAACCTTAGGCCGAGTCC-3' (SEQ.ID.NO.:106).

The 1.3 kb PCR fragment was digested with EcoRI and cloned into EcoRI-SmaI site of pCMV expression vector. Clones sequenced revealed a potential polymorphism involving a N94K change. Aside from this difference, nucleic acid (SEQ.ID.NO.: 107) and amino acid (SEQ.ID.NO.: 108) sequences for human H1M74 were thereafter determined and verified.

35. MIG (GenBank Accession Numbers: AF044600 and AF044601)

The cDNA for human MIG was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and TaqPlus Precision

polymerase (Stratagene) for first round PCR or pfu polymerase (Stratagene) for second round PCR with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM (TaqPlus Precision) or 0.5 mM (pfu) of each of the 4 nucleotides. When pfu was used, 10% DMSO was included in the buffer. The cycle condition was 30 cycles of: 94°C for 1 min; 65°C for 1min; and 72 °C for: (a) 1 min for first round PCR; and (b) 2 min for second round PCR. Because there is an intron in the coding region, two sets of primers were separately used to generate overlapping 5' and 3' fragments. The 5' fragment PCR primers were:

and

The 3' fragment PCR primers were:

15 (SEQ.ID.NO.: 111) and

The 5' and 3' fragments were ligated together by using the first round PCR as template and the kinased external sense primer and external antisense primer to perform second round PCR. The 1.2 kb PCR fragment was digested with EcoRI and cloned into the blunt-EcoRI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 113) and amino acid (SEQ.ID.NO.: 114) sequences for human MIG were thereafter determined and verified.

36. OGR1 (GenBank Accession Number: U48405)

- 48 -

The cDNA for human OGR1 was generated and cloned into pCMV expression vector as follows: PCR was performed using genomic DNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 65°C for 1 min; and 72°C for 1 min and 20 sec. The 5' PCR primer was kinased with the sequence: 5'-GGAAGCTTCAGGCCCAAGATGGGGAACAT-3' (SEQ.ID.NO.: 115); and the 3' primer contained a BamHI site with the sequence: 5'-GTGGATCCACCCGCGGAGGACCCAGGCTAG-3' (SEQ.ID.NO.: 116). The 1.1 kb PCR fragment was digested with BamHI and cloned into the EcoRV-BamHI site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 117) and amino acid (SEQ.ID.NO.: 118) sequences for human OGR1 were thereafter determined and verified.

37. Serotonin 5HT_{2A}

The cDNA encoding endogenous human 5HT_{2A} receptor was obtained by RT-PCR using human brain poly-A⁺ RNA; a 5' primer from the 5' untranslated region with an Xho I restriction site:

5'-GACCTCGAGTCCTTCTACACCTCATC-3' (SEQ.ID.NO: 119)

and a 3' primer from the 3' untranslated region containing an Xba I site:

5'-TGCTCTAGATTCCAGATAGGTGAAAAGTTG-3' (SEQ.ID.NO: 120)

PCR was performed using either TaqPlus™ precision polymerase (Stratagene) or rTth™ polymerase (Perkin Elmer) with the buffer system provided by the manufacturers, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 57°C for 1 min; and 72°C for 2 min. The 1.5 kb PCR fragment was digested with Xba I and subcloned into Eco RV-Xba I site of pBluescript. The resulting cDNA clones were fully

- 49 -

sequenced and found to encode two amino acid changes from the published sequences. The first one was a T25N mutation in the N-terminal extracellular domain; the second is an H452Y mutation. Because cDNA clones derived from two independent PCR reactions using Taq polymerase from two different commercial sources (TaqPlusTM from Stratagene and rTthTM Perkin Elmer) contained the same two mutations, these mutations are likely to represent sequence polymorphisms rather than PCR errors. With these exceptions, the nucleic acid (SEQ.ID.NO.: 121) and amino acid (SEQ.ID.NO.: 122) sequences for human 5HT_{2A} were thereafter determined and verified.

38. Serotonin 5HT_{2C}

The cDNA encoding endogenous human 5HT_{2C} receptor was obtained from human brain poly-A⁺ RNA by RT-PCR. The 5' and 3' primers were derived from the 5' and 3' untranslated regions and contained the following sequences:

5'-GACCTCGAGGTTGCTTAAGACTGAAGC-3' (SEQ.ID.NO.: 123)

5'-ATTTCTAGACATATGTAGCTTGACCG-3' (SEQ.ID.NO.: 124)

Nucleic acid (SEQ.ID.NO.: 125) and amino acid (SEQ.ID.NO.: 126) sequences for human 5HT_{2C} were thereafter determined and verified.

39. V28 (GenBank Accession Number: U20350)

The cDNA for human V28 was generated and cloned into pCMV expression vector as follows: PCR was performed using brain cDNA as template and rTth polymerase (Perkin Elmer) with the buffer system provided by the manufacturer, 0.25 μ M of each primer, and 0.2 mM of each of the 4 nucleotides. The cycle condition was 30 cycles of: 94°C for 1 min; 65°C for 1 min; and 72°C for 1 min and 20 sec. The 5' PCR primer contained a HindIII site with the sequence:

5'-GGTAAGCTTGGCAGTCCACGCCAGGCCTTC-3' (SEQ.ID.NO.: 127)

- 50 -

and the 3' primer contained an EcoRI site with the sequence:

5'-TCCGAATTCTCTGTAGACACAAGGCTTTGG-3' (SEQ.ID.NO.: 128)

The 1.1 kb PCR fragment was digested with HindIII and EcoRI and cloned into HindIII-EcoRI

site of pCMV expression vector. Nucleic acid (SEQ.ID.NO.: 129) and amino acid (SEQ.ID.NO.:

130) sequences for human V28 were thereafter determined and verified.

Example 2

PREPARATION OF NON-ENDOGENOUS HUMAN GPCRS

1. Site-Directed Mutagenesis

Mutagenesis based upon the Human GPCR Proline Marker approach disclosed herein was performed on the foregoing endogenous human GPCRs using Transformer Site-Directed Mutagenesis Kit (Clontech) according to the manufacturer instructions. For this mutagenesis approach, a Mutation Probe and a Selection Marker Probe (unless otherwise indicated, the probe of SEQ.ID.NO.: 132 was the same throughout) were utilized, and the sequences of these for the specified sequences are listed below in Table B (the parenthetical number is the SEQ. ID.NO.). For convenience, the codon mutation incorporated into the human GPCR is also noted, in standard form:

Table B

Receptor Identifier (Codon Mutation)	Mutation Probe Sequence (5'-3') (SEQ.ID.NO.)	Selection Marker Probe Sequence (5'-3') (SEQ.ID.NO.)
GPR1 (F245K)	GATCTCCAGTAGGCAT <u>A</u> AGT GGACAATTCTGG (131)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAG (132)
GPR4 (K223A)	AGAAGGCCAAGATC <u>G</u> CGCGG CTGGCCCTCA (133)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR5 (V224K)	CGGCGCCACCGCACG <u>A</u> AAAA GCTCATCTTC	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT

- 51 -

GPR7 (I250K)	(134) GCCAAGAAGCGG <u>G</u> TGAAGT CCTGGTGGTGGCA (135)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR8 (T259K)	CAGGCGGAAGGTGA <u>AA</u> GTCC TGGTCCTCGT (136)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR9 (M254K)	CGGCGCCTGCGGGCC <u>AAG</u> CG GCTGGTGGTGGT (137)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR9-6 (L241K)	CCAAGCACAAAGCC <u>AA</u> GAAA GTGACCATCAC (138)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR10 (F276K)	GCGCCGCGCAC <u>AA</u> TGCT TGCTGGTGGT (139)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR15 (I240K)	CAAAAAGCTGAAGAAATCTA <u>A</u> GAGATCATCTTATTTGTCG (140)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR17 (V234K)	CAAGACCAAGGCCAA <u>AA</u> CGCA TGATCGCCAT (141)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR18 (I231K)	GTCAAGGAGAAGTCCAA <u>AA</u> AG GATCATCAIC (142)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR20 (M240K)	CGCCGCGTGGGGCC <u>AA</u> GCA GCTCCTGCTC (143)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR21 (A251E)	CCTGATAAGCGCTATA <u>AAA</u> AT GGTCCTGTTTCGA (144)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR22 (F312K)	GAAAGACAAAAGAGAGTCA <u>A</u> GAGGATGTCTTTATIG (145)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR24 (T304K)	CGGAGAAAGAGGGTGA <u>AA</u> C GCACAGCCATCGCC (146)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR30 (L258K)	alternate approach; <i>see</i> below	alternate approach; <i>see</i> below
GPR31 (Q221K)	AAGCTTCAGCGGGCC <u>AAG</u> GC ACTGGTCAC (147)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR32 (K255A)	CATGCCAACCAGGCC <u>GCG</u> AG GCTGCTGCTGGT (279)	ACCAGCAGCAGCCTCGCGGG CCGGITGGCATG (280)
GPR40 (A223K)	CGGAAGCTGCGGGCC <u>AA</u> ATG GGTGCCCGGC (265)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT
GPR41	CAGAGGAGGGTGAAGGGGCT GTTGGCG	CTCCTTCGGTCCTCCTATCGT TGTCAGAAAGT

- 52 -

	(A223K)	(266)	
10	GPR43 (V221K)	GGCGGCGCCGAGCC <u>AAGGGG</u> CTGGCTGTGG (267)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
5	API (L247K)	alternate approach; see below	alternate approach; see below
15	BLR1 (V258K)	CAGCGGCAGAAGGCC <u>AAAA</u> GGGTGGCCATC (148)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
	CEPR (L258K)	CGGCAGAAGGGC <u>AAGCGCA</u> GATCCTCGCG (149)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
20	EBI1 (I262K)	GAGCGCAACAAGGCC <u>AAAA</u> AGGTGATCATC (150)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
	EBI2 (L243K)	GGTGTAACAACAAAAGGCT <u>AA</u> <u>AAACACAATTATTCTTAT</u> (151)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
25	ETBR-LP2 (N358K)	GAGAGCCAGCTC <u>AAGAGCAC</u> CGTGGTG (152)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
	GHSR (V262K)	CCACAAGCAAAACC <u>AAGAAAA</u> TGCTGGCTGT (153)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
30	GPCR-CNS (N491K)	CTAGAGAGTCAGATG <u>AAGTG</u> TACAGTAGTGGCAC (155)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
20	GPR-NGA (I275K)	CGGACAAAAGTGAAAAC <u>TAA</u> <u>AAAGATGTTCCTCATT</u> (156)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
35	H9a and H9b (F236K)	GCTGAGGTTGCAAT <u>AAACT</u> AACCATGTTTGTG (157)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
25	HB954 (H265K)	GGGAGGCCGAGCTG <u>AAAGCC</u> ACCCTGCTC (158)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
40	HG38 (V765K)	GGGACTGCTCTATG <u>AAAAAA</u> CACATTGCCCTG (268)	CATCAAGTGATCATGTGCC AAGTACGCC (154)
	HM74 (I230K)	CAAGATCAAGAGAGCC <u>AAAA</u> CCTTCATCATG (159)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
30	MIG (T273K)	CCGGAGACAAAGTG <u>AAGAAG</u> ATGCTGTTTGTG (160)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
45	OGR1 (Q227K)	GCAAGGACCAGATC <u>AAGCGG</u> CTGGTGCTCA (161)	CTCCTTCGGTCTCCTATCGT TGTCAGAAAGT
50	Serotonin 5HT _{2A} (C322K)	alternate approach; see below	alternate approach; see below
35	Serotonin 5HT _{2C} (S310K)	alternate approach; see below	alternate approach; see below

- 53 -

V28 (I230K)	CAAGAAAGCCAAAGCC <u>AAG</u> AAACTGATCCTTCIG (162)	CTCCTTCGGTCCTCCTATCGT TGTCAGAAGT
----------------	---	-------------------------------------

The non-endogenous human GPCRs were then sequenced and the derived and verified nucleic acid and amino acid sequences are listed in the accompanying "Sequence Listing" appendix to this patent document, as summarized in Table C below:

Table C

Mutated GPCR	Nucleic Acid Sequence Listing	Amino Acid Sequence Listing
GPR1 (F245K)	SEQ.ID.NO.: 163	SEQ.ID.NO.: 164
GPR4 (K223A)	SEQ.ID.NO.: 165	SEQ.ID.NO.: 166
GPR5 (V224K)	SEQ.ID.NO.: 167	SEQ.ID.NO.: 168
GPR7 (T250K)	SEQ.ID.NO.: 169	SEQ.ID.NO.: 170
GPR8 (T259K)	SEQ.ID.NO.: 171	SEQ.ID.NO.: 172
GPR9 (M254K)	SEQ.ID.NO.: 173	SEQ.ID.NO.: 174
GPR9-6 (L241K)	SEQ.ID.NO.: 175	SEQ.ID.NO.: 176
GPR10 (F276K)	SEQ.ID.NO.: 177	SEQ.ID.NO.: 178
GPR15 (I240K)	SEQ.ID.NO.: 179	SEQ.ID.NO.: 180
GPR17 (V234K)	SEQ.ID.NO.: 181	SEQ.ID.NO.: 182
GPR18 (I231K)	SEQ.ID.NO.: 183	SEQ.ID.NO.: 184
GPR20 (M240K)	SEQ.ID.NO.: 185	SEQ.ID.NO.: 186
GPR21 (A251K)	SEQ.ID.NO.: 187	SEQ.ID.NO.: 188
GPR22 (F312K)	SEQ.ID.NO.: 189	SEQ.ID.NO.: 190
GPR24 (T304K)	SEQ.ID.NO.: 191	SEQ.ID.NO.: 192
GPR30	SEQ.ID.NO.: 193	SEQ.ID.NO.: 194

- 54 -

	(L258K)		
10	GPR31 (Q221K)	SEQ.ID.NO.: 195	SEQ.ID.NO.: 196
5	GPR32 (K255A)	SEQ.ID.NO.: 269	SEQ.ID.NO.: 270
	GPR40 (A223K)	SEQ.ID.NO.: 271	SEQ.ID.NO.: 272
15	GPR41 (A223K)	SEQ.ID.NO.: 273	SEQ.ID.NO.: 274
10	GPR43 (V221K)	SEQ.ID.NO.: 275	SEQ.ID.NO.: 276
	APJ (L247K)	SEQ.ID.NO.: 197	SEQ.ID.NO.: 198
20	BI R1 (V258K)	SEQ.ID.NO.: 199	SEQ.ID.NO.: 200
	CEPR (L258K)	SEQ.ID.NO.: 201	SEQ.ID.NO.: 202
	EBI1 (I262K)	SEQ.ID.NO.: 203	SEQ.ID.NO.: 204
25	EBI2 (L243K)	SEQ.ID.NO.: 205	SEQ.ID.NO.: 206
	ETBR-LP2 (N358K)	SEQ.ID.NO.: 207	SEQ.ID.NO.: 208
	GHSR (V262K)	SEQ.ID.NO.: 209	SEQ.ID.NO.: 210
30	GPCR-CNS (N491K)	SEQ.ID.NO.: 211	SEQ.ID.NO.: 212
	GPR-NGA (I275K)	SEQ.ID.NO.: 213	SEQ.ID.NO.: 214
30	H9a (F236K)	SEQ.ID.NO.: 215	SEQ.ID.NO.: 216
35	H9b (F236K)	SEQ.ID.NO.: 217	SEQ.ID.NO.: 218
	HB954 (H265K)	SEQ.ID.NO.: 219	SEQ.ID.NO.: 220
35	HG38 (V765K)	SEQ.ID.NO.: 277	SEQ.ID.NO.: 278
	HM74 (I230K)	SEQ.ID.NO.: 221	SEQ.ID.NO.: 222
40	MITG (I273K)	SEQ.ID.NO.: 223	SEQ.ID.NO.: 224
	OGR1 (Q227K)	SEQ.ID.NO.: 225	SEQ.ID.NO.: 226
45	Serotonin 5HT _{2A} (C322K)	SEQ.ID.NO.: 227	SEQ.ID.NO.: 228
	Serotonin 5HT _{2C} (S310K)	SEQ.ID.NO.: 229	SEQ.ID.NO.: 230
	V28 (I230K)	SEQ.ID.NO.: 231	SEQ.ID.NO.: 232

- 55 -

2. **Alternate Mutation Approaches for Employment of the Proline Marker Algorithm: APJ; Serotonin 5HT_{2A}; Serotonin 5HT_{2C}; and GPR30**

Although the above site-directed mutagenesis approach is particularly preferred, other approaches can be utilized to create such mutations; those skilled in the art are readily credited with selecting approaches to mutating a GPCR that fits within the particular needs of the artisan.

a. APJ

Preparation of the non-endogenous, human APJ receptor was accomplished by mutating L247K. Two oligonucleotides containing this mutation were synthesized:

5'-GGCTTAAGAGCATCATCGTGGTGCTGGTG-3' (SEQ.ID.NO.: 233)

5'-GTCACCACCAGCACCACGATGATGCTCTTAAGCC-3' (SEQ.ID.NO.: 234)

The two oligonucleotides were annealed and used to replace the *Nae*I-*Bst*PII fragment of human, endogenous APJ to generate the non-endogenous, version of human APJ.

b. Serotonin 5HT_{2A}

cDNA containing the point mutation C322K was constructed by utilizing the restriction enzyme site *Sph* I which encompasses amino acid 322. A primer containing the C322K mutation:

5'-CAAAGAAAGTACTGGGCATCGTCTTCTTCCT-3' (SEQ.ID.NO: 235)

was used along with the primer from the 3' untranslated region of the receptor:

5'-TGCTCTAGATTCCAGATAGGTGAAAA CTTG-3' (SEQ.ID.NO.: 236)

to perform PCR (under the conditions described above). The resulting PCR fragment was then used to replace the 3' end of endogenous 5HT_{2A} cDNA through the T4 polymerase blunted *Sph* I site.

c. Serotonin 5HT_{2C}

The cDNA containing a S310K mutation was constructed by replacing the *Sty* I restriction fragment containing amino acid 310 with synthetic double stranded oligonucleotides that encode

- 56 -

the desired mutation. The sense strand sequence utilized had the following sequence:

5'-CTAGGGGCACCATGCAGGCTATCAACAATGAAAGAAAAGCTAAGAAAGTC-3'
(SEQ. ID.NO.: 237)

and the antisense strand sequence utilized had the following sequence:

5'-CAAGGACTTTCCTTAGCTTTTCTTTCATTGTTGATAGCCTGCATGGTGCCC-3' (SEQ.
ID. NO.: 238)

d. GPR30

Prior to generating non-endogenous GPR30, several independent pCR2.1/GPR30 isolates were sequenced in their entirety in order to identify clones with no PCR-generated mutations. A clone having no mutations was digested with EcoRI and the endogenous GPR30 cDNA fragment was transferred into the CMV-driven expression plasmid pCI-neo (Promega), by digesting pCI-Neo with EcoRI and subcloning the EcoRI-liberated GPR30 fragment from pCR2.1/GPR30, to generate pCI/GPR30. Thereafter, the leucine at codon 258 was mutated to a lysine using a Quick-Change™ Site-Directed Mutagenesis Kit (Stratagene, #200518), according to manufacturer's instructions, and the following primers:

5'-CGGCGGCAGAAGGCGAAACGCATGATCCTCGCGGT-3' (SEQ.ID.NO.: 239) and
5'-ACCGCGAGGATCATGCGTTTCGCCTTCTGC CGCCG-3' (SEQ.ID.NO.: 240)

Example 3

Receptor (Endogenous and Mutated) Expression

Although a variety of cells are available to the art for the expression of proteins, it is most preferred that mammalian cells be utilized. The primary reason for this is predicated upon practicalities, *i.e.*, utilization of, *e.g.*, yeast cells for the expression of a GPCR, while possible,

- 57 -

introduces into the protocol a non-mammalian cell which may not (indeed, in the case of yeast, does not) include the receptor-coupling, genetic-mechanism and secretory pathways that have evolved for mammalian systems - thus, results obtained in non-mammalian cells, while of potential use, are not as preferred as that obtained from mammalian cells. Of the mammalian cells, COS-7, 293 and 293T cells are particularly preferred, although the specific mammalian cell utilized can be predicated upon the particular needs of the artisan.

Unless otherwise noted herein, the following protocol was utilized for the expression of the endogenous and non-endogenous human GPCRs. Table D lists the mammalian cell and number utilized (per 150mm plate) for GPCR expression.

Table D

Receptor Name (Endogenous or Non-Endogenous)	Mammalian Cell (Number Utilized)
GPR17	293 (2×10^4)
GPR30	293 (4×10^3)
APJ	COS-7 (5×10^6)
ETBR-LP2	293 (1×10^5)
	293T (1×10^7)
GHSR	293 (1×10^7)
	293T (1×10^7)
MIG	293 (1×10^7)
Serotonin 5HT _{2A}	293T (1×10^7)
Serotonin 5HT _{2C}	293T (1×10^7)

On day one, mammalian cells were plated out. On day two, two reaction tubes were prepared (the proportions to follow for each tube are per plate): tube A was prepared by mixing 20µg DNA (e.g., pCMV vector; pCMV vector with endogenous receptor cDNA, and pCMV vector with non-endogenous receptor cDNA.) in 1.2ml serum free DMEM (Irvine Scientific,

- 58 -

Irvine, CA); tube B was prepared by mixing 120µl lipofectamine (Gibco BRL) in 1.2ml serum free DMEM. Tubes A and B were then admixed by inversions (several times), followed by incubation at room temperature for 30-45min. The admixture is referred to as the "transfection mixture". Plated cells were washed with 1XPBS, followed by addition of 10ml serum free DMEM. 2.4ml of the transfection mixture was then added to the cells, followed by incubation for 4hrs at 37°C/5% CO₂. The transfection mixture was then removed by aspiration, followed by the addition of 25ml of DMEM/10% Fetal Bovine Serum. Cells were then incubated at 37°C/5% CO₂. After 72hr incubation, cells were then harvested and utilized for analysis.

1. Gi-Coupled Receptors: Co-Transfection with Gs-Coupled Receptors

In the case of GPR30, it has been determined that this receptor couples the G protein Gi. Gi is known to inhibit the enzyme adenylyl cyclase, which is necessary for catalyzing the conversion of ATP to cAMP. Thus, a non-endogenous, constitutively activated form of GPR30 would be expected to be associated with decreased levels of cAMP. Assay confirmation of a non-endogenous, constitutively activated form of GPR30 directly via measurement of decreasing levels of cAMP, while viable, can be preferably measured by cooperative use of a Gs-coupled receptor. For example, a receptor that is Gs-coupled will stimulate adenylyl cyclase, and thus will be associated with an increase in cAMP. The assignee of the present application has discovered that the orphan receptor GPR6 is an endogenous, constitutively activated GPCR. GPR6 couples to the Gs protein. Thus when co-transfected, one can readily verify that a putative GPR30-mutation leads to constitutive activation thereof: *i.e.*, an endogenous, constitutively activated GPR6/endogenous, non-constitutively activated GPR30 cell will evidence an elevated level of cAMP when compared with an endogenous, constitutively active GPR6/non-endogenous, constitutively activated GPR30 (the latter evidencing a comparatively lower level of cAMP).

- 59 -

Assays that detect cAMP can be utilized to determine if a candidate compound is *e.g.*, an inverse agonist to a Gs-associated receptor (*i.e.*, such a compound would decrease the levels of cAMP) or a Gi-associated receptor (or a Go-associated receptor) (*i.e.*, such a candidate compound would increase the levels of cAMP). A variety of approaches known in the art for measuring cAMP can be utilized; a preferred approach relies upon the use of anti-cAMP antibodies. Another approach, and most preferred, utilizes a whole cell second messenger reporter system assay. Promoters on genes drive the expression of the proteins that a particular gene encodes. Cyclic AMP drives gene expression by promoting the binding of a cAMP-responsive DNA binding protein or transcription factor (CREB) which then binds to the promoter at specific sites called cAMP response elements and drives the expression of the gene. Reporter systems can be constructed which have a promoter containing multiple cAMP response elements before the reporter gene, *e.g.*, β -galactosidase or luciferase. Thus, an activated receptor such as GPR6 causes the accumulation of cAMP which then activates the gene and expression of the reporter protein. Most preferably, 293 cells are co-transfected with GPR6 (or another Gs-linked receptor) and GPR30 (or another Gi-linked receptor) plasmids, preferably in a 1:1 ratio, most preferably in a 1:4 ratio. Because GPR6 is an endogenous, constitutively active receptor that stimulates the production of cAMP, GPR6 strongly activates the reporter gene and its expression. The reporter protein such as β -galactosidase or luciferase can then be detected using standard biochemical assays (Chen et al. 1995). Co-transfection of endogenous, constitutively active GPR6 with endogenous, non-constitutively active GPR30 evidences an increase in the luciferase reporter protein. Conversely, co-transfection of endogenous, constitutively active GPR6 with non-endogenous, constitutively active GPR30 evidences a drastic decrease in expression of luciferase. Several reporter plasmids are known and available in the art for measuring a second messenger assay. It is considered well within the

- 60 -

skilled artisan to determine an appropriate reporter plasmid for a particular gene expression based primarily upon the particular need of the artisan. Although a variety of cells are available for expression, mammalian cells are most preferred, and of these types, 293 cells are most preferred. 293 cells were transfected with the reporter plasmid pCRE-Luc/GPR6 and non-endogenous, constitutively activated GPR30 using a Mammalian Transfection™ Kit (Stratagene, #200285) CaPO₄ precipitation protocol according to the manufacturer's instructions (see, 28 Genomics 347 (1995) for the published endogenous GPR6 sequence). The precipitate contained 400ng reporter, 80ng CMV-expression plasmid (having a 1:4 GPR6 to endogenous GPR30 or non-endogenous GPR30 ratio) and 20ng CMV-SEAP (a transfection control plasmid encoding secreted alkaline phosphatase). 50% of the precipitate was split into 3 wells of a 96-well tissue culture dish (containing 4X10⁴ cells/well); the remaining 50% was discarded. The following morning, the media was changed. 48 hr after the start of the transfection, cells were lysed and examined for luciferase activity using a Lucite™ Kit (Packard, Cat. # 6016911) and Trilux 1450 Microbeta™ liquid scintillation and luminescence counter (Wallac) as per the vendor's instructions. The data were analyzed using GraphPad Prism 2.0a (GraphPad Software Inc.).

With respect to GPR17, which has also been determined to be Gi-linked, a modification of the foregoing approach was utilized, based upon, *inter alia*, use of another Gs-linked endogenous receptor, GPR3 (see 23 Genomics 609 (1994) and 24 Genomics 391 (1994)). Most preferably, 293 cells are utilized. These cells were plated-out on 96 well plates at a density of 2 x 10⁴ cells per well and were transfected using Lipofectamine Reagent (BRL) the following day according to manufacturer instructions. A DNA/lipid mixture was prepared for each 6-well transfection as follows: 260ng of plasmid DNA in 100μl of DMEM were gently mixed with 2μl of lipid in 100μl of DMEM (the 260ng of plasmid DNA consisted of 200ng of a 8xCRE-Luc

- 61 -

reporter plasmid (*see below*), 50ng of pCMV comprising endogenous receptor or non-endogenous receptor or pCMV alone, and 10ng of a GPRS expression plasmid (GPRS in pcDNA3 (Invitrogen)). The 8xCRE-Luc reporter plasmid was prepared as follows: vector SRIF- β -gal was obtained by cloning the rat somatostatin promoter (-71/+51) at BglV-HindIII site in the p β gal-Basic Vector (Clontech). Eight (8) copies of cAMP response element were obtained by PCR from an adenovirus template AdpCF126CCRE8 (*see* 7 Human Gene Therapy 1883 (1996)) and cloned into the SRIF- β -gal vector at the Kpn-BglV site, resulting in the 8xCRE- β -gal reporter vector. The 8xCRE-Luc reporter plasmid was generated by replacing the beta-galactosidase gene in the 8xCRE- β -gal reporter vector with the luciferase gene obtained from the pGL3-basic vector (Promega) at the HindIII-BamHI site. Following 30min. incubation at room temperature, the DNA/lipid mixture was diluted with 400 μ l of DMEM and 100 μ l of the diluted mixture was added to each well. 100 μ l of DMEM with 10% FCS were added to each well after a 4hr incubation in a cell culture incubator. The next morning the transfected cells were changed with 200 μ l/well of DMEM with 10% FCS. Eight (8) hours later, the wells were changed to 100 μ l /well of DMEM without phenol red, after one wash with PBS. Luciferase activity were measured the next day using the LucLite™ reporter gene assay kit (Packard) following manufacturer instructions and read on a 1450 MicroBeta™ scintillation and luminescence counter (Wallac).

Figure 4 evidences that constitutively active GPR30 inhibits GPR6-mediated activation of CRE-Luc reporter in 293 cells. Luciferase was measured at about 4.1 relative light units in the expression vector pCMV. Endogenous GPR30 expressed luciferase at about 8.5 relative light units, whereas the non-endogenous, constitutively active GPR30 (L258K), expressed luciferase at about 3.8 and 3.1 relative light units, respectively. Co-transfection of endogenous GPR6 with endogenous GPR30, at a 1:4 ratio, drastically increased luciferase

- 62 -

expression to about 104.1 relative light units. Co-transfection of endogenous GPR6 with non-endogenous GPR30 (L258K), at the same ratio, drastically decreased the expression, which is evident at about 18.2 and 29.5 relative light units, respectively. Similar results were observed with respect to GPR17 with respect to co-transfection with GPR3, as set forth in Figure 5.

Example 3**ASSAYS FOR DETERMINATION OF CONSTITUTIVE ACTIVITY
OF NON-ENDOGENOUS GPCRS****A. Membrane Binding Assays****1. [³⁵S]GTPγS Assay**

When a G protein-coupled receptor is in its active state, either as a result of ligand binding or constitutive activation, the receptor couples to a G protein and stimulates the release of GDP and subsequent binding of GTP to the G protein. The alpha subunit of the G protein-receptor complex acts as a GTPase and slowly hydrolyzes the GTP to GDP, at which point the receptor normally is deactivated. Constitutively activated receptors continue to exchange GDP for GTP. The non-hydrolyzable GTP analog, [³⁵S]GTPγS, can be utilized to demonstrate enhanced binding of [³⁵S]GTPγS to membranes expressing constitutively activated receptors. The advantage of using [³⁵S]GTPγS binding to measure constitutive activation is that: (a) it is generically applicable to all G protein-coupled receptors; (b) it is proximal at the membrane surface making it less likely to pick-up molecules which affect the intracellular cascade.

The assay utilizes the ability of G protein coupled receptors to stimulate [³⁵S]GTPγS binding to membranes expressing the relevant receptors. The assay can, therefore, be used in the direct identification method to screen candidate compounds to known, orphan and constitutively activated G protein-coupled receptors. The assay is generic and has application

- 63 -

to drug discovery at all G protein-coupled receptors.

The [^{35}S]GTP γ S assay was incubated in 20 mM HEPES and between 1 and about 20mM MgCl₂ (this amount can be adjusted for optimization of results, although 20mM is preferred) pH 7.4, binding buffer with between about 0.3 and about 1.2 nM [^{35}S]GTP γ S (this amount can be adjusted for optimization of results, although 1.2 is preferred) and 12.5 to 75 μg membrane protein (*e.g.*, COS-7 cells expressing the receptor; this amount can be adjusted for optimization, although 75 μg is preferred) and 1 μM GDP (this amount can be changed for optimization) for 1 hour. Wheatgerm agglutinin beads (25 μl ; Amersham) were then added and the mixture was incubated for another 30 minutes at room temperature. The tubes were then centrifuged at 1500 x g for 5 minutes at room temperature and then counted in a scintillation counter.

A less costly but equally applicable alternative has been identified which also meets the needs of large scale screening. Flash platesTM and WallacTM scintistrips may be utilized to format a high throughput [^{35}S]GTP γ S binding assay. Furthermore, using this technique, the assay can be utilized for known GPCRs to simultaneously monitor tritiated ligand binding to the receptor at the same time as monitoring the efficacy via [^{35}S]GTP γ S binding. This is possible because the Wallac beta counter can switch energy windows to look at both tritium and ^{35}S -labeled probes. This assay may also be used to detect other types of membrane activation events resulting in receptor activation. For example, the assay may be used to monitor ^{32}P phosphorylation of a variety of receptors (both G protein coupled and tyrosine kinase receptors). When the membranes are centrifuged to the bottom of the well, the bound [^{35}S]GTP γ S or the ^{32}P -phosphorylated receptor will activate the scintillant which is coated of the wells. Scinti[®] strips (Wallac) have been used to demonstrate this principle. In addition, the assay also has utility for measuring ligand binding to receptors using radioactively labeled ligands. In a similar manner, when the radiolabeled bound

- 64 -

ligand is centrifuged to the bottom of the well, the scintistrip label comes into proximity with the radiolabeled ligand resulting in activation and detection.

Representative results of graph comparing Control (pCMV), Endogenous APJ and Non-Endogenous APJ, based upon the foregoing protocol, are set forth in Figure 6.

2. Adenylyl Cyclase

A Flash Plate™ Adenylyl Cyclase kit (New England Nuclear; Cat. No. SMP004A) designed for cell-based assays was modified for use with crude plasma membranes. The Flash Plate wells contain a scintillant coating which also contains a specific antibody recognizing cAMP. The cAMP generated in the wells was quantitated by a direct competition for binding of radioactive cAMP tracer to the cAMP antibody. The following serves as a brief protocol for the measurement of changes in cAMP levels in membranes that express the receptors.

Transfected cells were harvested approximately three days after transfection. Membranes were prepared by homogenization of suspended cells in buffer containing 20mM HEPES, pH 7.4 and 10mM MgCl₂. Homogenization was performed on ice using a Brinkman Polytron™ for approximately 10 seconds. The resulting homogenate was centrifuged at 49,000 X g for 15 minutes at 4°C. The resulting pellet was then resuspended in buffer containing 20mM HEPES, pH 7.4 and 0.1 mM EDTA, homogenized for 10 seconds, followed by centrifugation at 49,000 X g for 15 minutes at 4°C. The resulting pellet can be stored at -80°C until utilized. On the day of measurement, the membrane pellet was slowly thawed at room temperature, resuspended in buffer containing 20mM HEPES, pH 7.4 and 10mM MgCl₂ (these amounts can be optimized, although the values listed herein are preferred), to yield a final protein concentration of 0.60mg/ml (the resuspended membranes were placed on ice until use).

cAMP standards and Detection Buffer (comprising 2 µCi of tracer [¹²⁵I] cAMP (100 µl) to

- 65 -

11 ml Detection Buffer) were prepared and maintained in accordance with the manufacturer's instructions. Assay Buffer was prepared fresh for screening and contained 20mM HEPES, pH 7.4, 10mM $MgCl_2$, 20mM (Sigma), 0.1 units/ml creatine phosphokinase (Sigma), 50 μ M GTP (Sigma), and 0.2 mM ATP (Sigma); Assay Buffer can be stored on ice until utilized. The assay was initiated by addition of 50ul of assay buffer followed by addition of 50ul of membrane suspension to the NEN Flash Plate. The resultant assay mixture is incubated for 60 minutes at room temperature followed by addition of 100ul of detection buffer. Plates are then incubated an additional 2-4 hours followed by counting in a Wallac MicroBeta scintillation counter. Values of cAMP/well are extrapolated from a standard cAMP curve which is contained within each assay plate. The foregoing assay was utilized with respect to analysis of MIG.

B. Reporter-Based Assays

1. CREB Reporter Assay (Gs-associated receptors)

A method to detect Gs stimulation depends on the known property of the transcription factor CREB, which is activated in a cAMP-dependent manner. A PathDetect CREB Reporting System (Stratagene, Catalogue # 219010) was utilized to assay for Gs coupled activity in 293 or 293T cells. Cells were transfected with the plasmids components of this above system and the indicated expression plasmid encoding endogenous or mutant receptor using a Mammalian Transfection Kit (Stratagene, Catalogue #200285) according to the manufacturer's instructions. Briefly, 400 ng pFR-Luc (luciferase reporter plasmid containing Gal4 recognition sequences), 40 ng pFA2-CREB (Gal4-CREB fusion protein containing the Gal4 DNA-binding domain), 80 ng CMV-receptor expression plasmid (comprising the receptor) and 20 ng CMV-SEAP (secreted alkaline phosphatase expression plasmid; alkaline phosphatase activity is measured in the media of transfected cells to control for variations in

- 66 -

transfection efficiency between samples) were combined in a calcium phosphate precipitate as per the Kit's instructions. Half of the precipitate was equally distributed over 3 wells in a 96-well plate, kept on the cells overnight, and replaced with fresh medium the following morning. Forty-eight (48) hr after the start of the transfection, cells were treated and assayed for luciferase activity as set forth with respect to the GPR30 system, above. This assay was used with respect to GHSR.

2. AP1 reporter assay (Gq-associated receptors)

A method to detect Gq stimulation depends on the known property of Gq-dependent phospholipase C to cause the activation of genes containing AP1 elements in their promoter.

A Pathdetect AP-1 cis-Reporting System (Stratagene, Catalogue # 219073) was utilized following the protocol set forth above with respect to the CREB reporter assay, except that the components of the calcium phosphate precipitate were 410 ng pAP1-Luc, 80 ng receptor expression plasmid, and 20 ng CMV-SEAP. This assay was used with respect to ETBR-LP2

C. Intracellular IP3 Accumulation Assay

On day 1, cells comprising the serotonin receptors (endogenous and mutated) were plated onto 24 well plates, usually 1×10^5 cells/well. On day 2 cells were transfected by firstly mixing 0.25ug DNA in 50 ul serumfree DMEM/well and 2 ul lipofectamine in 50 ul serumfree DMEM/well. The solutions were gently mixed and incubated for 15-30 min at room temperature. Cells were washed with 0.5 ml PBS and 400 ul of serum free media was mixed with the transfection media and added to the cells. The cells were then incubated for 3-4 hrs at $37^\circ\text{C}/5\%\text{CO}_2$ and then the transfection media was removed and replaced with 1ml/well of regular growth media. On day 3 the cells were labeled with ^3H -myo-inositol. Briefly, the media was removed the cells were washed with 0.5 ml PBS. Then 0.5 ml inositol-free/serumfree media (GIBCO BRL) was added/well with 0.25 μCi of ^3H -myo-inositol / well

- 67 -

and the cells were incubated for 16-18 hrs o/n at 37°C/5%CO₂. On Day 4 the cells were washed with 0.5 ml PBS and 0.45 ml of assay medium was added containing inositol-free/serum free media 10 µM pargyline 10 mM lithium chloride or 0.4 ml of assay medium and 50 µl of 10x ketanserin (ket) to final concentration of 10µM. The cells were then incubated for 30 min at 37°C. The cells were then washed with 0.5 ml PBS and 200 µl of fresh/icecold stop solution (1M KOH; 18 mM Na-borate; 3.8 mM EDTA) was added/well. The solution was kept on ice for 5-10 min or until cells were lysed and then neutralized by 200 µl of fresh/ice cold neutralization sol. (7.5 % HCL). The lysate was then transferred into 1.5 ml eppendorf tubes and 1 ml of chloroform/methanol (1:2) was added/tube. The solution was vortexed for 15 sec and the upper phase was applied to a Biorad AG1-X8 anion exchange resin (100-200 mesh). Firstly, the resin was washed with water at 1:1.25 W/V and 0.9 ml of upper phase was loaded onto the column. The column was washed with 10 mls of 5 mM myo-inositol and 10 ml of 5 mM Na-borate/60mM Na-formate. The inositol tris phosphates were eluted into scintillation vials containing 10 ml of scintillation cocktail with 2 ml of 0.1 M formic acid/ 1 M ammonium formate. The columns were regenerated by washing with 10 ml of 0.1 M formic acid/3M ammonium formate and rinsed twice with dd H₂O and stored at 4°C in water.

Figure 7 provides an illustration of IP3 production from the human 5-HT_{2A} receptor that incorporates the C322K mutation. While these results evidence that the Proline Mutation Algorithm approach constitutively activates this receptor, for purposes of using such a receptor for screening for identification of potential therapeutics, a more robust difference would be preferred. However, because the activated receptor can be utilized for understanding and elucidating the role of constitutive activation and for the identification of compounds that

- 68 -

can be further examined, we believe that this difference is itself useful in differentiating between the endogenous and non-endogenous versions of the human 5HT_{2A} receptor.

D. Result Summary

The results for the GPCRs tested are set forth in Table E where the Per-Cent Increase indicates the percentage difference in results observed for the non-endogenous GPCR as compared to the endogenous GPCR; these values are followed by parenthetical indications as to the type of assay utilized. Additionally, the assay system utilized is parenthetically listed (and, in cases where different Host Cells were used, both are listed). As these results indicate, a variety of assays can be utilized to determine constitutive activity of the non-endogenous versions of the human GPCRs. Those skilled in the art, based upon the foregoing and with reference to information available to the art, are credited with the ability to select and/or maximize a particular assay approach that suits the particular needs of the investigator.

Table E

Receptor Identifier (Codon Mutation)	Per-Cent Difference
GPR17 (V234K)	74.5 (CRE-Luc)
GPR30 (L258K)	71.6 (CREB)
APJ (L247K)	49.0 (GTP γ S)
ETBR-LP2 (N358K)	48.4(AP1-Luc - 293) 61.1(AP1-Luc - 293T)
GHSR (V262K)	58.9(CREB - 293) 35.6(CREB - 293T)

- 69 -

MIG (I230K)	39 (cAMP)
Serotonin 5HT _{2A} (C322K)	33.2 (IP ₃)
Serotonin 5HT _{2C} (S310K)	39.1 (IP ₃)

Example 6**Tissue Distribution of Endogenous Orphan GPCRs**

Using a commercially available human-tissue dot-blot format, endogenous orphan GPCRs were probed for a determination of the areas where such receptors are localized. Except as indicate below, the entire receptor cDNA (radiolabelled) was used as the probe: radiolabeled probe was generated using the complete receptor cDNA (excised from the vector) using a Prime-It II™ Random Primer Labeling Kit (Stratagene, #300385), according to manufacturer's instructions. A human RNA Master Blot™ (Clontech, #7770-1) was hybridized with the GPCR radiolabeled probe and washed under stringent conditions according manufacturer's instructions. The blot was exposed to Kodak BioMax Autoradiography film overnight at - 80°C.

Representative dot-blot format results are presented in Figure 8 for GPR1 (8A), GPR30 (8B), and APJ (8C), with results being summarized for all receptors in Table F

Table F

GPCR	Tissue Distribution (highest levels, relative to other tissues in the dot-blot)
GPR1	Placenta, Ovary, Adrenal

- 70 -

GPR4	Broad; highest in Heart, Lung, Adrenal, Thyroid, Spinal Cord
GPR5	Placenta, Thymus, Fetal Thymus Lesser levels in spleen, fetal spleen
GPR7	Liver, Spleen, Spinal Cord, Placenta
GPR8	No expression detected
GPR9-6	Thymus, Fetal Thymus Lesser levels in Small Intestine
GPR18	Spleen, Lymph Node, Fetal Spleen, Testis
GPR20	Broad
GPR21	Broad; very low abundance
GPR22	Heart, Fetal Heart Lesser levels in Brain
GPR30	Stomach
GPR31	Broad
BLR1	Spleen
CEPR	Stomach, Liver, Thyroid, Putamen
EBI1	Pancreas Lesser levels in Lymphoid Tissues
EBI2	Lymphoid Tissues, Aorta, Lung, Spinal Cord
ETBR-LP2	Broad; Brain Tissue
GPCR-CNS	Brain Lesser levels in Testis, Placenta
GPR-NGA	Pituitary Lesser levels in Brain
H9	Pituitary
HB954	Aorta, Cerebellum Lesser levels in most other tissues
HM74	Spleen, Leukocytes, Bone marrow, Mammary Glands, Lung, Trachea
MIG	Low levels in Kidney, Liver, Pancreas, Lung, Spleen
ORG1	Pituitary, Stomach, Placenta
V28	Brain, Spleen, Peripheral Leukocytes

Based upon the foregoing information, it is noted that human GPCRs can also be assessed for distribution in diseased tissue; comparative assessments between "normal" and diseased tissue can then be utilized to determine the potential for over-expression or under-expression of a particular receptor in a diseased state. In those circumstances where it is desirable to utilize the non-endogenous versions of the human GPCRs for the purpose of screening to directly identify

- 71 -

candidate compounds of potential therapeutic relevance, it is noted that inverse agonists are useful in the treatment of diseases and disorders where a particular human GPCR is over-expressed, whereas agonists or partial agonists are useful in the treatment of diseases and disorders where a particular human GPCR is under-expressed.

As desired, more detailed, cellular localization of the receptors, using techniques well-known to those in the art (e.g., in-situ hybridization) can be utilized to identify particular cells within these tissues where the receptor of interest is expressed.

It is intended that each of the patents, applications, and printed publications mentioned in this patent document be hereby incorporated by reference in their entirety.

As those skilled in the art will appreciate, numerous changes and modifications may be made to the preferred embodiments of the invention without departing from the spirit of the invention. It is intended that all such variations fall within the scope of the invention.

Although a variety of expression vectors are available to those in the art, for purposes of utilization for both the endogenous and non-endogenous human GPCRs, it is most preferred that the vector utilized be pCMV. This vector has been deposited with the American Type Culture Collection (ATCC) on October 13, 1998 (10801 University Blvd., Manassas, VA 20110-2209 USA) under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purpose of patent Procedure. The vector was tested by the ATCC on _____, 1998 and determined to be viable on _____, 1998. The ATCC has assigned the following deposit number to pCMV: _____.

- 72 -

CLAIMS

What is claimed is:

1. A constitutively active, non-endogenous version of an endogenous human orphan G protein-coupled receptor (GPCR) comprising the following amino acid residues (carboxy-terminus to amino-terminus orientation) transversing the transmembrane-6 (TM6) and intracellular loop-3 (IC3) regions of the non-endogenous GPCR:

$P^1 AA_{15} X$

wherein:

- (1) P^1 is an amino acid residue located within the TM6 region of the non-endogenous GPCR, where P^1 is selected from the group consisting of (i) the endogenous orphan GPCR proline residue, and (ii) a non-endogenous amino acid residue other than proline;
- (2) AA_{15} are 15 amino acid residues selected from the group consisting of (a) the 15 endogenous amino acid residues of the endogenous orphan GPCR, (b) 15 non-endogenous amino acid residues, and (c) a combination of 15 amino acid residues, the combination comprising at least one endogenous amino acid residue of the endogenous orphan GPCR and at least one non-endogenous amino acid residue, excepting that none of the 15 endogenous amino acid residues that are positioned within the TM6 region of the GPCR is proline; and
- (2) X is a non-endogenous amino acid residue located within the IC3 region of said non-endogenous GPCR.

2. The non-endogenous human GPCR of claim 1 wherein P^1 is the endogenous proline

5

- 73 -

residue.

10

3. The non-endogenous human GPCR of claim 1 wherein P¹ is a non-endogenous amino acid residue other than a proline residue.

15

4. The non-endogenous human GPCR of claim 1 wherein AA₁₋₁₅ are the 15 endogenous amino acid residues of the endogenous GPCR.

5

20

5. The non-endogenous human GPCR of claim 1 wherein X is selected from the group consisting of lysine, histidine, arginine and alanine residues, excepting that when the endogenous amino acid in position X of said endogenous human GPCR is lysine, X is selected from the group consisting of histidine, arginine and alanine.

25

- 10 6. The non-endogenous human GPCR of claim 1 wherein X is a lysine residue, excepting that when the endogenous amino acid in position X of said endogenous human GPCR is lysine, X is an amino acid other than lysine.

30

7. The non-endogenous human GPCR of claim 4 wherein X is a lysine residue, excepting that when the endogenous amino acid in position X of said endogenous human GPCR is lysine, X is an amino acid other than lysine.

35

15

8. The non-endogenous, human GPCR of claim 1 wherein P¹ is a proline residue and X is a lysine residue, excepting that when the endogenous amino acid in position X of said endogenous human GPCR is lysine, X is an amino acid other than lysine.

40

9. A host cell comprising the non-endogenous human GPCR of claim 1.

- 20 10. The material of claim 9 wherein said host cell is of mammalian origin.

45

11. The non-endogenous human GPCR of claim 1 in a purified and isolated form.


12. A nucleic acid sequence encoding a constitutively active, non-endogenous version of an endogenous human orphan G protein-coupled receptor (GPCR) comprising the following

50

55

- 74 -

nucleic acid sequence region transversing the transmembrane-6 (TM6) and intracellular loop-3 (IC3) regions of the orphan GPCR:



wherein:

- (1) P^{codon} is a nucleic acid encoding region within the TM6 region of the non-endogenous GPCR, where P^{codon} encodes an amino acid selected from the group consisting of (i) the endogenous GPCR proline residue, and (ii) a non-endogenous amino acid residue other than proline;
- (2) $(AA\text{-codon})_{15}$ are 15 codons encoding 15 amino acid residues selected from the group consisting of (a) the 15 endogenous amino acid residues of the endogenous orphan GPCR, (b) 15 non-endogenous amino acid residues, and (c) a combination of 15 amino acid residues, the combination comprising at least one endogenous amino acid residue of the endogenous orphan GPCR and at least one non-endogenous amino acid residue, excepting that none of the 15 endogenous amino acid residues that are positioned within the TM6 region of the orphan GPCR is proline; and
- (3) X_{codon} is a nucleic acid encoding region residue located within the IC3 region of said non-endogenous human GPCR, where X_{codon} encodes a non-endogenous amino acid.

13. The nucleic acid sequence of claim 12 wherein P^{codon} encodes an endogenous proline residue.

14. The nucleic acid sequence of claim 12 wherein P^{codon} encodes a non-endogenous

5

- 75 -

amino acid residue other than a proline residue.

10

15. The nucleic acid sequence of claim 12 wherein X_{codon} encodes a non-endogenous amino acid selected from the group consisting of lysine, histidine, arginine and alanine, excepting that when the endogenous amino acid in position X of said

15

5 endogenous human GPCR is lysine, X_{codon} encodes an amino acid selected from the group consisting of histidine, arginine and alanine.

20

16. The nucleic acid sequence of claim 13 wherein X_{codon} encodes a non-endogenous lysine amino acid excepting that when the endogenous amino acid in position X of said endogenous human GPCR is lysine, X_{codon} encodes an amino acid selected from the group consisting of histidine, arginine and alanine.

25

10

17. The nucleic acid sequence of claim 12 wherein X_{codon} is selected from the group consisting of AAA, AAG, GCA, GCG, GCC and GCU.

30

18. The nucleic acid sequence of claim 12 wherein X_{codon} is selected from the group consisting of AAA and AAG.

35

15

19. The nucleic acid sequence of claim 12 wherein P_{codon} is selected from the group consisting of CCA, CCC, CCG and CCU, and X_{codon} is selected from the group consisting of AAA and AAG.

40

20. A vector comprising the nucleic acid sequence of claim 12.

21. A plasmid comprising the nucleic acid sequence of claim 12.

20 22. A host cell comprising the nucleic acid sequence of claim 21.

45

23. The nucleic acid sequence of claim 12 in a purified and isolated form.

24. A method for selecting for alteration an endogenous amino acid residue within the third intracellular loop of a human G protein-coupled receptor ("GPCR"), said receptor

50

55

- 76 -

comprising a transmembrane 6 region and an intracellular loop 3 region, which endogenous amino acid, when altered to a non-endogenous amino acid, constitutively activates said human GPCR, comprising the following steps:

- (a) identifying an endogenous proline residue within the transmembrane 6 region of a human GPCR;
 - (b) identifying, by moving in a direction of the carboxy-terminus region of said GPCR towards the amino-terminus region of said GPCR, the endogenous, 16th amino acid residue from said proline residue;
 - (c) altering the endogenous residue of step (b) to a non-endogenous amino acid residue to create a non-endogenous version of an endogenous human GPCR; and
 - (d) determining whether the non-endogenous human GPCR of step (c) is constitutively active.
25. The method of claim 24 wherein the amino acid residue that is two residues from said proline residue in the transmembrane 6 region, in a carboxy-terminus to amino-terminus direction, is tryptophan.
26. A constitutively active, non-endogenous human GPCR produced by the process of claim 24.
27. A constitutively active, non-endogenous human GPCR produced by the process of claim 25.
28. An algorithmic approach for creating a non-endogenous, constitutively active version of an endogenous human G protein coupled receptor (GPCR), said endogenous GPCR comprising a transmembrane 6 region and an intracellular loop 3 region, the

5

- 77 -

algorithmic approach comprising the steps of:

10

(a) selecting an endogenous human GPCR comprising a proline residue in the transmembrane-6 region;

15

5

(b) identifying, by counting 16 amino acid residues from the proline residue of step (a), in a carboxy-terminus to amino-terminus direction, an endogenous amino acid residue;

20

(c) altering the identified amino acid residue of step (b) to a non-endogenous amino acid residue to create a non-endogenous version of the endogenous human GPCR; and

25

10

(d) determining if the non-endogenous version of the endogenous human GPCR of step (c) is constitutively active.

30

29. The algorithmic approach of claim 28 wherein the amino acid residue that is two residues from said proline residue in the transmembrane 6 region, in a carboxy-terminus to amino-terminus direction, is tryptophan.

35

15

30. A constitutively active, non-endogenous human GPCR produced by the algorithmic approach of claim 28.

31. A constitutively active, non-endogenous human GPCR produced by the algorithmic approach of claim 29.

40

32. A method for directly identifying a compound selected from the group consisting of inverse agonists, agonists and partial agonists to a non-endogenous, constitutively activated human G protein coupled receptor, said receptor comprising a transmembrane-6 region and an intracellular loop-3 region, comprising the steps of:

45

20

(a) selecting an endogenous human GPCR;

50

55

5

- 78 -

10

(b) identifying a proline residue within the transmembrane-6 region of the GPCR of step (a);

15

(c) identifying, in a carboxy-terminus to amino-terminus direction, the endogenous, 16th amino acid residue from the proline residue of step (b);

5

(d) altering the endogenous amino acid of step (c) to a non-endogenous amino acid;

20

(e) confirming that the non-endogenous GPCR of step (d) is constitutively active;

(f) contacting a candidate compound with the non-endogenous, constitutively-activated GPCR of step (e); and

25

10

(g) determining, by measurement of the compound efficacy at said contacted receptor, whether said compound is an inverse agonist, agonist or partial agonist of said receptor.

30

33. The method of claim 32 wherein the non-endogenous amino acid of step (d) is lysine.

35

34. A compound directly identified by the method of claim 32.

15 35. The method of claim 32 wherein the directly identified compound is an inverse agonist.

40

36. The method of claim 32 wherein the directly identified compound is an agonist.--

37. The method of claim 32 wherein the directly identified compound is a partial agonist.

45

38. A composition comprising the inverse agonist of claim 35.

20 39. A composition comprising the agonist of claim 36.

40. A composition comprising the partial agonist of claim 37.

50

41. A method for directly identifying an inverse agonist to a non-endogenous,

55

- 79 -

constitutively activated human G protein coupled receptor ("GPCR"), said GPCR comprising a transmembrane-6 region and an intracellular loop-3 region, comprising the steps of:

- (a) selecting an endogenous human GPCR;
- (b) identifying a proline residue within the transmembrane-6 region of the GPCR of step (a);
- (c) identifying, in a carboxy-terminus to amino-terminus direction, the endogenous, 16th amino acid residue from the proline residue of step (b);
- (d) altering the endogenous amino acid of step (c) to a non-endogenous lysine residue;
- (e) confirming that the non-endogenous GPCR of step (d) is constitutively active;
- (f) contacting a candidate compound with the non-endogenous, constitutively-activated GPCR of step (e); and
- (g) determining, by measurement of the compound efficacy at said contacted receptor, whether said compound is an inverse agonist of said receptor.

42. An inverse agonist directly identified by the method of claim 37.

43. A composition comprising an inverse agonist of claim 38.




FIGURE 1




FIGURE 2

pCMV Sequence and Restriction Site




FIGURE 3A

TTTGCTCAGAAGAAATGCCATCTAGTGTATGAGGCTACTGCTGACTCTCAACATTCTACTCTCCAAAAAGAGAGA 400
AAACGAGTCTTCTTTACGGTAGATCACTACTACTCCGATGACGACTGAGAGTTGTAAGATGAGGAGGTTTTTCTTCTCT

L L R R N A I G Y C . L S T F Y S S K K E E
F C S E E M P S S D D E A T A D S Q H S T P P K K K R
F A Q K K C H L V M M R L L L T L N I L L L O K R R E
K S L L F A M . H H H P . Q Q S E V N . E E L F S S F
Q E S S I G D L S S S A V A S E . C E V G G F F F L
K A . F F H W R T I I L S S S V R L M R S R W F L L S

Sty I

AAGGTAGAAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTTTTTGGTCTGCTGTGTTTAGTAATAGAACTCTTGC 480
TTCCATCTTCTGGGGTTCCTGAAAGGAAGCTTAACGATTCAAAAACTCAGTACGACACAAATCATTATCTTGAGAACG

K G R R P Q G L S F R I A K F F E S C C V . . . N S C
K V E D P K D F P S E L L S F L S H A V F S N R T L A
R . K T P R T F L O N C . V F . V M L C L V I E L L

P L L G W P S E K L I A L N K S D H Q T . Y Y F E Q
F T S S G L S K G E S N S L K K L . A T N L L L V R A
L Y F V G L V K R . F Q . T K Q T M S H K T I S S K S

TTGCTTTGCTATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAATATTCTGTAACCTTTA 560
AACGAAACGATAAATGTGGTGTTTCTTTTTCGACGTGACGATATGTTCTTTTAATACCTTTTATAAGACATTGGAAAT

L L C Y L H H K G K S C T A I O E N Y G K I F C N L Y
C F A I Y T T K E K A L L Y K K I M E K Y S V T F
L A L L F T P Q R K K L H C Y T R K L W K N I L . P L
K S Q . K C W L P F L O V A I C S F . P F I N O L R .
Q K A I . V V F S F A A S S Y L F I I S F Y E T V K I
A K S N V G C L F F S C Q . V L F N H F F I R Y G K

Ase I

TAAGTAGGCATAACAGTTATAATCATAACTACTGTTTTTCTTACTCCACACAGGCATAGAGTGTCTGCTATTAATAAC 640
ATTCAACCGTATTGTCAATATTAGTATTGTATGACAAAAAGAATGAGGTGTGTCCTATCTCACAGACGATAATTATTG

K . A . O L . S . H T V F S Y S T O A . S V C Y . .
I S R H N S Y N H N I L F F L T P H R H R V S A I N N
V G I T V I I I T Y C F F L L H T G I E C L L L I T
L Y A Y C N Y D Y C V T K E . E V C A Y L T Q . . Y S
L L C L L . L . L M S N K R V G C L C L T D A I L L
Y T P M V T I I M V Y Q K K K S W V P M S H R S N I V

Rsa I

TATGCTCAAAAATTGTGTACCTTTAGCTTTTAAATTTGTAAGGGGTAAATAAGGAATATTTGATGTATAGTGCCTTGAC 720
ATACGAGTTTTTAACACATGGAAATCGAAAAATTAAACATTTCCCAATTATTCTTATAAACTACATATCACGGAAGT

L C S K I V Y L . L F N L . R G . . G I F D V . C L D
Y A Q K L C T F S F L I C K G V N K E Y L M Y S A L T
M L K N C V P L A F . F V K G L I R N I . C I V P .

H E F I T Y R . S K L K Y L P . Y P I N S T Y H R S
A . F N H V K L K K I O L P T L L S Y K I Y L A K V
I S L F O T G K A K . N T F P N I L F I O H I T G O S

FIGURE 3B

FIGURE 3C




FIGURE 3D




FIGURE 3E




FIGURE 3f

Hae III

TGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAAC 2160
ACCGTCGTCGGTGACCATTTGTCTAATCGTCTCGCTCCATACATCGCCACGATGCTCAAGAAGTTCAACACCGGATTG

L A A A T G N R I S R A R Y V G G A T E F L K W W P N
W Q Q P L V T G L A E R G M . A V L Q S S . S G G L T
G S S H W . Q D . Q S E V C R R C Y R V L E V V A .

A A A V P L L I L L A L Y T P P A V S N K F H H G L
Q C C G S T V P N A S R P I Y A T S C L E Q L P P R V
P L L W Q Y C S . C L S T H L R H . L T R S T T A . S

TACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTC 2240
ATGCCGATGTGATCTTCTGTCTATAAACCATAGACGCGAGACGACTTCGGTCAATGGAAGCCTTTTTTCTCAACCATCGAG

Y G Y T R R T V F G I C A L L K P V T F G K R V G S S
T A T L E G Q Y L V S A L C . S Q L P S E K E L V A
L R L H . K D S I W Y L R S A E A S Y L R K K S W . L

P . V L L V T N P I Q A R S F G T V K P F L T P L E
V A Y S S P C Y K T D A S Q Q L W N G E S F S N T A R
R V S C . F S L I Q Y R R E A S A L . R R F F L Q Y S

TTGATCGGCAACAACCAACCGCTGGTAGCGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGAT 2320
AACTAGGCCGTTTGTGTTGGTGGCGACCATCGCCACCAAAAAAACAACGTTTCGTCTAATGCGCGTCTTTTTTCTCA

S G K O T T A G S G G F F V C K Q Q I T R R K K G
L D P A N K P P L V A V V F L F A S S R L R A E K K D
L I R Q T N H R W . R W F F C L Q A A D Y A Q K K R I

D D P L C V V A P L P P K K T O L C C I V R L F F P D
S G A F L G G S T A T T K K N A L L L N R A S F F S
K I R C V F W R Q Y R H N K Q K C A A S . A C F F L I

BspH I

CTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAACTCACGTTAAGGGATTTTGGTCATG 2400
GAGTTCTTCTAGGAACTAGAAAAGATGCCCCAGACTGCGAGTCACCTTGCTTTTGAGTGCAATTCCTAAAAACAGTAC

S O E D P L I F S T G S D A Q W N E N S R . G I L V M
L K K I L . S F L R G L T L S G T K T H V K G F W S .
S R R S F D L F Y G V . R S V E R K L T L R D F G H

S S G K I K E V P D S A . H F S F E R . P I K T M
R L F I R Q D K R R P R V S L P V F V . T L P N Q D H
E L L D K S R K . P T O R E T S R F S V N L S K P . S

Dra I Dra I


AGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAATAAGTGTAAATCAATCTAAAGTATATATGAGTA 2480
TCTAATAGTTTTTCTAGAGTGGATCTAGGAAAATTAATTTTACTTCAAAATTTAGTTAGATTTCATATATATCTAT

R L S K R I F T . I L L N . K . S F K S I . S I Y E .
D Y O K G S S P R S F . I K N E V L N Q S K V Y M S
E I I K K D L H L D P F K L K M K F . I N L K Y I . V

L N D F L I K V . I R K F . F H L K L D I . L I Y S Y
S . . F P D E G L D K . I L F S T K F . D L T Y I L L
I I L F S R . R S G K L N F I F N . I L R F Y I H T

FIGURE 34

10/19

FIGURE 3_H




FIGURE 3I




FIGURE 3J




FIGURE 3K

FIGURE 3 L




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7

FIGURE 8A




FIGURE 8B





FIGURE 8C

1

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Behan, Dominic P.
Chalmers, Derek T.
Liaw, Chen W.
- (ii) TITLE OF INVENTION: Non-Endogenous, Constitutively
Activated Human G Protein-Coupled
Orphan Receptors
- 10 (iii) NUMBER OF SEQUENCES: 280
- (iv) CORRESPONDENCE ADDRESS:
- 15 (A) ADDRESSEE: Arena Pharmaceuticals, Inc.
(B) STREET: 6166 Nancy Ridge Drive
(C) CITY: San Diego
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 92122
- (v) COMPUTER READABLE FORM:
- 20 (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
- 25 (A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIFICATION:
- (vii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Burgoon, Richard P.
(B) REGISTRATION NUMBER: 34,787
- 30 (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (619)453-7200
(B) TELEFAX: (619)453-7210

(2) INFORMATION FOR SEQ ID NO:1:

- 35 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1068 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGGAAGATT TGGAGGAAAC ATTATTTGAA GAATTTGAAA ACTATTCCTA TGACCTAGAC 60

TATTACTCTC TGGAGTCTGA TTGGAGGAG AAAGTCCAGC TGGGAGTTGT TCACTGGGTC 120
 TCCCTGGTGT TATATTGTTT GGCTTTTGTT CTGGGAATTC CAGGAAATGC CATCGTCATT 180
 TGGTTCACGG GGCTCAAGTG GAAGAAGACA GTCACCACTC TGTGGTTCCT CAATCTACCC 240
 ATTGCGGATT TCATTTTCTT TCTCTTCTG CCCCTGTACA TCTCCTATGT GGCCATGAAT 300
 5 TTCCACTGGC CCTTTGGCAT CTGGCTGTGC AAAGCCAATT CCTTCACTGC CCAGTTGAAC 360
 ATGTTTGCCA GTGTTTTTTT CCTGACAGTG ATCAGCCTGG ACCACTATAT CCACTTGATC 420
 CATCCTGTCT TATCTCATCG GCATCGAACC CTCAAGAACT CTCTGATTGT CATTATATTC 480
 ATCTGGCTTT TGGCTTCTCT AATTGGCGGT CCTGCCCTGT ACTTCCGGGA CACTGTGGAG 540
 TTCAATAATC ATACTCTTG CTATAACAAT TTTCAGAAAG ATGATCCTGA CCTCACTTTG 600
 10 ATCAGGCACC ATGTTCTGAC TTGGGTGAAA TTTATCAITG GCTATCTCTT CCCTTTGCTA 660
 ACAATGAGTA TTTGCTACTT GTGTCTCATC TTCAAGGTGA AGAAGCGAAC AGTCCTGATC 720
 TCCAGTAGGC ATTTCTGGAC AATTCTGGTT GTGGTTGTGG CCTTTGTGGT TTGCTGGACT 780
 CCTTATCACC TGTTTAGCAT TTGGGAGCTC ACCATTCAAC ACAATAGCTA TTCCCACCAT 840
 GTGATGCAGG CTGGAATCCC CCTCTCCACT GCTTTGGCAT TCCTCAATAG TTGCTTGAAC 900
 15 CCCATCCTTT ATGTCTAAT TAGTAAGAAG TTCCAAGCTC GCTTCCGGTC CTCAGTTGCT 960
 GAGATACTCA AGTACACACT GTGGGAAGTC AGCTGTTCTG GCACAGTGAG TGAACAGCTC 1020
 AGGAACTCAG AAACCAAGAA TCTGTGTCTC CTGGAAACAG CTCAATAA 1068

(3) INFORMATION FOR SEQ ID NO:2:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 355 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

 (ii) MOLECULE TYPE: protein
- 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

 Met Glu Asp Leu Glu Glu Thr Leu Phe Glu Glu Phe Glu Asn Tyr Ser
 1 5 10 15
 Tyr Asp Leu Asp Tyr Tyr Ser Leu Glu Ser Asp Leu Glu Glu Lys Val
 20 25 30
 30 Gln Leu Gly Val Val His Trp Val Ser Leu Val Leu Tyr Cys Leu Ala
 35 40 45

Phe Val Leu Gly Ile Pro Gly Asn Ala Ile Val Ile Trp Phe Thr Gly
 50 55 60
 Leu Lys Trp Lys Lys Thr Val Thr Thr Leu Trp Phe Leu Asn Leu Ala
 65 70 75 80
 5 Ile Ala Asp Phe Ile Phe Leu Leu Phe Leu Pro Leu Tyr Ile Ser Tyr
 85 90 95
 Val Ala Met Asn Phe His Trp Pro Phe Gly Ile Trp Leu Cys Lys Ala
 100 105 110
 10 Asn Ser Phe Thr Ala Gln Leu Asn Met Phe Ala Ser Val Phe Phe Leu
 115 120 125
 Thr Val Ile Ser Leu Asp His Tyr Ile His Leu Ile His Pro Val Leu
 130 135 140
 Ser His Arg His Arg Thr Leu Lys Asn Ser Leu Ile Val Ile Ile Phe
 145 150 155 160
 15 Ile Trp Leu Leu Ala Ser Leu Ile Gly Gly Pro Ala Leu Tyr Phe Arg
 165 170 175
 Asp Thr Val Glu Phe Asn Asn His Thr Leu Cys Tyr Asn Asn Phe Gln
 180 185 190
 20 Lys His Asp Pro Asp Leu Thr Leu Ile Arg His His Val Leu Thr Trp
 195 200 205
 Val Lys Phe Ile Ile Gly Tyr Leu Phe Pro Leu Leu Thr Met Ser Ile
 210 215 220
 Cys Tyr Leu Cys Leu Ile Phe Lys Val Lys Lys Arg Thr Val Leu Ile
 225 230 235 240
 25 Ser Ser Arg His Phe Trp Thr Ile Leu Val Val Val Val Ala Phe Val
 245 250 255
 Val Cys Trp Thr Pro Tyr His Leu Phe Ser Ile Trp Glu Leu Thr Ile
 260 265 270
 30 His His Asn Ser Tyr Ser His His Val Met Gln Ala Gly Ile Pro Leu
 275 280 285
 Ser Thr Gly Leu Ala Phe Leu Asn Ser Cys Leu Asn Pro Ile Leu Tyr
 290 295 300
 Val Leu Ile Ser Lys Lys Phe Gln Ala Arg Phe Arg Ser Ser Val Ala
 305 310 315 320
 35 Glu Ile Leu Lys Tyr Thr Leu Trp Glu Val Ser Cys Ser Gly Thr Val
 325 330 335
 Ser Glu Gln Leu Arg Asn Ser Glu Thr Lys Asn Leu Cys Leu Leu Glu

340

345

350

Thr Ala Gln
355

(4) INFORMATION FOR SEQ ID NO:3:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1089 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGGGCAACC ACACGTGGGA GGGCTGCCAC GTGGACTCGC GCGTGGACCA CCTCTTTCCG 60
CCATCCCTCT ACATCTTTGT CATCGGCGTG GGGCTGCCCA CCAACTGCCT GGCTCTGTGC 120
GCGGCCTACC GCCAGGTGCA ACAGCGCAAC GAGCTGGGCG TCTACCTGAT GAACCTCAGC 180
15 ATCGCCGACC TGCTGTACAT CTGCACGCTG CCGCTGTGGG TGGACTACTT CCTGCACCAC 240
GACAACTGGA TCCACGGCCC CGGGTCCTGC AAGCTCTTTG GGTTCATCTT CTACACCAAT 300
ATCTACATCA GCATCGCCTT CCTGTGCTGC ATCTCGGTGG ACCGCTACCT GGCTGTGGCC 360
CACCCACTCC GCTTCGCCCC CCTGCGCCCG GTCAAGACCG CCGTGGCCGT GAGCTCCGTG 420
GTCTGGGCCA CGGAGCTGGG CGCCAACTCG GCGCCCCTGT TCCATGACGA GCTCTTCCGA 480
20 GACCGCTACA ACCACACCTT CTGCTTTGAG AAGTTCCCCA TGAAGGCTG GGTGGCCTGG 540
ATGAACCTCT ATCGGGTGTG CGTGGGCTTC CTCTTCCCGT GGGCGCTCAT GCTGCTGTGG 600
TACCGGGGCA TCCTGCGGGC CGTGCGGGGC AGCGTGTTCA CCGAGCGCCA GGAGAAGGCC 660
AAGATCAAGC GGCTGGCCCT CAGCCTCATC GCCATCGTGC TGGTCTGCTT TGCGCCCTAT 720
CACGTGCTCT TGCTGTCCCG CAGCGCCATC TACCTGGGCC GCCCCTGGGA CTGCGGCTTC 780
25 GAGGAGCGCG TCTTTTCTGC ATACCACAGC TCACTGGCTT TCACCAGCCT CAACTGTGTG 840
GCGGACCCCA TCCTCTACTG CCTGGTCAAC GAGGGCGCCC GCAGCGATGT GGCCAAGGCC 900
CTGCACAACC TGCTCCGCTT TCTGGCCAGC GACAAGCCCC AGGAGATGGC CAATGCCTCG 960
CTCACCTTGG AGACCCCACT CACCTCCAAG AGGAACAGCA CAGCCAAAGC CATGACTGGC 1020
AGCTGGGCGG CCACTCCGCC TTCCAGGGG GACCAGGTGC AGCTGAAGAT GCTGCCGCCA 1080
30 GCACAATGA 1089

(5) INFORMATION FOR SEO ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 362 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

10	Met 1	Gly	Asn	His	Thr	Trp	Glu	Gly	Cys	His	Val	Asp	Ser	Arg	Val	Asp
					5					10					15	
	His	Leu	Phe	Pro	Pro	Ser	Leu	Tyr	Ile	Phe	Val	Ile	Gly	Val	Gly	Leu
				20					25					30		
	Pro	Thr	Asn	Cys	Leu	Ala	Leu	Trp	Ala	Ala	Tyr	Arg	Gln	Val	Gln	Gln
			35					40					45			
15	Arg	Asn	Glu	Leu	Gly	Val	Tyr	Leu	Met	Asn	Leu	Ser	Ile	Ala	Asp	Leu
	50						55					60				
	Leu	Tyr	Ile	Cys	Thr	Leu	Pro	Leu	Trp	Val	Asp	Tyr	Phe	Leu	His	His
	65					70					75					80
20	Asp	Asn	Trp	Ile	His	Gly	Pro	Gly	Ser	Cys	Lys	Leu	Phe	Gly	Phe	Ile
				85						90					95	
	Phe	Tyr	Thr	Asn	Ile	Tyr	Ile	Ser	Ile	Ala	Phe	Leu	Cys	Cys	Ile	Ser
				100					105					110		
	Val	Asp	Arg	Tyr	Leu	Ala	Val	Ala	His	Pro	Leu	Arg	Phe	Ala	Arg	Leu
			115					120					125			
25	Arg	Arg	Val	Lys	Thr	Ala	Val	Ala	Val	Ser	Ser	Val	Val	Trp	Ala	Thr
	130						135					140				
	Glu	Leu	Gly	Ala	Asn	Ser	Ala	Pro	Leu	Phe	His	Asp	Glu	Leu	Phe	Arg
	145					150					155					160
30	Asp	Arg	Tyr	Asn	His	Thr	Phe	Cys	Phe	Glu	Lys	Phe	Pro	Met	Glu	Gly
				165						170					175	
	Trp	Val	Ala	Trp	Met	Asn	Leu	Tyr	Arg	Val	Phe	Val	Gly	Phe	Leu	Phe
				180					185					190		
	Pro	Trp	Ala	Leu	Met	Leu	Leu	Ser	Tyr	Arg	Gly	Ile	Leu	Arg	Ala	Val
			195					200					205			
35	Arg	Gly	Ser	Val	Ser	Thr	Glu	Arg	Gln	Glu	Lys	Ala	Lys	Ile	Lys	Arg
	210						215					220				
	Leu	Ala	Leu	Ser	Leu	Ile	Ala	Ile	Val	Leu	Val	Cys	Phe	Ala	Pro	Tyr

6

	225		230		235		240
	His Val Leu Leu Leu Ser Arg Ser Ala Ile Tyr Leu Gly Arg Pro Trp						
		245			250		255
5	Asp Cys Gly Phe Glu Glu Arg Val Phe Ser Ala Tyr His Ser Ser Leu						
		260		265		270	
	Ala Phe Thr Ser Leu Asn Cys Val Ala Asp Pro Ile Leu Tyr Cys Leu						
		275		280		285	
	Val Asn Glu Gly Ala Arg Ser Asp Val Ala Lys Ala Leu His Asn Leu						
		290		295		300	
10	Leu Arg Phe Leu Ala Ser Asp Lys Pro Gln Glu Met Ala Asn Ala Ser						
		305		310		315	320
	Leu Thr Leu Glu Thr Pro Leu Thr Ser Lys Arg Asn Ser Thr Ala Lys						
			325		330		335
	Ala Met Thr Gly Ser Trp Ala Ala Thr Pro Pro Ser Gln Gly Asp Gln						
15		340		345		350	
	Val Gln Leu Lys Met Leu Pro Pro Ala Gln						
		355		360			

(6) INFORMATION FOR SEQ ID NO:5:

- 20 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TATGAATTCA GATGCTCTAA ACGTCCCTGC

30

(7) INFORMATION FOR SEQ ID NO:6:

- 30 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

35 TCCGGATCCA CCTGCACCTG CGCCTGCACC

30

(8) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1002 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATGGAGTCCT CAGGCAACCC AGAGAGCACC ACCTTTTTTT ACTATGACCT TCAGAGCCAG 60
 CCGTGTGAGA ACCAGGCCTG GGTCTTTGCT ACCCTCGCCA CCACTGTCCT GTACTGCCTG 120
 10 GTGTTTCTCC TCAGCCTAGT GGGCAACAGC CTGGTCCTBT GGGTCCTGGT GAAGTATGAG 180
 AGCCTGGAGT CCGTCACCAA CATCTTCATC CTC AACCTBT GCTCTCAGA CTTGGTGTTC 240
 GCCTGCTTGT TGCCTGTGTG GATCTCCCA TACCACTGGG GCTGGGTGCT GGGAGACTTC 300
 CTCTGCAAC TCCTCAATAT GATCTTCTCC ATCAGCCTBT ACAGCAGCAT CTTCTTCCTG 360
 ACCATCATGA CCATCCACCG CTACCTGTGG GTAGTGAGTC CTTCTCCAC CCGCGCGTC 420
 15 CCCACCTCC GCTGCCGGGT GCTGGTGACC ATGGCTGTBT GGGTAGCCAG CATCTGTCC 480
 TCCATCTCG ACACCATCTT CCACAAGGTG CTTCTTCGG GCTGTGATTA TTCCGAACTC 540
 ACGTGGTACC TCACCTCCGT CTACCAAGC AACCTCTTBT TCCTGCTGTC CTTGGGGATT 600
 ATCTGTCTT GCTACGTGGA GATCTCAGG ACCCTGTTC GCTCACGTC CAAGCGCGGC 660
 CACCGCACGG TCAAGCTCAT CTTGCCATC GTGGTGGCTT ATTCTCTAG CTGGGGTCCC 720
 20 TACAACCTCA CCCTGTTTCT GCAGACGCTG TTTCGGACCC AGATCATCCG GAGCTGCGAG 780
 GCCAACAGC AGCTAGAATA CGCCCTGCTC ATCTGCCGCA ACCTCGCCTT CTCCCACTGC 840
 TGCTTTAACC CCGTGTCTTA TGTCTTCGTG GGGGTCAAAT TCCGCACACA CTTGAAACAT 900
 GTTCTCCGC AGTTCTGGTT CTGCCGGCTG CAGGCACCCA GCCCAGCCTC GATCCCCAC 960
 TCCCCTGGTG CTTTCGCCTA TGAGGGCGCC TCCTTCTACT GA 1002

25 (9) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 333 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

	Met	Glu	Ser	Ser	Gly	Asn	Pro	Glu	Ser	Thr	Thr	Phe	Phe	Tyr	Tyr	Asp	
	1				5					10					15		
	Leu	Gln	Ser	Gln	Pro	Cys	Glu	Asn	Gln	Ala	Trp	Val	Phe	Ala	Thr	Leu	
				20					25					30			
5	Ala	Thr	Thr	Val	Leu	Tyr	Cys	Leu	Val	Phe	Leu	Leu	Ser	Leu	Val	Gly	
			35					40					45				
	Asn	Ser	Leu	Val	Leu	Trp	Val	Leu	Val	Lys	Tyr	Glu	Ser	Leu	Glu	Ser	
		50					55					60					
10	Leu	Thr	Asn	Ile	Phe	Ile	Leu	Asn	Leu	Cys	Leu	Ser	Asp	Leu	Val	Phe	
	65				70						75					80	
	Ala	Cys	Leu	Leu	Pro	Val	Trp	Ile	Ser	Pro	Tyr	His	Trp	Gly	Trp	Val	
					85					90				95			
	Leu	Gly	Asp	Phe	Leu	Cys	Lys	Leu	Leu	Asn	Met	Ile	Phe	Ser	Ile	Ser	
				100					105					110			
15	Leu	Tyr	Ser	Ser	Ile	Phe	Phe	Leu	Thr	Ile	Met	Thr	Ile	His	Arg	Tyr	
			115					120					125				
	Leu	Ser	Val	Val	Ser	Pro	Leu	Ser	Thr	Leu	Arg	Val	Pro	Thr	Leu	Arg	
		130					135					140					
20	Cys	Arg	Val	Leu	Val	Thr	Met	Ala	Val	Trp	Val	Ala	Ser	Ile	Leu	Ser	
	145					150					155				160		
	Ser	Ile	Leu	Asp	Thr	Ile	Phe	His	Lys	Val	Leu	Ser	Ser	Gly	Cys	Asp	
				165						170				175			
	Tyr	Ser	Glu	Leu	Thr	Trp	Tyr	Leu	Thr	Ser	Val	Tyr	Gln	His	Asn	Leu	
				180				185					190				
25	Phe	Phe	Leu	Leu	Ser	Leu	Gly	Ile	Ile	Leu	Phe	Cys	Tyr	Val	Glu	Ile	
			195				200					205					
	Leu	Arg	Thr	Leu	Phe	Arg	Ser	Arg	Ser	Lys	Arg	Arg	His	Arg	Thr	Val	
		210				215					220						
30	Lys	Leu	Ile	Phe	Ala	Ile	Val	Val	Ala	Tyr	Phe	Leu	Ser	Trp	Gly	Pro	
	225				230					235				240			
	Tyr	Asn	Phe	Thr	Leu	Phe	Leu	Gln	Thr	Leu	Phe	Arg	Thr	Gln	Ile	Ile	
				245				250						255			
	Arg	Ser	Cys	Glu	Ala	Lys	Gln	Gln	Leu	Glu	Tyr	Ala	Leu	Leu	Ile	Cys	
			260					265					270				
35	Arg	Asn	Leu	Ala	Phe	Ser	His	Cys	Cys	Phe	Asn	Pro	Val	Leu	Tyr	Val	
		275					280					285					

Phe Val Gly Val Lys Phe Arg Thr His Leu Lys His Val Leu Arg Gln
 290 295 300

Phe Trp Phe Cys Arg Leu Gln Ala Pro Ser Pro Ala Ser Ile Pro His
 305 310 315 320

5 Ser Pro Gly Ala Phe Ala Tyr Glu Gly Ala Ser Phe Tyr
 325 330

(10) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

10

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

15 GCAAGCTTGG GGGACGCCAG GTCGCCGGCT 30

(11) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

20

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GCGGATCCGG ACGCTGGGGG AGTCAGGCTG C 31

25 (12) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

30

- (A) LENGTH: 987 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATGGACAACG CCTCGTTCTC GGAGCCCTGG CCCGCCAACG CATCGGGCCC GGACCCGGCG 60

CTGAGCTGCT CCAACGCGTC GACTCTGGCG CCGCTGCCGG CGCCGCTGGC GGTGGCTGTA 120

35 CCAGTTGTCT ACGCGGTGAT CTGCGCCGTG GGTCTGGCGG GCAACTCCGC CGTGCTGTAC 180

GTGTTGCTGC GGGCGCCCCG CATGAAGACC GTCACCAACC TGTTCATCCT CAACCTGGCC 240
 ATCGCCGACG AGCTCTTCAC GCTGGTGCTG CCCATCAACA TCGCCGACTT CCTGCTGCGG 300
 CAGTGGCCCT TCGGGGAGCT CATGTGCAAG CTCATCGTG GTCATCGACCA GTACAACACC 360
 TTCTCCAGCC TCTACTTCCT CACCGTCATG AGCGCCGACC GCTACCTGGT GGTGTTGGCC 420
 5 ACTGCGGAGT CGCGCCGGGT GGCCGGCCGC ACCTACAGC GCGCGCGCGC GGTGAGCCTG 480
 GCCGTGTGGG GGATCGTCAC ACTCGTCGTG CTGCCCTTC GAGTCTTCGC CCGGCTAGAC 540
 GACGAGCAGG GCCGGCGCCA GTGCGTGCTA GTCTTTCCGC AGCCCGAGGC CTTCTGGTGG 600
 CGCGCGAGCC GCCTCTACAC GCTCGTGCTG GGCTTCGCCA TCCCGGTGTC CACCATCTGT 660
 GTCCTCTATA CCACCCCTGCT GTGCCGGCTG CATGCCATG GGTGCGACAG CCACGCCAAG 720
 10 GCCCTGGAGC GCGCCAAGAA GCGGGTGACC TTCCTGGTGG TGGCAATCCT GGCGGTGTGC 780
 CTCCTCTGCT GGACGCCCTA CCACCTGAGC ACCGTGGTGG CGCTCACCAC CGACCTCCCC 840
 CAGACGCCGC TGGTCATCGC TATCTCTAC TTCATCACCA GCCTGACGTA CGCCAACAGC 900
 TGCCTCAACC CCTTCTCTA CGCCTTCTG GACGCCAGCT TCCGCAGGAA CCTCCGCCAG 960
 CTGATAACTT GCCGCGCGGC AGCCTGA 987

15 (13) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 328 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 20 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Asp Asn Ala Ser Phe Ser Glu Pro Trp Pro Ala Asn Ala Ser Gly
 1 5 10 15
 25 Pro Asp Pro Ala Leu Ser Cys Ser Asn Ala Ser Thr Leu Ala Pro Leu
 20 25 30
 Pro Ala Pro Leu Ala Val Ala Val Pro Val Val Tyr Ala Val Ile Cys
 35 40 45
 30 Ala Val Gly Leu Ala Gly Asn Ser Ala Val Leu Tyr Val Leu Leu Arg
 50 55 60
 Ala Pro Arg Met Lys Thr Val Thr Asn Leu Phe Ile Leu Asn Leu Ala
 65 70 75 80

11

Ile Ala Asp Glu Leu Phe Thr Leu Val Leu Pro Ile Asn Ile Ala Asp
85 90 95

Phe Leu Leu Arg Gln Trp Pro Phe Gly Glu Leu Met Cys Lys Leu Ile
100 105 110

5 Val Ala Ile Asp Gln Tyr Asn Thr Phe Ser Ser Leu Tyr Phe Leu Thr
115 120 125

Val Met Ser Ala Asp Arg Tyr Leu Val Val Leu Ala Thr Ala Glu Ser
130 135 140

10 Arg Arg Val Ala Gly Arg Thr Tyr Ser Ala Ala Arg Ala Val Ser Leu
145 150 155 160

Ala Val Trp Gly Ile Val Thr Leu Val Val Leu Pro Phe Ala Val Phe
165 170 175

Ala Arg Leu Asp Asp Glu Gln Gly Arg Arg Gln Cys Val Leu Val Phe
180 185 190

15 Pro Gln Pro Glu Ala Phe Trp Trp Arg Ala Ser Arg Leu Tyr Thr Leu
195 200 205

Val Leu Gly Phe Ala Ile Pro Val Ser Thr Ile Cys Val Leu Tyr Thr
210 215 220

20 Thr Leu Leu Cys Arg Leu His Ala Met Arg Leu Asp Ser His Ala Lys
225 230 235 240

Ala Leu Glu Arg Ala Lys Lys Arg Val Thr Phe Leu Val Val Ala Ile
245 250 255

Leu Ala Val Cys Leu Leu Cys Trp Thr Pro Tyr His Leu Ser Thr Val
260 265 270

25 Val Ala Leu Thr Thr Asp Leu Pro Gln Thr Pro Leu Val Ile Ala Ile
275 280 285

Ser Tyr Phe Ile Thr Ser Leu Thr Tyr Ala Asn Ser Cys Leu Asn Pro
290 295 300

30 Phe Leu Tyr Ala Phe Leu Asp Ala Ser Phe Arg Arg Asn Leu Arg Gln
305 310 315 320

Leu Ile Thr Cys Arg Ala Ala Ala
325

(14) INFORMATION FOR SEQ ID NO:13:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CGGAATTCGT CAACGGTCCC AGCTACAATG

30

(15) INFORMATION FOR SEQ ID NO:14:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 10 (ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ATGGATCCCA GGCCCTTCAG CACCGCAATA T

31

(16) INFORMATION FOR SEQ ID NO:15:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1002 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATGCAGGCCG CTGGGCACCC AGAGCCCCCTT GACAGCAGGG GCTCCTTCTC CCTCCCCACG 60

ATGGGTGCCA ACGTCTCTCA GGACAATGGC ACTGGCCACA ATGCCACCTT CTCGAGCCA 120

CTGCCGTTCC TCTATGTGCT CCTGCCCCGC GTGTACTCCG GGATCTGTGC TGTGGGGCTG 180

ACTGGCAACA CGGCCGTCAT CCTTGTAATC CTAAGGGCGC CCAAGATGAA GACGGTGACC 240

- 25 AACGTGTTC A TCCTGAACCT GGCCGTCGCC GACGGGCTCT TCACGCTGGT ACTGCCCCGC 300

AACATCGCG AGCACCTGCT GCAGTACTGG CCCTTCGGGG AGCTGCTCTG CAAGCTGGTG 360

CTGGCCGTCG ACCACTACAA CATCTTCTCC AGCATCTACT TCCTAGCCGT GATGAGCGTG 420

GACCGATACC TGGTGGTGCT GGCCACCGTG AGGTCCCGCC ACATGCCCTG GCGCACCTAC 480

CGGGGGGCGA AGGTCGCCAG CCTGTGTGTC TGGCTGGGCG TCACGGTCCT GGTCTGCCC 540

- 30 TTCTTCTCTT TCGCTGGCGT CTACAGCAAC GAGCTGCAGG TCCCAAGCTG TGGGCTGAGC 600

TTCCCGTGGC CCGAGCGGGT CTGTTCAAG GCCAGCCGTG TCTACACTTT GGTCTGGGC 660

TTCGTGCTGC CCGTGTGCAC CATCTGTGTG CTCTACACAG ACCTCCTGCG CAGGCTGCGG 720

13

GCCGTGCGGC TCCGCTCTGG AGCCAAGGCT CTAGGCAAAG CCAGGCGGAA GGTGACCGTC 780
 CTGGTCCTCG TCGTGCTGGC CGTGTCCTC CTCTGCTGGA GCGCCCTTCCA CCTGGCCTCT 840
 GTCGTGGCCC TGACCACGGA CCTGCCCCAG ACCCCACTGG TCATCAGTAT GTCCTACGTC 900
 ATCACCAGCC TCACGTACGC CAACTCGTGC CTGAACCCCT TCCTCTACGC CTTTCTAGAT 960
 5 GACAACTTCC GGAAGAACTT CCGCAGCATA TTGCGGTGCT GA 1002

(17) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 333 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

15 Met Gln Ala Ala Gly His Pro Glu Pro Leu Asp Ser Arg Gly Ser Phe
 1 5 10 15
 Ser Leu Pro Thr Met Gly Ala Asn Val Ser Gln Asp Asn Gly Thr Gly
 20 25 30
 His Asn Ala Thr Phe Ser Glu Pro Leu Pro Phe Leu Tyr Val Leu Leu
 35 40 45
 20 Pro Ala Val Tyr Ser Gly Ile Cys Ala Val Gly Leu Thr Gly Asn Thr
 50 55 60
 Ala Val Ile Leu Val Ile Leu Arg Ala Pro Lys Met Lys Thr Val Thr
 65 70 75 80
 25 Asn Val Phe Ile Leu Asn Leu Ala Val Ala Asp Gly Leu Phe Thr Leu
 85 90 95
 Val Leu Pro Val Asn Ile Ala Glu His Leu Leu Gln Tyr Trp Pro Phe
 100 105 110
 Gly Glu Leu Leu Cys Lys Leu Val Leu Ala Val Asp His Tyr Asn Ile
 115 120 125
 30 Phe Ser Ser Ile Tyr Phe Leu Ala Val Met Ser Val Asp Arg Tyr Leu
 130 135 140
 Val Val Leu Ala Thr Val Arg Ser Arg His Met Pro Trp Arg Thr Tyr
 145 150 155 160
 35 Arg Gly Ala Lys Val Ala Ser Leu Cys Val Trp Leu Gly Val Thr Val
 165 170 175

14

Leu Val Leu Pro Phe Phe Ser Phe Ala Gly Val Tyr Ser Asn Glu Leu
 180 185 190

Gln Val Pro Ser Cys Gly Leu Ser Phe Pro Trp Pro Glu Arg Val Trp
 195 200 205

5 Phe Lys Ala Ser Arg Val Tyr Thr Leu Val Leu Gly Phe Val Leu Pro
 210 215 220

Val Cys Thr Ile Cys Val Leu Tyr Thr Asp Leu Leu Arg Arg Leu Arg
 225 230 235 240

10 Ala Val Arg Leu Arg Ser Gly Ala Lys Ala Leu Gly Lys Ala Arg Arg
 245 250 255

Lys Val Thr Val Leu Val Leu Val Val Leu Ala Val Cys Leu Leu Cys
 260 265 270

Trp Thr Pro Phe His Leu Ala Ser Val Val Ala Leu Thr Thr Asp Leu
 275 280 285

15 Pro Gln Thr Pro Leu Val Ile Ser Met Ser Tyr Val Ile Thr Ser Leu
 290 295 300

Thr Tyr Ala Asn Ser Cys Leu Asn Pro Phe Leu Tyr Ala Phe Leu Asp
 305 310 315 320

20 Asp Asn Phe Arg Lys Asn Phe Arg Ser Ile Leu Arg Cys
 325 330

(18) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 48 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ACGAATTCAG CCATGGTCCT TGAGGTGAGT GACCACCAAG TGCTAAAT

48

30 (19) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GAGGATCCTG GAATGCGGGG AAGTCAG

27

(20) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1107 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

10 ATGGTCCCTG AGGTGAGTGA CCACCAAGTG CTAAATGACG CCGAGGTTGC CGCCCTCCTG 60
GAGAACTTCA GCTCTTCCTA TGACTATGGA GAAAACGAGA GTGACTCGTG CTGTACCTCC 120
CCGCCCTGCC CACAGGACTT CAGCTGAAC TTCGACCGGG CCTTCCTGCC AGCCCTCTAC 180
AGCCTCCTCT TTCTGCTGGG GCTGCTGGGC AACGGCGGCG TGBCAGCCCT GCTGCTGAGC 240
CGGCGGACAG CCGTGAGCAG CACCGACACC TTCCTGCTCC ACCTAGCTCT AGCAGACACG 300
15 CTGCTGGTGC TGACACTGCC GCTGTGGGCA GTGGACGCTG CGGTCCAGTG GGTCTTTGGC 360
TCTGGCCTCT GCAAAGTGGC AGGTGCCCTC TTCAACATCA ACTTCTACGC AGGAGCCCTC 420
CTGCTGGCCT GCATCAGCTT TGACCGCTAC CTGAACATAE TTCATGCCAC CCAGCTCTAC 480
CGCCGGGGGC CCCCAGGCGG CGTGACCCCT ACCTGCCTGG CTGTCTGGGG GCTCTGCCTG 540
CTTTTCGCCC TCCCAACTT CATCTTCCTG TCGGCCACCC ACGAGGAGCG CCTCAACGCC 600
20 ACCCACTGCC AATACAACTT CCCACAGGTG GGCCGCAAGG CTCTCCGGGT GGTGCAGCTG 660
GTGGCTGGGT TTCTGCTGCC CCTGCTGGTC ATGGCCTACT GGTATGCCCA CATCCTGGCC 720
GTGCTGCTGG TTTCAGGGG CCAGCGGGCG CTGGGGGCGA TGCGGCTGGT GGTGGTGGTC 780
GTGGTGGCCT TTGCCCTCTG CTGGACCCCC TATCACCTGG TGGTCTGGT GGACATCCTC 840
ATGGACCTGG GCGCTTTGGC CCGCAACTGT GGCCGAGAAA GCAGGGTAGA CGTGGCCAAE 900
25 TCGGTCACCT CAGGCCTGGG CTACATGCAC TGCTGCCTCA ACCCGCTGCT CTATGCCTTT 960
GTAGGGGTCA AGTTCCGGA GCGGATGTGG ATGCTGCTCT TGCGCCTGGG CTGCCCCAAC 1020
CAGAGAGGGC TCCAGAGGCA GCCATCGTCT TCCCGCGGG ATTCATCCTG GTCTGAGACC 1080
TCAGAGGCCT CCTACTCGGG CTTGTGA 1107

(21) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 368 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

5

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

	Met	Val	Leu	Glu	Val	Ser	Asp	His	Gln	Val	Leu	Asn	Asp	Ala	Glu	Val	
	1				5					10					15		
10	Ala	Ala	Leu	Leu	Glu	Asn	Phe	Ser	Ser	Ser	Tyr	Asp	Tyr	Gly	Glu	Asn	
				20				25						30			
	Glu	Ser	Asp	Ser	Cys	Cys	Thr	Ser	Pro	Pro	Cys	Pro	Gln	Asp	Phe	Ser	
				35				40					45				
15	Leu	Asn	Phe	Asp	Arg	Ala	Phe	Leu	Pro	Ala	Leu	Tyr	Ser	Leu	Leu	Phe	
		50					55					60					
	Leu	Leu	Gly	Leu	Leu	Gly	Asn	Gly	Ala	Val	Ala	Ala	Val	Leu	Leu	Ser	
	65				70					75					80		
	Arg	Arg	Thr	Ala	Leu	Ser	Ser	Thr	Asp	Thr	Phe	Leu	Leu	His	Leu	Ala	
					85					90					95		
20	Val	Ala	Asp	Thr	Leu	Leu	Val	Leu	Thr	Leu	Pro	Leu	Trp	Ala	Val	Asp	
				100					105					110			
	Ala	Ala	Val	Gln	Trp	Val	Phe	Gly	Ser	Gly	Leu	Cys	Lys	Val	Ala	Gly	
				115				120					125				
25	Ala	Leu	Phe	Asn	Ile	Asn	Phe	Tyr	Ala	Gly	Ala	Leu	Leu	Leu	Ala	Cys	
		130					135					140					
	Ile	Ser	Phe	Asp	Arg	Tyr	Leu	Asn	Ile	Val	His	Ala	Thr	Gln	Leu	Tyr	
	145					150					155				160		
	Arg	Arg	Gly	Pro	Pro	Ala	Arg	Val	Thr	Leu	Thr	Cys	Leu	Ala	Val	Trp	
				165						170					175		
30	Gly	Leu	Cys	Leu	Leu	Phe	Ala	Leu	Pro	Asp	Phe	Ile	Phe	Leu	Ser	Ala	
				180					185					190			
	His	His	Asp	Glu	Arg	Leu	Asn	Ala	Thr	His	Cys	Gln	Tyr	Asn	Phe	Pro	
				195				200					205				
35	Gln	Val	Gly	Arg	Thr	Ala	Leu	Arg	Val	Leu	Gln	Leu	Val	Ala	Gly	Phe	
		210					215					220					
	Leu	Leu	Pro	Leu	Leu	Val	Met	Ala	Tyr	Cys	Tyr	Ala	His	Ile	Leu	Ala	
	225					230					235				240		

17

Val Leu Leu Val Ser Arg Gly Gln Arg Arg Leu Arg Ala Met Arg Leu
245 250 255

Val Val Val Val Val Val Ala Phe Ala Leu Cys Trp Thr Pro Tyr His
260 265 270

5 Leu Val Val Leu Val Asp Ile Leu Met Asp Leu Gly Ala Leu Ala Arg
275 280 285

Asn Cys Gly Arg Glu Ser Arg Val Asp Val Ala Lys Ser Val Thr Ser
290 295 300

10 Gly Leu Gly Tyr Met His Cys Cys Leu Asn Pro Leu Leu Tyr Ala Phe
305 310 315 320

Val Gly Val Lys Phe Arg Glu Arg Met Trp Met Leu Leu Leu Arg Leu
325 330 335

Gly Cys Pro Asn Gln Arg Gly Leu Gln Arg Gln Pro Ser Ser Ser Arg
340 345 350

15 Arg Asp Ser Ser Trp Ser Glu Thr Ser Glu Ala Ser Tyr Ser Gly Leu
355 360 365

(22) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

25 TTAAGCTTGA CCTAATGCCA TCTTGTGTCC 30

(23) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

TTGGATCCAA AAGAACCATG CACCTCAGAG 30

35 (24) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1074 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

	ATGGCTGATG ACTATGGCTC TGAATCCACA TCTTCCATGG AAGACTACGT TAACTTCAAC	60
	TTCACTGACT TTTACTGTGA GAAAAACAAT GTCAGGCAGT TTGCGAGCCA TTTCTCCCA	120
	CCCTTGTA CT G3CTCGTGT CATCGTGGGT GCCTTGGGGA ACAGTCTTGT TATCCTTGTC	180
10	TACTGGTACT GCACAAGAGT GAAGACCATG ACCGACATGT TCCTTTTGAA TTTGGCAATT	240
	GCTGACCTCC TCTTTCTTGT CACTCTTCCC TTGTGGGCGA TTGCTGCTGC TGACCAGTGG	300
	AAGTTCCAGA CTTTCATGTG CAAGGTGGTC AACAGCATGT ACAAGATGAA CTTCTACAGC	360
	TGTGTGTTGC T3ATCATGTG CATCAGCGTG GACAGGTACA TTGCCATTGC CCAGGCCATG	420
	AGAGCACATA CTTGGAGGGA GAAAAGGCTT TTGTACAGCA AAATGGTTTG CTTTACCATC	480
15	TGGGTATTGG CAGCTGCTCT CTGCATCCCA GAAATCTTAT ACAGCCAAAT CAAGGAGGAA	540
	TCCGGCATTG CTATCTGCAC CATGGTTTAC CCTAGCGATG AGAGTACCAA ACTGAAGTCA	600
	GCTGTCTTGA CCTTGAAGGT CATCTGGGG TTCTTCTTC CCTTCGTGGT CATGCTTGC	660
	TGCTATACCA T3ATCATTCA CACCCTGATA CAAGCCAAGA AGTCTTCCAA GCACAAAGCT	720
	CTAAAAGTGA CCATCACTGT CCTGACCGTC TTGTCTTGT CTCAGTTTCC CTACAACCTG	780
20	ATTTTGTGG T3CAGACCAT TGACGCCTAT G3CATGTCA TCTCCAACTG TGCCGTTTCC	840
	ACCAACATTG ACATCTGCTT CCAGGTCACC CAGACCATCG CCTTCTTCCA CAGTTGCCTG	900
	AACCCGTGTC TCTATGTTTT TGTGGGTGAG AGATTCCGCG GGGATCTCGT GAAAACCCCTG	960
	AAGAACTTGG GTTGCAATCAG CCAGGCCAG TGGGTTTCAT TTACAAGGAG AGAGGGAAGC	1020
	TTGAAGCTGT G3TCTATCTT GCTGGAGACA ACCTCAGGAG CACTCTCCCT CTGA	1074

25 (25) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 357 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

30

(ii) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:24:

	Met	Ala	Asp	Asp	Tyr	Gly	Ser	Glu	Ser	Thr	Ser	Ser	Met	Glu	Asp	Tyr	
	1				5					10					15		
5	Val	Asn	Phe	Asn	Phe	Thr	Asp	Phe	Tyr	Cys	Glu	Lys	Asn	Asn	Val	Arg	
				20					25					30			
	Gln	Phe	Ala	Ser	His	Phe	Leu	Pro	Pro	Leu	Tyr	Trp	Leu	Val	Phe	Ile	
			35					40					45				
	Val	Gly	Ala	Leu	Gly	Asn	Ser	Leu	Val	Ile	Leu	Val	Tyr	Trp	Tyr	Cys	
		50				55						60					
10	Thr	Arg	Val	Lys	Thr	Met	Thr	Asp	Met	Phe	Leu	Leu	Asn	Leu	Ala	Ile	
	65					70					75					80	
	Ala	Asp	Leu	Leu	Phe	Leu	Val	Thr	Leu	Pro	Phe	Trp	Ala	Ile	Ala	Ala	
					85					90					95		
15	Ala	Asp	Gln	Trp	Lys	Phe	Gln	Thr	Phe	Met	Cys	Lys	Val	Val	Asn	Ser	
				100					105					110			
	Met	Tyr	Lys	Met	Asn	Phe	Tyr	Ser	Cys	Val	Leu	Leu	Ile	Met	Cys	Ile	
			115					120						125			
	Ser	Val	Asp	Arg	Tyr	Ile	Ala	Ile	Ala	Gln	Ala	Met	Arg	Ala	His	Thr	
			130				135						140				
20	Trp	Arg	Glu	Lys	Arg	Leu	Leu	Tyr	Ser	Lys	Met	Val	Cys	Phe	Thr	Ile	
	145					150					155					160	
	Trp	Val	Leu	Ala	Ala	Ala	Leu	Cys	Ile	Pro	Glu	Ile	Leu	Tyr	Ser	Gln	
					165					170					175		
25	Ile	Lys	Glu	Glu	Ser	Gly	Ile	Ala	Ile	Cys	Thr	Met	Val	Tyr	Pro	Ser	
				180					185					190			
	Asp	Glu	Ser	Thr	Lys	Leu	Lys	Ser	Ala	Val	Leu	Thr	Leu	Lys	Val	Ile	
			195					200					205				
	Leu	Gly	Phe	Phe	Leu	Pro	Phe	Val	Val	Met	Ala	Cys	Cys	Tyr	Thr	Ile	
		210					215					220					
30	Ile	Ile	His	Thr	Leu	Ile	Gln	Ala	Lys	Lys	Ser	Ser	Lys	His	Lys	Ala	
	225					230					235					240	
	Leu	Lys	Val	Thr	Ile	Thr	Val	Leu	Thr	Val	Phe	Val	Leu	Ser	Gln	Phe	
				245						250					255		
35	Pro	Tyr	Asn	Cys	Ile	Leu	Leu	Val	Gln	Thr	Ile	Asp	Ala	Tyr	Ala	Met	
				260					265						270		
	Phe	Ile	Ser	Asn	Cys	Ala	Val	Ser	Thr	Asn	Ile	Asp	Ile	Cys	Phe	Gln	
				275					280					285			

20

Val Thr Gln Thr Ile Ala Phe Phe His Ser Cys Leu Asn Pro Val Leu
 290 295 300

Tyr Val Phe Val Gly Glu Arg Phe Arg Arg Asp Leu Val Lys Thr Leu
 305 310 315 320

5 Lys Asn Leu Gly Cys Ile Ser Gln Ala Gln Trp Val Ser Phe Thr Arg
 325 330 335

Arg Glu Gly Ser Leu Lys Leu Ser Ser Met Leu Leu Glu Thr Thr Ser
 340 345 350

Gly Ala Leu Ser Leu
 355

10

(26) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1110 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

ATGGCCTCAT CGACCACTCG GGGCCCCAGG GTTCTGAET TATTTTCTCG GCTGCCGCCG 60

20 GCGGTCAAA CTCCCGCAA CCAGAGCGCA GAGGCCTCG CGGCAACGG GTCGGTGGCT 120

GGCGCGGAG CTCCAGCCGT CACGCTCTC CAGAGCTGC AGCTGGTGCA TCAGCTGAAG 180

GGGCTGATCG TGCTGCTCTA CAGCTCTG TGCTGCTGG CGCTGGTGG CAACTGCCTG 240

CTGGTGCTGG TGATCGCGCG GGTGCGCGCG CTGCACAAAG TGACGAACCT CCTCATCGGC 300

AACCTGGCCT TGTCGGACCT GCTCATGTGC ACCGCCTGCG TGCCGCTCAC GCTGGCCTAT 360

25 GCCTTCGAGC CACGCGGCTG GGTGTTCTGG GCGGCCTGT GCCACTGGT CTTCTTCCTG 420

CAGCCGGTCA CCGTCTATCT GTCGGTGTTC ACGCTACCA CCATCGCAGT GGACCGCTAC 480

GTGCTGCTGG TGCACCCGCT GAGGCGCGCA TCTCGCTGG CCTCAGCCTA CGCTGTGCTG 540

GCCATCTGGG CGCTGTCCGC GGTGTGGGCG CTGCCGCCCG CCGTGACAC CTATCACGTG 600

GAGCTCAAGC CGCACGACGT GCGCTCTGCG GAGGAGTTCT GGGGCTCCCA GGAGCGCCAG 660

30 CGCCAGCTCT ACGCCTGGGG GCTGCTGCTG GTCACCTAG TGCTCCCTCT GCTGGTCATC 720

CTCCTGTCTT ACGTCCGGGT GTCAGTGAAG CTCCGCAACC GCGTGGTGCC GGGCTGCGTG 780

ACCCAGAGCC AGGCCGACTG GGACCGCGCT CGGCGCCGGG GCACCTTCTG CTTGCTGGTG 840

21

GTGGTCGTGG TGGTGTTCGC CTTCTGCTGG CTGCCGCTGC ACGTCTTCAA CCTGCTGCGG 900
 GACCTCGACC CCCACGCCAT CGACCCITAC GCCTTTGGGC TGGTGCAGCT GCTCTGCCAC 960
 TGGCTCGCCA TGAGTTCGGC CTGCTACAAC CCCTTCATCT ACCCTGGCT GCACGACAGC 1020
 TTCCGCGAGG AGCTGCGCAA ACTGTTGGTC GCTTGGCCCC GCAAGATAGC CCCCCATGCC 1080
 5 CAGAATATGA CCGTCAGCGT GGTTCATCTGA 1110

(27) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 359 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

15	Met	Ala	Ser	Ser	Thr	Thr	Arg	Gly	Pro	Arg	Val	Ser	Asp	Leu	Phe	Ser	1	5	10	15
	Gly	Leu	Pro	Pro	Ala	Val	Thr	Thr	Pro	Ala	Asn	Gln	Ser	Ala	Glu	Ala	20	25	30	
	Ser	Ala	Gly	Asn	Gly	Ser	Val	Ala	Gly	Ala	Asp	Ala	Pro	Ala	Val	Thr	35	40	45	
20	Pro	Phe	Gln	Ser	Leu	Gln	Leu	Val	His	Gln	Leu	Lys	Gly	Leu	Ile	Val	50	55	60	
	Leu	Leu	Tyr	Ser	Val	Val	Val	Val	Val	Gly	Leu	Val	Gly	Asn	Cys	Leu	65	70	75	80
25	Leu	Val	Leu	Val	Ile	Ala	Arg	Val	Pro	Arg	Leu	His	Asn	Val	Thr	Asn	85	90	95	
	Phe	Leu	Ile	Gly	Asn	Leu	Ala	Leu	Ser	Asp	Val	Leu	Met	Cys	Thr	Ala	100	105	110	
	Cys	Val	Pro	Leu	Thr	Leu	Ala	Tyr	Ala	Phe	Glu	Pro	Arg	Gly	Trp	Val	115	120	125	
30	Phe	Gly	Gly	Gly	Leu	Cys	His	Leu	Val	Phe	Phe	Leu	Gln	Pro	Val	Thr	130	135	140	
	Val	Tyr	Val	Ser	Val	Phe	Thr	Leu	Thr	Thr	Ile	Ala	Val	Asp	Arg	Tyr	145	150	155	160
35	Val	Val	Leu	Val	His	Pro	Leu	Arg	Arg	Ala	Ser	Arg	Cys	Ala	Ser	Ala	165	170	175	

22

Tyr Ala Val Leu Ala Ile Trp Ala Leu Ser Ala Val Leu Ala Leu Pro
 180 185 190
 Pro Ala Val His Thr Tyr His Val Glu Leu Lys Pro His Asp Val Arg
 195 200 205
 5 Leu Cys Glu Glu Phe Trp Gly Ser Gln Glu Arg Gln Arg Gln Leu Tyr
 210 215 220
 Ala Trp Gly Leu Leu Leu Val Thr Tyr Leu Leu Pro Leu Leu Val Ile
 225 230 235 240
 10 Leu Leu Ser Tyr Val Arg Val Ser Val Lys Leu Arg Asn Arg Val Val
 245 250 255
 Pro Gly Cys Val Thr Gln Ser Gln Ala Asp Trp Asp Arg Ala Arg Arg
 260 265 270
 Arg Arg Thr Phe Cys Leu Leu Val Val Val Val Val Val Phe Ala Val
 275 280 285
 15 Cys Trp Leu Pro Leu His Val Phe Asn Leu Leu Arg Asp Leu Asp Pro
 290 295 300
 His Ala Ile Asp Pro Tyr Ala Phe Gly Leu Val Gln Leu Leu Cys His
 305 310 315 320
 20 Trp Leu Ala Met Ser Ser Ala Cys Tyr Asn Pro Phe Ile Tyr Ala Trp
 325 330 335
 Leu His Asp Ser Phe Arg Glu Glu Leu Arg Lys Leu Leu Val Ala Trp
 340 345 350
 Pro Arg Lys Ile Ala Pro His Gly Gln Asn Met Thr Val Ser Val Val
 355 360 365
 25 Ile

(28) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1083 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 30
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
 35 ATGGACCCAG AAGAAACTTC AGTTTATTG GATTATTACT ATGCTACGAG CCCAACTCT 60
 GACATCAGGG AGACCCACTC CCATGTTCTT TACACCTCTG TCTTCCTTCC AGTCTTTTAC 120

ACAGCTGTGT TCCTGACTGG AGTGCTGGGG AACCTTGTTT TCATGGGAGC GTTGCATTTC 180
 AAACCCGGCA GCCGAAGACT GATCGACATC TTTATCATCA ATCTGGCTGC CTCGACTTC 240
 ATTTTCTTTS TCACATTGCC TCTCTGSETG GATAAAGAAG CATCTCTAGS ACTGTGGAGS 300
 ACGGGCTCCT TCCTGTGCAA AGGGAGCTCC TACATGATCT CCGTGAATAT GCACTGCACT 360
 5 GTCTCTCTGC TCACTTGCAT GAGTGTGAC CGCTACCTGG CCATTGTGTG GGCAGTCGTA 420
 TCCAGGAAAT TCAGAAGGAC AGACTGTGCA TATGTAGTCT GTGCCAGCAT CTGTTTATC 480
 TCCTGCCTGC TGGGGTTGCC TACTCTCTG TCCAGGGAGC TCACGCTGAT TGATGATAAG 540
 CCATACTGTG CAGAGAAAAA GGCAACTCA ATTAAGTCA TATGGTCCCT GGTGGCCTTA 600
 ATTTTCACCT TTTTGTCCC TTGTTGAGC ATTGTGACCT GCTACTGTG CATGCAAGG 660
 10 AAGCTGTGTG CCCATTACCA GCAATCAGGA AAGCACAACA AAAAGCTGAA GAAATCTATA 720
 AAGATCATCT TTATTGTCGT GGCAGCCTTT CTGTCTCCT GGCTGCCCTT CAATACCTTC 780
 AAGTCTCTGG CCATTGTCTC TGGGTTGCGG CAAGAACACT ATTTACCTTC AGCTATTCTT 840
 CAGCTTGTA TGGAGGTGAG TGGACCCTTG GCATTTGCCA ACAGTGTGT CAACCTTTC 900
 ATTTACTATA TCTTCGACAG CTACATCCGC CGGGCCATTG TCCATTGTT GTGCCCTTGC 960
 15 CTGAAAAACT ATGACTTTGG GAGTAGCACT GAGACATCAG ATAGTCACCT CACTAAGGCT 1020
 CTCTCCACCT TCATTATGC AGAAGATTTT GCCAGGAGSA GGAAGAGGTG TGTGTCACTC 1080
 TAA 1083

(29) INFORMATION FOR SEQ ID NO:28:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 360 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

- 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Met Asp Pro Glu Glu Thr Ser Val Tyr Leu Asp Tyr Tyr Tyr Ala Thr
 1 5 10 15
 Ser Pro Asn Ser Asp Ile Arg Glu Thr His Ser His Val Pro Tyr Thr
 20 25 30
 30 Ser Val Phe Leu Pro Val Phe Tyr Thr Ala Val Phe Leu Thr Gly Val
 35 40 45

24

Leu Gly Asn Leu Val Leu Met Gly Ala Leu His Phe Lys Pro Gly Ser
 50 55 60

Arg Arg Leu Ile Asp Ile Phe Ile Ile Asn Leu Ala Ala Ser Asp Phe
 65 70 75 80

5 Ile Phe Leu Val Thr Leu Pro Leu Trp Val Asp Lys Glu Ala Ser Leu
 85 90 95

Gly Leu Trp Arg Thr Gly Ser Phe Leu Cys Lys Gly Ser Ser Tyr Met
 100 105 110

10 Ile Ser Val Asn Met His Cys Ser Val Leu Leu Leu Thr Cys Met Ser
 115 120 125

Val Asp Arg Tyr Leu Ala Ile Val Trp Pro Val Val Ser Arg Lys Phe
 130 135 140

Arg Arg Thr Asp Cys Ala Tyr Val Val Cys Ala Ser Ile Trp Phe Ile
 145 150 155 160

15 Ser Cys Leu Leu Gly Leu Pro Thr Leu Leu Ser Arg Glu Leu Thr Leu
 165 170 175

Ile Asp Asp Lys Pro Tyr Cys Ala Glu Lys Lys Ala Thr Pro Ile Lys
 180 185 190

20 Leu Ile Trp Ser Leu Val Ala Leu Ile Phe Thr Phe Phe Val Pro Leu
 195 200 205

Leu Ser Ile Val Thr Cys Tyr Cys Cys Ile Ala Arg Lys Leu Cys Ala
 210 215 220

His Tyr Gln Gln Ser Gly Lys His Asn Lys Lys Leu Lys Lys Ser Ile
 225 230 235 240

25 Lys Ile Ile Phe Ile Val Val Ala Ala Phe Leu Val Ser Trp Leu Pro
 245 250 255

Phe Asn Thr Phe Lys Phe Leu Ala Ile Val Ser Gly Leu Arg Gln Glu
 260 265 270

30 His Tyr Leu Pro Ser Ala Ile Leu Gln Leu Gly Met Glu Val Ser Gly
 275 280 285

Pro Leu Ala Phe Ala Asn Ser Cys Val Asn Pro Phe Ile Tyr Tyr Ile
 290 295 300

Phe Asp Ser Tyr Ile Arg Arg Ala Ile Val His Cys Leu Cys Pro Cys
 305 310 315 320

35 Leu Lys Asn Tyr Asp Phe Gly Ser Ser Thr Glu Thr Ser Asp Ser His
 325 330 335

Leu Thr Lys Ala Leu Ser Thr Phe Ile His Ala Glu Asp Phe Ala Arg

25

340

345

350

Arg Arg Lys Arg Ser Val Ser Leu
355 360

(30) INFORMATION FOR SEQ ID NO:29:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- 10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CTAGAATTCT GACTCCAGCC AAAGCATGAA T 31

(31) INFORMATION FOR SEQ ID NO:30:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GCTGGATCCT AAACAGTCTG CGCTCGGCCT 30

(32) INFORMATION FOR SEQ ID NO:31:

- 25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1020 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

- 30 ATGAATGGCC TTGAAGTGGC TCCCCAGGT CTGATCACCA ACTTCTCCCT GGCCACGGCA 60
GAGCAATGTG GCCAGGAGAC GCCACTGGAG AACATGCTGT TCGCCTCCTT CTACCTTCTG 120
GATTTTATCC TGGCTTTAGT TGGCAATACC CTGGCTCTGT GGCTTTTCAT CCGAGACCAC 180
AAGTCCGGGA CCCC GGCCAA CGTGTTCCTG ATGCATCTGG CCGTGGCCGA CTGTCTGTGC 240
GTGCTGGTCC TGCCACCCG CCTGGTCTAC CACTTCTCTG GGAACCACTG GCCATTGCGG 300

GAAATCGCAT GCCGTCTCAC CGGCTTCCTC TTCTACCTCA ACATGTACGC CAGCATCTAC 360
 TTCCTCACCT GCATCAGGCG CGACCGTTTC CTGGCCATTG TGCACCCGGT CAAGTCCCTC 420
 AAGCTCCGCA GGGCCCTCTA CGCACACCTG GCCTGTGCCT TCCTGTGGGT GGTGGTGGCT 480
 GTGGCCATGG CCCCGCTGCT GGTGAGCCCA CAGACCGTGC A3ACCAACCA CACGGTGGTC 540
 5 TGCCTGCAGC TGTACCGGGA GAAGGCCTCC CACCATGCCC TGGTGTCCCT GGCAGTGGCC 600
 TTCACCTTCC CGTTCATCAC CACGGTCACC TGCTACCTGC TGATCATCCG CAGCCTGCGG 660
 CAGGGCCTGC GTGTGGAGAA GCGCCTCAAG ACCAAGGCAG TSCGCATGAT CGCCATAGTG 720
 CTGGCCATCT TCCTGGTCTG CTCCTGCGCC TACCACGTCA ACCGCTCCGT CTACGTGCTG 780
 CACTACCGCA GCCATGGGGC CTCCTGCGCC ACCCAGCGCA TCCTGGCCCT GGCAAACCGC 840
 10 ATCACCTCCT GCCTCACCAG CCTCAACGGG GCACTCGACC CCATCATGTA TTTCTTCGTG 900
 GCTGAGAAGT TCCGCCACGC CCGTGCAAC TTGCTCTGTG GCAAAAGGCT CAAGGGCCCCG 960
 CCCCCAGCT TCGAAGGGAA AACCAACGAG AGCTCGCTGA GTGCCAAGTC AGAGCTGTGA 1020

(33) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
 15 (A) LENGTH: 339 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant
 (ii) MOLECULE TYPE: protein
 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32.
 Met Asn Gly Leu Glu Val Ala Pro Pro Gly Leu Ile Thr Asn Phe Ser
 1 5 10 15
 Leu Ala Thr Ala Glu Gln Cys Gly Gln Glu Thr Pro Leu Glu Asn Met
 20 25 30
 25 Leu Phe Ala Ser Phe Tyr Leu Leu Asp Phe Ile Leu Ala Leu Val Gly
 35 40 45
 Asn Thr Leu Ala Leu Trp Leu Phe Ile Arg Asp His Lys Ser Gly Thr
 50 55 60
 30 Pro Ala Asn Val Phe Leu Met His Leu Ala Val Ala Asp Leu Ser Cys
 65 70 75 80
 Val Leu Val Leu Pro Thr Arg Leu Val Tyr His Phe Ser Gly Asn His
 85 90 95
 Trp Pro Phe Gly Glu Ile Ala Cys Arg Leu Thr Gly Phe Leu Phe Tyr

27

	100	105	110
	Leu Asn Met Tyr Ala Ser Ile Tyr Phe Leu Thr Cys Ile Ser Ala Asp		
	115	120	125
5	Arg Phe Leu Ala Ile Val His Pro Val Lys Ser Leu Lys Leu Arg Arg		
	130	135	140
	Pro Leu Tyr Ala His Leu Ala Cys Ala Phe Leu Trp Val Val Val Ala		
	145	150	155 160
	Val Ala Met Ala Pro Leu Leu Val Ser Pro Gln Thr Val Gln Thr Asn		
	165	170	175
10	His Thr Val Val Cys Leu Gln Leu Tyr Arg Glu Lys Ala Ser His His		
	180	185	190
	Ala Leu Val Ser Leu Ala Val Ala Phe Thr Phe Pro Phe Ile Thr Thr		
	195	200	205
15	Val Thr Cys Tyr Leu Leu Ile Ile Arg Ser Leu Arg Gln Gly Leu Arg		
	210	215	220
	Val Glu Lys Arg Leu Lys Thr Lys Ala Val Arg Met Ile Ala Ile Val		
	225	230	235 240
	Leu Ala Ile Phe Leu Val Cys Phe Val Pro Tyr His Val Asn Arg Ser		
	245	250	255
20	Val Tyr Val Leu His Tyr Arg Ser His Gly Ala Ser Cys Ala Thr Gln		
	260	265	270
	Arg Ile Leu Ala Leu Ala Asn Arg Ile Thr Ser Cys Leu Thr Ser Leu		
	275	280	285
25	Asn Gly Ala Leu Asp Pro Ile Met Tyr Phe Phe Val Ala Glu Lys Phe		
	290	295	300
	Arg His Ala Leu Cys Asn Leu Leu Cys Gly Lys Arg Leu Lys Gly Pro		
	305	310	315 320
	Pro Pro Ser Phe Glu Gly Lys Thr Asn Glu Ser Ser Leu Ser Ala Lys		
	325	330	335
30	Ser Glu Leu		

(34) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

ATAAGATGAT CACCCTGAAC AATCAAGAT

29

(35) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

TCCGAATTCA TAACATTTC A CTGTTTATAT TGC

33

(36) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 996 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

20 ATGATCACCC TGAACAATCA AGATCAACCT GTCACCTTTTA ACAGCTCACA TCCAGATGAA 60
TACAAAATTG CAGCCCTTGT CTTCTATAGC TGTATCTTCA TAATTGGATT ATTTGTTAAC 120
ATCACTGCAT TATGGGTTTT CAGTTGTACC ACCAAGAAGA GAACCACGGT AACCATCTAT 180
ATGATGAAATG TGGCATTAGT GGAATTGATA TTTATAATGA CTTTACCCTT TCGAATGTTT 240
TATTATGCAA AAGATGCATG GCCATTGGA GAGTACTTCT GCCAGATTAT TGGAGCTCTC 300
25 ACAGTGTTTT ACCCAAGCAT TGCTTTATGG CTTCTTGCCT TTATTAGTGC TGACAGATAC 360
ATGGCCATTG TACAGCCGAA GTACGCCAAA GAACTTAAAA ACACGTGCAA AGCCGTGCTG 420
GCGTGTGTGG GAGTCTGGAT AATGACCCTG ACCACGACCA CCCCTCTGCT ACTGCTCTAT 480
AAAGACCCAG ATAAAGACTC CACTCCCGCC ACCTGCCTCA AGATTTCTGA CATCATCTAT 540
CTAAAAGCTG TGAACGTGCT GAACCTCACT CGACTGACAT TTTTTTCTT GATTCCTTTG 600
30 TTCATCATGA TTGGGTGCTA CTTGGTCATT ATTCTAATC TCCTTCACGG CAGGACGTCT 660
AAGCTGAAAC CCAAAGTCAA GGAGAAGTCC ATAAGGATCA TCATCACGCT GCTGGTGCAG 720

GTGCTCGTCT GCTTTATGCC CTTCACATC TGTTCGCTT TCCTGATGCT GGGAACGGGG 780
 GAGAACAGTT ACAATCCCTG GGGAGCCTTT ACCACCTTCC TCATGAACCT CAGCACGTGT 840
 CTGGATGTGA TTCTCTACTA CATCGTTTCA AAACAATTTC AGGCTCGAGT CATTAGTGTC 900
 ATGCTATACC GTAATTACCT TCGAAGCCTG CGCAGAAAAA GTTCCGATC TGGTAGTCTA 960
 5 AGGTCATAA GCAATATAAA CAGTGAAATG TTATGA 996

(37) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 331 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

15 Met Ile Thr Leu Asn Asn Gln Asp Gln Pro Val Thr Phe Asn Ser Ser
 1 5 10 15
 His Pro Asp Glu Tyr Lys Ile Ala Ala Leu Val Phe Tyr Ser Cys Ile
 20 25 30
 Phe Ile Ile Gly Leu Phe Val Asn Ile Thr Ala Leu Trp Val Phe Ser
 35 40 45
 20 Cys Thr Thr Lys Lys Arg Thr Thr Val Thr Ile Tyr Met Met Asn Val
 50 55 60
 Ala Leu Val Asp Leu Ile Phe Ile Met Thr Leu Pro Phe Arg Met Phe
 65 70 75 80
 25 Tyr Tyr Ala Lys Asp Ala Trp Pro Phe Gly Glu Tyr Phe Cys Gln Ile
 85 90 95
 Ile Gly Ala Leu Thr Val Phe Tyr Pro Ser Ile Ala Leu Trp Leu Leu
 100 105 110
 Ala Phe Ile Ser Ala Asp Arg Tyr Met Ala Ile Val Gln Pro Lys Tyr
 115 120 125
 30 Ala Lys Glu Leu Lys Asn Thr Cys Lys Ala Val Leu Ala Cys Val Gly
 130 135 140
 Val Trp Ile Met Thr Leu Thr Thr Thr Thr Pro Leu Leu Leu Tyr
 145 150 155 160
 35 Lys Asp Pro Asp Lys Asp Ser Thr Pro Ala Thr Cys Leu Lys Ile Ser
 165 170 175

30

Asp Ile Ile Tyr Leu Lys Ala Val Asn Val Leu Asn Leu Thr Arg Leu
 180 185 190
 Thr Phe Phe Phe Leu Ile Pro Leu Phe Ile Met Ile Gly Cys Tyr Leu
 195 200 205
 5 Val Ile Ile His Asn Leu Leu His Gly Arg Thr Ser Lys Leu Lys Pro
 210 215 220
 Lys Val Lys Glu Lys Ser Ile Arg Ile Ile Ile Thr Leu Leu Val Gln
 225 230 235 240
 10 Val Leu Val Cys Phe Met Pro Phe His Ile Cys Phe Ala Phe Leu Met
 245 250 255
 Leu Gly Thr Gly Glu Asn Ser Tyr Asn Pro Trp Gly Ala Phe Thr Thr
 260 265 270
 Phe Leu Met Asn Leu Ser Thr Cys Leu Asp Val Ile Leu Tyr Tyr Ile
 275 280 285
 15 Val Ser Lys Gln Phe Gln Ala Arg Val Ile Ser Val Met Leu Tyr Arg
 290 295 300
 Asn Tyr Leu Arg Ser Leu Arg Arg Lys Ser Phe Arg Ser Gly Ser Leu
 305 310 315 320
 20 Arg Ser Leu Ser Asn Ile Asn Ser Glu Met Leu
 325 330

(38) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 28 base pairs
 (B) TYPE: nucleic acid
 25 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CCAAGCTTCC AGGCCTGGGG TGTGCTGG

28

30 (39) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 base pairs
 (B) TYPE: nucleic acid
 35 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

ATGGATCCTG ACCTTCGGCC CCTGGCAGA

29

(40) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 1077 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

10 ATGCCCTCTG TGTCTCCAGC GGGGCCCTCG GCCGGGGCAG TCCCCAATGC CACCGCAGTG 60
ACAACAGTGC GGACCAATGC CAGCGGGCTG GAGGTGCCCC TGTCCACCT GTTTGCCCGG 120
CTGGACGAGG AGCTGCATGG CACCTTCCCA GGCTGTGCG TGGCGCTGAT GGCGGTGCAC 180
GGAGCCATCT TCCTGGCAGG GCTGGTGCTC AACGGGCTGG CGCTGTACGT CTTCTGCTGC 240
CGCACCCGGG CCAAGACACC CTCAGTCATC TACACCATCA ACCTGGTGGT GACCGATCTA 300
15 CTGGTAGGGC TGTCCTGCCC CACGCGCTTC GCTGTGTACT ACGGCGCCAG GGGCTGCCTG 360
CGCTGTGCCT TCCCGCACGT CCTCGGTTAC TTCCTCAACA TGCACTGCTC CATCCTCTTC 420
CTCACTGCA TCTGCGTGA CCGCTACCTG GCCATCGTGC GGCCCGAAGG CTCCCGCCGC 480
TGCCGCCAGC CTGCCTGTGC CAGGGCCGTG TGGCCCTTCG TGTGGCTGGC CGCCGGTGCC 540
GTCAACCCTGT CGGTGCTGGG CGTGACAGGC AGCCGGCCCT GCTGCCGTGT CTTTGCGCTG 600
20 ACTGTCCTGG AGTTCCTGCT GCCCCTGCTG GTCATCAGCG TGTTTACCGG CCGCATCATG 660
TGTGCACTGT CGCGGCCGGG TCTGCTCCAC CAGGTCGCC AGCGCCCGGT GCGGGCCATG 720
CAGCTCCTGC TCACGGTGCT CATCATCTTT CTCGTCTGCT TCACGCCCTT CCACGCCCGC 780
CAAGTGCCG TGGCGCTGTG GCCCACATG CCACACCACA CGAGCCTCGT GGTCTACCAC 840
GTGGCCGTGA CCCTCAGCAG CCTCAACAGC TGCATGGACC CCATCGTCTA CTGCTTCGTC 900
25 ACCAGTGGCT TCCAGGCCAC CGTCCGAGGC CTCTTCGGCC AGCACGGAGA GCGTGAGCCC 960
AGCAGCGGTG ACGTGGTCAG CATGCACAGG AGCTCCAAGG GCTCAGGCCG TCATCACATC 1020
CTCAGTGCCG GCCCTCACGC CCTCACCCAG GCCCTGGCTA ATGGGCCCCG GGCTTAG 1077

(41) INFORMATION FOR SEQ ID NO:40:

30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 358 amino acids

(B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

	Met	Pro	Ser	Val	Ser	Pro	Ala	Gly	Pro	Ser	Ala	Gly	Ala	Val	Pro	Asn	
	1				5					10					15		
	Ala	Thr	Ala	Val	Thr	Thr	Val	Arg	Thr	Asn	Ala	Ser	Gly	Leu	Glu	Val	
				20					25					30			
10	Pro	Leu	Phe	His	Leu	Phe	Ala	Arg	Leu	Asp	Glu	Glu	Leu	His	Gly	Thr	
		35						40					45				
	Phe	Pro	Gly	Leu	Cys	Val	Ala	Leu	Met	Ala	Val	His	Gly	Ala	Ile	Phe	
		50				55					60						
	Leu	Ala	Gly	Leu	Val	Leu	Asn	Gly	Leu	Ala	Leu	Tyr	Val	Phe	Cys	Cys	
15		65				70					75				80		
	Arg	Thr	Arg	Ala	Lys	Thr	Pro	Ser	Val	Ile	Tyr	Thr	Ile	Asn	Leu	Val	
					85					90					95		
	Val	Thr	Asp	Leu	Val	Gly	Leu	Ser	Leu	Pro	Thr	Arg	Phe	Ala	Val		
				100				105					110				
20	Tyr	Tyr	Gly	Ala	Arg	Gly	Cys	Leu	Arg	Cys	Ala	Phe	Pro	His	Val	Leu	
			115					120					125				
	Gly	Tyr	Phe	Leu	Asn	Met	His	Cys	Ser	Ile	Leu	Phe	Leu	Thr	Cys	Ile	
		130					135					140					
	Cys	Val	Asp	Arg	Tyr	Leu	Ala	Ile	Val	Arg	Pro	Glu	Ala	Pro	Ala	Ala	
25		145				150				155					160		
	Cys	Arg	Gln	Pro	Ala	Cys	Ala	Arg	Ala	Val	Cys	Ala	Phe	Val	Trp	Leu	
				165						170					175		
	Ala	Ala	Gly	Ala	Val	Thr	Leu	Ser	Val	Leu	Gly	Val	Thr	Gly	Ser	Arg	
				180					185					190			
30	Pro	Cys	Cys	Arg	Val	Phe	Ala	Leu	Thr	Val	Leu	Glu	Phe	Leu	Leu	Pro	
			195					200					205				
	Leu	Leu	Val	Ile	Ser	Val	Phe	Thr	Gly	Arg	Ile	Met	Cys	Ala	Leu	Ser	
		210					215					220					
	Arg	Pro	Gly	Leu	Leu	His	Gln	Gly	Arg	Gln	Arg	Arg	Val	Arg	Ala	Met	
35		225				230				235					240		
	Gln	Leu	Leu	Leu	Thr	Val	Leu	Ile	Ile	Phe	Leu	Val	Cys	Phe	Thr	Pro	
				245					250					255			

Phe His Ala Arg Gln Val Ala Val Ala Leu Trp Pro Asp Met Pro His
260 265 270

His Thr Ser Leu Val Val Tyr His Val Ala Val Thr Leu Ser Ser Leu
275 280 285

Asn Ser Cys Met Asp Pro Ile Val Tyr Cys Phe Val Thr Ser Gly Phe
290 295 300

Gln Ala Thr Val Arg Gly Leu Phe Gly Gln His Gly Glu Arg Glu Pro
305 310 315 320

10 Ser Ser Gly Asp Val Val Ser Met His Arg Ser Ser Lys Gly Ser Gly
325 330 335

Arg His His Ile Leu Ser Ala Gly Pro His Ala Leu Thr Gln Ala Leu
340 345 350

Ala Asn Gly Pro Glu Ala
355

15 (42) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

GAGAATTCAC TCCTGAGCTC AAGATGAACT

30

(43) INFORMATION FOR SEQ ID NO:42:

```

25      (i) SEQUENCE CHARACTERISTICS:
          (A) LENGTH: 30 base pairs
          (B) TYPE: nucleic acid
          (C) STRANDEDNESS: single
          (D) TOPOLOGY: linear

```

30 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

CGGGATCCCC GTAAGTGAGC CACTTCAGAT

30

(44) INFORMATION FOR SEQ ID NO:43:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1050 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

```
ATGAACTCCA CCTGGATGG TAATCAGAGC AGCCACCCTT TTTGCCTCTT GGCATTGGC    60
5  TATTTGAAA CTGTCAATTT TTGCCTTTTG GAAGTATTGA TTATTGTCTT TCTAACTGTA    120
   TTGATTATTT CTGGCAACAT CATTGTGATT TTTGTATTTT ACTGTGCACC TTTGTTGAAC    180
   CATCACACTA CAAGTTATTT TATCCAGACT ATGGCATATG CTGACCTTTT TGTGTTGGGTG    240
   AGCTGCGTGG TCCCTTCTTT ATCACTCCTC CATCACCCCC TTCCAGTAGA GGAGTCCTTG    300
   ACTGCCAGA TATTTGGTTT TGTAGTATCA GTTCTGAAGA GCGTCTCCAT GGCTTCTCTG    360
10 GCCTGTATCA GCATTGATAG ATACATTGCC ATTACTAAAC CTTTAACCTA TAATACTCTG    420
   GTTACACCCT GGAGACTACG CCTGTGTATT TTCCTGATTT GGCTATACTC GACCCTGGTC    480
   TTCCTGCCTT CCTTTTCCA CTGGGGCAA CCTGGATATC ATGGAGATGT GTTTCAGTGG    540
   TGTGCGGAGT CCTGGCACAC CGACTCCTAC TTCACCCTGT TCATCSTGAT GATGTTATAT    600
   GCCCCAGCAG CCCTTATGT CTGCTTCACC TATTCAACA TCTCCGCAT CTGCCAACAG    660
15 CACACAAAGG ATATCAGCGA AAGGCAAGCC CGCTTCAGCA GCCAGAGTGG GGAGACTGGG    720
   GAAGTGCAGG CCTGTCCTGA TAAGCGCTAT GCCATGGTCC TGTTCGAAT CACTAGTGTA    780
   TTTTACATCC TCTGGTTGCC ATATATCATC TACTTCTTGT TGGAAAGCTC CACTGGCCAC    840
   AGCAACCGCT TCGCATCCTT CTTGACCACC TGGCTTGCTA TTAGTAACAG TTTCTGCAAC    900
   TGTGTAATTT ATAGTCTCTC CAACAGTGTA TTCCAAAGAG GACTAAAGCG CCTCTCAGGG    960
20 GCTATGTGTA CTTCTTGTGC AAGTCAGACT ACAGCCAACG ACCCTTACAC AGTTAGAAGC   1020
   AAAGGCCCTC TTAATGGATG TCATATCTGA                               1050
```

(45) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:
25 (A) LENGTH: 349 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

30 Met Asn Ser Thr Leu Asp Gly Asn Gln Ser Ser His Pro Phe Cys Leu

35

	1	5	10	15
	Leu	Ala Phe Gly Tyr	Leu Glu Thr Val	Asn Phe Cys Leu Leu Glu Val
		20	25	30
5	Leu Ile Ile Val	Phe Leu Thr Val	Leu Ile Ile Ser	Gly Asn Ile Ile
	35	40	45	
	Val Ile Phe Val	Phe His Cys Ala	Pro Leu Leu Asn	His His Thr Thr
	50	55	60	
	Ser Tyr Phe Ile	Gln Thr Met Ala	Tyr Ala Asp	Leu Phe Val Gly Val
	65	70	75	80
10	Ser Cys Val Val	Pro Ser Leu Ser	Leu Leu His His	Pro Leu Pro Val
		85	90	95
	Glu Glu Ser Leu	Thr Cys Gln Ile	Phe Gly Phe Val	Val Ser Val Leu
		100	105	110
15	Lys Ser Val Ser	Met Ala Ser Leu	Ala Cys Ile Ser	Ile Asp Arg Tyr
	115	120	125	
	Ile Ala Ile Thr	Lys Pro Leu Thr	Tyr Asn Thr Leu	Val Thr Pro Trp
	130	135	140	
	Arg Leu Arg Leu	Cys Ile Phe Leu	Ile Trp Leu Tyr	Ser Thr Leu Val
	145	150	155	160
20	Phe Leu Pro Ser	Phe Phe His Trp	Gly Lys Pro Gly	Tyr His Gly Asp
		165	170	175
	Val Phe Gln Trp	Cys Ala Glu Ser	Trp His Thr Asp	Ser Tyr Phe Thr
		180	185	190
25	Leu Phe Ile Val	Met Met Leu Tyr	Ala Pro Ala Ala	Leu Ile Val Cys
	195	200	205	
	Phe Thr Tyr Phe	Asn Ile Phe Arg	Ile Cys Gln Gln	His Thr Lys Asp
	210	215	220	
	Ile Ser Glu Arg	Gln Ala Arg Phe	Ser Ser Gln Ser	Gly Glu Thr Gly
	225	230	235	240
30	Glu Val Gln Ala	Cys Pro Asp Lys	Arg Tyr Ala Met	Val Leu Phe Arg
		245	250	255
	Ile Thr Ser Val	Phe Tyr Ile Leu	Trp Leu Pro Tyr	Ile Ile Tyr Phe
		260	265	270
35	Leu Leu Glu Ser	Ser Thr Gly His	Ser Asn Arg Phe	Ala Ser Phe Leu
	275	280	285	
	Thr Thr Trp Leu	Ala Ile Ser Asn	Ser Phe Cys Asn	Cys Val Ile Tyr
	290	295	300	

36

Ser Leu Ser Asn Ser Val Phe Gln Arg Gly Leu Lys Arg Leu Ser Gly
305 310 315 320

Ala Met Cys Thr Ser Cys Ala Ser Gln Thr Thr Ala Asn Asp Pro Tyr
325 330 335

5 Thr Val Arg Ser Lys Gly Pro Leu Asn Gly Cys His Ile
340 345

(46) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
10 (A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

15 TCCCCCGGGA AAAAAACCAA CTGCTCCAAA 30

(47) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:
20 (A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

TAGGATCCAT TTGAATGTGG ATTTGGTGAA A 31

25 (48) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:
30 (A) LENGTH: 1302 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

ATGTGTTTTT CTCCCATTCT GGAAATCAAC ATGCAGTCTG AATCTAACAT TACAGTGCGA 60
GATGACATTG ATGACATCAA CACCAATATG TACCAACCAC TATCATATCC GTTAAGCTTT 120
35 CAAGTGTCTC TCACCGGATT TCTTATGTTA GAAATTGTGT TGGGACTTGG CAGCAACCTC 180

ACTGTATTGG TACTTTACTG CATGAAATCC AACTTAATCA ACTCTGTCAG TAACATTATT 240
 ACAATGAATC TTCATGTACT TGATGTAATA ATTTGTGTGG GATGTATTCC TCTAACTATA 300
 GTTATCCTTC TGCTTTCAC TGGAGAGTAAC ACTGCTCTCA TTTGCTGTTT CCATGAGGCT 360
 TGTGTATCTT TTGCAAGTGT CTCAACAGCA ATCAACGTTT TTGCTATCAC TTTGGACAGA 420
 5 TATGACATCT CTGTAAAACC TGCAAACCGA ATTCTGACAA TGGGCAGAGC TGTAATGTTA 480
 ATGATATCCA TTTGGATTTT TTCTTTTTC TCTTTCCTGA TTCCTTTTAT TGAGGTAAAT 540
 TTTTTCAGTC TTCAAAGTGG AAATACCTGG GAAAACAAGA CACTTTTATG TGTCAGTACA 600
 AATGAATACT ACACTGAAC TGGGAATGTAT TATCACCTGT TAGTACAGAT CCCAATATTC 660
 TTTTTCAGTC TTGTAGTAAT GTTAATCACA TACACCAAAA TACTTCAGGC TCTTAATATT 720
 10 CGAATAGGCA CAAGATTTTC AACAGGGCAG AAGAAGAAAG CAAGAAAGAA AAAGACAATT 780
 TCTCTAACCA CACAACATGA GGCTACAGAC ATGTCACAAA GCAGTGGTGG GAGAAATGTA 840
 GTCTTTGGTG TAAGAACTTC AGTTTCTGTA ATAATTGCCC TCCGGCGAGC TGTGAAACGA 900
 CACCGTGAAC GACGAGAAAG ACAAAGAGA GTCTTCAGGA TGTCTTTATT GATTATTTCT 960
 ACATTTCTTC TCTGCTGGAC ACCAATTCT GTTTTAAATA CCACCATTTT ATGTTTAGGC 1020
 15 CCAAGTGACC TTTTAGTAAA ATTAAGATTG TGTTTTTTAG TCATGGCTTA TGGAACAAC T 1080
 ATATTTTACC CTCTATTATA TGCATTCAC T AGACAAAAAT TTCAAAGGT CTTGAAAAGT 1140
 AAAATGAAAA AGCGAGTTGT TTCTATAGTA GAAGCTGATC CCCTGCCTAA TAATGCTGTA 1200
 ATACACAAC CTTGGATAGA TCCCAAAAGA AACAAAAAAA TTACCTTTGA AGATAGTGAA 1260
 ATAAGAGAAA AACGTTTAGT GCCTCAGGT GTCACAGACT AG 1302

20 (49) INFORMATION FOR SEQ ID NO:48:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 433 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 25 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Met Cys Phe Ser Pro Ile Leu Glu Ile Asn Met Gln Ser Glu Ser Asn
 1 5 10 15

30 Ile Thr Val Arg Asp Asp Ile Asp Asp Ile Asn Thr Asn Met Tyr Gln
 20 25 30

Pro Leu Ser Tyr Pro Leu Ser Phe Gln Val Ser Leu Thr Gly Phe Leu
 35 40 45
 Met Leu Glu Ile Val Leu Gly Leu Gly Ser Asn Leu Thr Val Leu Val
 50 55 60
 5 Leu Tyr Cys Met Lys Ser Asn Leu Ile Asn Ser Val Ser Asn Ile Ile
 65 70 75 80
 Thr Met Asn Leu His Val Leu Asp Val Ile Ile Cys Val Gly Cys Ile
 85 90 95
 10 Pro Leu Thr Ile Val Ile Leu Leu Leu Ser Leu Glu Ser Asn Thr Ala
 100 105 110
 Leu Ile Cys Cys Phe His Glu Ala Cys Val Ser Phe Ala Ser Val Ser
 115 120 125
 Thr Ala Ile Asn Val Phe Ala Ile Thr Leu Asp Arg Tyr Asp Ile Ser
 130 135 140
 15 Val Lys Pro Ala Asn Arg Ile Leu Thr Met Gly Arg Ala Val Met Leu
 145 150 155 160
 Met Ile Ser Ile Trp Ile Phe Ser Phe Phe Ser Phe Leu Ile Pro Phe
 165 170 175
 20 Ile Glu Val Asn Phe Phe Ser Leu Gln Ser Gly Asn Thr Trp Glu Asn
 180 185 190
 Lys Thr Leu Leu Cys Val Ser Thr Asn Glu Tyr Tyr Thr Glu Leu Gly
 195 200 205
 Met Tyr Tyr His Leu Leu Val Gln Ile Pro Ile Phe Phe Phe Thr Val
 210 215 220
 25 Val Val Met Leu Ile Thr Tyr Thr Lys Ile Leu Gln Ala Leu Asn Ile
 225 230 235 240
 Arg Ile Gly Thr Arg Phe Ser Thr Gly Gln Lys Lys Lys Ala Arg Lys
 245 250 255
 30 Lys Lys Thr Ile Ser Leu Thr Thr Gln His Glu Ala Thr Asp Met Ser
 260 265 270
 Gln Ser Ser Gly Gly Arg Asn Val Val Phe Gly Val Arg Thr Ser Val
 275 280 285
 Ser Val Ile Ile Ala Leu Arg Arg Ala Val Lys Arg His Arg Glu Arg
 290 295 300
 35 Arg Glu Arg Gln Lys Arg Val Phe Arg Met Ser Leu Leu Ile Ile Ser
 305 310 315 320
 Thr Phe Leu Leu Cys Trp Thr Pro Ile Ser Val Leu Asn Thr Thr Ile

325

335

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1209 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

```
ATGTTGTGTC CTTCCAAGAC AGATGGCTCA GGGCACTCTG GTAGGATTCA CCAGGAAACT    60
CATGGAGAAG GGAAAAGGGA CAAGATTAGC AACAGTGAAG GGAGGGAGAA TGGTGGGAGA    120
GGATTCCAGA TGAACGGTGG GTCGCTGGAG GCTGAGCATG CCAGCAGGAT GTCAGTTCTC    180
AGAGCAAAGC CCATGTCAA CAGCCAACGC TTGCTCCTTC TGTCCCCAGG ATCACCTCCT    240
10 CGCACGGGGA GCATCTCCTA CATCAACATC ATCATGCCTT CGGTGTTCCG CACCATCTGC    300
CTCCTGGGCA TCATCGGAA CTCCACGGTC ATCTTCGCGG TCGTGAAGAA GTCCAAGCTG    360
CACTGGTGCA ACAACGTCCC CGACATCTTC ATCATCAACC TCTCGGTAGT AGATCTCCTC    420
TTTCTCCTGG GCATGCCCTT CATGATCCAC CAGCTCATGG GCAATGGGGT GTGGCACTTT    480
GGGGAGACCA TGTGCACCCT CATCACGGCC ATGGATGCCA ATAGTCAGTT CACCAGCACC    540
15 TACATCCTGA CCGCCATGGC CATTGACCGC TACCTGGCCA CTGTCCACCC CATCTCTTCC    600
ACGAAGTTCC GGAAGCCCTC TGTGGCCACC CTGGTGATCT GCCTCCTGTG GGCCCTCTCC    660
TTCATCAGCA TCACCCCTGT GTGGCTGTAT GCCAGACTCA TCCCCTTCCC AGGAGGTGCA    720
GTGGGCTGCG GCATACGCCT GCCCAACCCA GACACTGACC TCTACTGGTT CACCCTGTAC    780
CAGTTTTTCC TGGCCTTTGC CCTGCCTTTT GTGGTCATCA CAGCCGCATA CGTGAGGATC    840
20 CTGCAGCGCA TGACGTCCTC AGTGGCCCCC GCCTCCCAGC GCAGCATCCG GCTGCGGACA    900
AAGAGGGTGA CCCGCACAGC CATCGCCATC TGTCTGGTCT TCTTTGTGTG CTGGGCACCC    960
TACTATGTGC TACAGCTGAC CCAGTTGTCC ATCAGCCGCC CGACCCCTAC CTTTGTCTAC   1020
TTATACAATG CGGCCATCAG CTTGGGCTAT GCCAACAGCT GCCTCAACCC CTTTGTGTAC   1080
ATCGTGCTCT GTGAGACGTT CCGCAAACGC TTGGTCCTGT CGGTGAAGCC TGCAGCCCAG   1140
25 GGGCAGCTTC GCGCTGTCAG CAACGCTCAG ACGGCTGACG AGGAGAGGAC AGAAAGCAAA   1200
GGCACCTGA                                         1209
```

(53) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 402 amino acids
(B) TYPE: amino acid

30

(C) STRANDEDNESS:

(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

5	Met Leu Cys Pro Ser Lys Thr Asp Gly Ser Gly His Ser Gly Arg Ile	1	5	10	15
	His Gln Glu Thr His Gly Glu Gly Lys Arg Asp Lys Ile Ser Asn Ser	20	25	30	
10	Glu Gly Arg Glu Asn Gly Gly Arg Gly Phe Gln Met Asn Gly Gly Ser	35	40	45	
	Leu Glu Ala Glu His Ala Ser Arg Met Ser Val Leu Arg Ala Lys Pro	50	55	60	
	Met Ser Asn Ser Gln Arg Leu Leu Leu Leu Ser Pro Gly Ser Pro Pro	65	70	75	80
15	Arg Thr Gly Ser Ile Ser Tyr Ile Asn Ile Ile Met Pro Ser Val Phe	85	90	95	
	Gly Thr Ile Cys Leu Leu Gly Ile Ile Gly Asn Ser Thr Val Ile Phe	100	105	110	
20	Ala Val Val Lys Lys Ser Lys Leu His Trp Cys Asn Asn Val Pro Asp	115	120	125	
	Ile Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu Phe Leu Leu Gly	130	135	140	
	Met Pro Phe Met Ile His Gln Leu Met Gly Asn Gly Val Trp His Phe	145	150	155	160
25	Gly Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp Ala Asn Ser Gln	165	170	175	
	Phe Thr Ser Thr Tyr Ile Leu Thr Ala Met Ala Ile Asp Arg Tyr Leu	180	185	190	
30	Ala Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg Lys Pro Ser Val	195	200	205	
	Ala Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser Phe Ile Ser Ile	210	215	220	
	Thr Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe Pro Gly Gly Ala	225	230	235	240
35	Val Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr Asp Leu Tyr Trp	245	250	255	

42

Phe Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu Pro Phe Val Val
 260 265 270
 Ile Thr Ala Ala Tyr Val Arg Ile Leu Gln Arg Met Thr Ser Ser Val
 275 280 285
 5 Ala Pro Ala Ser Gln Arg Ser Ile Arg Leu Arg Thr Lys Arg Val Thr
 290 295 300
 Arg Thr Ala Ile Ala Ile Cys Leu Val Phe Phe Val Cys Trp Ala Pro
 305 310 315 320
 10 Tyr Tyr Val Leu Gln Leu Thr Gln Leu Ser Ile Ser Arg Pro Thr Leu
 325 330 335
 Thr Phe Val Tyr Leu Tyr Asn Ala Ala Ile Ser Leu Gly Tyr Ala Asn
 340 345 350
 Ser Cys Leu Asn Pro Phe Val Tyr Ile Val Leu Cys Glu Thr Phe Arg
 355 360 365
 15 Lys Arg Leu Val Leu Ser Val Lys Pro Ala Ala Gln Gly Gln Leu Arg
 370 375 380
 Ala Val Ser Asn Ala Gln Thr Ala Asp Glu Glu Arg Thr Glu Ser Lys
 385 390 395 400
 Gly Thr

20

(54) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 25 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GGCGGATCCA TGGATGTGAC TTCCCAA

27

30

(55) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 35 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

GGCGGATCCC TACACGGCAC TGCTGAA

27

(56) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1128 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

10 ATGGATGTGA CTTCCCAAGC CCGGGGCGTG GGCCTGGAGA TGTACCCAGG CACCGCGCAC 60
GCTGCGGCCC CCAACACCAC CTCCCCGAG CTCAACCTGT CCCACCCGCT CTTGGGCACC 120
GCCCTGGCCA ATGGGACAGG TGAGCTCTCG GAGCACCAGC AGTACGTGAT CGGCCTGTTC 180
CTCTCGTGCC TCTACACCAT CTTCTCTTC CCCATCGGCT TTGTGGGCAA CATCCTGATC 240
CTGGTGGTGA ACATCAGCTT CCGCGAGAAG ATGACCATCC CCGACCTGTA CTTTCATCAAC 300
15 CTGGCGGTGG CGGACCTCAT CCTGGTGGCC GACTCCCTCA TTGAGGTGTT CAACCTGCAC 360
GAGCGGTACT ACGACATCGC CGTCTGTGC ACCTTCATGT CGCTCTTCCT GCAGGTCAAC 420
ATGTACAGCA GCGTCTTCTT CTTACCTGG ATGAGCTTCG ACCGCTACAT CGCCCTGGCC 480
AGGGCCATGC GCTGCAGCCT GTTCCGCACC AAGCACCAGC CCCGGCTGAG CTGTGGCCTC 540
ATCTGGATGG CATCCGTGTC AGCCACGCTG GTGCCCTTCA CCGCCGTGCA CCTGCAGCAC 600
20 ACCGACGAGG CTGCTTCTG TTTCCGGGAT GTCCGGGAGG TGCAGTGGCT CGAGGTCACG 660
CTGGGCTTCA TCGTGCCCTT CGCCATCATC GGCCTGTGCT ACTCCCTCAT TGTCGGGTG 720
CTGGTCAGGG CGCACCAGCA CCGTGGGCTG CGGCCCGGCG GGCAGAAGGC GCTCCGCATG 780
ATCCTCGCGG TGGTGCTGGT CTTCTTCGTC TGCTGGCTGC CGGAGAACGT CTTTCATCAGC 840
GTGCACCTCC TGCAGCGGAC GCAGCCTGGG GCCGCTCCCT GCAAGCAGTC TTTCCGCCAT 900
25 GCCCCACCCC TCACGGGCCA CATTGTCAAC CTCGCCGCT TCTCCAACAG CTGCCTAAAC 960
CCCCTCATCT ACAGCTTTCT CGGGGAGACC TTCAGGGACA AGCTGAGGCT GTACATTGAG 1020
CAGAAAACAA ATTTGCCGGC CCTGAACCGC TTCTGTACG CTGCCCTGAA GGCCGTTCATT 1080
CCAGACAGCA CCGAGCAGTC GGATGTGAGG TTCAGCAGTG CCGTGTGA 1128

(57) INFORMATION FOR SEQ ID NO:56:

- 30 (i) SEQUENCE CHARACTERISTICS:

44

(A) LENGTH: 375 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

5 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

	Met	Asp	Val	Thr	Ser	Gln	Ala	Arg	Gly	Val	Gly	Leu	Glu	Met	Tyr	Pro
	1				5					10				15		
10	Gly	Thr	Ala	His	Ala	Ala	Ala	Pro	Asn	Thr	Thr	Ser	Pro	Glu	Leu	Asn
				20					25					30		
	Leu	Ser	His	Pro	Leu	Leu	Gly	Thr	Ala	Leu	Ala	Asn	Gly	Thr	Gly	Glu
			35					40					45			
	Leu	Ser	Glu	His	Gln	Gln	Tyr	Val	Ile	Gly	Leu	Phe	Leu	Ser	Cys	Leu
		50					55					60				
15	Tyr	Thr	Ile	Phe	Leu	Phe	Pro	Ile	Gly	Phe	Val	Gly	Asn	Ile	Leu	Ile
	65					70					75				80	
	Leu	Val	Val	Asn	Ile	Ser	Phe	Arg	Glu	Lys	Met	Thr	Ile	Pro	Asp	Leu
				85						90					95	
20	Tyr	Phe	Ile	Asn	Leu	Ala	Val	Ala	Asp	Leu	Ile	Leu	Val	Ala	Asp	Ser
				100					105					110		
	Leu	Ile	Glu	Val	Phe	Asn	Leu	His	Glu	Arg	Tyr	Tyr	Asp	Ile	Ala	Val
			115					120					125			
	Leu	Cys	Thr	Phe	Met	Ser	Leu	Phe	Leu	Gln	Val	Asn	Met	Tyr	Ser	Ser
		130					135					140				
25	Val	Phe	Phe	Leu	Thr	Trp	Met	Ser	Phe	Asp	Arg	Tyr	Ile	Ala	Leu	Ala
	145					150					155				160	
	Arg	Ala	Met	Arg	Cys	Ser	Leu	Phe	Arg	Thr	Lys	His	His	Ala	Arg	Leu
				165						170					175	
30	Ser	Cys	Gly	Leu	Ile	Trp	Met	Ala	Ser	Val	Ser	Ala	Thr	Leu	Val	Pro
			180					185						190		
	Phe	Thr	Ala	Val	His	Leu	Gln	His	Thr	Asp	Glu	Ala	Cys	Phe	Cys	Phe
			195				200						205			
	Ala	Asp	Val	Arg	Glu	Val	Gln	Trp	Leu	Glu	Val	Thr	Leu	Gly	Phe	Ile
		210					215					220				
35	Val	Pro	Phe	Ala	Ile	Ile	Gly	Leu	Cys	Tyr	Ser	Leu	Ile	Val	Arg	Val
	225					230				235				240		
	Leu	Val	Arg	Ala	His	Arg	His	Arg	Gly	Leu	Arg	Pro	Arg	Arg	Gln	Lys

45

	245	250	255
	Ala Leu Arg Met Ile Leu Ala Val	Val Leu Val Phe Phe Val Cys Trp	
	260	265	270
5	Leu Pro Glu Asn Val Phe Ile Ser Val His Leu Leu Gln Arg Thr Gln		
	275	280	285
	Pro Gly Ala Ala Pro Cys Lys Gln Ser Phe Arg His Ala His Pro Leu		
	290	295	300
	Thr Gly His Ile Val Asn Leu Ala Ala Phe Ser Asn Ser Cys Leu Asn		
	305	310	315
10	Pro Leu Ile Tyr Ser Phe Leu Gly Glu Thr Phe Arg Asp Lys Leu Arg		
	325	330	335
	Leu Tyr Ile Glu Gln Lys Thr Asn Leu Pro Ala Leu Asn Arg Phe Cys		
	340	345	350
15	His Ala Ala Leu Lys Ala Val Ile Pro Asp Ser Thr Glu Gln Ser Asp		
	355	360	365
	Val Arg Phe Ser Ser Ala Val		
	370	375	

(58) INFORMATION FOR SEQ ID NO:57:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 31 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

AAGGAATTCA CGGCCGGGTG ATGCCATTCC C

31

(59) INFORMATION FOR SEQ ID NO:58:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

35 GGTGGATCCA TAAACACGGG CGTTGAGGAC

30

(60) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 960 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:
- | | | |
|----|---|-----|
| | ATGCCATTCC CAAACTGCTC AGCCCCAGC ACTGTGGTGG CCACAGCTGT GGGTGTCTTG | 60 |
| | CTGGGGCTGG AGTGTGGGCT GGGTCTGCTG GGCAACGCGG TGGCGCTGTG GACCTTCCTG | 120 |
| 10 | TTCCGGGTCA GGGTGTGGAA GCCGTACGCT GTCTACCTGC TCAACCTGGC CCTGGCTGAC | 180 |
| | CTGCTGTTGG CTGCGTGCCT GCCTTCCTG GCCGCCTTCT ACCTGAGCCT CCAGGCTTGG | 240 |
| | CATCTGGGCC GTGTGGGCTG CTGGGCCCTG CGCTTCCTGC TGGACCTCAG CCGCAGCGTG | 300 |
| | GGGATGGCCT TCCTGGCCGC CGTGGCTTTG GACCGGTACC TCGTGTGGT CCACCCTCGG | 360 |
| | CTTAAGGTCA ACCTGCTGTC TCCTCAGGCG GCCCTGGGGG TCTCGGGCCT CGTCTGGCTC | 420 |
| 15 | CTGATGGTCG CCCTCACCTG CCCGGGCTTG CTCATCTCTG AGGCCGCCCA GAATCCACC | 480 |
| | AGGTGCCACA GTTTCTACTC CAGGGCAGAC GGCTCCTTCA GCATCATCTG GCAGGAAGCA | 540 |
| | CTCTCCTGCC TTCAGTTTGT CCTCCCTTT GGCCTCATCG TGTCTGCAA TGCAGGCATC | 600 |
| | ATCAGGGCTC TCCAGAAAAG ACTCCGGGAG CCTGAGAAAC AGCCCAAGCT TCAGCGGGCC | 660 |
| | CAGGCACTGG TCACCTTGGT GGTGGTGCTG TTGCTCTGT GCTTTCTGCC CTGCTTCCTG | 720 |
| 20 | GCCAGAGTCC TGATGCACAT CTCCAGAAT CTGGGAGCT GCAGGGCCCT TTGTGCAGTG | 780 |
| | GTCATACCT CGGATGTCAC GGGCAGCCTC ACCTACCTGC ACAGTGTCGT CAACCCCGTG | 840 |
| | GTATACTGCT TCTCCAGCCC CACCTTCAGG AGCTCCTATC GGAGGGTCTT CCACACCCTC | 900 |
| | CGAGGCAAAG GGCAGGCAGC AGAGCCCCCA GATTTCACC CCAGAGACTC CTATTCCTGA | 960 |
- (61) INFORMATION FOR SEQ ID NO:60:
- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 319 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- 30 (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:
- Met Pro Phe Pro Asn Cys Ser Ala Pro Ser Thr Val Val Ala Thr Ala

47

	1		5		10		15
	Val Gly Val	Leu Leu Gly	Leu Glu Cys	Gly Leu Gly	Leu Leu Gly	Asn	
		20		25		30	
5	Ala Val Ala	Leu Trp Thr	Phe Leu Phe	Arg Val Arg	Val Trp Lys	Pro	
		35		40		45	
	Tyr Ala Val	Tyr Leu Leu	Asn Leu Ala	Leu Ala Asp	Leu Leu Leu	Ala	
		50		55		60	
	Ala Cys Leu	Pro Phe Leu	Ala Ala Phe	Tyr Leu Ser	Leu Gln Ala	Trp	
		65		70		75	80
10	His Leu Gly	Arg Val Gly	Cys Trp Ala	Leu Arg Phe	Leu Leu Asp	Leu	
		85		90		95	
	Ser Arg Ser	Val Gly Met	Ala Phe Leu	Ala Ala Val	Ala Leu Asp	Arg	
		100		105		110	
15	Tyr Leu Arg	Val Val His	Pro Arg Leu	Lys Val Asn	Leu Leu Ser	Pro	
		115		120		125	
	Gln Ala Ala	Leu Gly Val	Ser Gly Leu	Val Trp Leu	Leu Met Val	Ala	
		130		135		140	
	Leu Thr Cys	Pro Gly Leu	Ile Ser Glu	Ala Ala Gln	Asn Ser Thr		
		145		150		155	160
20	Arg Cys His	Ser Phe Tyr	Ser Arg Ala	Asp Gly Ser	Phe Ser Ile	Ile	
		165		170		175	
	Trp Gln Glu	Ala Leu Ser	Cys Leu Gln	Phe Val Leu	Pro Phe Gly	Leu	
		180		185		190	
25	Ile Val Phe	Cys Asn Ala	Gly Ile Ile	Arg Ala Leu	Gln Lys Arg	Leu	
		195		200		205	
	Arg Glu Pro	Glu Lys Gln	Pro Lys Leu	Gln Arg Ala	Gln Ala Leu	Val	
		210		215		220	
	Thr Leu Val	Val Val Leu	Phe Ala Leu	Cys Phe Leu	Pro Cys Phe	Leu	
		225		230		235	240
30	Ala Arg Val	Leu Met His	Ile Phe Gln	Asn Leu Gly	Ser Cys Arg	Ala	
		245		250		255	
	Leu Cys Ala	Val Ala His	Thr Ser Asp	Val Thr Gly	Ser Leu Thr	Tyr	
		260		265		270	
35	Leu His Ser	Val Val Asn	Pro Val Val	Tyr Cys Phe	Ser Ser Pro	Thr	
		275		280		285	
	Phe Arg Ser	Ser Tyr Arg	Arg Val Phe	His Thr Leu	Arg Gly Lys	Gly	
		290		295		300	

Gln Ala Ala Glu Pro Pro Asp Phe Asn Pro Arg Asp Ser Tyr Ser
 305 310 315

(62) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1143 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

ATGGAGGAAG GTGGTGATTT TGACAACTAC TATGGGGCAG ACAACCAGTC TGAGTGTGAG 60
 TACACAGACT GGAAATCCTC GGGGGCCCTC ATCCCTGCCA TCTACATGTT GGTCTTCCTC 120
 CTGGGCACCA CGGGAAACGG TCTGGTGCTC TGGACCGTGT TTCGGAGCAG CCGGGAGAAG 180
 AGGCGCTCAG CTGATATCTT CATTGCTAGC CTGGCGGTGG CTGACCTGAC CTTCTGGGTG 240
 15 ACGCTGCCCC TGTGGGCTAC CTACACGTAC CGGGACTATG ACTGGCCCTT TGGGACCTTC 300
 TTCTGCAAGC TCAGCAGCTA CCTCATCTTC GTCAACATGT ACGCCAGCGT CTTCTGCCTC 360
 ACCGGCCTCA GCTTCGACCG CTACCTGGCC ATCGTGAGGC CAGTGCCAA TGCTCGGCTG 420
 AGGCTGCGGG TCAGCGGGG CGTGGCCACG GCAGTTCTTT GGGTGCTGGC CGCCCTCCTG 480
 GCCATGCCTG TCATGGTGTT ACGCACCACC GGGGACTTGG AGAACACCAC TAAGGTGCAG 540
 20 TGCTACATGG ACTACTCCAT GGTGGCCACT GTGAGCTCAG AGTGGGCCTG GGAGGTGGGC 600
 CTGGGGTCT CGTCCACCAC CGTGGGCTTT GTGGTGCCCT TCACCATCAT GCTGACCTGT 660
 TACTTCTTCA TCGCCCAAAC CATCGCTGGC CACTTCCGCA AGGAACGCAT CGAGGGCCTG 720
 CGGAAGCGGC GCCCGCTGCT CAGCATCATC GTGGTGCTGG TGGTGACCTT TGCCCTGTGC 780
 TGGATGCCCT ACCACCTGGT GAAGACGCTG TACATGCTGG GCAGCCTGCT GCACTGGCCC 840
 25 TGTGACTTTG ACCTCTTCCT CATGAACATC TTCCCCTACT GCACCTGCAT CAGCTACGTC 900
 AACAGCTGCC TCAACCCCTT CCTCTATGCC TTTTTCGACC CCCGCTTCCG CCAGGCCTGC 960
 ACCTCCATGC TCTGCTGTGG CCAGAGCAGG TGCGCAGGCA CCTCCCACAG CAGCAGTGGG 1020
 GAGAAGTCAG CCAGCTACTC TTCGGGGCAC AGCCAGGGGC CCGGCCCCAA CATGGGCAAG 1080
 GGTGGAGAAC AGATGCACGA GAAATCCATC CCCTACAGCC AGGAGACCCT TGTGGTTGAC 1140
 30 TAG 1143

(63) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 380 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

Met Glu Glu Gly Gly Asp Phe Asp Asn Tyr Tyr Gly Ala Asp Asn Gln
 1 5 10 15

Ser Glu Cys Glu Tyr Thr Asp Trp Lys Ser Ser Gly Ala Leu Ile Pro
 20 25 30

Ala Ile Tyr Met Leu Val Phe Leu Leu Gly Thr Thr Gly Asn Gly Leu
 35 40 45

Val Leu Trp Thr Val Phe Arg Ser Ser Arg Glu Lys Arg Arg Ser Ala
 50 55 60

Asp Ile Phe Ile Ala Ser Leu Ala Val Ala Asp Leu Thr Phe Val Val
 65 70 75 80

Thr Leu Pro Leu Trp Ala Thr Tyr Thr Tyr Arg Asp Tyr Asp Trp Pro
 85 90 95

Phe Gly Thr Phe Phe Cys Lys Leu Ser Ser Tyr Leu Ile Phe Val Asn
 100 105 110

Met Tyr Ala Ser Val Phe Cys Leu Thr Gly Leu Ser Phe Asp Arg Tyr
 115 120 125

Leu Ala Ile Val Arg Pro Val Ala Asn Ala Arg Leu Arg Leu Arg Val
 130 135 140

Ser Gly Ala Val Ala Thr Ala Val Leu Trp Val Leu Ala Ala Leu Leu
 145 150 155 160

Ala Met Pro Val Met Val Leu Arg Thr Thr Gly Asp Leu Glu Asn Thr
 165 170 175

Thr Lys Val Gln Cys Tyr Met Asp Tyr Ser Met Val Ala Thr Val Ser
 180 185 190

Ser Glu Trp Ala Trp Glu Val Gly Leu Gly Val Ser Ser Thr Thr Val
 195 200 205

Gly Phe Val Val Pro Phe Thr Ile Met Leu Thr Cys Tyr Phe Phe Ile
 210 215 220

Ala Gln Thr Ile Ala Gly His Phe Arg Lys Glu Arg Ile Glu Gly Leu

50

	225					230					235					240
	Arg	Lys	Arg	Arg	Arg	Leu	Leu	Ser	Ile	Ile	Val	Val	Leu	Val	Val	Thr
					245					250					255	
5	Phe	Ala	Leu	Cys	Trp	Met	Pro	Tyr	His	Leu	Val	Lys	Thr	Leu	Tyr	Met
				260					265					270		
	Leu	Gly	Ser	Leu	Leu	His	Trp	Pro	Cys	Asp	Phe	Asp	Leu	Phe	Leu	Met
			275					280					285			
	Asn	Ile	Phe	Pro	Tyr	Cys	Thr	Cys	Ile	Ser	Tyr	Val	Asn	Ser	Cys	Leu
		290					295					300				
10	Asn	Pro	Phe	Leu	Tyr	Ala	Phe	Phe	Asp	Pro	Arg	Phe	Arg	Gln	Ala	Cys
	305					310					315					320
	Thr	Ser	Met	Leu	Cys	Cys	Gly	Gln	Ser	Arg	Cys	Ala	Gly	Thr	Ser	His
				325						330				335		
	Ser	Ser	Ser	Gly	Glu	Lys	Ser	Ala	Ser	Tyr	Ser	Ser	Gly	His	Ser	Gln
				340					345					350		
15	Gly	Pro	Gly	Pro	Asn	Met	Gly	Lys	Gly	Gly	Glu	Gln	Met	His	Glu	Lys
		355					360						365			
	Ser	Ile	Pro	Tyr	Ser	Gln	Glu	Thr	Leu	Val	Val	Asp				
	370						375					380				

20 (64) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

TGAGAATTCT GGTGACTCAC AGCCGGCACA G

31

(65) INFORMATION FOR SEQ ID NO:64:

30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

51

GCCGGATCCA AGGAAAAGCA GCAATAAAAG G

31

(66) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1119 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

10 ATGAACTACC CGCTAACGCT GGAAATGGAC CTCGAGAAC TGGAGGACCT GTTCTGGGAA 60
CTGGACAGAT TGGACAAC TAACGACACC TCCCTGGTGG AAAATCATCT CTGCCCTGCC 120
ACAGAGGGTC CCCTCATGGC CTCCTCAAG GCCGTGTTGG TGCCCGTGGC CTACAGCCTC 180
ATCTTCCTCC TGGGCGTGAT CGGCAACGTC CTGGTGCTGG TGATCCTGGA GCGGCACCGG 240
CAGACACGCA GTTCCACGGA GACCTTCCTG TTCCACCTGG CCGTGGCCGA CCTCCTGCTG 300
15 GTCTTCATCT TGCCCTTTGC CGTGGCCGAG GGCTCTGTGG GCTGGGTCTT GGGGACCTTC 360
CTCTGCAAAA CTGTGATTGC CCTGCACAAA GTCAACTTCT ACTGCAGCAG CCTGCTCCTG 420
GCCTGCATCG CCGTGGACCG CTACCTGGCC ATTGTCCAG CCGTCCATGC CTACCGCCAC 480
CGCCGCCTCC TCTCCATCCA CATCACCTGT GGGACCATCT GGCTGCTGG CTTCCTCCTT 540
GCCTTGCCAG AGATTCTCTT CGCCAAAGTC AGCCAAGGCC ATCACAACAA CTCCCTGCCA 600
20 CGTTGCACCT TCTCCCAAGA GAACCAAGCA GAAACGCATG CCTGCTTAC CTCCCGATTG 660
CTCTACCATG TGGCGGGATT CCTGCTGCCC ATGCTGGTGA TGGGCTGGTG CTACGTGGGG 720
GTAGTGACA GGTGCGCCA GGCCAGCGG CGCCCTCAGC GGCAGAAGGC AGTCAGGGTG 780
GCCATCCTGG TGACAAGCAT CTTCTTCCTC TGCTGGTCAC CCTACCACAT CGTCATCTTC 840
CTGGACACCC TGGCGAGGCT GAAGGCCGTG GACAATACCT GCAAGCTGAA TGGCTCTCTC 900
25 CCGTGGCCA TCACCATGTG TGAGTTCCTG GGCTGGCCC ACTGCTGCTT CAACCCCATG 960
CTCTACACTT TCGCCGGCGT GAAGTTCGCG AGTGACCTGT CGCGGCTCCT GACCAAGCTG 1020
GGCTGTACCG GCCCTGCTC CTGTGCCAG CTCTCCCTA GCTGGCGCAG GAGCAGTCTC 1080
TCTGAGTCAG AGAATGCCAC CTCTCTCACC ACGTTCTAG 1119

(67) INFORMATION FOR SEQ ID NO:66:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 372 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

5 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

	Met	Asn	Tyr	Pro	Leu	Thr	Leu	Glu	Met	Asp	Leu	Glu	Asn	Leu	Glu	Asp	
	1				5					10					15		
10	Leu	Phe	Trp	Glu	Leu	Asp	Arg	Leu	Asp	Asn	Tyr	Asn	Asp	Thr	Ser	Leu	
				20					25					30			
	Val	Glu	Asn	His	Leu	Cys	Pro	Ala	Thr	Glu	Gly	Pro	Leu	Met	Ala	Ser	
			35					40					45				
	Phe	Lys	Ala	Val	Phe	Val	Pro	Val	Ala	Tyr	Ser	Leu	Ile	Phe	Leu	Leu	
			50				55					60					
15	Gly	Val	Ile	Gly	Asn	Val	Leu	Val	Leu	Val	Ile	Leu	Glu	Arg	His	Arg	
	65				70					75					80		
	Gln	Thr	Arg	Ser	Ser	Thr	Glu	Thr	Phe	Leu	Phe	His	Leu	Ala	Val	Ala	
					85					90					95		
20	Asp	Leu	Leu	Leu	Val	Phe	Ile	Leu	Pro	Phe	Ala	Val	Ala	Glu	Gly	Ser	
				100					105					110			
	Val	Gly	Trp	Val	Leu	Gly	Thr	Phe	Leu	Cys	Lys	Thr	Val	Ile	Ala	Leu	
			115				120						125				
	His	Lys	Val	Asn	Phe	Tyr	Cys	Ser	Ser	Leu	Leu	Leu	Ala	Cys	Ile	Ala	
			130				135						140				
25	Val	Asp	Arg	Tyr	Leu	Ala	Ile	Val	His	Ala	Val	His	Ala	Tyr	Arg	His	
	145				150					155					160		
	Arg	Arg	Leu	Leu	Ser	Ile	His	Ile	Thr	Cys	Gly	Thr	Ile	Trp	Leu	Val	
					165					170				175			
30	Gly	Phe	Leu	Leu	Ala	Leu	Pro	Glu	Ile	Leu	Phe	Ala	Lys	Val	Ser	Gln	
			180					185					190				
	Gly	His	His	Asn	Asn	Ser	Leu	Pro	Arg	Cys	Thr	Phe	Ser	Gln	Glu	Asn	
			195				200						205				
	Gln	Ala	Glu	Thr	His	Ala	Trp	Phe	Thr	Ser	Arg	Phe	Leu	Tyr	His	Val	
		210				215						220					
35	Ala	Gly	Phe	Leu	Leu	Pro	Met	Leu	Val	Met	Gly	Trp	Cys	Tyr	Val	Gly	
	225				230					235					240		
	Val	Val	His	Arg	Leu	Arg	Gln	Ala	Gln	Arg	Arg	Pro	Gln	Arg	Gln	Lys	

53

		245		250		255
	Ala Val Arg Val Ala Ile Leu Val Thr Ser Ile Phe Phe Leu Cys Trp					
	260		265		270	
5	Ser Pro Tyr His Ile Val Ile Phe Leu Asp Thr Leu Ala Arg Leu Lys					
	275		280		285	
	Ala Val Asp Asn Thr Cys Lys Leu Asn Gly Ser Leu Pro Val Ala Ile					
	290		295		300	
	Thr Met Cys Glu Phe Leu Gly Leu Ala His Cys Cys Leu Asn Pro Met					
	305		310		315	320
10	Leu Tyr Thr Phe Ala Gly Val Lys Phe Arg Ser Asp Leu Ser Arg Leu					
	325		330		335	
	Leu Thr Lys Leu Gly Cys Thr Gly Pro Ala Ser Leu Cys Gln Leu Phe					
	340		345		350	
	Pro Ser Trp Arg Arg Ser Ser Leu Ser Glu Ser Glu Asn Ala Thr Ser					
15	355		360		365	
	Leu Thr Thr Phe					
	370					

(68) INFORMATION FOR SEQ ID NO:67:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

CAAAGCTTGA AAGCTGCACG GTGCAGAGAC

30

(69) INFORMATION FOR SEQ ID NO:68:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

35 GCGGATCCCG AGTCACACCC TGGCTGGGCC

30

(70) INFORMATION FOR SEQ ID NO:69:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1128 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

ATGGATGTGA CTTCCCAAGC CCGGGGCGTG GGCCTGGAGA TGTACCCAGG CACCGCGCAG 60
CCTGCGGCCC CCAACACCAC CTCCCCGAG CTCAACCTGT CCCACCCGCT CCTGGGCACC 120
10 GCCCTGGCCA ATGGGACAGG TGAGCTCTCG GAGCACCAGC AGTACGTGAT CGGCCTGTTC 180
CTCTCGTGCC TCTACACCAT CTTCTCTTC CCCATCGGCT TTGTGGGCAA CATCCTGATC 240
CTGGTGGTGA ACATCAGCTT CCGCGAGAAG ATGACCATCC CCGACCTGTA CTTTCATCAAC 300
CTGGCGGTGG CGGACCTCAT CCTGGTGGCC GACTCCCTCA TTGAGGTGTT CAACCTGCAC 360
GAGCGGTACT ACGACATCGC CGTCCTGTGC ACCTTCATGT CGCTCTTCCT GCAGGTCAAC 420
15 ATGTACAGCA GCGTCTTCTT CTCACCTGG ATGAGCTTCG ACCGCTACAT CGCCCTGGCC 480
AGGGCCATGC GCTGCAGCCT GTTCCGCACC AAGCACCACG CCGGCTGAG CTGTGGCCTC 540
ATCTGGATGG CATCCGTGTC AGCCACGCTG GTGCCCTTCA CCGCGTGCA CCTGCAGCAC 600
ACCGACGAGG CCTGCTTCTG TTTCGCGGAT GTCCGGGAGG TGCACTGGCT CGAGGTCACG 660
CTGGGCTTCA TCGTGCCCTT CGCCATCATC GGCCTGTGCT ACTCCCTCAT TGTCGGGTG 720
20 CTGGTCAGGG CGCACCGCA CCGTGGGCTG CGGCCCCGGC GGCAGAAGGC GCTCCGCATG 780
ATCCTCGCGG TGGTGCTGGT CTTCTTCGTC TGCTGGCTGC CGGAGAACGT CTTTCATCAGC 840
GTGCACCTCC TGCAGCGGAC GCAGCCTGGG GCGCTCCCT GCAAGCAGTC TTTCCGCCAT 900
GCCCCCCCC TCACGGGCCA CATTGTCAAC CTCACCGCCT TCTCCAACAG CTGCCTAAAC 960
CCCCTCATCT ACAGCTTTCT CGGGGAGACC TTCAGGGACA AGCTGAGGCT GTACATTGAG 1020
25 CAGAAAACAA ATTTGCCGGC CCTGAACCGC TTCTGTCACG CTGCCCTGAA GGCCGTCATT 1080
CCAGACAGCA CCGAGCAGTC GGATGTGAGG TTCAGCAGTG CCGTGTAG 1128

(71) INFORMATION FOR SEQ ID NO:70:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 375 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: not relevant

30

55

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

	Met	Asp	Val	Thr	Ser	Gln	Ala	Arg	Gly	Val	Gly	Leu	Glu	Met	Tyr	Pro	
	1				5					10					15		
5	Gly	Thr	Ala	Gln	Pro	Ala	Ala	Pro	Asn	Thr	Thr	Ser	Pro	Glu	Leu	Asn	
				20					25					30			
	Leu	Ser	His	Pro	Leu	Leu	Gly	Thr	Ala	Leu	Ala	Asn	Gly	Thr	Gly	Glu	
			35					40					45				
10	Leu	Ser	Glu	His	Gln	Gln	Tyr	Val	Ile	Gly	Leu	Phe	Leu	Ser	Cys	Leu	
		50					55					60					
	Tyr	Thr	Ile	Phe	Leu	Phe	Pro	Ile	Gly	Phe	Val	Gly	Asn	Ile	Leu	Ile	
	65					70					75				80		
	Leu	Val	Val	Asn	Ile	Ser	Phe	Arg	Glu	Lys	Met	Thr	Ile	Pro	Asp	Leu	
				85						90					95		
15	Tyr	Phe	Ile	Asn	Leu	Ala	Val	Ala	Asp	Leu	Ile	Leu	Val	Ala	Asp	Ser	
				100					105					110			
	Leu	Ile	Glu	Val	Phe	Asn	Leu	His	Glu	Arg	Tyr	Tyr	Asp	Ile	Ala	Val	
			115					120					125				
20	Leu	Cys	Thr	Phe	Met	Ser	Leu	Phe	Leu	Gln	Val	Asn	Met	Tyr	Ser	Ser	
		130					135					140					
	Val	Phe	Phe	Leu	Thr	Trp	Met	Ser	Phe	Asp	Arg	Tyr	Ile	Ala	Leu	Ala	
	145					150					155				160		
	Arg	Ala	Met	Arg	Cys	Ser	Leu	Phe	Arg	Thr	Lys	His	His	Ala	Arg	Leu	
				165						170					175		
25	Ser	Cys	Gly	Leu	Ile	Trp	Met	Ala	Ser	Val	Ser	Ala	Thr	Leu	Val	Pro	
			180				185							190			
	Phe	Thr	Ala	Val	His	Leu	Gln	His	Thr	Asp	Glu	Ala	Cys	Phe	Cys	Phe	
			195				200						205				
30	Ala	Asp	Val	Arg	Glu	Val	Gln	Trp	Leu	Glu	Val	Thr	Leu	Gly	Phe	Ile	
		210					215					220					
	Val	Pro	Phe	Ala	Ile	Ile	Gly	Leu	Cys	Tyr	Ser	Leu	Ile	Val	Arg	Val	
	225					230				235					240		
	Leu	Val	Arg	Ala	His	Arg	His	Arg	Gly	Leu	Arg	Pro	Arg	Arg	Gln	Lys	
				245					250					255			
35	Ala	Leu	Arg	Met	Ile	Leu	Ala	Val	Val	Leu	Val	Phe	Phe	Val	Cys	Trp	
			260					265						270			

56

Leu Pro Glu Asn Val Phe Ile Ser Val His Leu Leu Gln Arg Thr Gln
 275 280 285
 Pro Gly Ala Ala Pro Cys Lys Gln Ser Phe Arg His Ala His Pro Leu
 290 295 300
 5 Thr Gly His Ile Val Asn Leu Thr Ala Phe Ser Asn Ser Cys Leu Asn
 305 310 315 320
 Pro Leu Ile Tyr Ser Phe Leu Gly Glu Thr Phe Arg Asp Lys Leu Arg
 325 330 335
 10 Leu Tyr Ile Glu Gln Lys Thr Asn Leu Pro Ala Leu Asn Arg Phe Cys
 340 345 350
 His Ala Ala Leu Lys Ala Val Ile Pro Asp Ser Thr Glu Gln Ser Asp
 355 360 365
 Val Arg Phe Ser Ser Ala Val
 370 375

15 (72) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

ACAGAATTCC TGTGTGGTTT TACCGCCCAG

30

(73) INFORMATION FOR SEQ ID NO:72:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

CTCGGATCCA GGCAGAAGAG TCGCCTATGG

30

(74) INFORMATION FOR SEQ ID NO:73:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1137 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

```

ATGGACCTGG GGAAACCAAT GAAAAGCGTG CTGGTGGTGG CTCTCCTTGT CATTTTCCAG   60
5  GTATGCCTGT GTCAAGATGA GGTACGGAC GATTACATCG GAGACAACAC CACAGTGGAC   120
TACACTTGTG TCGAGTCTTT GTGCTCCAAG AAGGACGTGC GGAACCTTAA AGCCTGGTTC   180
CTCCCTATCA TGTACTCCAT CATTTGTTTC GTGGGCCTAC TGGGCAATGG GCTGTCGTG   240
TTGACCTATA TCTATTTCAG GAGGCTCAAG ACCATGACCG ATACCTACCT GCTCAACCTG   300
GCGGTGGCAG ACATCCTCTT CCTCCTGACC CTTCCTTCTT GGGCCTACAG CGCGGCCAAG   360
10 TCCTGGGTCT TCGGTGTCCA CTTTGTCAAG CTCATCTTTG CCATCTACAA GATGAGCTTC   420
TTGAGTGGCA TGCTCCTACT TCTTTGCATC AGCATTGACC GCTACGTGGC CATCGTCCAG   480
GCTGTCTCAG CTCACCGCCA CCGTGCCCGC GTCCTTCTCA TCAGCAAGCT GTCCTGTGTG   540
GGCATCTGGA TACTAGCCAC AGTGCTCTCC ATCCAGAGC TCCTGTACAG TGACCTCCAG   600
AGGAGCAGCA GTGAGCAAGC GATGCGATGC TCTCTCATCA CAGAGCATGT GGAGGCCTTT   660
15 ATCACCATCC AGGTGGCCCA GATGGTGATC GGCTTTCTGG TCCCCCTGCT GGCCATGAGC   720
TTCTGTTACC TTGTATCAT CCGCACCCCTG CTCCAGGCAC GCAACTTTGA GCGCAACAAG   780
GCCATCAAGG TGATCATCGC TGTGGTCGTG GTCTTCATAG TCTTCCAGCT GCCCTACAAT   840
GGGGTGGTCC TGGCCCAGAC GGTGGCCAAC TTCAACATCA CCAGTAGCAC CTGTGAGCTC   900
AGTAAGCAAC TCAACATCGC CTACGACGTC ACCTACAGCC TGGCCTGCGT CCGCTGCTGC   960
20 GTCAACCCTT TCTTGTACGC CTTATCGGC GTCAAGTTCC GCAACGATCT CTTCAAGCTC  1020
TTCAAGGACC TGGGCTGCCT CAGCCAGGAG CAGCTCCGGC AGTGGTCTTC CTGTCGGCAC  1080
ATCCGGCGCT CCTCCATGAG TGTGGAGGCC GAGACCACCA CCACCTTCTC CCCATAG   1137

```

(75) INFORMATION FOR SEQ ID NO:74:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 378 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

	Met	Asp	Leu	Gly	Lys	Pro	Met	Lys	Ser	Val	Leu	Val	Val	Ala	Leu	Leu	
	1				5					10					15		
	Val	Ile	Phe	Gln	Val	Cys	Leu	Cys	Gln	Asp	Glu	Val	Thr	Asp	Asp	Tyr	
				20					25					30			
5	Ile	Gly	Asp	Asn	Thr	Thr	Val	Asp	Tyr	Thr	Leu	Phe	Glu	Ser	Leu	Cys	
			35					40					45				
	Ser	Lys	Lys	Asp	Val	Arg	Asn	Phe	Lys	Ala	Trp	Phe	Leu	Pro	Ile	Met	
		50					55					60					
10	Tyr	Ser	Ile	Ile	Cys	Phe	Val	Gly	Leu	Leu	Gly	Asn	Gly	Leu	Val	Val	
	65					70					75				80		
	Leu	Thr	Tyr	Ile	Tyr	Phe	Lys	Arg	Leu	Lys	Thr	Met	Thr	Asp	Thr	Tyr	
				85						90					95		
	Leu	Leu	Asn	Leu	Ala	Val	Ala	Asp	Ile	Leu	Phe	Leu	Leu	Thr	Leu	Pro	
				100					105					110			
15	Phe	Trp	Ala	Tyr	Ser	Ala	Ala	Lys	Ser	Trp	Val	Phe	Gly	Val	His	Phe	
			115					120					125				
	Cys	Lys	Leu	Ile	Phe	Ala	Ile	Tyr	Lys	Met	Ser	Phe	Phe	Ser	Gly	Met	
		130					135					140					
20	Leu	Leu	Leu	Leu	Cys	Ile	Ser	Ile	Asp	Arg	Tyr	Val	Ala	Ile	Val	Gln	
	145					150					155				160		
	Ala	Val	Ser	Ala	His	Arg	His	Arg	Ala	Arg	Val	Leu	Leu	Ile	Ser	Lys	
				165						170					175		
	Leu	Ser	Cys	Val	Gly	Ile	Trp	Ile	Leu	Ala	Thr	Val	Leu	Ser	Ile	Pro	
				180					185					190			
25	Glu	Leu	Leu	Tyr	Ser	Asp	Leu	Gln	Arg	Ser	Ser	Ser	Glu	Gln	Ala	Met	
		195					200						205				
	Arg	Cys	Ser	Leu	Ile	Thr	Glu	His	Val	Glu	Ala	Phe	Ile	Thr	Ile	Gln	
		210				215						220					
30	Val	Ala	Gln	Met	Val	Ile	Gly	Phe	Leu	Val	Pro	Leu	Leu	Ala	Met	Ser	
	225					230					235				240		
	Phe	Cys	Tyr	Leu	Val	Ile	Ile	Arg	Thr	Leu	Leu	Gln	Ala	Arg	Asn	Phe	
				245					250					255			
	Glu	Arg	Asn	Lys	Ala	Ile	Lys	Val	Ile	Ile	Ala	Val	Val	Val	Val	Phe	
			260					265						270			
35	Ile	Val	Phe	Gln	Leu	Pro	Tyr	Asn	Gly	Val	Val	Leu	Ala	Gln	Thr	Val	
		275						280					285				

59

Ala Asn Phe Asn Ile Thr Ser Ser Thr Cys Glu Leu Ser Lys Gln Leu
 290 295 300

Asn Ile Ala Tyr Asp Val Thr Tyr Ser Leu Ala Cys Val Arg Cys Cys
 305 310 315 320

5 Val Asn Pro Phe Leu Tyr Ala Phe Ile Gly Val Lys Phe Arg Asn Asp
 325 330 335

Leu Phe Lys Leu Phe Lys Asp Leu Gly Cys Leu Ser Gln Glu Gln Leu
 340 345 350

10 Arg Gln Trp Ser Ser Cys Arg His Ile Arg Arg Ser Ser Met Ser Val
 355 360 365

Glu Ala Glu Thr Thr Thr Thr Phe Ser Pro
 370 375

(76) INFORMATION FOR SEQ ID NO:75:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 32 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CTGGAATTCA CCTGGACCAC CACCAATGGA TA

32

(77) INFORMATION FOR SEQ ID NO:76:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

30 CTCGGATCCT GCAAAGTTTG TCATACAGTT

30

(78) INFORMATION FOR SEQ ID NO:77:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1085 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

ATGGATATAC AAATGGCAAA CAATTTTACT CCGCCCTCTG CAACTCCTCA GGGAAATGAC 60
TGTGACCTCT ATGCACATCA CAGCACGGCC AGGATAGTAA TGCCTCTGCA TTACAGCCTC 120
GTCTTCATCA TTGGGCTCGT GGGAAACTTA CTAGCCTTGG TCGTCATTGT TCAAAACAGG 180
5 AAAAAAATCA ACTCTACCAC CCTCTATTCA ACAAATTTGG TGATTCTGA TATACTTTTT 240
ACCACGGCTT TGCCTACACG AATAGCCTAC TATGCAATGG GCTTTGACTG GAGAATCGGA 300
GATGCCTTGT GTAGGATAAC TGCCTAGTG TTTTACATCA ACACATATGC AGGTGTGAAC 360
TTTATGACCT GCCTGAGTAT TGACCGCTTC ATTGCTGTGG TGCACCTCT ACCTACAAC 420
AAGATAAAAA GGATTGAACA TGAAAAGGC GTGTGCATAT TTGTCTGGAT TCTAGTATTT 480
10 GCTCAGACAC TCCCACTCCT CATCAACCCT ATGTCAAAGC AGGAGGCTGA AAGGATTACA 540
TGCAATGGAGT ATCCAAACTT TGAAGAACT AAATCTCTTC CCTGGATTCT GCTTGGGGCA 600
TGTTTCATAG GATATGTACT TCCACTTATA ATCATTCTCA TCTGCTATTC TCAGATCTGC 660
TGCAAACTCT TCAGAACTGC CAAACAAAAC CCACTCACTG AGAAATCTGG TGTAACAAA 720
AAGGCTCTCA ACACAATTAT TCTTATTATT GTTGTGTTT TTCTCTGTT CACACCTTAC 780
15 CATGTTGCAA TTATTCAACA TATGATTAAG AAGCTTCGTT TCTCTAATTT CCTGGAATGT 840
AGCCAAAGAC ATTCGTTCCA GATTCTCTG CACTTACAG TATGCCTGAT GAACTTCAAT 900
TGCTGCATGG ACCCTTTTAT CTAATTCTTT GCATGTAAAG GGTATAAGAG AAAGGTTATG 960
AGGATGCTGA AACGGCAAGT CAGTGTATCG ATTTCTAGTG CTGTGAAGTC AGCCCTGAA 1020
GAAAATTCAC GTGAAATGAC AGAAACGCAG ATGATGATAC ATTCCAAGTC TTCAAATGGA 1080
20 AAGTGA 1086

(79) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 361 amino acids
(B) TYPE: amino acid
25 (C) STRANDEDNESS:
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

30 Met Asp Ile Gln Met Ala Asn Asn Phe Thr Pro Pro Ser Ala Thr Pro
1 5 10 15

61

Gln Gly Asn Asp Cys Asp Leu Tyr Ala His His Ser Thr Ala Arg Ile
 20 25 30
 Val Met Pro Leu His Tyr Ser Leu Val Phe Ile Ile Gly Leu Val Gly
 35 40 45
 5 Asn Leu Leu Ala Leu Val Val Ile Val Gln Asn Arg Lys Lys Ile Asn
 50 55 60
 Ser Thr Thr Leu Tyr Ser Thr Asn Leu Val Ile Ser Asp Ile Leu Phe
 65 70 75 80
 10 Thr Thr Ala Leu Pro Thr Arg Ile Ala Tyr Tyr Ala Met Gly Phe Asp
 85 90 95
 Trp Arg Ile Gly Asp Ala Leu Cys Arg Ile Thr Ala Leu Val Phe Tyr
 100 105 110
 Ile Asn Thr Tyr Ala Gly Val Asn Phe Met Thr Cys Leu Ser Ile Asp
 115 120 125
 15 Arg Phe Ile Ala Val Val His Pro Leu Arg Tyr Asn Lys Ile Lys Arg
 130 135 140
 Ile Glu His Ala Lys Gly Val Cys Ile Phe Val Trp Ile Leu Val Phe
 145 150 155 160
 20 Ala Gln Thr Leu Pro Leu Leu Ile Asn Pro Met Ser Lys Gln Glu Ala
 165 170 175
 Glu Arg Ile Thr Cys Met Glu Tyr Pro Asn Phe Glu Glu Thr Lys Ser
 180 185 190
 Leu Pro Trp Ile Leu Leu Gly Ala Cys Phe Ile Gly Tyr Val Leu Pro
 195 200 205
 25 Leu Ile Ile Ile Leu Ile Cys Tyr Ser Gln Ile Cys Cys Lys Leu Phe
 210 215 220
 Arg Thr Ala Lys Gln Asn Pro Leu Thr Glu Lys Ser Gly Val Asn Lys
 225 230 235 240
 30 Lys Ala Leu Asn Thr Ile Ile Leu Ile Ile Val Val Phe Val Leu Cys
 245 250 255
 Phe Thr Pro Tyr His Val Ala Ile Ile Gln His Met Ile Lys Lys Leu
 260 265 270
 Arg Phe Ser Asn Phe Leu Glu Cys Ser Gln Arg His Ser Phe Gln Ile
 275 280 285
 35 Ser Leu His Phe Thr Val Cys Leu Met Asn Phe Asn Cys Cys Met Asp
 290 295 300
 Pro Phe Ile Tyr Phe Phe Ala Cys Lys Gly Tyr Lys Arg Lys Val Met

(80) INFORMATION FOR SEQ ID NO:79:

(ii) MOLECULE TYPE: DNA (genomic)

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79;

CTGGAATTCT CCTGCTCATC CAGCCATGCG G 31

(81) INFORMATION FOR SEQ ID NO:80:

20 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

25 CCTGGATCCC CACCCCTACT GGGGCCTCAG 30

(82) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1446 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

ATGCGGTGGC TGTGGCCCTT GGCTGTCTCT CTTGCTGTGA TTTTGGCTGT GGGGCTAAGC 60

35 AGGGTCTCTG GGGGTGCCCC CCTGCACCTG GGCAGGCACA GAGCCGAGAC CCAGGAGCAG 120

CAGAGCCGAT CCAAGAGGGG CACCGAGGAT GAGGAGGCCA AGGGCCTGCA GCAGTATGTG 180
 CCTGAGGAGT GGGCGGAGTA CCCCCGCCCC ATTCACCCCTG CTGGCCTGCA GCCAACCAAG 240
 CCCTTGGTGG CCACCAGCCC TAACCCCGAC AAGGATGGGG GCACCCGAGA CAGTGGGCAG 300
 GAACTGAGGG GCAATCTGAC AGGGGCACCA GGGCAGAGGC TACAGATCCA GAACCCCTG 360
 5 TATCCGGTGA CCGAGAGCTC CTACAGTGCC TATGCCATCA TGCTTCTGGC GCTGGTGGTG 420
 TTTGCGGTGG GCATTGTGGG CAACCTGTCG GTCATGTGCA TCGTGTGGCA CAGCTACTAC 480
 CTGAAGAGCG CCTGGAATC CATCCTTGCC AGCCTGGCCC TCTGGGATTT TCTGGTCTC 540
 TTTTCTGCC TCCCTATTGT CATCTTCAAC GAGATCACCA AGCAGAGGCT ACTGGGTGAC 600
 GTTCTTGTC GTGCCGTGCC CTTCATGGAG GTCTCTCTC TGGGAGTCAC GACTTTCAGC 660
 10 CTCTGTGCCC TGGGCATTGA CCGCTTCCAC GTGGCCACCA GCACCTGCC CAAGGTGAGG 720
 CCCATCGAGC GGTGCCAATC CATCCTGGCC AAGTTGGCTG TCATCTGGGT GGGCTCCATG 780
 ACGCTGGCTG TGCCTGAGCT CTTGCTGTGG CAGCTGGCAC AGGAGCCTGC CCCCACCATG 840
 GGCACCCTGG ACTCATGCAT CATGAAACCC TCAGCCAGCC TGCCCGAGTC CCTGTATTCA 900
 CTGGTGATGA CCTACCAGAA CGCCCGCATG TGGTGGTACT TTGGCTGCTA CTTCTGCCTG 960
 15 CCCATCCTCT TCACAGTCAC CTGCCAGCTG GTGACATGGC GGGTGCAGAG CCCTCCAGGG 1020
 AGGAAGTCAG AGTGCAGGGC CAGCAAGCAC GAGCAGTGTG AGAGCCAGCT CAACAGCACC 1080
 GTGGTGGGCC TGACCGTGGT CTACGCCTTC TGCACCTCC CAGAGAACGT CTGCAACATC 1140
 GTGGTGGCCT ACCTCTCCAC CGAGCTGACC CGCCAGACCC TGGACCTCCT GGGCCTCATC 1200
 AACCAGTTCT CCACCTTCTT CAAGGGCGCC ATCACCCAG TGCTGCTCCT TTGCATCTGC 1260
 20 AGGCCGCTGG GCCAGGCTT CCTGGACTGC TGCTGCTGCT GCTGCTGTGA GGAGTGCGGC 1320
 GGGGCTTCGG AGGCCTCTGC TGCCAATGGG TCGGACAACA AGCTCAAGAC CGAGGTGTCC 1380
 TCTTCCATCT ACTTCCACAA GCCCAGGGAG TCACCCCCAC TCCTGCCCTT GGGCACACCT 1440
 TGCTGA 1446

(83) INFORMATION FOR SEQ ID NO:82:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 481 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant
- 30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

	Met	Arg	Trp	Leu	Trp	Pro	Leu	Ala	Val	Ser	Leu	Ala	Val	Ile	Leu	Ala
	1				5					10					15	
5	Val	Gly	Leu	Ser	Arg	Val	Ser	Gly	Gly	Ala	Pro	Leu	His	Leu	Gly	Arg
			20					25					30			
	His	Arg	Ala	Glu	Thr	Gln	Glu	Gln	Gln	Ser	Arg	Ser	Lys	Arg	Gly	Thr
			35					40					45			
	Glu	Asp	Glu	Glu	Ala	Lys	Gly	Val	Gln	Gln	Tyr	Val	Pro	Glu	Glu	Trp
		50					55					60				
10	Ala	Glu	Tyr	Pro	Arg	Pro	Ile	His	Pro	Ala	Gly	Leu	Gln	Pro	Thr	Lys
	65					70					75					80
	Pro	Leu	Val	Ala	Thr	Ser	Pro	Asn	Pro	Asp	Lys	Asp	Gly	Gly	Thr	Pro
					85					90					95	
15	Asp	Ser	Gly	Gln	Glu	Leu	Arg	Gly	Asn	Leu	Thr	Gly	Ala	Pro	Gly	Gln
				100					105					110		
	Arg	Leu	Gln	Ile	Gln	Asn	Pro	Leu	Tyr	Pro	Val	Thr	Glu	Ser	Ser	Tyr
			115					120					125			
	Ser	Ala	Tyr	Ala	Ile	Met	Leu	Leu	Ala	Leu	Val	Val	Phe	Ala	Val	Gly
		130					135					140				
20	Ile	Val	Gly	Asn	Leu	Ser	Val	Met	Cys	Ile	Val	Trp	His	Ser	Tyr	Tyr
	145				150					155						160
	Leu	Lys	Ser	Ala	Trp	Asn	Ser	Ile	Leu	Ala	Ser	Leu	Ala	Leu	Trp	Asp
				165					170						175	
25	Phe	Leu	Val	Leu	Phe	Phe	Cys	Leu	Pro	Ile	Val	Ile	Phe	Asn	Glu	Ile
			180					185						190		
	Thr	Lys	Gln	Arg	Leu	Leu	Gly	Asp	Val	Ser	Cys	Arg	Ala	Val	Pro	Phe
			195					200					205			
	Met	Glu	Val	Ser	Ser	Leu	Gly	Val	Thr	Thr	Phe	Ser	Leu	Cys	Ala	Leu
		210					215					220				
30	Gly	Ile	Asp	Arg	Phe	His	Val	Ala	Thr	Ser	Thr	Leu	Pro	Lys	Val	Arg
	225					230					235					240
	Pro	Ile	Glu	Arg	Cys	Gln	Ser	Ile	Leu	Ala	Lys	Leu	Ala	Val	Ile	Trp
				245						250				255		
35	Val	Gly	Ser	Met	Thr	Leu	Ala	Val	Pro	Glu	Leu	Leu	Leu	Trp	Gln	Leu
			260						265					270		
	Ala	Gln	Glu	Pro	Ala	Pro	Thr	Met	Gly	Thr	Leu	Asp	Ser	Cys	Ile	Met

65

	275	280	285
	Lys Pro Ser Ala Ser Leu	Pro Glu Ser Leu Tyr	Ser Leu Val Met Thr
	290	295	300
5	Tyr Gln Asn Ala Arg Met Trp Trp Tyr Phe Gly Cys Tyr Phe Cys Leu		
	305	310	315 320
	Pro Ile Leu Phe Thr Val Thr Cys Gln Leu Val Thr Trp Arg Val Arg		
		325	330 335
	Gly Pro Pro Gly Arg Lys Ser Glu Cys Arg Ala Ser Lys His Glu Gln		
		340	345 350
10	Cys Glu Ser Gln Leu Asn Ser Thr Val Val Gly Leu Thr Val Val Tyr		
		355	360 365
	Ala Phe Cys Thr Leu Pro Glu Asn Val Cys Asn Ile Val Val Ala Tyr		
		370	375 380
15	Leu Ser Thr Glu Leu Thr Arg Gln Thr Leu Asp Leu Leu Gly Leu Ile		
		385	390 395 400
	Asn Gln Phe Ser Thr Phe Phe Lys Gly Ala Ile Thr Pro Val Leu Leu		
		405	410 415
	Leu Cys Ile Cys Arg Pro Leu Gly Gln Ala Phe Leu Asp Cys Cys Cys		
		420	425 430
20	Cys Cys Cys Cys Glu Glu Cys Gly Gly Ala Ser Glu Ala Ser Ala Ala		
		435	440 445
	Asn Gly Ser Asp Asn Lys Leu Lys Thr Glu Val Ser Ser Ser Ile Tyr		
		450	455 460
25	Phe His Lys Pro Arg Glu Ser Pro Pro Leu Leu Pro Leu Gly Thr Pro		
		465	470 475 480
	Cys		

(84) INFORMATION FOR SEQ ID NO:83:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

ATGTGGAACG CGACGCCAG CG

22

(85) INFORMATION FOR SEQ ID NO:84:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

TCATGTATTA ATACTAGATT CT

22

10 (86) INFORMATION FOR SEQ ID NO:85:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 38 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

TACCATGTGG AACGCGACGC CCAGCGAAGA GCCGGGGT

38

(87) INFORMATION FOR SEQ ID NO:86:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 39 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 25 (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

CGGAATTCAT GTATTAATAC TAGATTCTGT CCAGGCCCG

39

(88) INFORMATION FOR SEQ ID NO:87:

- 30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1101 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

ATGTGGAACG CGACGCCAG CGAAGAGCCG GGGTTCAACC TCACACTGGC CGACCTGGAC 60
 TGGGATGCTT CCCCCGGCAA CGACTCGCTG GCGACGAGC TGCTGCAGCT CTTCCCCGCG 120
 CCGCTGCTGG CGGGCGTCAC AGCCACCTGC GTGGCACTCT TCGTGGTGGG TATCGCTGGC 180
 AACCTGCTCA CCATGCTGGT GGTGTGCGGC TTCCGCGAGC TGCGCACCAC CACCAACCTC 240
 5 TACCTGTCCA GCATGGCCTT CTCCGATCTG CTCATCTTCC TCTGCATGCC CCTGGACCTC 300
 GTTCGCCTCT GGCAGTACCG GCCCTGGAAC TTCGGCGACC TCCTCTGCAA ACTCTTCCAA 360
 TTCGTCAAGT AGAGCTGCAC CTACGCCACG GTGCTCACCA TCACAGCGCT GAGCGTCGAG 420
 CGCTACTTCG CCATCTGCTT CCCACTCCGG GCCAAGGTGG TGGTCACCAA GGGGCGGGTG 480
 AAGCTGGTCA TCTTCGTCTT CTGGGCCGTG GCCTTCTGCA GCGCCGGGCC CATCTTCGTG 540
 10 CTAGTCGGGG TGGAGCACGA GAACGGCACC GACCCTTGGG ACACCAACGA GTGCCGCCCC 600
 ACCGAGTTTG CGGTGCGCTC TGGACTGCTC ACGGTCATGG TGTGGGTGTC CAGCATCTTC 660
 TTCTTCCTTC CTGTCTTCTG TCTACGGTC CTCTACAGTC TCATCGGCAG GAAGCTGTGG 720
 CGGAGGAGGC GCGGCGATGC TGTGCTGGGT GCCTCGCTCA GGGACCAGAA CCACAAGCAA 780
 ACCGTGAAAA TGCTGGCTGT AGTGGTGTTC GCCTTCATCC TCTGCTGGCT CCCCTTCCAC 840
 15 GTAGGGCGAT ATTTATTTTC CAAATCCTTT GAGCCTGGGT CCTTGGAGAT TGCTCAGATC 900
 AGCCAGTACT GCAACCTCGT GTCCTTTGTC CTCTTCTACC TCAGTGCTGC CATCAACCCC 960
 ATTCTGTACA ACATCATGTC CAAGAAGTAC CGGGTGGCAG TGTCAGACT TCTGGGATTC 1020
 GAACCCCTCT CCCAGAGAAA GCTCTCCACT CTGAAAGATG AAAGTTCTCG GGCCTGGACA 1080
 GAATCTAGTA TTAATACATG A 1101

20 (89) INFORMATION FOR SEQ ID NO:88:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 366 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 25 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Met Trp Asn Ala Thr Pro Ser Glu Glu Pro Gly Phe Asn Leu Thr Leu
 1 5 10 15
 30 Ala Asp Leu Asp Trp Asp Ala Ser Pro Gly Asn Asp Ser Leu Gly Asp
 20 25 30

68

	Glu	Leu	Leu	Gln	Leu	Phe	Pro	Ala	Pro	Leu	Leu	Ala	Gly	Val	Thr	Ala	
		35						40					45				
	Thr	Cys	Val	Ala	Leu	Phe	Val	Val	Gly	Ile	Ala	Gly	Asn	Leu	Leu	Thr	
		50					55					60					
5	Met	Leu	Val	Val	Ser	Arg	Phe	Arg	Glu	Leu	Arg	Thr	Thr	Thr	Asn	Leu	
	65					70					75					80	
	Tyr	Leu	Ser	Ser	Met	Ala	Phe	Ser	Asp	Leu	Leu	Ile	Phe	Leu	Cys	Met	
					85					90					95		
10	Pro	Leu	Asp	Leu	Val	Arg	Leu	Trp	Gln	Tyr	Arg	Pro	Trp	Asn	Phe	Gly	
				100					105					110			
	Asp	Leu	Leu	Cys	Lys	Leu	Phe	Gln	Phe	Val	Ser	Glu	Ser	Cys	Thr	Tyr	
			115					120					125				
	Ala	Thr	Val	Leu	Thr	Ile	Thr	Ala	Leu	Ser	Val	Glu	Arg	Tyr	Phe	Ala	
		130					135						140				
15	Ile	Cys	Phe	Pro	Leu	Arg	Ala	Lys	Val	Val	Val	Thr	Lys	Gly	Arg	Val	
	145					150					155					160	
	Lys	Leu	Val	Ile	Phe	Val	Ile	Trp	Ala	Val	Ala	Phe	Cys	Ser	Ala	Gly	
				165						170					175		
20	Pro	Ile	Phe	Val	Leu	Val	Gly	Val	Glu	His	Glu	Asn	Gly	Thr	Asp	Pro	
				180					185					190			
	Trp	Asp	Thr	Asn	Glu	Cys	Arg	Pro	Thr	Glu	Phe	Ala	Val	Arg	Ser	Gly	
			195					200					205				
	Leu	Leu	Thr	Val	Met	Val	Trp	Val	Ser	Ser	Ile	Phe	Phe	Phe	Leu	Pro	
		210					215					220					
25	Val	Phe	Cys	Leu	Thr	Val	Leu	Tyr	Ser	Leu	Ile	Gly	Arg	Lys	Leu	Trp	
	225					230					235					240	
	Arg	Arg	Arg	Arg	Gly	Asp	Ala	Val	Val	Gly	Ala	Ser	Leu	Arg	Asp	Gln	
					245					250				255			
30	Asn	His	Lys	Gln	Thr	Val	Lys	Met	Leu	Ala	Val	Val	Val	Phe	Ala	Phe	
				260					265					270			
	Ile	Leu	Cys	Trp	Leu	Pro	Phe	His	Val	Gly	Arg	Tyr	Leu	Phe	Ser	Lys	
		275						280					285				
	Ser	Phe	Glu	Pro	Gly	Ser	Leu	Glu	Ile	Ala	Gln	Ile	Ser	Gln	Tyr	Cys	
		290					295					300					
35	Asn	Leu	Val	Ser	Phe	Val	Leu	Phe	Tyr	Leu	Ser	Ala	Ala	Ile	Asn	Pro	
	305					310					315					320	
	Ile	Leu	Tyr	Asn	Ile	Met	Ser	Lys	Lys	Tyr	Arg	Val	Ala	Val	Phe	Arg	

(90) INFORMATION FOR SEQ ID NO:89:

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

GCAAGCTTGT GCCCTCACCA AGCCATGCGA GCC 33

15 (91) INFORMATION FOR SEO ID NO:90:

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

CGGAATTCAG CAATGAGTTC CGACAGAAGC 30

(92) INFORMATION FOR SEO ID NO:91:

30 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

	ATGCGAGCCC	CGGGCGCGCT	TCTCGCCCGC	ATGTCGCGGC	TACTGCTTCT	GCTACTGCTC	60
	AAGGTGTCTG	CCTCTTCTGC	CCTCGGGGTC	GCCCCTGCGT	CCAGAAACGA	AACTTGTCTG	120
	GGGGAGAGCT	GTGCACCTAC	AGTGATCCAG	CGCCCGCGCA	GGGACGCCCTG	GGGACCGGGA	180
35	AATTCTGCAA	GAGACGTTCT	GCGAGCCCGA	GCACCCAGGG	AGGAGCAGGG	GGCAGCGTTT	240

CTTGCGGGAC CCTCCTGGGA CTGCGCGCG GCGCCGGGCC GTGACCCGGC TGCAGGCAGA 300
 GGGGCGGAGG CGTCGGCAGC CGGACCCCGG GGACCTCCAA CCAGGCCACC TGGCCCTGG 360
 AGGTGGAAG GTGCTCGGG TCAGGAGCCT TCTGAACTT TGGGGAGAGG GAACCCACG 420
 GCGCTCCAGC TCTCCTTCA GATCTCAGAG GAGGAAGAGA AGGGTCCAG AGGCGCTGGC 480
 5 ATTTCCGGGC GTAGCCAGGA GCAGAGTGTG AAGACAGTCC CCGGAGCCAG CGATCTTTT 540
 TACTGGCCAA GGAGAGCCGG GAAACTCCAG GGTTCACC ACCAGCCCT GTCCAAGACG 600
 GCCAATGGAC TGGCGGGCA CGAAGGGTGG ACAATTGCAC TCCCGGGCCG GCGCTGGC 660
 CAGAATGGAT CCTTGGGTGA AGGAATCCAT GAGCCTGGG GTCCCGCCG GGGAAACAGC 720
 ACGAACCGGC GTGTGAGACT GAAGAACCC TTCTACCCG TGACCCAGGA GTCCTATGGA 780
 10 GCCTACGCG TCATGTGTCT GTCCGTGGT ATCTTCGGGA CCGGCATCAT TGGCAACCTG 840
 GCGGTGATGA GCATCGTGT CCACAACCTAC TACATGCGGA GCATCTCAA CTCCCTCTTG 900
 GCCAACCTGG CCTTCTGGGA CTTTCTCATC ATCTTCTTCT GCCTTCGGCT GGTATCTTC 960
 CACGAGCTGA CCAAGAAGTG GTGTGTGGAG GACTTCTCCT GCAAGATCGT GCCCTATATA 1020
 GAGGTCGCTT CTCTGGGAGT CACCACTTTC ACCTTATGTG CTCTGTGCAT AGACCGCTTC 1080
 15 CGTGTGCCA CCAACGTACA GATGTACTAC GAAATGATCG AAAACTGTTC CTCAACAACT 1140
 GCCAACTTG CTGTTATATG GGTGGGAGCT CTATGTGTTAG CACTTCAGA AGTTGTCTC 1200
 CGCCAGCTGA GCAAGGAGGA TTTGGGTTT AGTGCCGAG CTCCGGCAGA AAGGTGCATT 1260
 ATTAAGATCT CTCCTGATTT ACCAGACACC ATCTATGTTT TAGCCCTCAC CTACGACAGT 1320
 GCGAGACTGT GGTGGTATTT TGGCTGTAC TTTTGTGTC CCACGCTTTT CACCATCACC 1380
 20 TGCTCTCTAG TGA CTGCGAG GAAAATCCG AAAGCAGAGA AAGCCTGTAC CCGAGGGAAT 1440
 AAACGGCAGA TTCAACTAGA GAGTCAGATG AACTGTACAG TAGTGGCACT GACCATTTTA 1500
 TATGGATTTT GCATTATTCC TGAAAATATC TGCAACATTG TTACTGCCTA CATGGCTACA 1560
 GGGGTTTCAC AGCAGACAAT GGACCTCCTT AATATCATCA GCCAGTTCCT TTTGTTCTTT 1620
 AAGTCCTGTG TCACCCAGT CCTCCTTTT TGTCTCTGCA AACCTTCAG TCGGGCCTTC 1680
 25 ATGGAGTGCT GCTGCTGTTG CTGTGAGGAA TGCAATCAGA AGTCTTCAAC GGTGACCACT 1740
 GATGACAATG ACAACGAGTA CACCACGGA CTCGAACTCT CGCCTTTCAG TACCATACGC 1800
 CGTGAAATGT CCACTTTTGC TTCTGTGGA ACTCATGCT GA 1842

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 613 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Met Arg Ala Pro Gly Ala Leu Leu Ala Arg Met Ser Arg Leu Leu Leu
 1 5 10 15

Leu Leu Leu Leu Lys Val Ser Ala Ser Ser Ala Leu Gly Val Ala Pro
 20 25 30

Ala Ser Arg Asn Glu Thr Cys Leu Gly Glu Ser Cys Ala Pro Thr Val
 35 40 45

Ile Gln Arg Arg Gly Arg Asp Ala Trp Gly Pro Gly Asn Ser Ala Arg
 50 55 60

Asp Val Leu Arg Ala Arg Ala Pro Arg Glu Glu Gln Gly Ala Ala Phe
 65 70 75 80

Leu Ala Gly Pro Ser Trp Asp Leu Pro Ala Ala Pro Gly Arg Asp Pro
 85 90 95

Ala Ala Gly Arg Gly Ala Glu Ala Ser Ala Ala Gly Pro Pro Gly Pro
 100 105 110

Pro Thr Arg Pro Pro Gly Pro Trp Arg Trp Lys Gly Ala Arg Gly Gln
 115 120 125

Glu Pro Ser Glu Thr Leu Gly Arg Gly Asn Pro Thr Ala Leu Gln Leu
 130 135 140

Phe Leu Gln Ile Ser Glu Glu Glu Glu Lys Gly Pro Arg Gly Ala Gly
 145 150 155 160

Ile Ser Gly Arg Ser Gln Glu Gln Ser Val Lys Thr Val Pro Gly Ala
 165 170 175

Ser Asp Leu Phe Tyr Trp Pro Arg Arg Ala Gly Lys Leu Gln Gly Ser
 180 185 190

His His Lys Pro Leu Ser Lys Thr Ala Asn Gly Leu Ala Gly His Glu
 195 200 205

Gly Trp Thr Ile Ala Leu Pro Gly Arg Ala Leu Ala Gln Asn Gly Ser
 210 215 220

Leu Gly Glu Gly Ile His Glu Pro Gly Gly Pro Arg Arg Gly Asn Ser
 225 230 235 240

Thr Asn Arg Arg Val Arg Leu Lys Asn Pro Phe Tyr Pro Leu Thr Gln
 245 250 255
 Glu Ser Tyr Gly Ala Tyr Ala Val Met Cys Leu Ser Val Val Ile Phe
 260 265 270
 5 Gly Thr Gly Ile Ile Gly Asn Leu Ala Val Met Ser Ile Val Cys His
 275 280 285
 Asn Tyr Tyr Met Arg Ser Ile Ser Asn Ser Leu Leu Ala Asn Leu Ala
 290 295 300
 10 Phe Trp Asp Phe Leu Ile Ile Phe Phe Cys Leu Pro Leu Val Ile Phe
 305 310 315 320
 His Glu Leu Thr Lys Lys Trp Leu Leu Glu Asp Phe Ser Cys Lys Ile
 325 330 335
 Val Pro Tyr Ile Glu Val Ala Ser Leu Gly Val Thr Thr Phe Thr Leu
 340 345 350
 15 Cys Ala Leu Cys Ile Asp Arg Phe Arg Ala Ala Thr Asn Val Gln Met
 355 360 365
 Tyr Tyr Glu Met Ile Glu Asn Cys Ser Ser Thr Thr Ala Lys Leu Ala
 370 375 380
 20 Val Ile Trp Val Gly Ala Leu Leu Leu Ala Leu Pro Glu Val Val Leu
 385 390 395 400
 Arg Gln Leu Ser Lys Glu Asp Leu Gly Phe Ser Gly Arg Ala Pro Ala
 405 410 415
 Glu Arg Cys Ile Ile Lys Ile Ser Pro Asp Leu Pro Asp Thr Ile Tyr
 420 425 430
 25 Val Leu Ala Leu Thr Tyr Asp Ser Ala Arg Leu Trp Trp Tyr Phe Gly
 435 440 445
 Cys Tyr Phe Cys Leu Pro Thr Leu Phe Thr Ile Thr Cys Ser Leu Val
 450 455 460
 30 Thr Ala Arg Lys Ile Arg Lys Ala Glu Lys Ala Cys Thr Arg Gly Asn
 465 470 475 480
 Lys Arg Gln Ile Gln Leu Glu Ser Gln Met Asn Cys Thr Val Val Ala
 485 490 495
 Leu Thr Ile Leu Tyr Gly Phe Cys Ile Ile Pro Glu Asn Ile Cys Asn
 500 505 510
 35 Ile Val Thr Ala Tyr Met Ala Thr Gly Val Ser Gln Gln Thr Met Asp
 515 520 525
 Leu Leu Asn Ile Ile Ser Gln Phe Leu Leu Phe Phe Lys Ser Cys Val

[illegible]

(94) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93;

20 CAGAATTCAG AGAAAAAAG TGAATATGGT TTTT

34

(95) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

TTGGATCCCT GGTGCATAAC AATTGAAAGA AT

32

30 (96) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1248 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

```

ATGGTTTTTG CTCACAGAAT GGATAACAGC AAGCCACATT TGATTATTCC TACACTTCTG    60
GTGCCCCTCC AAAACCGCAG CTGCACTGAA ACAGCCACAC CTCTGCCAAG CCAATACCTG    120
ATGGAATTAA GTGAGGAGCA CAGTTGGATG AGCAACCAA CAGACCTTCA CTATGTGCTG    180
5  AAACCCGGGG AAGTGGCCAC AGCCAGCATC TTCTTTGGGA TTCTGTGGTT GTTTTCTATC    240
TTCGGCAATT CCCTGGTTTG TTTGGTCATC CATAGGAGTA GGAGGACTCA GTCTACCACC    300
AACTACTTTG TGGTCTCCAT GGCATGTGCT GACCTTCTCA TCAGCGTTGC CAGCAGCCT    360
TTCGTCCTGC TCCAGTTCAC CACTGGAAGG TGGACGCTGG GTAGTGCAAC GTGCAAGGTT    420
GTGCGATATT TTCAATATCT CACTCCAGGT GTCCAGATCT ACGTTCTCCT CTCCATCTGC    480
10 ATAGACCGGT TCTACACCAT CGTCTATCCT CTGAGCTTCA AGGTGTCCAG AGAAAAAGCC    540
AAGAAAATGA TTGCGGCATC GTGCATCTTT GATGCAGGCT TTGTGACCCC TGTGCTCTTT    600
TTCATATGGCT CCAACTGGGA CAGTCATTGT AACTATTTCC TCCCCTCCTC TTGGGAAGGC    660
ACTGCCTACA CTGTCATCCA CTTCTTGGTG GGCTTTGTGA TTCCATCTGT CCTCATAATT    720
TTATTTTACC AAAAGGTCAT AAAATATATT TGGAGAATAG GCACAGATGG CCGAACGGTG    780
15 AGGAGGACAA TGAACATTGT CCCTCGGACA AAAGTGAAAA CTATCAAGAT GTTCCTCATT    840
TTAAATCTGT TGTTTTGTCT CTCCTGGCTG CCTTTTCATG TAGCTCAGCT ATGGCACCCC    900
CATGAACAAG ACTATAAGAA AAGTTCCTTT GTTTTCACAG CTATCACATG GATATCCTTT    960
AGTTCTTCAG CCTCTAAACC TACTCTGTAT TCAATTTATA ATGCCAATTT TCGGAGAGGG    1020
ATGAAAGAGA CTTTTTGCAT GTCCTCTATG AAATGTTACC GAAGCAATGC CTATACTATC    1080
20 ACAACAAGTT CAAGGATGGC CAAAAAAAC TACGTTGGCA TTTCAGAAAT CCCTTCCATG    1140
GCCAAACTA TTACCAAAGA CTCGATCTAT GACTCATTTG ACAGAGAAGC CAAGGAAAAA    1200
AAGCTTGCTT GGCCCATTA CTCAAATCCA CCAATACTT TTGTCTAA    1248

```

(97) INFORMATION FOR SEQ ID NO:96:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 415 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

	Met	Val	Phe	Ala	His	Arg	Met	Asp	Asn	Ser	Lys	Pro	His	Leu	Ile	Ile
	1				5							10			15	
	Pro	Thr	Leu	Leu	Val	Pro	Leu	Gln	Asn	Arg	Ser	Cys	Thr	Glu	Thr	Ala
				20					25					30		
5	Thr	Pro	Leu	Pro	Ser	Gln	Tyr	Leu	Met	Glu	Leu	Ser	Glu	Glu	His	Ser
		35						40					45			
	Trp	Met	Ser	Asn	Gln	Thr	Asp	Leu	His	Tyr	Val	Leu	Lys	Pro	Gly	Glu
		50					55					60				
10	Val	Ala	Thr	Ala	Ser	Ile	Phe	Phe	Gly	Ile	Leu	Trp	Leu	Phe	Ser	Ile
	65					70					75					80
	Phe	Gly	Asn	Ser	Leu	Val	Cys	Leu	Val	Ile	His	Arg	Ser	Arg	Arg	Thr
				85						90					95	
	Gln	Ser	Thr	Thr	Asn	Tyr	Phe	Val	Val	Ser	Met	Ala	Cys	Ala	Asp	Leu
				100					105					110		
15	Leu	Ile	Ser	Val	Ala	Ser	Thr	Pro	Phe	Val	Leu	Leu	Gln	Phe	Thr	Thr
			115					120					125			
	Gly	Arg	Trp	Thr	Leu	Gly	Ser	Ala	Thr	Cys	Lys	Val	Val	Arg	Tyr	Phe
		130					135					140				
20	Gln	Tyr	Leu	Thr	Pro	Gly	Val	Gln	Ile	Tyr	Val	Leu	Leu	Ser	Ile	Cys
		145				150					155					160
	Ile	Asp	Arg	Phe	Tyr	Thr	Ile	Val	Tyr	Pro	Leu	Ser	Phe	Lys	Val	Ser
				165						170					175	
	Arg	Glu	Lys	Ala	Lys	Lys	Met	Ile	Ala	Ala	Ser	Trp	Ile	Phe	Asp	Ala
				180					185					190		
25	Gly	Phe	Val	Thr	Pro	Val	Leu	Phe	Phe	Tyr	Gly	Ser	Asn	Trp	Asp	Ser
			195					200					205			
	His	Cys	Asn	Tyr	Phe	Leu	Pro	Ser	Ser	Trp	Glu	Gly	Thr	Ala	Tyr	Thr
		210					215					220				
30	Val	Ile	His	Phe	Leu	Val	Gly	Phe	Val	Ile	Pro	Ser	Val	Leu	Ile	Ile
		225				230					235					240
	Leu	Phe	Tyr	Gln	Lys	Val	Ile	Lys	Tyr	Ile	Trp	Arg	Ile	Gly	Thr	Asp
				245						250					255	
	Gly	Arg	Thr	Val	Arg	Arg	Thr	Met	Asn	Ile	Val	Pro	Arg	Thr	Lys	Val
				260					265					270		
35	Lys	Thr	Ile	Lys	Met	Phe	Leu	Ile	Leu	Asn	Leu	Leu	Phe	Leu	Leu	Ser
			275					280					285			

76

Trp Leu Pro Phe His Val Ala Gln Leu Trp His Pro His Glu Gln Asp
 290 295 300

Tyr Lys Lys Ser Ser Leu Val Phe Thr Ala Ile Thr Trp Ile Ser Phe
 305 310 315 320

5 Ser Ser Ser Ala Ser Lys Pro Thr Leu Tyr Ser Ile Tyr Asn Ala Asn
 325 330 335

Phe Arg Arg Gly Met Lys Glu Thr Phe Cys Met Ser Ser Met Lys Cys
 340 345 350

10 Tyr Arg Ser Asn Ala Tyr Thr Ile Thr Thr Ser Ser Arg Met Ala Lys
 355 360 365

Lys Asn Tyr Val Gly Ile Ser Glu Ile Pro Ser Met Ala Lys Thr Ile
 370 375 380

Thr Lys Asp Ser Ile Tyr Asp Ser Phe Asp Arg Glu Ala Lys Glu Lys
 385 390 395 400

15 Lys Leu Ala Trp Pro Ile Asn Ser Asn Pro Pro Asn Thr Phe Val
 405 410 415

(98) INFORMATION FOR SEQ ID NO:97:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

25 GGAAAGCTTA ACGATCCCCA GGAGCAACAT 30

(99) INFORMATION FOR SEQ ID NO:98:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 31 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

CTGGGATCCT ACGAGAGCAT TTTCACACA G 31

35 (100) INFORMATION FOR SEQ ID NO:99:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1842 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

```
ATGGGGCCCA CCCTAGCGGT TCCCACCCCC TATGGCTGTA TTGGCTGTAA GCTACCCAG 60
CCAGAATACC CACCGGCTCT AATCATCTTT ATGTTCTGCG CGATGGTTAT CACCATCGTT 120
GTAGACCTAA TCGGCAACTC CATGGTCATT TTGGCTGTGA CGAAGAACAA GAAGCTCCGG 180
10 AATTCTGGCA ACATCTTCGT GGTCACTCTC TCTGTGGCCG ATATGCTGGT GGCCATCTAC 240
CCATACCCTT TGATGCTGCA TGCCATGTCC ATTGGGGGCT GGGATCTGAG CCAATTACAG 300
TGCCAGATGG TCGGGTTCAT CACAGGGCTG AGTGTGGTCG GCTCCATCTT CAACATCGTG 360
GCAATCGCTA TCAACCGTTA CTGCTACATC TGCCACAGCC TCCAGTACGA ACGGATCTTC 420
AGTGTGCGCA ATACCTGCAT CTACCTGGTC ATCACCTGGA TCATGACCGT CCTGGCTGTC 480
15 CTGCCCCAACA TGTACATTGG CACCATCGAG TACGATCCTC GCACCTACAC CTGCATCTTC 540
AACTATCTGA ACAACCCTGT CTTCACTGTT ACCATCGTCT GCATCCACTT CGTCCTCCCT 600
CTCCTCATCG TGGGTTTCTG CTACGTGAGG ATCTGGACCA AAGTGCTGGC GGCCCGTGAC 660
CCTGCAGGGC AGAATCCTGA CAACCAACTT GCTGAGGTTT GCAATTTTCT AACCATGTTT 720
GTGATCTTCC TCCTCTTTGC AGTGTGCTGG TGCCCTATCA ACGTGCTCAC TGTCTTGGTG 780
20 GCTGTCAATC CGAAGGAGAT GGCAGGCAAG ATCCCCAACT GGCTTTATCT TGCAGCCTAC 840
TTCATAGCCT ACTTCAACAG CTGCCTCAAC GCTGTGATCT ACGGGCTCCT CAATGAGAAT 900
TTCCGAAGAG AATACTGGAC CATCTTCCAT GCTATGCGGC ACCCTATCAT ATTCTTCCCT 960
GGCCTCATCA GTGATATTCG TGAGATGCAG GAGGCCCGTA CCCTGGCCCG CGCCCGTGCC 1020
CATGCTCGCG ACCAAGCTCG TGAACAAGAC CGTGCCCATG CCTGTCCTGC TGTGGAGGAA 1080
25 ACCCCGATGA ATGTCCGAA TGTTCCATTA CCTGGTGATG CTGCAGCTGG CCACCCCGAC 1140
CGTGCCTCTG GCCACCCTAA GCCCCATTCC AGATCCTCCT CTGCCTATCG CAAATCTGCC 1200
TCTACCCACC ACAAGTCTGT CTTTAGCCAC TCCAAGGCTG CCTCTGGTCA CCTCAAGCCT 1260
GTCTCTGGCC ACTCCAAGCC TGCCTCTGGT CACCCCAAGT CTGCCACTGT CTACCCTAAG 1320
CCTGCCTCTG TCCATTTCAA GGGTGACTCT GTCCATTTC AAGGTGACTC TGTCCATTTC 1380
```

AAGCCTGACT CTGTTCAATTT CAAGCCTGCT TCCAGCAACC CCAAGCCCAT CACTGGCCAC 1440
 CATGTCTCTG CTGSCAGCCA CTCCAAGTCT GCCTTCAGTG CTGCCACCAG CCACCCATAA 1500
 CCCATCAAGC CAGCTACCAG CCATGCTGAG CCCACCACTG CTGACTATCC CAAGCCTGCC 1560
 ACTACCAGCC ACCCTAAGCC CGCTGCTGCT GACAACCCTG AGCTCTCTGC CTCCCATTGC 1620
 5 CCCGAGATCC CTGCCATTGC CCACCCTGTG TCTGACGACA GTGACCTCCC TGAGTCGGCC 1680
 TCTAGCCCTG CCGCTGGGCC CACCAAGCCT GCTGCCAGCC AGCTGGAGTC TGACACCATC 1740
 GCTGACCTTC CTGACCCTAC TGTAGTCACT ACCAGTACCA ATGATTACCA TGATGTCGTG 1800
 GTTGTGATG TTGAAGATGA TCCTGATGAA ATGGCTGTGT GA 1842

(101) INFORMATION FOR SEQ ID NO:100:

- 10 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 613 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: not relevant

- 15 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

	Met	Gly	Pro	Thr	Leu	Ala	Val	Pro	Thr	Pro	Tyr	Gly	Cys	Ile	Gly	Cys
	1				5					10				15		
20	Lys	Leu	Pro	Gln	Pro	Glu	Tyr	Pro	Pro	Ala	Leu	Ile	Ile	Phe	Met	Phe
				20					25					30		
	Cys	Ala	Met	Val	Ile	Thr	Ile	Val	Val	Asp	Leu	Ile	Gly	Asn	Ser	Met
			35					40					45			
	Val	Ile	Leu	Ala	Val	Thr	Lys	Asn	Lys	Lys	Leu	Arg	Asn	Ser	Gly	Asn
			50				55					60				
25	Ile	Phe	Val	Val	Ser	Leu	Ser	Val	Ala	Asp	Met	Leu	Val	Ala	Ile	Tyr
			65			70				75					80	
	Pro	Tyr	Pro	Leu	Met	Leu	His	Ala	Met	Ser	Ile	Gly	Gly	Trp	Asp	Leu
				85					90						95	
	Ser	Gln	Leu	Gln	Cys	Gln	Met	Val	Gly	Phe	Ile	Thr	Gly	Leu	Ser	Val
30				100					105					110		
	Val	Gly	Ser	Ile	Phe	Asn	Ile	Val	Ala	Ile	Ala	Ile	Asn	Arg	Tyr	Cys
			115					120					125			
	Tyr	Ile	Cys	His	Ser	Leu	Gln	Tyr	Glu	Arg	Ile	Phe	Ser	Val	Arg	Asn
			130				135						140			

79

Thr Cys Ile Tyr Leu Val Ile Thr Trp Ile Met Thr Val Leu Ala Val
 145 150 155 160
 Leu Pro Asn Met Tyr Ile Gly Thr Ile Glu Tyr Asp Pro Arg Thr Tyr
 165 170 175
 5 Thr Cys Ile Phe Asn Tyr Leu Asn Asn Pro Val Phe Thr Val Thr Ile
 180 185 190
 Val Cys Ile His Phe Val Leu Pro Leu Leu Ile Val Gly Phe Cys Tyr
 195 200 205
 10 Val Arg Ile Trp Thr Lys Val Leu Ala Ala Arg Asp Pro Ala Gly Gln
 210 215 220
 Asn Pro Asp Asn Gln Leu Ala Glu Val Arg Asn Phe Leu Thr Met Phe
 225 230 235 240
 Val Ile Phe Leu Leu Phe Ala Val Cys Trp Cys Pro Ile Asn Val Leu
 245 250 255
 15 Thr Val Leu Val Ala Val Ser Pro Lys Glu Met Ala Gly Lys Ile Pro
 260 265 270
 Asn Trp Leu Tyr Leu Ala Ala Tyr Phe Ile Ala Tyr Phe Asn Ser Cys
 275 280 285
 20 Leu Asn Ala Val Ile Tyr Gly Leu Leu Asn Glu Asn Phe Arg Arg Glu
 290 295 300
 Tyr Trp Thr Ile Phe His Ala Met Arg His Pro Ile Ile Phe Phe Pro
 305 310 315 320
 Gly Leu Ile Ser Asp Ile Arg Glu Met Gln Glu Ala Arg Thr Leu Ala
 325 330 335
 25 Arg Ala Arg Ala His Ala Arg Asp Gln Ala Arg Glu Gln Asp Arg Ala
 340 345 350
 His Ala Cys Pro Ala Val Glu Glu Thr Pro Met Asn Val Arg Asn Val
 355 360 365
 30 Pro Leu Pro Gly Asp Ala Ala Ala Gly His Pro Asp Arg Ala Ser Gly
 370 375 380
 His Pro Lys Pro His Ser Arg Ser Ser Ser Ala Tyr Arg Lys Ser Ala
 385 390 395 400
 Ser Thr His His Lys Ser Val Phe Ser His Ser Lys Ala Ala Ser Gly
 405 410 415
 35 His Leu Lys Pro Val Ser Gly His Ser Lys Pro Ala Ser Gly His Pro
 420 425 430
 Lys Ser Ala Thr Val Tyr Pro Lys Pro Ala Ser Val His Phe Lys Gly

80

	435	440	445
	Asp Ser Val His Phe Lys Gly Asp Ser Val His Phe Lys Pro Asp Ser		
	450	455	460
5	Val His Phe Lys Pro Ala Ser Ser Asn Pro Lys Pro Ile Thr Gly His		
	465	470	475
	His Val Ser Ala Gly Ser His Ser Lys Ser Ala Phe Ser Ala Ala Thr		
	485	490	495
	Ser His Pro Lys Pro Ile Lys Pro Ala Thr Ser His Ala Glu Pro Thr		
	500	505	510
10	Thr Ala Asp Tyr Pro Lys Pro Ala Thr Thr Ser His Pro Lys Pro Ala		
	515	520	525
	Ala Ala Asp Asn Pro Glu Leu Ser Ala Ser His Cys Pro Glu Ile Pro		
	530	535	540
15	Ala Ile Ala His Pro Val Ser Asp Asp Ser Asp Leu Pro Glu Ser Ala		
	545	550	555
	Ser Ser Pro Ala Ala Gly Pro Thr Lys Pro Ala Ala Ser Gln Leu Glu		
	565	570	575
	Ser Asp Thr Ile Ala Asp Leu Pro Asp Pro Thr Val Val Thr Thr Ser		
	580	585	590
20	Thr Asn Asp Tyr His Asp Val Val Val Val Asp Val Glu Asp Asp Pro		
	595	600	605
	Asp Glu Met Ala Val		
	610		

(102) INFORMATION FOR SEQ ID NO:101:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 32 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 30 (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

TCCAAGCTTC GCCATGGGAC ATAACGGGAG CT

32

(103) INFORMATION FOR SEQ ID NO:102:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

CGTGAATTCC AAGAATTAC AATCCTTGCT

30

5 (104) INFORMATION FOR SEQ ID NO:103:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1548 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

ATGGGACATA ACGGGAGCTG GATCTCTCCA AATGCCAGCG AGCCGCACAA CGCGTCCGEC 60

GCCGAGGCTG CGGGTGTGAA CCGCAGCGCG CTCGGGGAGT TCGGCGAGGC GCAGCTGTAC 120

15 CGCCAGTTCA CCACCACCGT GCAGGTCGTC ATCTTCATAG GCTCGCTGCT CGGAAACTTC 180

ATGGTGTAT GGTCAACTTG CCGCACAACC GTGTTCAAAT CTGTCACCAA CAGGTTTATT 240

AAAAACCTGG CCTGCTCGGG GATTGTGCC AGCCTGGTCT GTGTGCCCTT CGACATCATC 300

CTCAGCACCA GTCCTCACTG TTGCTGGTGG ATCTACACCA TGCTCTTCTG CAAGGTCGTC 360

AAATTTTTCG ACAAAGTATT CTGCTCTGTG ACCATCCTCA GCTTCCCTGC TATTGCTTTG 420

20 GACAGGTA CTCTAGTCCT CTATCCACTG GAGAGGAAAA TATCTGATGC CAAGTCCCGT 480

GAACTGGTGA TGTACATCTG GGCCCATGCA GTGGTGGCCA GTGTCCCTGT GTTTGCAGTA 540

ACCAATGTGG CTGACATCTA TGCCACGTCC ACCTGCACGG AAGTCTGGAG CAACTCCTTG 600

GGCCACCTGG TGTACGTTCT GGTGTATAAC ATCACCACGG TCATTGTGCC TGTGGTGGTG 660

GTGTTCTCT TCTTGATACT GATCCGACGG GCCCTGAGTG CCAGCCAGAA GAAGAAGGTC 720

25 ATCATAGCAG CGCTCCGGAC CCCACAGAAC ACCATCTCTA TTCCCTATGC CTCCCAGCGG 780

GAGGCCGAGC TGCACGCCAC CCTGCTCTCC ATGGTGATGG TCTTCATCTT GTGTAGCGTG 840

CCCTATGCCA CCCTGGTCTG CTACCAGACT GTGCTCAATG TCCCTGACAC TTCCGTCTTC 900

TTGCTGCTCA CTGCTGTTTG GCTGCCCAAA GTCTCCCTGC TGGCAAACCC TGTCTCTTT 960

CTTACTGTGA ACAAATCTGT CCGCAAGTGC TTGATAGGGA CCCTGGTGCA ACTACACCAC 1020

30 CGGTACAGTC GCCGTAATGT GGTCAGTACA GGGAGTGGCA TGGCTGAGGC CAGCCTGGAA 1080

CCCAGCATAC GCTCGGGTAG CCAGCTCCTG GAGATGTTCC ACATTGGGCA GCACGAGATC 1140
 TTTAAGCCCA CAGAGGATGA GGAACAGAGT GAGGCCAAGT ACATTGGCTC AGCTGACTTC 1200
 CAGGCCAAGG AGATATTTAG CACCTGCCTC GAGGGAGAGC AGGGGCCACA GTTTGCGCCC 1260
 TCTGCCCCAC CCCTGAGCAC AGTGGACTCT GTATCCCAGG TGGCACCGGC AGCCCCGTGTG 1320
 5 GAACCTGAAA CATTCCTTGA TAAGTATTCC CTGCAGTTTG GCTTTGGGCC TTTTGAGTTG 1380
 CCTCCTCAGT GGCTCTCAGA GACCCGAAAC AGCAAGAAGC GGCTGCTTCC CCCCTTGGGC 1440
 AACACCCAG AAGAGCTGAT CCAGACAAAG GTGCCCAAGG TAGGCAGGGT GGAGCGGAAG 1500
 ATGAGCAGAA ACAATAAAGT GAGCATT TTTT CCAAAGGTGG ATTCCTAG 1548

(105) INFORMATION FOR SEQ ID NO:104:

- 10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 515 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant
- 15 (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:
- | | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | Met | Gly | His | Asn | Gly | Ser | Trp | Ile | Ser | Pro | Asn | Ala | Ser | Glu | Pro | His |
| | 1 | | | | 5 | | | | | 10 | | | | 15 | | |
| 20 | Asn | Ala | Ser | Gly | Ala | Glu | Ala | Ala | Gly | Val | Asn | Arg | Ser | Ala | Leu | Gly |
| | | | | 20 | | | | | 25 | | | | | 30 | | |
| | Glu | Phe | Gly | Glu | Ala | Gln | Leu | Tyr | Arg | Gln | Phe | Thr | Thr | Thr | Val | Gln |
| | | | 35 | | | | 40 | | | | | | 45 | | | |
| | Val | Val | Ile | Phe | Ile | Gly | Ser | Leu | Leu | Gly | Asn | Phe | Met | Val | Leu | Trp |
| | | | 50 | | | | 55 | | | | | 60 | | | | |
| 25 | Ser | Thr | Cys | Arg | Thr | Thr | Val | Phe | Lys | Ser | Val | Thr | Asn | Arg | Phe | Ile |
| | | | | | | | 70 | | | | | 75 | | | 80 | |
| | Lys | Asn | Leu | Ala | Cys | Ser | Gly | Ile | Cys | Ala | Ser | Leu | Val | Cys | Val | Pro |
| | | | | | | | 85 | | | | | 90 | | | 95 | |
| 30 | Phe | Asp | Ile | Ile | Leu | Ser | Thr | Ser | Pro | His | Cys | Cys | Trp | Trp | Ile | Tyr |
| | | | | | 100 | | | | 105 | | | | | 110 | | |
| | Thr | Met | Leu | Phe | Cys | Lys | Val | Val | Lys | Phe | Leu | His | Lys | Val | Phe | Cys |
| | | | | | 115 | | | | 120 | | | | | 125 | | |
| | Ser | Val | Thr | Ile | Leu | Ser | Phe | Pro | Ala | Ile | Ala | Leu | Asp | Arg | Tyr | Tyr |
| | | | | | 130 | | | | 135 | | | | | 140 | | |

83

Ser Val Leu Tyr Pro Leu Glu Arg Lys Ile Ser Asp Ala Lys Ser Arg
 145 150 155 160
 Glu Leu Val Met Tyr Ile Trp Ala His Ala Val Val Ala Ser Val Pro
 165 170 175
 5 Val Phe Ala Val Thr Asn Val Ala Asp Ile Tyr Ala Thr Ser Thr Cys
 180 185 190
 Thr Glu Val Trp Ser Asn Ser Leu Gly His Leu Val Tyr Val Leu Val
 195 200 205
 10 Tyr Asn Ile Thr Thr Val Ile Val Pro Val Val Val Val Phe Leu Phe
 210 215 220
 Leu Ile Leu Ile Arg Arg Ala Leu Ser Ala Ser Gln Lys Lys Lys Val
 225 230 235 240
 Ile Ile Ala Ala Leu Arg Thr Pro Gln Asn Thr Ile Ser Ile Pro Tyr
 245 250 255
 15 Ala Ser Gln Arg Glu Ala Glu Leu His Ala Thr Leu Leu Ser Met Val
 260 265 270
 Met Val Phe Ile Leu Cys Ser Val Pro Tyr Ala Thr Leu Val Val Tyr
 275 280 285
 20 Gln Thr Val Leu Asn Val Pro Asp Thr Ser Val Phe Leu Leu Leu Thr
 290 295 300
 Ala Val Trp Leu Pro Lys Val Ser Leu Leu Ala Asn Pro Val Leu Phe
 305 310 315 320
 Leu Thr Val Asn Lys Ser Val Arg Lys Cys Leu Ile Gly Thr Leu Val
 325 330 335
 25 Gln Leu His His Arg Tyr Ser Arg Arg Asn Val Val Ser Thr Gly Ser
 340 345 350
 Gly Met Ala Glu Ala Ser Leu Glu Pro Ser Ile Arg Ser Gly Ser Gln
 355 360 365
 30 Leu Leu Glu Met Phe His Ile Gly Gln Gln Gln Ile Phe Lys Pro Thr
 370 375 380
 Glu Asp Glu Glu Glu Ser Glu Ala Lys Tyr Ile Gly Ser Ala Asp Phe
 385 390 395 400
 Gln Ala Lys Glu Ile Phe Ser Thr Cys Leu Glu Gly Glu Gln Gly Pro
 405 410 415
 35 Gln Phe Ala Pro Ser Ala Pro Pro Leu Ser Thr Val Asp Ser Val Ser
 420 425 430
 Gln Val Ala Pro Ala Ala Pro Val Glu Pro Glu Thr Phe Pro Asp Lys

84

435 440 445

Tyr Ser Leu Gln Phe Gly Phe Gly Pro Phe Glu Leu Pro Pro Gln Trp
 450 455 460

5 Leu Ser Glu Thr Arg Asn Ser Lys Lys Arg Leu Leu Pro Pro Leu Gly
 465 470 475 480

Asn Thr Pro Glu Glu Leu Ile Gln Thr Lys Val Pro Lys Val Gly Arg
 485 490 495

Val Glu Arg Lys Met Ser Arg Asn Asn Lys Val Ser Ile Phe Pro Lys
 500 505 510

10 Val Asp Ser
 515

(106) INFORMATION FOR SEQ ID NO:105:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

20 GGAGAATTCA CTAGGCGAGG CGCTCCATC 29

(107) INFORMATION FOR SEQ ID NO:106:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

GGAGGATCCA GGAAACCTTA GGCCGAGTCC 30

30 (108) INFORMATION FOR SEQ ID NO:107:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1164 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

```

ATGAATCGGC ACCATCTGCA GGATCACTTT CTGGAAATAG ACAAGAAGAA CTGCTGTGTG      60
TTCGAGATG ACTTCATTGC CAAGGTGTG CCGCCGGTGT TGGGGCTGGA GTTTATCTTT      120
GGGCTTCTGG GCAATGGCCT TGGCCTGTGG ATTTTCTGTT TCCACCTCAA GTCTGGAAA      180
5  TCCAGCCGGA TTTTCCTGTT CAACCTGGCA GTAGCTGACT TTCTACTGAT CATCTGCCTG      240
CGGTTCTGTA TGGACTACTA TGTGCGCGGT TCAGACTGGA ACTTTGGGGA CATCCCTTGC      300
CGGCTGGTGC TCTTCATGTT TGCCATGAAC CGCCAGGGCA GCATCATCTT CCTCACGGTG      360
GTGGCGGTAG ACAGSTATTT CCGGGTGGTC CATCCCCACC ACGCCCTGAA CAAGATCTCC      420
AATTGGACAG CAGCCATCAT CTCTTGCCTT CTGTGGGGCA TCACTGTTGG CCTAACAGTC      480
10  CACCTCCTGA AGAAGAAGTT GCTGATCCAG AATGGCCCTG CAAATGTGTG CATCAGCTTC      540
AGCATCTGCC ATACCTCCG GTGGCAGGAA GCTATGTTCC TCCTGGAGTT CCTCCTGCCC      600
CTGGGCATCA TCCTGTTCTG CTCAGCCAGA ATTATCTGGA GCCTGCGGCA GAGACAAATG      660
GACCGGCATG CCAAGATCAA GAGAGCCATC ACCTTCATCA TGGTGGTGGC CATCGTCTTT      720
GTCTCTGCT TCCTTCCCAG CGTGGTGTG CGGATCCGCA TCTTCTGGCT CCTGCACACT      780
15  TCGGGCACGC AGAATTGTGA AGTGTACGC TCGGTGGACC TGGCGTTCTT TATCACTCTC      840
AGCTTCACCT ACATGAACAG CATGCTGGAC CCCGTGGTGT ACTACTTCTC CAGCCCATCC      900
TTTCCCAACT TCTTCTCCAC TTGATCAAC CGCTGCCTCC AGAGGAAGAT GACAGGTGAG      960
CCAGATAATA ACCGCAGCAC GAGCGTCGAG CTCACAGGGG ACCCCAACAA AACCAGAGGC      1020
GCTCCAGAGG CGTTAATGGC CAACTCCGGT GAGCCATGGA GCCCCTCTTA TCTGGGCCCA      1080
20  ACCTCAAATA ACCATTCAA GAAGGGACAT TGTACCAAG AACCAGCATC TCTGGAGAAA      1140
CAGTTGGGCT GTTGCATCGA GTAA
                                                                    1164

```

(109) INFORMATION FOR SEQ ID NO:108:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 387 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

30 Met Asn Arg His His Leu Gln Asp His Phe Leu Glu Ile Asp Lys Lys

87

Phe Ser Thr Leu Ile Asn Arg Cys Leu Gln Arg Lys Met Thr Gly Glu
 305 310 315 320
 Pro Asp Asn Asn Arg Ser Thr Ser Val Glu Leu Thr Gly Asp Pro Asn
 325 330 335
 5 Lys Thr Arg Gly Ala Pro Glu Ala Leu Met Ala Asn Ser Gly Glu Pro
 340 345 350
 Trp Ser Pro Ser Tyr Leu Gly Pro Thr Ser Asn Asn His Ser Lys Lys
 355 360 365
 10 Gly His Cys His Gln Glu Pro Ala Ser Leu Glu Lys Gln Leu Gly Cys
 370 375 380
 Cys Ile Glu
 385

(110) INFORMATION FOR SEQ ID NO:109:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 37 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

ACCATGGCTT GCAATGGCAG TCGGCCAGG GGGCACT

37

(111) INFORMATION FOR SEQ ID NO:110:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 39 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

30 (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

CGACCAGGAC AAACAGCATC TTGGTCACTT GTCTCCGGC

39

(112) INFORMATION FOR SEQ ID NO:111:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 39 base pairs
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

GACCAAGATG CTGTTTGTCC TGGTCGTGGT GTTTGGCAT 39

(113) INFORMATION FOR SEQ ID NO:112:

10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

15 (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

CGGAATTCAG GATGGATCGG TCTCTTGCTG CGCCT 35

(114) INFORMATION FOR SEQ ID NO:113:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1212 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

ATGGCTTGCA ATGGCAGTGC GGCCAGGGGG CACTTTGACC CTGAGGACTT GAACCTGACT 60

GACGAGGCAC TGAGACTCAA GTACCTGGGG CCCAGCAGA CAGAGCTGTT CATGCCCATC 120

TGTGCCACAT ACCTGCTGAT CTTGCTGGTG GGCCTGTGG GCAATGGGCT GACCTGTCTG 180

GTCATCCTGC GCCACAAGGC CATGCGCAGC CCTACCAACT ACTACCTCTT CAGCCTGGCC 240

30 GTGTGCGACC TGCTGGTGCT GCTGGTGGGC CTGCCCCTGG AGCTCTATGA GATGTGGCAC 300

AACTACCCCT TCCTGCTGGG CGTTGGTGGC TGCTATTTC GCACGCTACT GTTTGAGATG 360

GTCTGCCTGG CCTCAGTGCT CAACGTCCT GGCCTGAGCG TGAACGCTA TGTGGCCGTG 420

GTGCACCCAC TCCAGGCCAG GTCCATGGTG ACGCGGGCCC ATGTGCGCCG AGTGCTTGGG 480

GCCGTCTGGG GTCTTGCCAT GCTCTGCTCC CTGCCCAACA CCAGCCTGCA CGGCATCCGG 540
 CAGCTGCACG TGCCCTGCCG GGGCCAGTG CCAGACTCAG CTGTTTGCAT GCTGGTCCGC 600
 CCACGGGCCC TCTACAACAT GGTAGTGAG ACCACCGCGC TGCTCTTCTT CTGCCTGCCC 660
 ATGGCCATCA TGACCGTCT CTACCTGCTC ATTGGGCTGC GACTGCGGCG GGAGAGGCTG 720
 5 CTGCTCATGC AGGAGGCCAA GGGCAGGGGC TCTGCAGCAG CCAGGTCCAG ATACACCTGC 780
 AGGCTCCAGC AGCACGATCG GGGCCGAGA CAAGTGACCA AGATGCTGTT TGTCCTGCTC 840
 GTGGTGTGTTG GCATCTGCTG GGGCCGTTT CACGCCGACC GCGTCATGTG GAGCGTCGTG 900
 TCACAGTGA CAGATGGCCT GCACCTGGCC TTCCAGCAGC TGCACGTCAT CTCCGGCATC 960
 TTCTTCTACC TGGGCTCGGC GGCCAACCCC GTGCTCTATA GCCTCATGTC CAGCCGCTTC 1020
 10 CGAGAGACCT TCCAGGAGGC CCTGTGCCTC GGGGCTGCT GCCATCGCCT CAGACCCCGC 1080
 CACAGCTCCC ACAGCTCAG CAGGATGACC ACAGGCAGCA CCCTGTGTGA TGTGGGCTCC 1140
 CTGGGCAGCT GGGTCCACCC CCTGGCTGGG AACGATGGCC CAGAGGCGCA GCAAGAGACC 1200
 GATCCATCCT GA 1212

(115) INFORMATION FOR SEQ ID NO:114:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 403 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

20 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

Met Ala Cys Asn Gly Ser Ala Ala Arg Gly His Phe Asp Pro Glu Asp
 1 5 10 15

25 Leu Asn Leu Thr Asp Glu Ala Leu Arg Leu Lys Tyr Leu Gly Pro Gln
 20 25 30

Gln Thr Glu Leu Phe Met Pro Ile Cys Ala Thr Tyr Leu Leu Ile Phe
 35 40 45

Val Val Gly Ala Val Gly Asn Gly Leu Thr Cys Leu Val Ile Leu Arg
 50 55 60

30 His Lys Ala Met Arg Thr Pro Thr Asn Tyr Tyr Leu Phe Ser Leu Ala
 65 70 75 80

Val Ser Asp Leu Leu Val Leu Leu Val Gly Leu Pro Leu Glu Leu Tyr
 85 90 95

90

Glu Met Trp His Asn Tyr Pro Phe Leu Leu Gly Val Gly Gly Cys Tyr
 100 105 110
 Phe Arg Thr Leu Leu Phe Glu Met Val Cys Leu Ala Ser Val Leu Asn
 115 120 125
 5 Val Thr Ala Leu Ser Val Glu Arg Tyr Val Ala Val Val His Pro Leu
 130 135 140
 Gln Ala Arg Ser Met Val Thr Arg Ala His Val Arg Arg Val Leu Gly
 145 150 155 160
 10 Ala Val Trp Gly Leu Ala Met Leu Cys Ser Leu Pro Asn Thr Ser Leu
 165 170 175
 His Gly Ile Arg Gln Leu His Val Pro Cys Arg Gly Pro Val Pro Asp
 180 185 190
 Ser Ala Val Cys Met Leu Val Arg Pro Arg Ala Leu Tyr Asn Met Val
 195 200 205
 15 Val Gln Thr Thr Ala Leu Leu Phe Phe Cys Leu Pro Met Ala Ile Met
 210 215 220
 Ser Val Leu Tyr Leu Leu Ile Gly Leu Arg Leu Arg Arg Glu Arg Leu
 225 230 235 240
 20 Leu Leu Met Gln Glu Ala Lys Gly Arg Gly Ser Ala Ala Ala Arg Ser
 245 250 255
 Arg Tyr Thr Cys Arg Leu Gln Gln His Asp Arg Gly Arg Arg Gln Val
 260 265 270
 Thr Lys Met Leu Phe Val Leu Val Val Val Phe Gly Ile Cys Trp Ala
 275 280 285
 25 Pro Phe His Ala Asp Arg Val Met Trp Ser Val Val Ser Gln Trp Thr
 290 295 300
 Asp Gly Leu His Leu Ala Phe Gln His Val His Val Ile Ser Gly Ile
 305 310 315 320
 30 Phe Phe Tyr Leu Gly Ser Ala Ala Asn Pro Val Leu Tyr Ser Leu Met
 325 330 335
 Ser Ser Arg Phe Arg Glu Thr Phe Gln Glu Ala Leu Cys Leu Gly Ala
 340 345 350
 Cys Cys His Arg Leu Arg Pro Arg His Ser Ser His Ser Leu Ser Arg
 355 360 365
 35 Met Thr Thr Gly Ser Thr Leu Cys Asp Val Gly Ser Leu Gly Ser Trp
 370 375 380
 Val His Pro Leu Ala Gly Asn Asp Gly Pro Glu Ala Gln Gln Glu Thr

385

390

395

400

Asp Pro Ser

(116) INFORMATION FOR SEQ ID NO:115:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

- 10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

GGAAGCTTCA GGCCCAAAGA TGGGGAACAT

30

(117) INFORMATION FOR SEQ ID NO:116:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

GTGGATCCAC CCGCGGAGGA CCCAGGCTAG

30

(118) INFORMATION FOR SEQ ID NO:117:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1098 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

- 30 ATGGGGAACA TCACTGCAGA CAACTCCTCG ATGAGCTGTA CCATCGACCA TACCATCCAC 60
 CAGACGCTGG CCCCCTGGT CTATGTTACC GTGCTGGTGG TGGGCTTCCC GGCCAACTGC 120
 CTGTCCCTCT ACTTCGGCTA CCTGCAGATC AAGGCCCGGA ACGAGCTGGG CGTGTACCTG 180
 TGCAACCTGA CGGTGGCCGA CCTCTTCTAC ATCTGCTCGC TGGCCCTTCTG GCTGCAGTAC 240
 GTGCTGCAGC ACGACAACTG GTCTCACGGC GACCTGTCCT GCCAGGTGTG CGGCATCCTC 300
 35 CTGTACGAGA ACATCTACAT CAGCGTGGGC TTCCTCTGCT GCATCTCCGT GGACCGCTAC 360

```

CTGGCTGTGG CCCATCCCTT CCGCTTCCAC CAGTTCCGGA CCCTGAAGGC GGCCGTCGGC 420
GTCAGCGTGG TCATCTGGGC CAAGGAGCTG CTGACCAGCA TCTACTTCCT GATGCACGAG 480
GAGGTCATCG AGGACGAGAA CCAGCACCGC GTGTGCTTTG AGCACTAACC CATCCAGGCA 540
TGGCAGCGCG CCATCAACTA CTACCGCTTC CTGGTGGGCT TCCTCTTCCC CATCTGCCTG 600
5 CTGCTGGCGT CCTACCAGGG CATCCTGCGC GCCGTGCGCC GGAGCCACGG CACCCAGAAG 660
AGCCGCAAGG ACCAGATCCA GCGGCTGGTG CTCAGCACCG TGATCATCTT CCTGGCCTGC 720
TTCTGCCCCT ACCACGTGTT GCTGCTGGTG CGCAGCGTCT GGGAGGCCAG CTGCGACTTC 780
GCCAAGGGCG TTTTCAACGC CTACCACTTC TCCCTCCTGC TCACCAGCTT CAACTGCGTC 840
GCCGACCCCG TGCTCTACTG CTTGCTCAGC GAGACCACCC ACCGGGACCT GGCCCCGCTC 900
10 CGCGGGGCCT GCCTGGCCTT CCTCACCTGC TCCAGGACCG GCCGGGCCAG GGAGGCCTAC 960
CCGCTGGGTG CCCCCGAGGC CTCCGGGAAA AGCGGGGCCC AGGGTGAGGA GCCCGAGCTG 1020
TTGACCAAGC TCCACCCGGC CTTCCAGACC CTTAACTCGC CAGGGTCGGG CGGGTTCCCC 1080
ACGGGCAGGT TGGCCTAG 1098

```

(119) INFORMATION FOR SEQ ID NO:118:

```

15 (i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 365 amino acids
    (B) TYPE: amino acid
    (C) STRANDEDNESS:
    (D) TOPOLOGY: not relevant

20 (ii) MOLECULE TYPE: protein

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

Met Gly Asn Ile Thr Ala Asp Asn Ser Ser Met Ser Cys Thr Ile Asp
1          5          10          15

His Thr Ile His Gln Thr Leu Ala Pro Val Val Tyr Val Thr Val Leu
25          20          25          30

Val Val Gly Phe Pro Ala Asn Cys Leu Ser Leu Tyr Phe Gly Tyr Leu
35          40          45

Gln Ile Lys Ala Arg Asn Glu Leu Gly Val Tyr Leu Cys Asn Leu Thr
50          55          60

30 Val Ala Asp Leu Phe Tyr Ile Cys Ser Leu Pro Phe Trp Leu Gln Tyr
65          70          75          80

Val Leu Gln His Asp Asn Trp Ser His Gly Asp Leu Ser Cys Gln Val
85          90          95

```

Cys Gly Ile Leu Leu Tyr Glu Asn Ile Tyr Ile Ser Val Gly Phe Leu
 100 105 110
 Cys Cys Ile Ser Val Asp Arg Tyr Leu Ala Val Ala His Pro Phe Arg
 115 120 125
 5 Phe His Gln Phe Arg Thr Leu Lys Ala Ala Val Gly Val Ser Val Val
 130 135 140
 Ile Trp Ala Lys Glu Leu Leu Thr Ser Ile Tyr Phe Leu Met His Glu
 145 150 155 160
 10 Glu Val Ile Glu Asp Glu Asn Gln His Arg Val Cys Phe Glu His Tyr
 165 170 175
 Pro Ile Gln Ala Trp Gln Arg Ala Ile Asn Tyr Tyr Arg Phe Leu Val
 180 185 190
 Gly Phe Leu Phe Pro Ile Cys Leu Leu Leu Ala Ser Tyr Gln Gly Ile
 195 200 205
 15 Leu Arg Ala Val Arg Arg Ser His Gly Thr Gln Lys Ser Arg Lys Asp
 210 215 220
 Gln Ile Gln Arg Leu Val Leu Ser Thr Val Val Ile Phe Leu Ala Cys
 225 230 235 240
 20 Phe Leu Pro Tyr His Val Leu Leu Leu Val Arg Ser Val Trp Glu Ala
 245 250 255
 Ser Cys Asp Phe Ala Lys Gly Val Phe Asn Ala Tyr His Phe Ser Leu
 260 265 270
 Leu Leu Thr Ser Phe Asn Cys Val Ala Asp Pro Val Leu Tyr Cys Phe
 275 280 285
 25 Val Ser Glu Thr Thr His Arg Asp Leu Ala Arg Leu Arg Gly Ala Cys
 290 295 300
 Leu Ala Phe Leu Thr Cys Ser Arg Thr Gly Arg Ala Arg Glu Ala Tyr
 305 310 315 320
 30 Pro Leu Gly Ala Pro Glu Ala Ser Gly Lys Ser Gly Ala Gln Gly Glu
 325 330 335
 Glu Pro Glu Leu Leu Thr Lys Leu His Pro Ala Phe Gln Thr Pro Asn
 340 345 350
 Ser Pro Gly Ser Gly Gly Phe Pro Thr Gly Arg Leu Ala
 355 360 365

35 (120) INFORMATION FOR SEQ ID NO:119:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

GACCTCGAGT CCTTCTACAC CTCATC

26

(121) INFORMATION FOR SEQ ID NO:120:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

15 TGCTCTAGAT TCCAGATAGG TGAAAACCTG

30

(122) INFORMATION FOR SEQ ID NO:121:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 1416 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

ATGGATATTC TTTGTGAAGA AAATACTTCT TTGAGCTCAA CTACGAACTC CCTAATGCAA 60

25 TTAAATGATG ACAACAGGCT CTACAGTAAT GACTTTAACT CCGGAGAAGC TAACACTTCT 120

GATGCATTTA ACTGGACAGT CGACTCTGAA AATCGAACCA ACCTTTCCTG TGAAGGGTGC 180

CTCTCACCGT CGTGTCTCTC CTTACTTCAT CTCCAGGAAA AAAACTGGTC TGCTTTACTG 240

ACAGCCGTAG TGATTATTCT AACTATTGCT GGAAACATAC TCGTCATCAT GGCAGTGTCC 300

CTAGAGAAAA AGCTGCAGAA TGCCACCAAC TATTTCTTGA TGTCACTTGC CATAGCTGAT 360

30 ATGCTGCTGG GTTTCCTTGT CATGCCCGTG TCCATGTAA CCATCCTGTA TGGGTACCGG 420

TGGCCTCTGC CGAGCAAGCT TTGTGCAGTC TGGATTACC TGGACGTGCT CTTCTCCACG 480

GCCTCCATCA TGCACCTCTG CGCCATCTCG CTGGACCGCT ACGTCGCCAT CCAGAATCCC 540

ATCCACCACA GCCGCTTCAA CTCCAGAACT AAGGCATTTT TGAAAATCAT TGCTGTTTGG 600

ACCATATCAG TAGGTATATC CATGCCAATA CCAGTCTTTG GGCTACAGGA CGATTGGAAG 660
 GTCTTTAAGG AGGGGAGTTG CTTACTCGCC GATGATAACT TTGTCCTGAT CGGCTCTTTT 720
 GTGTCATTTT TCATTCCCTT AACCATCATG GTGATCACCT ACTTTCTAAC TATCAAGTCA 780
 TCCAGAAAG AAGCTACTTT GTGTGTAAGT GATCTTGGCA CACGGGCCAA ATTAGCTTCT 840
 5 TTCAGCTTCC TCCCTCAGAG TTCTTTGTCT TCAGAAAAGC TCTTCCAGCG GTCGATCCAT 900
 AGGGAGCCAG GGTCTACAC AGGCAGGAGG ACTATGCAGT CCATCAGCAA TGAGCAAAAG 960
 GCATGCAAGG TGCTGGGCAT CGTCTCTTC CTGTTTGTGG TGATGTGGTG CCCTTCTTC 1020
 ATCACAACA TCATGGCCGT CATCTGCAA GAGTCCTGCA ATGAGGATGT CATTGGGGCC 1080
 CTGCTCAATG TGTITGTTG GATCGGTAT CTCTCTCAG CAGTCAACCC ACTAGTCTAC 1140
 10 ACACTGTTCA ACAAGACCTA TAGGTCAGCC TTTTCACGGT ATATTCAGTG TCAGTACAAG 1200
 GAAAACAAA AACCATGCA GTTAATTTA GTGAACACAA TACCGGCTTT GGCCTACAAG 1260
 TCTAGCCAAC TTCAAATGGG ACAAAAAAG AATTCAAAGC AAGATGCCAA GACAACAGAT 1320
 AATGACTGCT CAATGGTTGC TCTAGGAAAG CAGTATTCTG AAGAGGCTTC TAAAGACAAT 1380
 AGCGACGGAG TGAATGAAA GGTGAGCTGT GTGTGA 1416

15 (123) INFORMATION FOR SEQ ID NO:122:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 471 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - 20 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

	Met	Asp	Ile	Leu	Cys	Glu	Glu	Asn	Thr	Ser	Leu	Ser	Ser	Thr	Thr	Asn
	1				5					10					15	
25	Ser	Leu	Met	Gln	Leu	Asn	Asp	Asp	Asn	Arg	Leu	Tyr	Ser	Asn	Asp	Phe
				20				25					30			
	Asn	Ser	Gly	Glu	Ala	Asn	Thr	Ser	Asp	Ala	Phe	Asn	Trp	Thr	Val	Asp
			35				40					45				
30	Ser	Glu	Asn	Arg	Thr	Asn	Leu	Ser	Cys	Glu	Gly	Cys	Leu	Ser	Pro	Ser
		50				55				60						
	Cys	Leu	Ser	Leu	Leu	His	Leu	Gln	Glu	Lys	Asn	Trp	Ser	Ala	Leu	Leu
	65				70					75					80	

96

Thr Ala Val Val Ile Ile Leu Thr Ile Ala Gly Asn Ile Leu Val Ile
 85 90 95
 Met Ala Val Ser Leu Glu Lys Lys Leu Gln Asn Ala Thr Asn Tyr Phe
 100 105 110
 5 Leu Met Ser Leu Ala Ile Ala Asp Met Leu Leu Gly Phe Leu Val Met
 115 120 125
 Pro Val Ser Met Leu Thr Ile Leu Tyr Gly Tyr Arg Trp Pro Leu Pro
 130 135 140
 10 Ser Lys Leu Cys Ala Val Trp Ile Tyr Leu Asp Val Leu Phe Ser Thr
 145 150 155 160
 Ala Ser Ile Met His Leu Cys Ala Ile Ser Leu Asp Arg Tyr Val Ala
 165 170 175
 Ile Gln Asn Pro Ile His His Ser Arg Phe Asn Ser Arg Thr Lys Ala
 180 185 190
 15 Phe Leu Lys Ile Ile Ala Val Trp Thr Ile Ser Val Gly Ile Ser Met
 195 200 205
 Pro Ile Pro Val Phe Gly Leu Gln Asp Asp Ser Lys Val Phe Lys Glu
 210 215 220
 20 Gly Ser Cys Leu Leu Ala Asp Asp Asn Phe Val Leu Ile Gly Ser Phe
 225 230 235 240
 Val Ser Phe Phe Ile Pro Leu Thr Ile Met Val Ile Thr Tyr Phe Leu
 245 250 255
 Thr Ile Lys Ser Leu Gln Lys Glu Ala Thr Leu Cys Val Ser Asp Leu
 260 265 270
 25 Gly Thr Arg Ala Lys Leu Ala Ser Phe Ser Phe Leu Pro Gln Ser Ser
 275 280 285
 Leu Ser Ser Glu Lys Leu Phe Gln Arg Ser Ile His Arg Glu Pro Gly
 290 295 300
 30 Ser Tyr Thr Gly Arg Arg Thr Met Gln Ser Ile Ser Asn Glu Gln Lys
 305 310 315 320
 Ala Cys Lys Val Leu Gly Ile Val Phe Phe Leu Phe Val Val Met Trp
 325 330 335
 Cys Pro Phe Phe Ile Thr Asn Ile Met Ala Val Ile Cys Lys Glu Ser
 340 345 350
 35 Cys Asn Glu Asp Val Ile Gly Ala Leu Leu Asn Val Phe Val Trp Ile
 355 360 365
 Gly Tyr Leu Ser Ser Ala Val Asn Pro Leu Val Tyr Thr Leu Phe Asn

370 375 380

Lys Thr Tyr Arg Ser Ala Phe Ser Arg Tyr Ile Gln Cys Gln Tyr Lys
 385 390 395 400

5 Glu Asn Lys Lys Pro Leu Gln Leu Ile Leu Val Asn Thr Ile Pro Ala
 405 410 415

Leu Ala Tyr Lys Ser Ser Gln Leu Gln Met Gly Gln Lys Lys Asn Ser
 420 425 430

Lys Gln Asp Ala Lys Thr Thr Asp Asn Asp Cys Ser Met Val Ala Leu
 435 440 445

10 Gly Lys Gln Tyr Ser Glu Glu Ala Ser Lys Asp Asn Ser Asp Gly Val
 450 455 460

Asn Glu Lys Val Ser Cys Val
 465 470

(124) INFORMATION FOR SEQ ID NO:123:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 20 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

GACCTCGAGG TTGCTTAAGA CTGAAGC

27

(125) INFORMATION FOR SEQ ID NO:124:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

ATTTCTAGAC ATATGTAGCT TGTACCG

27

(126) INFORMATION FOR SEQ ID NO:125:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1377 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

```
ATGGTGAACC TGAGGAATGC GGTGCATTCA TTCCTTGTGC ACCTAATTGG CCTATTGGTT 60
TGGCAATGTG ATATTTCTGT GAGCCAGTA GCAGCTATAG TAACTGACAT TTTCAATACC 120
5 TCCGATGGTG GACGCTCAA ATCCCAGAC GGGGTACAAA ACTGGCCAGC ACTTTCATC 180
GTCATCATAA TAATCATGAC AATAGGTGGC AACATCCTTG TGATCATGGC AGTAAGCATG 240
GAAAAGAAAC TGCACAATGC CACCAATTAC TTCTTAATGT CCCTAGCCAT TGCTGATATG 300
CTAGTGGGAC TACTTGTCAT GCCCTGTCT CTCCTGGCAA TCCTTTATGA TTATGTCTGG 360
CCACTACCTA GATATTGTG CCCCCTCTGG ATTCTTTAG ATGTTTATT TTCAACAGCG 420
10 TCCATCATGC ACCTCTGCGC TATATCGCTG GATCGGTATG TAGCAATACG TAATCCTATT 480
GAGCATAGCC GTTTCATTC GCGGACTAAG GCCATCATGA AGATTGCTAT TGTTTGGGCA 540
ATTTCTATAG GTGTATCAGT TCCTATCCCT GTGATTGGAC TGAGGGACGA AGAAAAGGTG 600
TTCGTGAACA ACACGACGTG CGTGCTCAAC GACCCAAATT TCGTTCCTAT TGGGTCCTTC 660
GTAGCTTCT TCATACCGCT GACGATTATG GTGATTACGT ATTGCCTGAC CATCTACGTT 720
15 CTGCGCCGAC AAGCTTTGAT GTTACTGCAC GGCCACACCG AGGAACCGCC TGGACTAAGT 780
CTGGATTTC TGAAGTGCTG CAAGAGGAAT ACGGCCGAGG AAGAGAACTC TGCAAACCCT 840
AACCAAGACC AGAACGCACG CCGAAGAAAG AAGAAGGAGA GACGTCCTAG GGGCACCATG 900
CAGGCTATCA ACAATGAAAG AAAAGCTTCG AAAGTCCTTG GGATTGTTTT CTTTGTGTTT 960
CTGATCATGT GGTGCCCATT TTTATTACC AATATTCTGT CTGTTCTTTG TGAGAAGTCC 1020
20 TGTAACCAAA AGCTCATGGA AAAGCTTCTG AATGTGTTTG TTTGGATTGG CTATGTTTGT 1080
TCAGGAATCA ATCCTCTGGT GTATACTCTG TTCAACAAAA TTTACCGAAG GGCATTCTCC 1140
AACTATTTGC GTTGCAATTA TAAGGTAGAG AAAAAGCCTC CTGTCAGGCA GATTCCAAGA 1200
GTTGCCGCCA CTGCTTTGTC TGGGAGGGAG CTTAATGTTA ACATTATCG GCATACCAAT 1260
GAACCGGTGA TCGAGAAAGC CAGTGACAAT GAGCCCGGTA TAGAGATGCA AGTTGAGAAT 1320
25 TTAGAGTTAC CAGTAAATCC CTCCAGTGTG GTTAGCGAAA GGATTAGCAG TGTGTGA 1377
```

(127) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 458 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

5	Met Val Asn Leu Arg Asn Ala Val His Ser Phe Leu Val His Leu Ile	1 5 10 15
	Gly Leu Leu Val Trp Gln Cys Asp Ile Ser Val Ser Pro Val Ala Ala	20 25 30
10	Ile Val Thr Asp Ile Phe Asn Thr Ser Asp Gly Gly Arg Phe Lys Phe	35 40 45
	Pro Asp Gly Val Gln Asn Trp Pro Ala Leu Ser Ile Val Ile Ile Ile	50 55 60
	Ile Met Thr Ile Gly Gly Asn Ile Leu Val Ile Met Ala Val Ser Met	65 70 75 80
15	Glu Lys Lys Leu His Asn Ala Thr Asn Tyr Phe Leu Met Ser Leu Ala	85 90 95
	Ile Ala Asp Met Leu Val Gly Leu Leu Val Met Pro Leu Ser Leu Leu	100 105 110
20	Ala Ile Leu Tyr Asp Tyr Val Trp Pro Leu Pro Arg Tyr Leu Cys Pro	115 120 125
	Val Trp Ile Ser Leu Asp Val Leu Phe Ser Thr Ala Ser Ile Met His	130 135 140
	Leu Cys Ala Ile Ser Leu Asp Arg Tyr Val Ala Ile Arg Asn Pro Ile	145 150 155 160
25	Glu His Ser Arg Phe Asn Ser Arg Thr Lys Ala Ile Met Lys Ile Ala	165 170 175
	Ile Val Trp Ala Ile Ser Ile Gly Val Ser Val Pro Ile Pro Val Ile	180 185 190
30	Gly Leu Arg Asp Glu Glu Lys Val Phe Val Asn Asn Thr Thr Cys Val	195 200 205
	Leu Asn Asp Pro Asn Phe Val Leu Ile Gly Ser Phe Val Ala Phe Phe	210 215 220
	Ile Pro Leu Thr Ile Met Val Ile Thr Tyr Cys Leu Thr Ile Tyr Val	225 230 235 240
35	Leu Arg Arg Gln Ala Leu Met Leu Leu His Gly His Thr Glu Glu Pro	245 250 255

100

Pro Gly Leu Ser Leu Asp Phe Leu Lys Cys Cys Lys Arg Asn Thr Ala
 260 265 270
 Glu Glu Glu Asn Ser Ala Asn Pro Asn Gln Asp Gln Asn Ala Arg Arg
 275 280 285
 5 Arg Lys Lys Lys Glu Arg Arg Pro Arg Gly Thr Met Gln Ala Ile Asn
 290 295 300
 Asn Glu Arg Lys Ala Ser Lys Val Leu Gly Ile Val Phe Phe Val Phe
 305 310 315 320
 10 Leu Ile Met Trp Cys Pro Phe Phe Ile Thr Asn Ile Leu Ser Val Leu
 325 330 335
 Cys Glu Lys Ser Cys Asn Gln Lys Leu Met Glu Lys Leu Leu Asn Val
 340 345 350
 Phe Val Trp Ile Gly Tyr Val Cys Ser Gly Ile Asn Pro Leu Val Tyr
 355 360 365
 15 Thr Leu Phe Asn Lys Ile Tyr Arg Arg Ala Phe Ser Asn Tyr Leu Arg
 370 375 380
 Cys Asn Tyr Lys Val Glu Lys Lys Pro Pro Val Arg Gln Ile Pro Arg
 385 390 395 400
 20 Val Ala Ala Thr Ala Leu Ser Gly Arg Glu Leu Asn Val Asn Ile Tyr
 405 410 415
 Arg His Thr Asn Glu Pro Val Ile Glu Lys Ala Ser Asp Asn Glu Pro
 420 425 430
 Gly Ile Glu Met Gln Val Glu Asn Leu Glu Leu Pro Val Asn Pro Ser
 435 440 445
 25 Ser Val Val Ser Glu Arg Ile Ser Ser Val
 450 455

(128) INFORMATION FOR SEQ ID NO:127:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

 (ii) MOLECULE TYPE: DNA (genomic)

 (iii) SEQUENCE DESCRIPTION: SEQ ID NO:127:

35 GGTAAGCTTG GCAGTCCACG CCAGGCCTTC

30

(129) INFORMATION FOR SEQ ID NO:128:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
5 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

TCCGAATTCT CTGTAGACAC AAGGCTTTGG

30

(130) INFORMATION FOR SEQ ID NO:129:

- 10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1088 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

ATGGATCAGT TCCCTGAATC AGTGACAGAA AACTTTGAGT ACGATGATTT GGCTGAGGCC 60

TGTTATATTG GGGACATCGT GGTCTTTGGG ACTGTGTTCC TGTCATATT CTACTCCGTC 120

ATTTTGGCCA TTGGCCTGGT GGGAAATTG TTGGTAGTGT TTGCCCCAC CAACAGCAAG 180

20 AAGCCCAAGA GTGTCACCGA CATTACCTC CTGAACCTGG CCTGTGTGA TCTGCTGTTT 240

GTAGCCACTT TCCCTTCTG GACTCAGTAT TTGATAAATG AAAAGGGCT CCACAATGCC 300

ATGTGCAAAAT TCACTACCGC CTCTCTTTC ATCGGCTTT TTGGAAGCAT ATTCTTCATC 360

ACCGTCATCA GCATTGATAG GTACCTGGCC ATCGTCTTG CCGCCAACTC CATGAACAAC 420

CGGACCGTGC AGCATGGCGT CACCATCAGC CTAGGCSTGT GGGCAGCAGC CATTTTGGTG 480

25 GCAGCACCCC AGTTCATGTT CACAAAGCAG AAAGAAAATG AATGCCTTGE TGACTACCCC 540

GAGGTCTCTC AGGAAATCTG GCGGTGCTC CGCAATGTG AAACAAATT TCTTGGCTTC 600

CTACTCCCCC TGCTATTAT GAGTTATTGC TACTTCAGAA TCATCAGAG GCTGTTTTCC 660

TGCAAGAAGC ACAAGAAAGC CAAAGCCATT AACTGATCC TTCTGGTGGT CATCGTGTTC 720

TTCTCTTCTT GGACACCTA CAACGTATG ATTTTCTTGG AGACCTTAA GCTCTATGAC 780

30 TTCTTTCCCA GTTGTGACAT GAGGAAGGAT CTGAGGCTGG CCTCAGTGT GACTGAGACG 840

GTTGCATTTA GCCATTGTG CCTGAATCCT CTCATCTATG CATTTGCTGG GGAGAAGTTC 900

AGAAGATACC TTTACCACCT GTATGGGAAA TGCTGGCTG TCCTGTGTGG GCGCTCAGTC 960

102

CACGTTGATT TCTCTCATC TGAATCACA AGGAGCAGG ATGGAAGTGT TCTGAGCAGC 1020

AATTTTACTT ACCACACGAG TGATGCAGAT GCATTGCTCC TTCTCTGA 1068

(131) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 355 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

Met Asp Gln Phe Pro Glu Ser Val Thr Glu Asn Phe Glu Tyr Asp Asp
 1 5 10 15

Leu Ala Glu Ala Cys Tyr Ile Gly Asp Ile Val Val Phe Gly Thr Val
 20 25 30

15 Phe Leu Ser Ile Phe Tyr Ser Val Ile Phe Ala Ile Gly Leu Val Gly
 35 40 45

Asn Leu Leu Val Val Phe Ala Leu Thr Asn Ser Lys Lys Pro Lys Ser
 50 55 60

20 Val Thr Asp Ile Tyr Leu Leu Asn Leu Ala Leu Ser Asp Leu Leu Phe
 65 70 75 80

Val Ala Thr Leu Pro Phe Trp Thr His Tyr Leu Ile Asn Glu Lys Gly
 85 90 95

Leu His Asn Ala Met Cys Lys Phe Thr Thr Ala Phe Phe Phe Ile Gly
 100 105 110

25 Phe Phe Gly Ser Ile Phe Phe Ile Thr Val Ile Ser Ile Asp Arg Tyr
 115 120 125

Leu Ala Ile Val Leu Ala Ala Asn Ser Met Asn Asn Arg Thr Val Gln
 130 135 140

30 His Gly Val Thr Ile Ser Leu Gly Val Trp Ala Ala Ala Ile Leu Val
 145 150 155 160

Ala Ala Pro Gln Phe Met Phe Thr Lys Gln Lys Glu Asn Glu Cys Leu
 165 170 175

Gly Asp Tyr Pro Glu Val Leu Gln Glu Ile Trp Pro Val Leu Arg Asn
 180 185 190

35 Val Glu Thr Asn Phe Leu Gly Phe Leu Leu Pro Leu Leu Ile Met Ser
 195 200 205

103

Tyr Cys Tyr Phe Arg Ile Ile Gln Thr Leu Phe Ser Cys Lys Asn His
 210 215 220
 Lys Lys Ala Lys Ala Ile Lys Leu Ile Leu Leu Val Val Ile Val Phe
 225 230 235 240
 5 Phe Leu Phe Tyr Thr Pro Tyr Asn Val Met Ile Phe Leu Glu Thr Leu
 245 250 255
 Lys Leu Tyr Asp Phe Phe Pro Ser Cys Asp Met Arg Lys Asp Leu Arg
 260 265 270
 10 Leu Ala Leu Ser Val Thr Glu Thr Val Ala Phe Ser His Cys Cys Leu
 275 280 285
 Asn Pro Leu Ile Tyr Ala Phe Ala Gly Glu Lys Phe Arg Arg Tyr Leu
 290 295 300
 Tyr His Leu Tyr Gly Lys Cys Leu Ala Val Leu Cys Gly Arg Ser Val
 305 310 315 320
 15 His Val Asp Phe Ser Ser Ser Glu Ser Gln Arg Ser Arg His Gly Ser
 325 330 335
 Val Leu Ser Ser Asn Phe Thr Tyr His Thr Ser Asp Gly Asp Ala Leu
 340 345 350
 20 Leu Leu Leu
 355

(132) INFORMATION FOR SEQ ID NO:131:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 32 base pairs
 (B) TYPE: nucleic acid
 25 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

GATCTCCAGT AGGCATAAGT GGACAATTCT GG

32

30 (133) INFORMATION FOR SEQ ID NO:132:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 35 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

CTCCTTCGGT CCTCCTATCG TTSTCAGAAG

30

(134) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

10 AGAAGGCCAA GATCGCGCGG CTGGCCCTCA

30

(135) INFORMATION FOR SEQ ID NO:134:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

CGGCGCCACC GCACGAAAAA GCTCATCTTC

30

20 (136) INFORMATION FOR SEQ ID NO:135:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

GCCAAGAAGC GGGTGAAGTT CTTGGTGGTG GCA

33

(137) INFORMATION FOR SEQ ID NO:136:

30 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136.

CAGGCGGAAG GTGAAAGTCC TGGTCCTCGT

30

(136) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

CGGCGCCTGC GGGCCAASCG GCTGGTGSTG GTG

33

(137) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

20 CCAAGCACAA AGCCAAGAAA GTGACCATCA C

31

(140) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

GCGCCGGCGC ACCAAATGCT TGCTGGTGST

30

30 (141) INFORMATION FOR SEQ ID NO:140:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

106

- (i) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:
- CAAAAAGCTG AAGAAATCTA AGAAGATCAT CTTTATTGTC G 41
- (142) INFORMATION FOR SEQ ID NO:141:
- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- 10 (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:
- CAAGACCAAG GCAAAACGCA TGATCGCCAT 30
- (143) INFORMATION FOR SEQ ID NO:142:
- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:
- GTCAAGGAGA AGTCCAAAAG GATCATCATC 30
- (144) INFORMATION FOR SEQ ID NO:143:
- 25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:
- 30 CGCCGCGTGC GGGCCAAGCA GCTCCTGCTC 30
- (145) INFORMATION FOR SEQ ID NO:144:
- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

107

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

CCTGATAAGC GCTATAAAAT GGTCTGTGTT CGA

33

(146) INFORMATION FOR SEQ ID NO:145:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

GAAAGACAAA AGAGACTCAA GAGGATGTCT TTATTG

36

(147) INFORMATION FOR SEQ ID NO:146:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

CGGAGAAAGA GGGT3AAACG CACAGCCATC GCC

33

(148) INFORMATION FOR SEQ ID NO:147:

- 25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

30 AAGCTTCAGC GGGCCAAGGC ACTGCTCACC

30

(149) INFORMATION FOR SEQ ID NO:148:

- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

CAGCGGCAGA AGGCNAAAAG BGTGGCCATC

30

(150) INFORMATION FOR SEQ ID NO:149:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

CGGCAGAAGG CGAAGCGCAT GATCCTCGCG

30

(151) INFORMATION FOR SEQ ID NO:150:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

GAGCGCAACA AGGCCAAAAA GGTGATCATC

30

(152) INFORMATION FOR SEQ ID NO:151:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

30 GGTGTAAACA AAAAGGCTAA AAACACAATT ATTCTTATT

39

(153) INFORMATION FOR SEQ ID NO:152:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

109

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

GAGAGCCAGC TCAAGAGCAC CGTGGTG

27

(154) INFORMATION FOR SEQ ID NO:153:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

CCACAAGCAA ACCAAGAAAA TGCTGGCTGT

30

(155) INFORMATION FOR SEQ ID NO:154:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

CATCAAGTGT ATCATGTGCC AAGTACGCCC

30

(156) INFORMATION FOR SEQ ID NO:155:

- 25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

30 CTAGAGAGTC AGATGAAGTG TACAGTASTG GCAC

34

(157) INFORMATION FOR SEQ ID NO:156:

- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

110

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

CGGACAAAAG TGAAACTAA AAAGATGTTT CTCATT

36

(156) INFORMATION FOR SEQ ID NO:157:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

GCTGAGGTTC GCAATAAACT AACCATGTTT GTG

33

(157) INFORMATION FOR SEQ ID NO:158:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

GGGAGGCCGA GCTGAAAGCC ACCCTGCTC

29

(158) INFORMATION FOR SEQ ID NO:159:

- 25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

30 CAAGATCAAG AGAGCCAAAA CCTTCATCAT G

31

(159) INFORMATION FOR SEQ ID NO:160:

- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

111

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

CCGGAGACAA GTGAAGAAGA TGCTGTTGT C

31

(162) INFORMATION FOR SEQ ID NO:161:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

GCAAGGACCA GATCAAGCGG CTGGTGCTCA

30

(163) INFORMATION FOR SEQ ID NO:162:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

CAAGAAAGCC AAAGCCAAGA AACTGATCCT TCTG

34

(164) INFORMATION FOR SEQ ID NO:163:

- 25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1068 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

30 ATGGAAGATT TGGAGGAAAC ATTATTGAA GAATTTGAAA ACTATTCCTA TGACCTAGAC 60
TATTACTCTC TGGAGTCTGA TTTGGAGGAG AAAGTCCAGC TGGGAGTTGT TCACTGGGTC 120
TCCCTGGTGT TATATTGTTT GGCITTTGTT CTGGGAATTC CAGGAAATGC CATCGTCATT 180
TGTTTCACGG GGCTCAAGTG GAAGAAGACA GTCACCACTC TGTGGTTCCT CAATCTAGCC 240
ATTGCGGATT TCATTTTCT TCTCTTCTG CCCCCTGTACA TCTCCTA1GT GGCCATGAAT 300

112

TTCCACTGGC CCTTTGGCAT CTGGCTGTGC AAAGCCAAT CTCTACTGC CCAGTTGAAC 360
 ATGTTTGCCA GTGTTTTTTT CCGACAGTG ATCAGGCTGG ACCACTATAT CCACCTTGATC 420
 CATCTCTCTT TATCTCATCG GCATCGAACC CTCAGAACT CTCTGATTGT CATATATTC 480
 ATCTGGGTTT TGGCTTCTCT AATTGGCGGT CCGGCTCTT ACTTCCGGSA CACTGTGGAG 540
 5 TTCAATAATC ATACTCTTTG STATAACAAT TTTCAGAAAC ATGATCCTGA CCTCACTTTG 600
 ATCAGGCACC ATGTTCTGAC TTGGGTGAAA TTTATCATTC GCTATCTCTT CCGTTTCTCA 660
 ACAATGAGTA TTGCTACTT GTGTCTCATC TTCAAGGTGA AGAAGCGAAC AGTCCTGATC 720
 TCCAGTAGGC ATAAGTGGAC AATTCTGGTT GTGGTGTGG CTTTGTGCT TTGCTGGACT 780
 CCTTATCACC TCTTAGCAT TTGGGAGCTC ACCATTCAAC ACAATAGCTA TTCCACCACAT 840
 10 GTGATGCAGG CTGGAATCCC CCTCTCCACT GGTTTGGCAT TCTCAATAG TTGCTTGAAC 900
 CCCATCCTTT ATGTCTAAT TAGTAAGAAG TTCCAAGCTC GATTCCGGTC CTCAGTTGCT 960
 GAGATACTCA AGTACACAAT GTGGGAAGTC AGCTGTTCTG GCACAGTGAG TGAACAGCTC 1020
 AGGAATCAG AAACCAAGAA TCTGTCTCTC CTGGAACAG CTCATAAA 1068

(165) INFORMATION FOR SEQ ID NO:164:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 355 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

20 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

Met Glu Asp Leu Glu Glu Thr Leu Phe Glu Glu Phe Glu Asn Tyr Ser
 1 5 10 15

Tyr Asp Leu Asp Tyr Tyr Ser Leu Glu Ser Asp Leu Glu Glu Lys Val
 20 25 30

25 Gln Leu Gly Val Val His Trp Val Ser Leu Val Leu Tyr Cys Leu Ala
 35 40 45

Phe Val Leu Gly Ile Pro Gly Asn Ala Ile Val Ile Trp Phe Thr Gly
 50 55 60

30 Leu Lys Trp Lys Lys Thr Val Thr Thr Leu Trp Phe Leu Asn Leu Ala
 65 70 75 80

Ile Ala Asp Phe Ile Phe Leu Leu Phe Leu Pro Leu Tyr Ile Ser Tyr
 85 90 95

113

Val Ala Met Asn Phe His Trp Pro Phe Gly Ile Trp Leu Cys Lys Ala
 100 105 110
 Asn Ser Phe Thr Ala Gln Leu Asn Met Phe Ala Ser Val Phe Phe Leu
 115 120 125
 5 Thr Val Ile Ser Leu Asp His Tyr Ile His Leu Ile His Pro Val Leu
 130 135 140
 Ser His Arg His Arg Thr Leu Lys Asn Ser Leu Ile Val Ile Ile Phe
 145 150 155 160
 10 Ile Trp Leu Leu Ala Ser Leu Ile Gly Gly Pro Ala Leu Tyr Phe Arg
 165 170 175
 Asp Thr Val Glu Phe Asn Asn His Thr Leu Cys Tyr Asn Asn Phe Gln
 180 185 190
 Lys His Asp Pro Asp Leu Thr Leu Ile Arg His His Val Leu Thr Trp
 195 200 205
 15 Val Lys Phe Ile Ile Gly Tyr Leu Phe Pro Leu Leu Thr Met Ser Ile
 210 215 220
 Cys Tyr Leu Cys Leu Ile Phe Lys Val Lys Lys Arg Thr Val Leu Ile
 225 230 235 240
 20 Ser Ser Arg His Lys Trp Thr Ile Leu Val Val Val Val Ala Phe Val
 245 250 255
 Val Cys Trp Thr Pro Tyr His Leu Phe Ser Ile Trp Glu Leu Thr Ile
 260 265 270
 His His Asn Ser Tyr Ser His His Val Met Gln Ala Gly Ile Pro Leu
 275 280 285
 25 Ser Thr Gly Leu Ala Phe Leu Asn Ser Cys Leu Asn Pro Ile Leu Tyr
 290 295 300
 Val Leu Ile Ser Lys Lys Phe Gln Ala Arg Phe Arg Ser Ser Val Ala
 305 310 315 320
 30 Glu Ile Leu Lys Tyr Thr Leu Trp Glu Val Ser Cys Ser Gly Thr Val
 325 330 335
 Ser Glu Gln Leu Arg Asn Ser Glu Thr Lys Asn Leu Cys Leu Leu Glu
 340 345 350
 Thr Ala Gln
 355

35 (166) INFORMATION FOR SEQ ID NO:165:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1089 base pairs

114

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

```

ATGGGCAACC ACACGTGGGA GGGCTGCCAC GTGGACTTTC CCGTGGACCA CCTCTTTTCG 60
CCATCCCTCT ACATCTTTGT CATCGGCGTG GGGCTGCCCA CCAACTGCCT GGCTCTGTGG 120
GCAGCCTACC GCCAGGTGCA ACAGGCAAC GABCTGGGGG TCTACCTGAT GAACCTCAGC 180
ATGCGCGACC TGCTGTACAT CTGCAAGCTG CCGCTCTGGG TGGACTACTT CCTGCACCAC 240
10 CACAACTGGA TCCACGGCCC CGGCTCTGTC AAGCTCTTTC GTTCATCTT CTACACCAAT 300
ATCTACATCA GCATCGCCTT CCTGTCTGT ATCTCGGTTC ACGCTACCT GGCTCTGGGC 360
CACTCCACTTC GCTTCGCCCC CCTGCGCCGC GTCAAGACGC CCGTGGCCGT GAGCTCCGTC 420
GTCTGGGCGA CGGAGCTGGG CGCCAACTCG GCGCCCTTGT TCCATGACGA GCTCTTCCGA 480
GACCGCTACA ACCACACCTT CTGCTTTGAG AAGTTCCCA TCGAAGCTG GGTGGGCTTG 540
15 ATGAACCTCT ATCGGGTGTT CGTGGCTTC CTCTCTCTGT GGGGTTCAT GCTGCTGTGG 600
TACCGGGGCA TCCTGCGGGC CCGCGGGG AAGCTCTTCA CCGAGCGCCA GGAGAAGGCT 660
AAGATCGGCG GGCTGGCCCT CAGCTTCATC GCACTCTTTC TGTCTGCTT TCGGCCCTAT 720
CACGTGCTCT TGCTGTCCC GAGCGGCATC TACCTGCGGC GCTCCTGGGA CTGCGGCTTC 780
GAGGAGCGCG TCTTTTCTGC ATACCACAGC TCACTGGCTT TCAACAGCCT CAACTGTGTG 840
20 GCGGACCCCA TCCTCTACTG CCGGTCAAC GAGGGCGGCT GAGCGATGT GGCCAAGGCC 900
CTGCACAACC TGCTCCGCTT TCTGGCCAGC GACAAGCCCC AGGAGATGGC CAATGCCTCG 960
CTCACCCTGG AGACCCCACT CACCTCCAAG AGGAACAGCA CAGCCAAAGC CATGACTGGC 1020
AGCTGGGCGG CCACTCCGCC TTCCAGGGG GACCAGGTGC AGCTGAAGAT GCTGCGGCCA 1080
GCACAATGA 1089

```

25 (167) INFORMATION FOR SEQ ID NO 166:

(i) SEQUENCE CHARACTERISTICS.
 (A) LENGTH: 362 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

30

(ii) MOLECULE TYPE: protein

115

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

	Met	Gly	Asn	His	Thr	Trp	Glu	Gly	Cys	His	Val	Asp	Ser	Arg	Val	Asp	
	1				5					10					15		
5	His	Leu	Phe	Pro	Pro	Ser	Leu	Tyr	Ile	Phe	Val	Ile	Gly	Val	Gly	Leu	
				20				25						30			
	Pro	Thr	Asn	Cys	Leu	Ala	Leu	Trp	Ala	Ala	Tyr	Arg	Gln	Val	Gln	Gln	
				35				40					45				
	Arg	Asn	Glu	Leu	Gly	Val	Tyr	Leu	Met	Asn	Leu	Ser	Ile	Ala	Asp	Leu	
		50					55					60					
10	Leu	Tyr	Ile	Cys	Thr	Leu	Pro	Leu	Trp	Val	Asp	Tyr	Phe	Leu	His	His	
	65				70						75				80		
	Asp	Asn	Trp	Ile	His	Gly	Pro	Gly	Ser	Cys	Lys	Leu	Phe	Gly	Phe	Ile	
				85						90					95		
15	Phe	Tyr	Thr	Asn	Ile	Tyr	Ile	Ser	Ile	Ala	Phe	Leu	Lys	Cys	Ile	Ser	
				100					105					110			
	Val	Asp	Arg	Tyr	Leu	Ala	Val	Ala	His	Pro	Leu	Arg	Phe	Ala	Arg	Leu	
			115					120					125				
	Arg	Arg	Val	Lys	Thr	Ala	Val	Ala	Val	Ser	Ser	Val	Val	Trp	Ala	Thr	
		130					135						140				
20	Glu	Leu	Gly	Ala	Asn	Ser	Ala	Pro	Leu	Phe	His	Asp	Glu	Leu	Phe	Arg	
	145					150						155				160	
	Asp	Arg	Tyr	Asn	His	Thr	Phe	Cys	Phe	Glu	Lys	Phe	Pro	Met	Glu	Gly	
					165					170					175		
25	Trp	Val	Ala	Trp	Met	Asn	Leu	Tyr	Arg	Val	Phe	Val	Gly	Phe	Leu	Phe	
				180					185					190			
	Pro	Trp	Ala	Leu	Met	Leu	Leu	Ser	Tyr	Arg	Gly	Ile	Leu	Arg	Ala	Val	
			195					200					205				
	Arg	Gly	Ser	Val	Ser	Thr	Glu	Arg	Gln	Glu	Lys	Ala	Lys	Ile	Ala	Arg	
		210					215					220					
30	Leu	Ala	Leu	Ser	Leu	Ile	Ala	Ile	Val	Leu	Val	Cys	Phe	Ala	Pro	Tyr	
	225					230						235				240	
	His	Val	Leu	Leu	Leu	Ser	Arg	Ser	Ala	Ile	Tyr	Leu	Gly	Arg	Pro	Trp	
					245					250					255		
35	Asp	Cys	Gly	Phe	Glu	Glu	Arg	Val	Phe	Ser	Ala	Tyr	His	Ser	Ser	Leu	
				260						265					270		
	Ala	Phe	Thr	Ser	Leu	Asn	Cys	Val	Ala	Asp	Pro	Ile	Leu	Tyr	Cys	Leu	

116

275 280 285

Val Asn Glu Gly Ala Arg Ser Asp Val Ala Lys Ala Leu His Asn Leu
290 295 300

5 Leu Arg Phe Leu Ala Ser Asp Lys Pro Gln Gln Met Ala Asn Ala Ser
305 310 315 320

Leu Thr Leu Glu Thr Pro Leu Thr Ser Lys Arg Asn Ser Thr Ala Lys
325 330 335

Ala Met Thr Gly Ser Trp Ala Ala Thr Pro Pro Ser Gln Gly Asp Gln
340 345 350

10 Val Gln Leu Lys Met Leu Pro Pro Ala Gln
355 360

(168) INFORMATION FOR SEQ ID NO:167:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 1002 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

20 ATGGAGTCCT CAGGCACCC AGAGAGCACC ACCTTTTTTT ACTATGACCT TCAGAGCCAG 60
CCGTGTGAGA ACCAGGCCTG GGTCTTTGCT ACCCTGGGCA CCAGTGTCTT STACTGCCTG 120
GTGTTTCTCC TCAGCCTAGT GGGCAACAGC CTGGTCTGTG TGGTCTGTGT GAAGTATGAG 180
AGCCTGGAGT CCCTCACCAA CATCTTCATC CTCAACCTGT CCTCTCAGA CTTGGTGTTC 240
GCCTGCTTGT TGCTGTGTG GATCTCCCA TACCACTGGG GCTGGGTGCT GGGAGACTTC 300

25 CTCTGCAAAC TCCTCAATAT GATCTTCTCC ATCAGCCTCT ACAGCAGCAT CTTCTTCTG 360
ACCATCATGA CCATCCACCG CTACCTGTCT GTAGTGAGCC CCTCTCCAC CTTGCGCGTC 420
CCCACCTCC GCTGCCGCGT GCTGGTGACC ATGGCTGTGT GGCTAGCCAG CATCTGTCTC 480
TCCATCTCTG ACACCATCTT CCACAAGGTG CTTTCTTCGG GCTGTGATTA TTCCGAACTC 540
ACGTGGTACC TCACCTCCGT CTACCAGCAC AACCTCTCTT TCCTGCTGTC CCTGGGGATT 600

30 ATCCTGTCTT GCTACGTGGA GATCCTCAGG ACCCTGTCTC GCTCAGGCTC CAAGCGGCGC 660
CACCGCACGA AAAAGCTCAT CTTGCGCATC GTGGTGGCCT ACTTCTCTAG CTGGGGTCCC 720
TACAACCTCA CCTGTCTTCT GCAGACGCTG TTTCGGACCC AGATCATCCG GAGCTGCGAG 780

117

GCCAAACAGC AGCTAGAATA CGCCCTGCTC ATCTGCCGUA ACCTCGCCTT CTCCCACTGC 840
 TGCTTTAACC CCGTGCTCTA TGTCTTCGTG GGGGTCAAGT TCCGCACACA CCTGAAACAT 900
 GTTCTCCGGC AGTTCTGGTT CTGCCGGCTG CAGGCACCCA GCCCAGCCTC GATCCCCCAC 960
 TCCCCTGGTG CCTTCGCCTA TGAGGGCGCC TCCTTCTACT GA 1002

5 (169) INFORMATION FOR SEQ ID NO:168:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 333 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

10 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

	Met	Glu	Ser	Ser	Gly	Asn	Pro	Glu	Ser	Thr	Thr	Phe	Phe	Tyr	Tyr	Asp	
	1				5					10					15		
15	Leu	Gln	Ser	Gln	Pro	Cys	Glu	Asn	Gln	Ala	Trp	Val	Phe	Ala	Thr	Leu	
				20					25					30			
	Ala	Thr	Thr	Val	Leu	Tyr	Cys	Leu	Val	Phe	Leu	Leu	Ser	Leu	Val	Gly	
				35				40					45				
20	Asn	Ser	Leu	Val	Leu	Trp	Val	Leu	Val	Lys	Tyr	Glu	Ser	Leu	Glu	Ser	
			50				55					60					
	Leu	Thr	Asn	Ile	Phe	Ile	Leu	Asn	Leu	Cys	Leu	Ser	Asp	Leu	Val	Phe	
	65			70						75					80		
	Ala	Cys	Leu	Leu	Pro	Val	Trp	Ile	Ser	Pro	Tyr	His	Trp	Gly	Trp	Val	
				85					90					95			
25	Leu	Gly	Asp	Phe	Leu	Cys	Lys	Leu	Leu	Asn	Met	Ile	Phe	Ser	Ile	Ser	
				100					105					110			
	Leu	Tyr	Ser	Ser	Ile	Phe	Phe	Leu	Thr	Ile	Met	Thr	Ile	His	Arg	Tyr	
				115				120					125				
30	Leu	Ser	Val	Val	Ser	Pro	Leu	Ser	Thr	Leu	Arg	Val	Pro	Thr	Leu	Arg	
			130				135					140					
	Cys	Arg	Val	Leu	Val	Thr	Met	Ala	Val	Trp	Val	Ala	Ser	Ile	Leu	Ser	
	145				150					155					160		
	Ser	Ile	Leu	Asp	Thr	Ile	Phe	His	Lys	Val	Leu	Ser	Ser	Gly	Cys	Asp	
				165					170					175			
35	Tyr	Ser	Glu	Leu	Thr	Trp	Tyr	Leu	Thr	Ser	Val	Tyr	Gln	His	Asn	Leu	
				180				185						190			

118

Phe Phe Leu Leu Ser Leu Gly Ile Ile Leu Phe Cys Tyr Val Glu Ile
 195 200 205
 Leu Arg Thr Leu Phe Arg Ser Arg Ser Lys Arg Arg His Arg Thr Lys
 210 215 220
 5 Lys Leu Ile Phe Ala Ile Val Val Ala Tyr Phe Leu Ser Trp Gly Pro
 225 230 235 240
 Tyr Asn Phe Thr Leu Phe Leu Gln Thr Leu Phe Arg Thr Gln Ile Ile
 245 250 255
 10 Arg Ser Cys Glu Ala Lys Gln Gln Leu Glu Tyr Ala Leu Leu Ile Cys
 260 265 270
 Arg Asn Leu Ala Phe Ser His Cys Cys Phe Asn Pro Val Leu Tyr Val
 275 280 285
 Phe Val Gly Val Lys Phe Arg Thr His Leu Lys His Val Leu Arg Gln
 290 295 300
 15 Phe Trp Phe Cys Arg Leu Gln Ala Pro Ser Pro Ala Ser Ile Pro His
 305 310 315 320
 Ser Pro Gly Ala Phe Ala Tyr Glu Gly Ala Ser Phe Tyr
 325 330

(170) INFORMATION FOR SEQ ID NO:169:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 987 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 25 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

ATGGACAACG CCTCGTTCTC GGAGCCCTGG CCCGCCAACG CATCGGGGTC GACCCGGGCG 60
 CTGAGCTGCT CCAACGGGTC GACTCTGGCG CCGCTGCCGG CGCGCTGGC GGTGGCTGTA 120
 CCAGTTGTCT ACGCGGTGAT CTGCGCCCTG GGTCTGGCGG GCAACTCGGC CTTGCTGTAT 180
 30 GTGTTGCTGC GGGCGGTCGG CATGAAGACC GTCAACCAACC TGTTCATGCT CAACCTGGGC 240
 ATGCGCCGACG AGCTCTTCAC GCTGGTGCTC CCCATCAACA TCGCCGACTT CCTGCTGGCG 300
 CAGTGGCCCT TCGGGGAGCT CATGTGCAAS CTCATCGTGG CTATCGAACA GTACAACACC 360
 TTCTCCAGCC TCTACTTCCT CACCGTCATG AGCGCCGACC GTACCTGGT GGTGTTGGCC 420
 ACTGCGGAGT CGCGCCGGGT GGCGGGCCGC ACCTACAGCG CGCGCGCGGT GGTGAGCCTG 480

GCGGTGTGGG GGATCGTCAC ACTCGTCGTG CTGCCCTTGG CAGTCTTCGC CCGGCTAGAC 540
 GACGAGCAGG GCCGAGCGCA GTGCGTGCTA GTCTTTCCGC AGCCCGAGGC CTTCTGGTGG 600
 CGCGCGAGGC GCCTCTACAC GCTCGTGCTG GGCTTGCCA TCCCGGTGTC CACCATCTGT 660
 GTCTCTATA CCACCTGCT GTGCCGCTG CATGCCATGC GGTGGACAG CCACGCCAAG 720
 5 GCCCTGGAGC GCGCCAAGAA GCGGGTGAAG TTCCTGGTGG TGGCAATCCT GCGGGTGTGC 780
 CTCCTCTGCT GGACGCTCTA CCACCTGAGC ACCGTGGTGG CGCTCACCAC CGACCTCCCG 840
 CAGACGCGGC TGCTCATCGC TATCTCTAC TTCATCAACA GCCTGACGTA CGCCAACAGC 900
 TGCCTCAACC CCTTCTCTA CGCCTTCTG GACGCCAGCT TCCGCAGGAA CCTCCGCCAG 960
 CTGATAACTT GCGGCGCGGC AGCCTGA 987

10 (171) INFORMATION FOR SEQ ID NO:170:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 328 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 15 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

	Met	Asp	Asn	Ala	Ser	Phe	Ser	Glu	Pro	Trp	Pro	Ala	Asn	Ala	Ser	Gly
	1			5					10					15		
20	Pro	Asp	Pro	Ala	Leu	Ser	Cys	Ser	Asn	Ala	Ser	Thr	Leu	Ala	Pro	Leu
				20					25					30		
	Pro	Ala	Pro	Leu	Ala	Val	Ala	Val	Pro	Val	Val	Tyr	Ala	Val	Ile	Cys
				35				40					45			
25	Ala	Val	Gly	Leu	Ala	Gly	Asn	Ser	Ala	Val	Leu	Tyr	Val	Leu	Leu	Arg
		50				55					60					
	Ala	Pro	Arg	Met	Lys	Thr	Val	Thr	Asn	Leu	Phe	Ile	Leu	Asn	Leu	Ala
		65			70					75				80		
	Ile	Ala	Asp	Glu	Leu	Phe	Thr	Leu	Val	Leu	Pro	Ile	Asn	Ile	Ala	Asp
				85					90					95		
30	Phe	Leu	Leu	Arg	Gln	Trp	Pro	Phe	Gly	Glu	Leu	Met	Cys	Lys	Leu	Ile
				100					105					110		
	Val	Ala	Ile	Asp	Gln	Tyr	Asn	Thr	Phe	Ser	Ser	Leu	Tyr	Phe	Leu	Thr
			115					120					125			
	Val	Met	Ser	Ala	Asp	Arg	Tyr	Leu	Val	Val	Leu	Ala	Thr	Ala	Glu	Ser

120

	130	135	140
	Arg Arg Val Ala Gly Arg Thr Tyr Ser Ala Ala Arg Ala Val Ser Leu		
	145	150	155 160
5	Ala Val Trp Gly Ile Val Thr Leu Val Val Leu Pro Phe Ala Val Phe		
		165	170 175
	Ala Arg Leu Asp Asp Glu Gln Gly Arg Arg Gln Cys Val Leu Val Phe		
		180	185 190
	Pro Gln Pro Glu Ala Phe Trp Trp Arg Ala Ser Arg Leu Tyr Thr Leu		
		195	200 205
10	Val Leu Gly Phe Ala Ile Pro Val Ser Thr Ile Cys Val Leu Tyr Thr		
		210	215 220
	Thr Leu Leu Cys Arg Leu His Ala Met Arg Leu Asp Ser His Ala Lys		
		225	230 235 240
15	Ala Leu Glu Arg Ala Lys Lys Arg Val Lys Phe Leu Val Val Ala Ile		
		245	250 255
	Leu Ala Val Cys Leu Leu Cys Trp Thr Pro Tyr His Leu Ser Thr Val		
		260	265 270
	Val Ala Leu Thr Thr Asp Leu Pro Gln Thr Pro Leu Val Ile Ala Ile		
		275	280 285
20	Ser Tyr Phe Ile Thr Ser Leu Thr Tyr Ala Asn Ser Cys Leu Asn Pro		
		290	295 300
	Phe Leu Tyr Ala Phe Leu Asp Ala Ser Phe Arg Arg Asn Leu Arg Gln		
		305	310 315 320
25	Leu Ile Thr Cys Arg Ala Ala Ala		
		325	

(172) INFORMATION FOR SEQ ID NO:171:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1002 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

	ATGCAGGCCG CTGGGCACCC AGAGCCCCCTT GACAGCAGGG GCTCCTTCTC CCTCCCCACG	60
35	ATGGGTGCCA ACGTCTCTCA GSACAATGGC ACTGGCCACA ATGCCACCTT CTCGAGCCA	120
	CTGCCGTTCC TCTATGTGCT CCTGCCCGCC GTGTACTCCG GGATCTGTGC TGTGGGGCTG	180

121

ACTGGCAACA CGGCCGTCAT CCTTGTAATC CTAAGGGGCG CCAAGATBAA GACGGTGACC 240
 AACGTGTTCA TCGTGAACCT GGGCCTCGCT GACGGGGTCT TCACGCTGCT ACTGCCTGTC 300
 AACATCGGGG AGCAGCTGCT GCAGTACTGG CCCTTCGGGG AGGTGCTCTG CAAGCTGGTG 360
 CTGGCCGTGG ACCACTAGAA CATCTTCTCC AGCATCTACT TCGTASCCGT GATGAGCGTG 420
 5 GACCGATACG TGGTGGTGCT GGCACCGTG AGGTCCCGGG ACATGCCCTG GCGCACCTAC 480
 CGGGGGGGGA AGGTGGCGAG CCTTGTGTGC TGGCTGGGG TCACGCTGCT GGTTCGCGG 540
 TTCTTCTCTT TCGCTGGGCT CTATAGCAAC GAGGTGCAGG TCCCAAGCTG TGGGCTGAGG 600
 TTCCCGTGGT CGAGAGAGGT CTGTTCAAG GCGAGCGTG TGTACAGTT GGTCTGGGG 660
 TTGCTGCTCG CGTGTGCAC CATCTGTGTG CTGTACAGAG ACCTCTGCG CAGGCTGCCG 720
 10 GCGGTGCGG TCGGCTCTG AGCTAAGCT CTAGGCAAGG CGAGGGGAA GGTGAAAGTC 780
 CTGGTCTTGG TCGTGTGGC CGTGTGCTC CTGTGCTGGA CGCCCTTGA CCGGCTCTG 840
 GTCGTGGGCG TGACACGGA CCTGCCCGAG ACCCGACTGG TCATCAGTAT GTCTACGTC 900
 ATCACCAGGC TCACGTAGC CAACTCGTGC CTGAACCGCT TCGTGTAGG CTCTTAGAT 960
 GACAACTTGG GGAAGAACTT CCGCAGCATA TTGCGTCTGT GA 1002

15 (173) INFORMATION FOR SEQ ID NO:172:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 333 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 20 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(x) SEQUENCE DESCRIPTION: SEQ ID NO:172:

Met Gln Ala Ala Gly His Pro Glu Pro Leu Asp Ser Arg Gly Ser Phe
 1 5 10 15
 25 Ser Leu Pro Thr Met Gly Ala Asn Val Ser Gln Asp Asn Gly Thr Gly
 20 25 30
 His Asn Ala Thr Phe Ser Glu Pro Leu Pro Phe Leu Tyr Val Leu Leu
 35 40 45
 30 Pro Ala Val Tyr Ser Gly Ile Cys Ala Val Gly Leu Thr Gly Asn Thr
 50 55 60
 Ala Val Ile Leu Val Ile Leu Arg Ala Pro Lys Met Lys Thr Val Thr
 65 70 75 80

122

Asn Val Phe Ile Leu Asn Leu Ala Val Ala Asp Gly Leu Phe Thr Leu
 85 90 95
 Val Leu Pro Val Asn Ile Ala Glu His Leu Leu Gln Tyr Trp Pro Phe
 100 105 110
 5 Gly Glu Leu Leu Cys Lys Leu Val Leu Ala Val Asp His Tyr Asn Ile
 115 120 125
 Phe Ser Ser Ile Tyr Phe Leu Ala Val Met Ser Val Asp Arg Tyr Leu
 130 135 140
 10 Val Val Leu Ala Thr Val Arg Ser Arg His Met Pro Trp Arg Thr Tyr
 145 150 155 160
 Arg Gly Ala Lys Val Ala Ser Leu Cys Val Trp Leu Gly Val Thr Val
 165 170 175
 Leu Val Leu Pro Phe Phe Ser Phe Ala Gly Val Tyr Ser Asn Glu Leu
 180 185 190
 15 Gln Val Pro Ser Cys Gly Leu Ser Phe Pro Trp Pro Glu Gln Val Trp
 195 200 205
 Phe Lys Ala Ser Arg Val Tyr Thr Leu Val Leu Gly Phe Val Leu Pro
 210 215 220
 20 Val Cys Thr Ile Cys Val Leu Tyr Thr Asp Leu Leu Arg Arg Leu Arg
 225 230 235 240
 Ala Val Arg Leu Arg Ser Gly Ala Lys Ala Leu Gly Lys Ala Arg Arg
 245 250 255
 Lys Val Lys Val Leu Val Leu Val Val Leu Ala Val Cys Leu Leu Cys
 260 265 270
 25 Trp Thr Pro Phe His Leu Ala Ser Val Val Ala Leu Thr Thr Asp Leu
 275 280 285
 Pro Gln Thr Pro Leu Val Ile Ser Met Ser Tyr Val Ile Thr Ser Leu
 290 295 300
 30 Thr Tyr Ala Asn Ser Cys Leu Asn Pro Phe Leu Tyr Ala Phe Leu Asp
 305 310 315 320
 Asp Asn Phe Arg Lys Asn Phe Arg Ser Ile Leu Arg Cys
 325 330

(174) INFORMATION FOR SEQ ID NO:173:

- 35 (1) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1107 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

ATGGTCCTTG AAGTGAGTGA CCACCAAGTG CTAAATGACG CCGAGGTTCG CGCCTCCTG 60
 GAGAACTTCA GCTCTTCTTA TGAATATGGA GAAAACGAGA GIGACTCGTG CTGTACCTCG 120
 5 CGGCCCTGCC CACAGGACTT CAGCCTGAAT TTCGACCGGG CTTTCTGTGG AGCCTCTATC 180
 AGCCTCCTCT TTCTGCTGGG GCTGCTGGGT AACGGCGCGG TGGCAGCCGT GGTGCTGAGG 240
 CGGCGGACAG CCTGAGCAG CACGACACCG TTCTGTCTCG ACCTAGCTGT AGCAGACACG 300
 CTGCTGTGTC TACACTGCC CTTCTGGGCA GTGACGCTG CCGTCCAGTG GCTTTTGGG 360
 TCTGGCCTCT GCAAGTGGC AGGTGCGCTC TTCAACATCA ACTTCTAGG AGGAGCCCTG 420
 10 CTGCTGGCCT GATCAGCTT TGAACGATAC CTGAACATAG TTATGCGAC CAGCTCTTAC 480
 CGCGGGGGGC CCGCGCGCGG CGTGACCTTC ACCTGCTGCG CTGTCTGGGG GCTCTGCTCT 540
 CTTTTGCGCC TCCAGACTT CATTTCTCTG TCGGCCAACG ACGACGAGGG CTTCAAGGCC 600
 ACCCACCTGC AATACAACTT CCCACAGTG GCGCGCAGGG CTCTGCGGGT GGTTCAGCTG 660
 GTGGCTGGCT TTCTGCTGCC CTTGCTGGTG ATGGCTACTT GCTATGCCCA CATCTCTGGC 720
 15 GTGCTGCTGG TTTCAGGGG CAGCGCGCGG CTGCGGGCCA AGCGGTGGT GGTGCTGGT 780
 GTGGTGGCTT TTGCTCTCTG CTGACCCCG TATCACTGG TGGTGTGGT GGACATCTCT 840
 ATGGACCTTG GCGCTTTGGC CGCAACTGT GCGCGAGAAA GCAGGTAGA CGTGGCCAGG 900
 TCGGTCACTT CAGGCTGGG CTACATGAC TGCTGCCTCA ACCCGCTGCT CTATGCTTTT 960
 GTAGGGGTCA AGTTCCGGGA GCGATGTGG ATGCTGCTCT TGCGCTGGG CTGCCCCAAC 1020
 20 CAGAGAGGBC TCCAGAGGCA GGCATCGTCT TCCGCGCGGG ATTCATCCTG GTCTGAGACC 1080
 TCAGAGGCCT CCTACTCGGG CTGTGA 1107

(175) INFORMATION FOR SEQ ID NO 174:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 368 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

	Met	Val	Leu	Glu	Val	Ser	Asp	His	Gln	Val	Leu	Asn	Asp	Ala	Glu	Val
	1				5					10						15
	Ala	Ala	Leu	Leu	Glu	Asn	Phe	Ser	Ser	Ser	Tyr	Asp	Tyr	Gly	Glu	Asn
			20						25					30		
5	Glu	Ser	Asp	Ser	Cys	Cys	Thr	Ser	Pro	Pro	Cys	Pro	Gln	Asp	Phe	Ser
			35					40					45			
	Leu	Asn	Phe	Asp	Arg	Ala	Phe	Leu	Pro	Ala	Leu	Tyr	Ser	Leu	Leu	Phe
		50					55					60				
10	Leu	Leu	Gly	Leu	Leu	Gly	Asn	Gly	Ala	Val	Ala	Ala	Val	Leu	Leu	Ser
	65				70						75					80
	Arg	Arg	Thr	Ala	Leu	Ser	Ser	Thr	Asp	Thr	Phe	Leu	Leu	His	Leu	Ala
				85						90					95	
	Val	Ala	Asp	Thr	Leu	Leu	Val	Leu	Thr	Leu	Pro	Leu	Trp	Ala	Val	Asp
				100					105					110		
15	Ala	Ala	Val	Gln	Trp	Val	Phe	Gly	Ser	Gly	Leu	Cys	Lys	Val	Ala	Gly
			115					120					125			
	Ala	Leu	Phe	Asn	Ile	Asn	Phe	Tyr	Ala	Gly	Ala	Leu	Leu	Leu	Ala	Cys
		130					135					140				
20	Ile	Ser	Phe	Asp	Arg	Tyr	Leu	Asn	Ile	Val	His	Ala	Thr	Gln	Leu	Tyr
	145				150						155					160
	Arg	Arg	Gly	Pro	Pro	Ala	Arg	Val	Thr	Leu	Thr	Cys	Leu	Ala	Val	Trp
				165						170					175	
	Gly	Leu	Cys	Leu	Leu	Phe	Ala	Leu	Pro	Asp	Phe	Ile	Phe	Leu	Ser	Ala
				180					185					190		
25	His	His	Asp	Glu	Arg	Leu	Asn	Ala	Thr	His	Cys	Gln	Tyr	Asn	Phe	Pro
			195					200					205			
	Gln	Val	Gly	Arg	Thr	Ala	Leu	Arg	Val	Leu	Gln	Leu	Val	Ala	Gly	Phe
		210					215					220				
30	Leu	Leu	Pro	Leu	Leu	Val	Met	Ala	Tyr	Cys	Tyr	Ala	His	Ile	Leu	Ala
	225					230					235					240
	Val	Leu	Leu	Val	Ser	Arg	Gly	Gln	Arg	Arg	Leu	Arg	Ala	Lys	Arg	Leu
				245						250					255	
	Val	Val	Val	Val	Val	Val	Ala	Phe	Ala	Leu	Cys	Trp	Thr	Pro	Tyr	His
				260					265					270		
35	Leu	Val	Val	Leu	Val	Asp	Ile	Leu	Met	Asp	Leu	Gly	Ala	Leu	Ala	Arg
			275					280					285			
	Asn	Cys	Gly	Arg	Glu	Ser	Arg	Val	Asp	Val	Ala	Lys	Ser	Val	Thr	Ser

125

290 295 300

Gly Leu Gly Tyr Met His Cys Cys Leu Asn Pro Leu Leu Tyr Ala Phe
305 310 315 320

5 Val Gly Val Lys Phe Arg Glu Arg Met Trp Met Leu Leu Leu Arg Leu
325 330 335

Gly Cys Pro Asn Gln Arg Gly Leu Gln Arg Gln Pro Ser Ser Ser Arg
340 345 350

Arg Asp Ser Ser Trp Ser Glu Thr Ser Glu Ala Ser Tyr Ser Gly Leu
355 360 365

10 (175) INFORMATION FOR SEQ ID NO:175:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1074 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

ATGGCTGATG ACTATGGCTC TGAATCCACA TCTTCCATGG AAGACTACGT TAACCTCAAC 60

TTCACTGACT TCTACTGTGA GAAAAACAAT GTCAGGCAGT TTGGGAGCCA TTTCCTCCCA 120

20 CCCTGTACTT GGCTCGTGTT CATCGTGGGT CCCTTGGGCA ACAGTCTTGT TATCCTTGTC 180

TACTGTACTT GCACAAGAGT GAAGACCATG ACCGACATGT TCCTTTTGAA TTGGCAATT 240

GCTGACCTCC TCTTTCTTGT CACTCTTCCC TTCTGGGCCA TTGCTGCTGC TGACCACTGC 300

AAGTCCAGA CCTTCATGTG CAAGGTGGTC AACAGCATGT ACAAGATGAA CTTCTACAGC 360

TGTGTGTTGC TGATCATGTG CATCAGCGTG GACAGGTACA TTGCCATTGC CCAGGCCATG 420

25 AGAGCACATA CTTGGAGGGA GAAAAGGCTT TTGTACAGCA AAATGGTTTG CTTTACCATC 480

TGGGTATTGG CAGCTGCTCT CTGCATCCCA GAAATCTTAT ACAGCCAAAT CAAGCAGGAA 540

TCCGGCATTG CTATCTGCAC CATGGTTTAC CCTAGCGATG AGAGCACCAA ACTGAAGTCA 600

GCTGTCTTGA CCCTGAAGGT CATCTGGGG TTCTTCCTTC CCTTCGTGGT CATGGCTTGC 660

TGCTATACCA TCATCATTCA CACCTGATA CAAGCCAAGA AGTCTTCCAA GCACAAAGCC 720

30 AAGAAAGTGA CCATCACTGT CCTGACCGTC TTTGTCTTGT CTCAGTTTCC CTACAAGTGC 780

ATTTTGTGTC TGCAGACCAT TGACGCTTAT GCCATGTTCA TCTCCAACTG TGCCGTTTCC 840

126

ACCAACATTG ACATCTGCTT CCAGGTCACC CAGACCATCG CCTTCTTCCA CAGTTGCCTG 900
 AACCCGTGTC TCTATGTTTT TGTGGGTGAG AGATTCCGCC GGGATCTCGT GAAAACCCCTG 960
 AAGAACTTGG GTTGCATCAG CCAGGCCACG TGGGTTTCAT TTACAAGGAG AGAGGGAAGC 1020
 TTGAAGCTGT CGTCTATGTT GCTGGAGACA ACCTCAGGAG CACTCTCCCT CTGA 1074

5 (177) INFORMATION FOR SEQ ID NO:176:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 357 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 10 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 176:

Met Ala Asp Asp Tyr Gly Ser Glu Ser Thr Ser Ser Met Glu Asp Tyr
 1 5 10 15
 15 Val Asn Phe Asn Phe Thr Asp Phe Tyr Cys Glu Lys Asn Asn Val Arg
 20 25 30
 Gln Phe Ala Ser His Phe Leu Pro Pro Leu Tyr Trp Leu Val Phe Ile
 35 40 45
 20 Val Gly Ala Leu Gly Asn Ser Leu Val Ile Leu Val Tyr Trp Tyr Cys
 50 55 60
 Thr Arg Val Lys Thr Met Thr Asp Met Phe Leu Leu Asn Leu Ala Ile
 65 70 75 80
 Ala Asp Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ala Ile Ala Ala
 85 90 95
 25 Ala Asp Gln Trp Lys Phe Gln Thr Phe Met Cys Lys Val Val Asn Ser
 100 105 110
 Met Tyr Lys Met Asn Phe Tyr Ser Cys Val Leu Leu Ile Met Cys Ile
 115 120 125
 30 Ser Val Asp Arg Tyr Ile Ala Ile Ala Gln Ala Met Arg Ala His Thr
 130 135 140
 Trp Arg Glu Lys Arg Leu Leu Tyr Ser Lys Met Val Cys Phe Thr Ile
 145 150 155 160
 Trp Val Leu Ala Ala Ala Leu Cys Ile Pro Glu Ile Leu Tyr Ser Gln
 165 170 175
 35 Ile Lys Glu Glu Ser Gly Ile Ala Ile Cys Thr Met Val Tyr Pro Ser
 180 185 190

127

Asp Glu Ser Thr Lys Leu Lys Ser Ala Val Ile Thr Leu Lys Val Ile
 195 200 205
 Leu Gly Phe Phe Leu Pro Phe Val Val Met Ala Cys Cys Tyr Thr Ile
 210 215 220
 5 Ile Ile His Thr Leu Ile Gln Ala Lys Lys Ser Ser Lys His Lys Ala
 225 230 235 240
 Lys Lys Val Thr Ile Thr Val Leu Thr Val Phe Val Leu Ser Gln Phe
 245 250 255
 10 Pro Tyr Asn Cys Ile Leu Leu Val Gln Thr Ile Asp Ala Tyr Ala Met
 260 265 270
 Phe Ile Ser Asn Cys Ala Val Ser Thr Asn Ile Asp Ile Cys Phe Gln
 275 280 285
 Val Thr Gln Thr Ile Ala Phe Phe His Ser Cys Leu Asn Pro Val Leu
 290 295 300
 15 Tyr Val Phe Val Gly Glu Arg Phe Arg Arg Asp Leu Val Lys Thr Leu
 305 310 315 320
 Lys Asn Leu Gly Cys Ile Ser Gln Ala Gln Trp Val Ser Phe Thr Arg
 325 330 335
 20 Arg Glu Gly Ser Leu Lys Leu Ser Ser Met Leu Leu Glu Thr Thr Ser
 340 345 350
 Gly Ala Leu Ser Leu
 355

(178) INFORMATION FOR SEQ ID NO:177:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1110 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:
 ATGGCCTCAT CGACCACTCG GGGCCCCAGG GTTCTGACT TATTTCTCG GCTGCCGCCG 60
 GCGGTCACAA CTCGCCCAA CCAGAGCGCA GAGGCTCGG CGGCAACCG GTCGGTGGCT 120
 GGCGGGGACG CTCACCCCGT CACGCCCTTC CAGAGCCTGC AGCTGGTGCA TCACCTGAAG 180
 GGGCTGATCG TGCTGCTCTA CAGCGTCGTG GTGGTCGTGG GGCTGGTGGG CAACTGCCCTG 240
 35 CTGGTGCTGG TGATCGCGCG GGTGCCGCGG CTGCACAACG TGACGAACCT CCTCATCGGC 300


```

AACCTGGCCT TGTCCGACGT GTCATGTGC ACCGCCTGCG TSCCGCTCAC GCTGGCCTAT 360
GCCTTCGAGC CACGCGGCTG GGTGTTCCGC GCGGCTCTGT GCCACCTGGT CTTCTTCCTG 420
CAGCCGGTCA CCGTCTATGT GTCGGTGTTC ACGETCACCA CCATCCAGT GGACCGCTAC 480
GTCGTGCTGG TGCACCCGCT GAGGCGCGCA TCTCGCTGCG CCTCAGCCTA CGCTGTGCTG 540
5  GCCATCTGGG CGCTGTCCGC GGTGCTGGCG CTGCCGCCCG CCGTGACACAC CTATCACGTG 600
GAGCTCAAGC CGCACGACGT GCGCCTCTGC GAGGAGTTCT GGGGTCCCA GGAGCGCCAG 660
CGCCAGCTCT ACGCCTGGGG GCTGCTGCTG GTCACTTACC TGCTCCCTCT GCTGGTCATC 720
CTCCTGTCTT ACGTCCGGGT GTCAGTGAAG CTCCGCAACC GGTGGTGCC GGGCTGCGTG 780
ACCCAGAGCC AGGCCGACTG GGACCCGCT CGGCGCCGCG GCACCAAATG CTTGCTGGTG 840
10 GTGGTCTGGG TGGTGTTCGC CGTCTGCTGG CTGCCGCTGC ACGTCTTCAA CCTGCTGCGG 900
GACCTCGACC CCCACGCCAT CGACCCCTAC GCCTTTGGGC TGGTGCAGCT GCTCTGCCAC 960
TGGCTCGCCA TGAGTTCGGC CTGCTACAAC CCCTTCATCT ACGCCTGGCT GCACGACAGC 1020
TTCCGCGAGG AGCTGCGCAA ACTGTTGGTC GCTTGGCCGC GCAAGATAGC CCCCCATGCC 1080
CAGAATATGA CCGTCAGCGT GGTCTCTGA 1110

```

15 (179) INFORMATION FOR SEQ ID NO:178:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 369 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

20 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

```

Met Ala Ser Ser Thr Thr Arg Gly Pro Arg Val Ser Asp Leu Phe Ser
1           5           10           15
25 Gly Leu Pro Pro Ala Val Thr Thr Pro Ala Asn Gln Ser Ala Glu Ala
    20           25           30
Ser Ala Gly Asn Gly Ser Val Ala Gly Ala Asp Ala Pro Ala Val Thr
    35           40           45
30 Pro Phe Gln Ser Leu Gln Leu Val His Gln Leu Lys Gly Leu Ile Val
    50           55           60
Leu Leu Tyr Ser Val Val Val Val Gly Leu Val Gly Asn Cys Leu
65           70           75           80

```

129

Leu Val Leu Val Ile Ala Arg Val Pro Arg Leu His Asn Val Thr Asn
 85 90 95
 Phe Leu Ile Gly Asn Leu Ala Leu Ser Asp Val Leu Met Cys Thr Ala
 100 105 110
 5 Cys Val Pro Leu Thr Leu Ala Tyr Ala Phe Glu Pro Arg Gly Trp Val
 115 120 125
 Phe Gly Gly Gly Leu Cys His Leu Val Phe Phe Leu Gln Pro Val Thr
 130 135 140
 10 Val Tyr Val Ser Val Phe Thr Leu Thr Thr Ile Ala Val Asp Arg Tyr
 145 150 155 160
 Val Val Leu Val His Pro Leu Arg Arg Ala Ser Arg Cys Ala Ser Ala
 165 170 175
 Tyr Ala Val Leu Ala Ile Trp Ala Leu Ser Ala Val Leu Ala Leu Pro
 180 185 190
 15 Pro Ala Val His Thr Tyr His Val Glu Leu Lys Pro His Asp Val Arg
 195 200 205
 Leu Cys Glu Glu Phe Trp Gly Ser Gln Glu Arg Gln Arg Gln Leu Tyr
 210 215 220
 20 Ala Trp Gly Leu Leu Leu Val Thr Tyr Leu Leu Pro Leu Leu Val Ile
 225 230 235 240
 Leu Leu Ser Tyr Val Arg Val Ser Val Lys Leu Arg Asn Arg Val Val
 245 250 255
 Pro Gly Cys Val Thr Gln Ser Gln Ala Asp Trp Asp Arg Ala Arg Arg
 260 265 270
 25 Arg Arg Thr Lys Cys Leu Leu Val Val Val Val Val Phe Ala Val
 275 280 285
 Cys Trp Leu Pro Leu His Val Phe Asn Leu Leu Arg Asp Leu Asp Pro
 290 295 300
 30 His Ala Ile Asp Pro Tyr Ala Phe Gly Leu Val Gln Leu Leu Cys His
 305 310 315 320
 Trp Leu Ala Met Ser Ser Ala Cys Tyr Asn Pro Phe Ile Tyr Ala Trp
 325 330 335
 Leu His Asp Ser Phe Arg Glu Glu Leu Arg Lys Leu Leu Val Ala Trp
 340 345 350
 35 Pro Arg Lys Ile Ala Pro His Gly Gln Asn Met Thr Val Ser Val Val
 355 360 365
 Ile

(180) INFORMATION FOR SEQ ID NO:179:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1083 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

10 ATGGACCCAG AAGAACTTC AGTTTATTG GATTATTACT ATGCTACGAG CCCAACTCT 60
GACATCAGGG AGACCCACTC CCATGTTCTT TACACCTCTG TCTTCCTTCC AGTCTTTTAC 120
ACAGCTGTGT TCCTGACTGG AGTGCTGGGG AACCTTGTTT TCATGGGAGC GTTGCAATTC 180
AAACCCGGCA GCGGAAGACT GATCGACATC TTTATCATCA ATCTGGCTGC CTCTGACTTC 240
ATTTTCTTTC TCACATTGCC TCTCTGGSTG GATAAAGAAG CATCTCTAGG ACTGTGGAGG 300
15 ACGGGCTCCT TCCTGTGCAA AGGGAGCTCC TACATGATCT CCGTCAATAT GCAGTGCAGT 360
GTCCCTCTGC TCACTTGCAAT GAGTGTTCAC CCTACCTGG CCATTGTGTG GCCAGTCGTA 420
TCCAGGAAAT TCAGAAGGAC AGACTGTGCA TAGTAGTCT GTGCCAGCAT CTGGTTTATC 480
TCCTGCCTGC TGGGGTTGCC TACTCTTCTG TCCAGGGAGC TCACGCTGAT TGATGATAAG 540
CCATACTGTG CAGAGAAAAA GGCAACTCCA ATTAACTCA TATGGTCCCT GGTGGCCTTA 600
20 ATTTTCACCT TTTTGTCCC TTTGTTGAGC ATTGTGACCT GCTACTGTTG CATTGCAAGG 660
AAGCTGTGTG CCCATTACCA GCAATCAGGA AAGCACAACA AAAAGTGA AATCTTAAG 720
AAGATCATCT TTATTGTCTT GGCAGCCTTT CTGTCTCCTT GGCTGCCCTT CAATACTTTC 780
AAGTTCCTGG CCATTGTCTC TGGGTTGCGG CAAGAACACT ATTTACCCCTC AGCTATTCTT 840
CAGCTTGCTA TGGAGGTGAG TGGACCCTTG GCATTTGCCA ACAGCTGTGT CAACCCCTTC 900
25 ATTTACTATA TCTTCGACAG CTACATCCGC CGGGCCATTG TCCACTGCTT GTGCCCTTGC 960
CTGAAAAACT ATGACTTTGG GAGTAGCACT GAGACATCAG ATAGTCACCT CACTAAGGCT 1020
CTCTCCACCT TCATTCAATG AGAAGATTTT GCCAGGAGGA GGAAGAGGTC TGTGTCACTC 1080
TAA 1083

(181) INFORMATION FOR SEQ ID NO:180:

- 30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 360 amino acids

131

(B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

	Met	Asp	Pro	Glu	Glu	Thr	Ser	Val	Tyr	Leu	Asp	Tyr	Tyr	Tyr	Ala	Thr	
	1				5					10					15		
	Ser	Pro	Asn	Ser	Asp	Ile	Arg	Glu	Thr	His	Ser	His	Val	Pro	Tyr	Thr	
				20					25					30			
10	Ser	Val	Phe	Leu	Pro	Val	Phe	Tyr	Thr	Ala	Val	Phe	Leu	Thr	Gly	Val	
			35					40					45				
	Leu	Gly	Asn	Leu	Val	Leu	Met	Gly	Ala	Leu	His	Phe	Lys	Pro	Gly	Ser	
			50				55						60				
	Arg	Arg	Leu	Ile	Asp	Ile	Phe	Ile	Ile	Asn	Leu	Ala	Ala	Ser	Asp	Phe	
15			65			70					75				80		
	Ile	Phe	Leu	Val	Thr	Leu	Pro	Leu	Trp	Val	Asp	Lys	Glu	Ala	Ser	Leu	
					85					90					95		
	Gly	Leu	Trp	Arg	Thr	Gly	Ser	Phe	Leu	Cys	Lys	Gly	Ser	Ser	Tyr	Met	
				100					105						110		
20	Ile	Ser	Val	Asn	Met	His	Cys	Ser	Val	Leu	Leu	Leu	Thr	Cys	Met	Ser	
				115				120					125				
	Val	Asp	Arg	Tyr	Leu	Ala	Ile	Val	Trp	Pro	Val	Val	Ser	Arg	Lys	Phe	
			130				135						140				
	Arg	Arg	Thr	Asp	Cys	Ala	Tyr	Val	Val	Cys	Ala	Ser	Ile	Trp	Phe	Ile	
25			145			150					155				160		
	Ser	Cys	Leu	Leu	Gly	Leu	Pro	Thr	Leu	Leu	Ser	Arg	Glu	Leu	Thr	Leu	
				165						170				175			
	Ile	Asp	Asp	Lys	Pro	Tyr	Cys	Ala	Glu	Lys	Lys	Ala	Thr	Pro	Ile	Lys	
				180					185					190			
30	Leu	Ile	Trp	Ser	Leu	Val	Ala	Leu	Ile	Phe	Thr	Phe	Phe	Val	Pro	Leu	
			195					200						205			
	Leu	Ser	Ile	Val	Thr	Cys	Tyr	Cys	Cys	Ile	Ala	Arg	Lys	Leu	Cys	Ala	
			210				215					220					
	His	Tyr	Gln	Gln	Ser	Gly	Lys	His	Asn	Lys	Lys	Leu	Lys	Lys	Ser	Lys	
35			225			230					235				240		
	Lys	Ile	Ile	Phe	Ile	Val	Val	Ala	Ala	Phe	Leu	Val	Ser	Trp	Leu	Pro	
				245						250					255		

132

Phe Asn Thr Phe Lys Phe Leu Ala Ile Val Ser Gly Leu Arg Gln Glu
260 265 270

His Tyr Leu Pro Ser Ala Ile Leu Gln Leu Gly Met Glu Val Ser Gly
275 280 285

5 Pro Leu Ala Phe Ala Asn Ser Cys Val Asn Pro Phe Ile Tyr Tyr Ile
290 295 300

Phe Asp Ser Tyr Ile Arg Arg Ala Ile Val His Cys Leu Cys Pro Cys
305 310 315 320

10 Leu Lys Asn Tyr Asp Phe Gly Ser Ser Thr Glu Thr Ser Asp Ser His
325 330 335

Leu Thr Lys Ala Leu Ser Thr Phe Ile His Ala Glu Asp Phe Ala Arg
340 345 350

Arg Arg Lys Arg Ser Val Ser Leu
355 360

15 (182) INFORMATION FOR SEQ ID NO:181:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1020 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

ATGAATGGCC TTGAAGTGGC TCCCCAGGT CTGATCACC AACTTCTCCCT GGCCACGGCA 60

GAGCAATGTG GCCAGGAGAC GCCACTGGAG AACATGCTGT TCGCCTCCTT CTACCTTCTG 120

25 GATTTTATCC TGGCTTTAGT TGGCAATACC CTGGCTCTGT GGCTTTTCTT CCGAGACCAC 180

AAGTCCGGGA CCCCCGCCAA CGTGTTCCTG ATGCATCTGG CCGTGGCCCA CTTGTCTGTG 240

GTGCTGGTCC TGCCACCCCG CCTGGTCTAC CACTTCTCTG GGAACCACTG GCCATTTGGG 300

GAAATCGCAT GCGTCTCAC CGGCTTCCTC TTCTACCTCA ACATGTACGC CAGCATCTAC 360

TTCTCACCT GCATCAGGC CGACCGTTTC CTGGCCATTG TGCACCGGT CAAGTCCCTC 420

30 AAGCTCCGCA GGCCCTCTA CGCACACCTG GCCTGTGCCT TCCTGTGGGT GGTGGTGGCT 480

GTGGCCATGG CCCCCTGCT GGTGAGCCCA CACACCGTGC AGACCAACCA CACGGTGGTC 540

TGCCTGCAGC TGTACCGGGA GAAGGCCTCC CACCATGCC TGGTGTCCCT GGCAGTGGCC 600

TTCACCTTCC CGTTCATCAC CACGGTCACC TGCTACCTGC TGATCATCTG CAGCCTGCGG 660

133

CAGGGCCTGC GTGTGGAGAA GCGCCTCAAG ACCAAGGCAA AACGCATGAT CGCCATAGTG 720
 CTGGCCATCT TCCTGGTCTG CTTCGTGCCC TACCACGTCA ACCGCTCCGT CTACGTGCTC 780
 CACTACCGCA GCCATGGGGC CTCCTGCGCC ACCCAGCGCA TCCTGGCCCT GSCAAACCGC 840
 ATCACCTCCT GCCTCACCAG CCTCAACGGG GCACTCGACC CCATCATGTA TTTCTTCGTG 900
 5 GCTGAGAAGT TCCGCCACGC CCTGTGCAAC TTGCTCTGTG GCAAAAGGCT CAAGGGCCCCG 960
 CCCCCCAGCT TCGAAGGGAA AACCAACGAG AGCTCGCTGA GTGCCAAGTC AGAGCTGTGA 1020

(183) INFORMATION FOR SEQ ID NO:182:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 339 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

15 Met Asn Gly Leu Glu Val Ala Pro Pro Gly Leu Ile Thr Asn Phe Ser
 1 5 10 15
 Leu Ala Thr Ala Glu Gln Cys Gly Gln Glu Thr Pro Leu Glu Asn Met
 20 25 30
 20 Leu Phe Ala Ser Phe Tyr Leu Leu Asp Phe Ile Leu Ala Leu Val Gly
 35 40 45
 Asn Thr Leu Ala Leu Trp Leu Phe Ile Arg Asp His Lys Ser Gly Thr
 50 55 60
 Pro Ala Asn Val Phe Leu Met His Leu Ala Val Ala Asp Leu Ser Cys
 65 70 75 80
 25 Val Leu Val Leu Pro Thr Arg Leu Val Tyr His Phe Ser Gly Asn His
 85 90 95
 Trp Pro Phe Gly Glu Ile Ala Cys Arg Leu Thr Gly Phe Leu Phe Tyr
 100 105 110
 30 Leu Asn Met Tyr Ala Ser Ile Tyr Phe Leu Thr Cys Ile Ser Ala Asp
 115 120 125
 Arg Phe Leu Ala Ile Val His Pro Val Lys Ser Leu Lys Leu Arg Arg
 130 135 140
 Pro Leu Tyr Ala His Leu Ala Cys Ala Phe Leu Trp Val Val Val Ala
 145 150 155 160
 35 Val Ala Met Ala Pro Leu Leu Val Ser Pro Gln Thr Val Gln Thr Asn

134

	165	170	175
	His Thr Val Val Cys Leu Gln Leu Tyr Arg Glu Lys Ala Ser His His		
	180	185	190
5	Ala Leu Val Ser Leu Ala Val Ala Phe Thr Phe Pro Phe Ile Thr Thr		
	195	200	205
	Val Thr Cys Tyr Leu Leu Ile Ile Arg Ser Leu Arg Gln Gly Leu Arg		
	210	215	220
	Val Glu Lys Arg Leu Lys Thr Lys Ala Lys Arg Met Ile Ala Ile Val		
	225	230	235 240
10	Leu Ala Ile Phe Leu Val Cys Phe Val Pro Tyr His Val Asn Arg Ser		
	245	250	255
	Val Tyr Val Leu His Tyr Arg Ser His Gly Ala Ser Cys Ala Thr Gln		
	260	265	270
15	Arg Ile Leu Ala Leu Ala Asn Arg Ile Thr Ser Cys Leu Thr Ser Leu		
	275	280	285
	Asn Gly Ala Leu Asp Pro Ile Met Tyr Phe Phe Val Ala Glu Lys Phe		
	290	295	300
	Arg His Ala Leu Cys Asn Leu Leu Cys Gly Lys Arg Leu Lys Gly Pro		
	305	310	315 320
20	Pro Pro Ser Phe Glu Gly Lys Thr Asn Glu Ser Ser Leu Ser Ala Lys		
	325	330	335
	Ser Glu Leu		

(183) INFORMATION FOR SEQ ID NO:183:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 996 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 30 (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:
- | | |
|--|-----|
| ATGATCACCC TGAACAATCA AGATCAACCT GTCCCTTTTA ACAGCTCACA TCCAGATGAA | 60 |
| TACAAAATTG CAGCCCTTGT CTTCTATAGC TGTATCTTCA TAATTGGATT ATTTGTIAAC | 120 |
| ATCACTGCAT TATGGGTTTT CAGTTGTACC ACCAAGAAGA GAACCACGGT AACCATCTAT | 180 |
| 35 ATGATGAATG TGGCATTAGT GGAATTGATA TTTATAATGA CTTTACCCTT TCGAATGTTT | 240 |

TATTATGCAA AAGATGAATG GCCATTTTGA GAGTACTTCT GCCAGATTCT TGGAGCTCTC 300
 ACAGTGTTTT ACCCAAGCAT TGCTTTATGG CTTCTTGCCT TTATTAGTGC TGACAGATAC 360
 ATGGCCATTG TACAGCCGAA GTACGCCAAA GAACTTAAAA ACACGTGCAA AGCCGTGCTG 420
 GCGTGTGTGG GAGTCTGGAT AATGACCTTG ACCACGACCA CCCCTCTGCT ACTGCTCTAT 480
 5 AAAGACCCAG ATAAAGACTC CACTCCCGCC ACCTGCCTCA AGATTCTCTGA CATCATCTAT 540
 CTAAAGCTG TGAACGTGCT GAACCTCACT CGACTGACAT TTTTCTTCTT GATTCCTTTG 600
 TTCATCATGA TTGGGTGCTA CTTGGTCATT ATTGATAATC TCCTTCACGG CAGGACGTCT 660
 AAGCTGAAAC CCAAAGTCAA GGAGAAGTCC AAAAGGATCA TCATCACGCT GCTGGTGCAG 720
 GTGCTCGTCT GCTTTATGCC CTTCCACATC TGTTTCGCTT TCCTGATGCT GGGAAACGGGG 780
 10 GAGAATAGTT ACAATCCCTG GGGAGCCTTT ACCACCTTCC TCATGAACCT CAGCACGTGT 840
 CTGGATGTGA TTCTCTACTA CATCGTTTCA AAACAATTTT AGGCTCGAGT CATTAGTGTC 900
 ATGCTATAAC GTAATTACCT TCGAAGCATG CGCAGAAAAA GTTTCCGATC TGGTAGTCTA 960
 AGGTCACTAA GCAATATAAA CAGTGAAATG TTATGA 996

(185) INFORMATION FOR SEQ ID NO:184:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 331 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant
- 20 (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:
- | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ile | Thr | Leu | Asn | Asn | Gln | Asp | Gln | Pro | Val | Pro | Phe | Asn | Ser | Ser |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| His | Pro | Asp | Glu | Tyr | Lys | Ile | Ala | Ala | Leu | Val | Phe | Tyr | Ser | Cys | Ile |
| 25 | | | 20 | | | | | 25 | | | | | 30 | | |
| Phe | Ile | Ile | Gly | Leu | Phe | Val | Asn | Ile | Thr | Ala | Leu | Trp | Val | Phe | Ser |
| | 35 | | | | | 40 | | | | | 45 | | | | |
| Cys | Thr | Thr | Lys | Lys | Arg | Thr | Thr | Val | Thr | Ile | Tyr | Met | Met | Asn | Val |
| | 50 | | | | 55 | | | | | 60 | | | | | |
| Ala | Leu | Val | Asp | Leu | Ile | Phe | Ile | Met | Thr | Leu | Pro | Phe | Arg | Met | Phe |
| 30 | 65 | | | 70 | | | | | 75 | | | | | 80 | |
| Tyr | Tyr | Ala | Lys | Asp | Glu | Trp | Pro | Phe | Gly | Glu | Tyr | Phe | Cys | Gln | Ile |
| | | | 85 | | | | | | 90 | | | | 95 | | |

136

	Leu Gly Ala Leu Thr Val Phe Tyr Pro Ser Ile Ala Leu Trp Leu Leu	
	100	110
	Ala Phe Ile Ser Ala Asp Arg Tyr Met Ala Ile Val Gln Pro Lys Tyr	
	115	125
5	Ala Lys Glu Leu Lys Asn Thr Cys Lys Ala Val Leu Ala Cys Val Gly	
	130	140
	Val Trp Ile Met Thr Leu Thr Thr Thr Thr Pro Leu Leu Leu Tyr	
	145	160
10	Lys Asp Pro Asp Lys Asp Ser Thr Pro Ala Thr Cys Leu Lys Ile Ser	
	165	175
	Asp Ile Ile Tyr Leu Lys Ala Val Asn Val Leu Asn Leu Thr Arg Leu	
	180	190
	Thr Phe Phe Phe Leu Ile Pro Leu Phe Ile Met Ile Gly Cys Tyr Leu	
	195	205
15	Val Ile Ile His Asn Leu Leu His Gly Arg Thr Ser Lys Leu Lys Pro	
	210	220
	Lys Val Lys Glu Lys Ser Lys Arg Ile Ile Ile Thr Leu Leu Val Gln	
	225	240
20	Val Leu Val Cys Phe Met Pro Phe His Ile Cys Phe Ala Phe Leu Met	
	245	255
	Leu Gly Thr Gly Glu Asn Ser Tyr Asn Pro Trp Gly Ala Phe Thr Thr	
	260	270
	Phe Leu Met Asn Leu Ser Thr Cys Leu Asp Val Ile Leu Tyr Tyr Ile	
	275	285
25	Val Ser Lys Gln Phe Gln Ala Arg Val Ile Ser Val Met Leu Tyr Arg	
	290	300
	Asn Tyr Leu Arg Ser Met Arg Arg Lys Ser Phe Arg Ser Gly Ser Leu	
	305	320
30	Arg Ser Leu Ser Asn Ile Asn Ser Glu Met Leu	
	325	330

(186) INFORMATION FOR SEQ ID NO:185:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1077 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

ATGCCCTCTG TGTCTCCAGC GGGGCCCTCG GCCGGGGCAG TCCCCAATGC CACCGCAGTG 60
 ACAACAGTGC GGACCAATGC CAGCGGGCTG GAGGTGCCCC TGTTCCACCT GTTTGCCCCG 120
 CTGGACGAGG AGCTGCATGG CACCTTCCCA GGCTGTGCG TGGCGCTGAT GCGGTGCAC 180
 5 GGAGCCATCT TCCTGGCAGG GCTGGTGCTC AACGGGCTGG CGCTGTACCT CTTCTGCTGC 240
 CGCACCCGGG CCAAGACACC CTCAGTCATC TACACCATCA ACCTGGTGCT GACCGATCTA 300
 CTGGTAGGGC TGTCCCTGCC CACGCGCTTC GCTGTGTA CTACGGCCAG GGGCTGCCTG 360
 CGCTGTGCCT TCCCGCACGT CCTCGGTTAC TTCTCAACA TGCCTGCTC CATCTCTTC 420
 CTCACCTGCA TCTGCGTGA CCGCTACCTG GCCATCGTGC GGGCGAAGG CTCGCCCGC 480
 10 TGCGCCAGC CTGCTGTGC CAGGGCCGTG TGCGCCTCG TGTGGTGGC GCGCGGTGCC 540
 GTCACCTCTT CGGTGCTGG CGTGACAGG AGCGGCGCT GTGGCGTGT CTTTGCGCTG 600
 ACTGTCTGG AGTTCTCTCT GCGCTGCTG GTCATCAGG TGTTCACGG CGGCATCATG 660
 TGTGCACTGT CGCGGCGGG TCTGCTCCAC CAGGCTGCG AGCGTGGCT GCGGGCCAAG 720
 CAGCTCCTGC TCACGGTGT CATCATCTTT CTCGTCTGT TCAGGCTCT CCACGCCCGC 780
 15 CAAGTGGCGG TGGCGCTGT GCGCGACATG CCACACCAGA CGAGCTTGT GGTCTACCAC 840
 GTGGCCGTGA CCTCAGCAG CCTCAACAGC TGCATGGAG CCATCTCTA CTGCTTCGTC 900
 ACCAGTGGCT TCCAGGCCAC CGTCCGAGG CTCTTCGGG AGCAGGAGA GCGTGAGCC 960
 AGCAGCGGTG ACGTGGTCAG CATGCACAGG AGCTCCAAGG GCTCAGGCG TCATCACATC 1020
 CTCAGTGGCG GCCCTCACGC CCTCACCCAG GCCCTGGCTA ATGGGCCCGA GGCTTAG 1077

20 (187) INFORMATION FOR SEQ ID NO:186:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 358 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 25 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

Met Pro Ser Val Ser Pro Ala Gly Pro Ser Ala Gly Ala Val Pro Asn
 1 5 10 15
 30 Ala Thr Ala Val Thr Thr Val Arg Thr Asn Ala Ser Gly Leu Glu Val
 20 25 30

138

Pro Leu Phe His Leu Phe Ala Arg Leu Asp Glu Glu Leu His Gly Thr
 35 40 45
 Phe Pro Gly Leu Cys Val Ala Leu Met Ala Val His Gly Ala Ile Phe
 50 55 60
 5 Leu Ala Gly Leu Val Leu Asn Gly Leu Ala Leu Tyr Val Phe Cys Cys
 65 70 75 80
 Arg Thr Arg Ala Lys Thr Pro Ser Val Ile Tyr Thr Ile Asn Leu Val
 85 90 95
 10 Val Thr Asp Leu Leu Val Gly Leu Ser Leu Pro Thr Arg Phe Ala Val
 100 105 110
 Tyr Tyr Gly Ala Arg Gly Cys Leu Arg Cys Ala Phe Pro His Val Leu
 115 120 125
 Gly Tyr Phe Leu Asn Met His Cys Ser Ile Leu Phe Leu Thr Cys Ile
 130 135 140
 15 Cys Val Asp Arg Tyr Leu Ala Ile Val Arg Pro Glu Gly Ser Arg Ala
 145 150 155 160
 Cys Arg Gln Pro Ala Cys Ala Arg Ala Val Cys Ala Phe Val Trp Leu
 165 170 175
 20 Ala Ala Gly Ala Val Thr Leu Ser Val Leu Gly Val Thr Gly Ser Arg
 180 185 190
 Pro Cys Cys Arg Val Phe Ala Leu Thr Val Leu Glu Phe Leu Leu Pro
 195 200 205
 Leu Leu Val Ile Ser Val Phe Thr Gly Arg Ile Met Cys Ala Leu Ser
 210 215 220
 25 Arg Pro Gly Leu Leu His Gln Gly Arg Gln Arg Arg Val Arg Ala Lys
 225 230 235 240
 Gln Leu Leu Leu Thr Val Leu Ile Ile Phe Leu Val Cys Phe Thr Pro
 245 250 255
 30 Phe His Ala Arg Gln Val Ala Val Ala Leu Trp Pro Asp Met Pro His
 260 265 270
 His Thr Ser Leu Val Val Tyr His Val Ala Val Thr Leu Ser Ser Leu
 275 280 285
 Asn Ser Cys Met Asp Pro Ile Val Tyr Cys Phe Val Thr Ser Gly Phe
 290 295 300
 35 Gln Ala Thr Val Arg Gly Leu Phe Gly Gln His Gly Glu Arg Glu Pro
 305 310 315 320
 Ser Ser Gly Asp Val Val Ser Met His Arg Ser Ser Lys Gly Ser Gly

325
330
335

Arg His His Ile Leu Ser Ala Gly Pro His Ala Leu Thr Gln Ala Leu
340
345
350

Ala Asn Gly Pro Glu Ala
355

(188) INFORMATION FOR SEQ ID NO:187:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1050 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEO ID NO:187:

	ATGAACTCCA	CCTTGGATGG	TAATCAGAGC	AGCCACCCTT	TTTGCCTCTT	GGCATTTGCC	60
15	TATTTGGAAA	CTGTCAATTT	TTGCCTTTGG	GAAGTATTGA	TTATTGTCTT	TCTAACTGTA	120
	TTGATTATTT	CTGGCAACAT	CATTGTGATT	TTTGTATTTC	ACTGTGCACC	TTGTTTGAAC	180
	CATCACACTA	CAAGTTATTT	TATCCAGACT	ATGGCATATG	CTGACCTTTT	TGTTGGGGTG	240
	AGCTGCGTGG	TCCCTTCTTT	ATCACTCCTC	CATCACCCCC	TTCCAGTAGA	GGACTCCTTG	300
	ACTTGCCAGA	TATTTGGTTT	TGTAGTATCA	GTTCTGAAGA	GCGTCTCCAT	GGCTTCTCTG	360
20	GCCTGTATCA	GCATTGATAG	ATACATTGCC	ATTACTAAAC	CTTTAACCTA	TAATACTCTG	420
	GTTACACCCT	GGAGACTACG	CCTGTGTATT	TTCTTGATTT	GGCTATACTC	GACCCTGGTC	480
	TTCTTGCCTT	CCTTTTTCCT	CTGGGGCAAA	CCTGGATATC	ATGGAGATGT	GTTTCAGTGG	540
	TGTGCGGAGT	CCTGGCACAC	CGACTCCTAC	TTCAACCCTG	TCATCGTGAT	GATGTTATAT	600
	GCCCCAGCAG	CCCTTATTGT	CTGCTTCACC	TATTTCAACA	TCTTCCGCAT	CTGCCAACAG	660
25	CACACAAAGG	ATATCAGCGA	AAGGCAAGCC	CGCTTCAGCA	GCCAGAGTGG	GGAGACTGGG	720
	GAAGTGCAGG	CCTGTCTCTG	TAAGCGCTAT	AAAATGGTCC	TGTTTCCGAAT	CACTAGTGTA	780
	TTTTCATATC	TCTGGTTGCC	ATATATCATC	TACTTCTTGT	TGGAAAGCTC	CACTGGCCAC	840
	AGCAACCGCT	TCGCATCCTT	CTTGACCACC	TGGCTTGCTA	TTAGTAACAG	TTTCTGCAAC	900
	TGTGTAATTT	ATAGTCTCTC	CAACAGTGTA	TTCCAAAGAG	GACTAAAGCG	CCTCTCAGGG	960
30	GCTATGTGTA	CTTCTTGTCG	AAGTCAGACT	ACAGCCAACG	ACCCTTACAC	AGTTAGAAGC	1020
	AAAGGCCCTC	TTAATGGATG	TCATATCTGA				1080

(189) INFORMATION FOR SEQ ID NO:188:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 349 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

Met Asn Ser Thr Leu Asp Gly Asn Gln Ser Ser His Pro Phe Cys Leu
 1 5 10 15

Leu Ala Phe Gly Tyr Leu Glu Thr Val Asn Phe Cys Leu Leu Glu Val
 20 25 30

Leu Ile Ile Val Phe Leu Thr Val Leu Ile Ile Ser Gly Asn Ile Ile
 35 40 45

Val Ile Phe Val Phe His Cys Ala Pro Leu Leu Asn His His Thr Thr
 50 55 60

Ser Tyr Phe Ile Gln Thr Met Ala Tyr Ala Asp Leu Phe Val Gly Val
 65 70 75 80

Ser Cys Val Val Pro Ser Leu Ser Leu Leu His His Pro Leu Pro Val
 85 90 95

Glu Glu Ser Leu Thr Cys Gln Ile Phe Gly Phe Val Val Ser Val Leu
 100 105 110

Lys Ser Val Ser Met Ala Ser Leu Ala Cys Ile Ser Ile Asp Arg Tyr
 115 120 125

Ile Ala Ile Thr Lys Pro Leu Thr Tyr Asn Thr Leu Val Thr Pro Trp
 130 135 140

Arg Leu Arg Leu Cys Ile Phe Leu Ile Trp Leu Tyr Ser Thr Leu Val
 145 150 155 160

Phe Leu Pro Ser Phe Phe His Trp Gly Lys Pro Gly Tyr His Gly Asp
 165 170 175

Val Phe Gln Trp Cys Ala Glu Ser Trp His Thr Asp Ser Tyr Phe Thr
 180 185 190

Leu Phe Ile Val Met Met Leu Tyr Ala Pro Ala Ala Leu Ile Val Cys
 195 200 205

Phe Thr Tyr Phe Asn Ile Phe Arg Ile Cys Gln Gln His Thr Lys Asp
 210 215 220

141

Ile Ser Glu Arg Gln Ala Arg Phe Ser Ser Gln Ser Gly Glu Thr Gly
 225 230 235 240

Glu Val Gln Ala Cys Pro Asp Lys Arg Tyr Lys Met Val Leu Phe Arg
 245 250 255

5 Ile Thr Ser Val Phe Tyr Ile Leu Trp Leu Pro Tyr Ile Ile Tyr Phe
 260 265 270

Leu Leu Glu Ser Ser Thr Gly His Ser Asn Arg Phe Ala Ser Phe Leu
 275 280 285

10 Thr Thr Trp Leu Ala Ile Ser Asn Ser Phe Cys Asn Cys Val Ile Tyr
 290 295 300

Ser Leu Ser Asn Ser Val Phe Gln Arg Gly Leu Lys Arg Leu Ser Gly
 305 310 315 320

Ala Met Cys Thr Ser Cys Ala Ser Gln Thr Thr Ala Asn Asp Pro Tyr
 325 330 335

15 Thr Val Arg Ser Lys Gly Pro Leu Asn Gly Cys His Ile
 340 345

(190) INFORMATION FOR SEQ ID NO:189:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1302 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

25 ATGTGTTTTT CTCCATTCT GGAAATCAAC ATGCAGTCTG AATCTAACAT TACAGTGCGA 60

GATGACATTG ATGACATCAA CACCAATATG TACCAACCAC TATCATATCC GTTAAGCTTT 120

CAAGTGTCTC TCACCGGATT TCTTATGTTA GAAATTGTGT TGGGACTTGG CAGCAACCTC 180

ACTGTATTGG TACTTTACTG CATGAAATCC AACTTAATCA ACTCTGTCAG TAACATTATT 240

ACAATGAATC TTCATGTACT TGATGTAATA ATTTGTGTGG GATGTATTCC TCTAACTATA 300

30 GTTATCCTTC TGCTTTCACT GGAGAGTAAC ACTGCTCTCA TTTGCTGTIT CCATGAGGCT 360

TGTGTATCTT TTGCAAGTGT CTCAACAGCA ATCAACGTTT TTGCTATCAC TTTGGACAGA 420

TATGACATCT CTGTAAAACC TGCAAACCGA ATTCTGACAA TGGGCAGAGC TGTAATGTTA 480

ATGATATCCA TTTGGATTIT TTCTTTTTC TCTTCTCTGA TTCCTTTTAT TGAGGTAAAT 540

TTTTTCAGTC TTCAAAGTGG AAATACCTGG GAAAACAAGA CACTTTTATG TGTCAGTACA 600

142

AATGAATACT ACACTGAACT GGGAATGTAT TATCACCTGT TAGTACAGAT CCCAATATTC 660
 TTTTTCAGTG TTGTAGTAAT GTTAATCACA TACACCAAAA TACTTCAGGC TCTTAATATT 720
 CGAATAGGCA CAAGATTTTC AACAGGGCAG AAGAAGAAAG CAAGAAAGAA AAAGACAATT 780
 TCTCTAACCA CACAACATGA GGCTACAGAC ATGTCACAAA GCAGTGGTGG GAGAAATGTA 840
 5 GTCTTTGGTG TAAGAACTTC AGTTTCTGTA ATAATTGCCC TCCGGCGAGC TGTGAAACGA 900
 CACCGTGAAC GACGAGAAAG ACAAAGAGA GTCAAGAGGA TGTCTTTATT GATTATTCTT 960
 ACATTTCTTC TCTGCTGGAC ACCAATTCTT GTTTTAAATA CCACCATTTT ATGTTTAGGC 1020
 CCAAGTGACC TTTTAGTAAA ATTAAGATTG TGTTTTTTAG TCATGGCTTA TGGAAACAACT 1080
 ATATTTCAAC CTCTATTATA TGCATTCACT AGACAAAAAT TTCAAAAGGT CTGAAAAGT 1140
 10 AAAATGAAAA AGCGAGTTGT TTCTATAGTA GAAGCTGATC CCTGCCTAA TAATGCTGTA 1200
 ATACACAACCT CTGGATAGA TCCCAAAAGA AACAAAAAAA TTACCTTTGA AGATAGTGAA 1260
 ATAAGAGAAA AACGTTTAGT GCCTCAGGTT GTCACAGACT AG 1302

(191) INFORMATION FOR SEQ ID NO:190:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 433 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

Met Cys Phe Ser Pro Ile Leu Glu Ile Asn Met Gln Ser Glu Ser Asn
 1 5 10 15
 Ile Thr Val Arg Asp Asp Ile Asp Asp Ile Asn Thr Asn Met Tyr Gln
 20 25 30
 25 Pro Leu Ser Tyr Pro Leu Ser Phe Gln Val Ser Leu Thr Gly Phe Leu
 35 40 45
 Met Leu Glu Ile Val Leu Gly Leu Gly Ser Asn Leu Thr Val Leu Val
 50 55 60
 30 Leu Tyr Cys Met Lys Ser Asn Leu Ile Asn Ser Val Ser Asn Ile Ile
 65 70 75 80
 Thr Met Asn Leu His Val Leu Asp Val Ile Ile Cys Val Gly Cys Ile
 85 90 95
 Pro Leu Thr Ile Val Ile Leu Leu Leu Ser Leu Glu Ser Asn Thr Ala

143

	100	105	110
	Leu Ile Cys Cys Phe His Glu Ala Cys Val Ser Phe Ala Ser Val Ser 115 120 125		
5	Thr Ala Ile Asn Val Phe Ala Ile Thr Leu Asp Arg Tyr Asp Ile Ser 130 135 140		
	Val Lys Pro Ala Asn Arg Ile Leu Thr Met Gly Arg Ala Val Met Leu 145 150 155 160		
	Met Ile Ser Ile Trp Ile Phe Ser Phe Phe Ser Phe Leu Ile Pro Phe 165 170 175		
10	Ile Glu Val Asn Phe Phe Ser Leu Gln Ser Gly Asn Thr Trp Glu Asn 180 185 190		
	Lys Thr Leu Leu Cys Val Ser Thr Asn Glu Tyr Tyr Thr Glu Leu Gly 195 200 205		
15	Met Tyr Tyr His Leu Leu Val Gln Ile Pro Ile Phe Phe Phe Thr Val 210 215 220		
	Val Val Met Leu Ile Thr Tyr Thr Lys Ile Leu Gln Ala Leu Asn Ile 225 230 235 240		
	Arg Ile Gly Thr Arg Phe Ser Thr Gly Gln Lys Lys Lys Ala Arg Lys 245 250 255		
20	Lys Lys Thr Ile Ser Leu Thr Thr Gln His Glu Ala Thr Asp Met Ser 260 265 270		
	Gln Ser Ser Gly Gly Arg Asn Val Val Phe Gly Val Arg Thr Ser Val 275 280 285		
25	Ser Val Ile Ile Ala Leu Arg Arg Ala Val Lys Arg His Arg Glu Arg 290 295 300		
	Arg Glu Arg Gln Lys Arg Val Lys Arg Met Ser Leu Leu Ile Ile Ser 305 310 315 320		
	Thr Phe Leu Leu Cys Trp Thr Pro Ile Ser Val Leu Asn Thr Thr Ile 325 330 335		
30	Leu Cys Leu Gly Pro Ser Asp Leu Leu Val Lys Leu Arg Leu Cys Phe 340 345 350		
	Leu Val Met Ala Tyr Gly Thr Thr Ile Phe His Pro Leu Leu Tyr Ala 355 360 365		
35	Phe Thr Arg Gln Lys Phe Gln Lys Val Leu Lys Ser Lys Met Lys Lys 370 375 380		
	Arg Val Val Ser Ile Val Glu Ala Asp Pro Leu Pro Asn Asn Ala Val 385 390 395 400		

144

Ile His Asn Ser Trp Ile Asp Pro Lys Arg Asn Lys Lys Ile Thr Phe
405 410 415

Glu Asp Ser Glu Ile Arg Glu Lys Arg Leu Val Pro Glu Val Val Thr
420 425 430

5 Asp

(192) INFORMATION FOR SEQ ID NO:191:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1209 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

15 ATGTTGTGTC CTTCCAAGAC AGATGGCTCA GGGCACTCTG GTAGGATTCA CCAGGAAACT 60
CATGGAGAAG GGAAAAGGGA CAAGATTAGC AACAGTGAAG GGAGGGAGAA TGGTGGGAGA 120
GGATTCCAGA TGAACGGTGG GTCGCTGGAG GCTGAGCATG CCAGCAGGAT GTCAGTTCTC 180
AGAGCAAAGC CCATGTCAAA CAGCCAACGC TTGCTCCTTC TGTCCCAGG ATCACCTCCT 240
CGCACGGGGA GCATCTCCTA CATCAACATC ATCATGCCCT CGGTGTTCCG CACCATCTGC 300
20 CTCCTGGGCA TCATCGGGAA CTCCACGGTC ATCTTCGGCG TCGTGAAGAA GTCCAAGCTG 360
CACTGGTGCA ACAACGTCCC CGACATCTTC ATCATCAACC TCTCGGTAGT AGATCTCCTC 420
TTTCTCCTGG GCATGCCCTT CATGATCCAC CAGCTCATGG GCAATGGGGT GTGGCACTTT 480
GGGAGACCA TGTGCACCCT CATCACGGCC ATGGATGCCA ATAGTCAGTT CACCAGCACC 540
TACATCCTGA CCGCCATGGC CATTGACCGC TACCTGGCCA CTGTCCACCC CATCTCTTCC 600
25 ACGAAGTTCC GGAAGCCCTC TGTGGCCACC CTGGTGATCT GCCTCCTGTG GGCCCTCTCC 660
TTCATCAGCA TCACCCCTGT GTGGCTGTAT GCCAGACTCA TCCCCTTCCC AGGAGGTGCA 720
GTGGGCTGCG GCATACGCCT GCCCAACCCA GACACTGACC TCTACTGSET CACCCTGTAC 780
CAGTTTTTCC TGGCCTTTGC CCTGCCTTTT GTGGTCATCA CAGCCGCATA CGTGAGGATC 840
CTGCAGCGCA TGACGTCTTC AGTGGCCCCC GCCTCCAGC GCAGCATCCG GCTGCGGACA 900
30 AAGAGGGTGA AACGCACAGC CATCGCCATC TGTCTGGTCT TCTTTGTGTG CTGGGCACCC 960
TACTATGTGC TACAGCTGAC CCAGTTGTCC ATCAGCCGCC CGACCCCTAC CTTTGTCTAC 1020
TTATACAATG CGGCCATCAG CTTGGGCTAT GCCAACAGCT GCCTCAACCC CTTTGTGTAC 1080

145

ATCGTGCTCT GTGAGACGTT CCGCAAACGC TTGGTCCTGT CGGTGAAGCC TGCAGCCCAG 1140
 GGGCAGCTTC GCGCTGTCAG CAACGCTCAG ACGGCTGACG AGGAGAGGAC AGAAAGCAAA 1200
 GGCACCTCA 1209

(193) INFORMATION FOR SEQ ID NO:192:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 402 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant
- 10 (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:
- | | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Leu | Cys | Pro | Ser | Lys | Thr | Asp | Gly | Ser | Gly | His | Ser | Gly | Arg | Ile | 1 | 5 | 10 | 15 |
| His | Gln | Glu | Thr | His | Gly | Glu | Gly | Lys | Arg | Asp | Lys | Ile | Ser | Asn | Ser | 20 | 25 | 30 | |
| Glu | Gly | Arg | Glu | Asn | Gly | Gly | Arg | Gly | Phe | Gln | Met | Asn | Gly | Gly | Ser | 35 | 40 | 45 | |
| Leu | Glu | Ala | Glu | His | Ala | Ser | Arg | Met | Ser | Val | Leu | Arg | Ala | Lys | Pro | 50 | 55 | 60 | |
| Met | Ser | Asn | Ser | Gln | Arg | Leu | Leu | Leu | Ser | Pro | Gly | Ser | Pro | Pro | 65 | 70 | 75 | 80 | |
| Arg | Thr | Gly | Ser | Ile | Ser | Tyr | Ile | Asn | Ile | Ile | Met | Pro | Ser | Val | Phe | 85 | 90 | 95 | |
| Gly | Thr | Ile | Cys | Leu | Leu | Gly | Ile | Ile | Gly | Asn | Ser | Thr | Val | Ile | Phe | 100 | 105 | 110 | |
| Ala | Val | Val | Lys | Lys | Ser | Lys | Leu | His | Trp | Cys | Asn | Asn | Val | Pro | Asp | 115 | 120 | 125 | |
| Ile | Phe | Ile | Ile | Asn | Leu | Ser | Val | Val | Asp | Leu | Leu | Phe | Leu | Leu | Gly | 130 | 135 | 140 | |
| Met | Pro | Phe | Met | Ile | His | Gln | Leu | Met | Gly | Asn | Gly | Val | Trp | His | Phe | 145 | 150 | 155 | 160 |
| Gly | Glu | Thr | Met | Cys | Thr | Leu | Ile | Thr | Ala | Met | Asp | Ala | Asn | Ser | Gln | 165 | 170 | 175 | |
| Phe | Thr | Ser | Thr | Tyr | Ile | Leu | Thr | Ala | Met | Ala | Ile | Asp | Arg | Tyr | Leu | 180 | 185 | 190 | |
| Ala | Thr | Val | His | Pro | Ile | Ser | Ser | Thr | Lys | Phe | Arg | Lys | Pro | Ser | Val | | | | |

146

	195	200	205
	Ala Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser Phe Ile Ser Ile 210 215 220		
5	Thr Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe Pro Gly Gly Ala 225 230 235 240		
	Val Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr Asp Leu Tyr Trp 245 250 255		
	Phe Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu Pro Phe Val Val 260 265 270		
10	Ile Thr Ala Ala Tyr Val Arg Ile Leu Gln Arg Met Thr Ser Ser Val 275 280 285		
	Ala Pro Ala Ser Gln Arg Ser Ile Arg Leu Arg Thr Lys Arg Val Lys 290 295 300		
15	Arg Thr Ala Ile Ala Ile Cys Leu Val Phe Phe Val Cys Trp Ala Pro 305 310 315 320		
	Tyr Tyr Val Leu Gln Leu Thr Gln Leu Ser Ile Ser Arg Pro Thr Leu 325 330 335		
	Thr Phe Val Tyr Leu Tyr Asn Ala Ala Ile Ser Leu Gly Tyr Ala Asn 340 345 350		
20	Ser Cys Leu Asn Pro Phe Val Tyr Ile Val Leu Cys Glu Thr Phe Arg 355 360 365		
	Lys Arg Leu Val Leu Ser Val Lys Pro Ala Ala Gln Gly Gln Leu Arg 370 375 380		
25	Ala Val Ser Asn Ala Gln Thr Ala Asp Glu Glu Arg Thr Glu Ser Lys 385 390 395 400		
	Gly Thr		

(194) INFORMATION FOR SEQ ID NO:193:

- 30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1128 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

ATGGATGTGA CTTCCCAAGC CCGGGGCGTG GGCCTGGAGA TGTACCCAGG CACCGCGCAC 60
 GCTGCGGCCC CCAACACCAC CTCCCCGAG CTCAACCTGT CCCACCGCT CCTGGGCACC 120

147

GCCCTGGCCA ATGGGACAGG TGAGCTCTCG GAGCACCAGC AGTAGGTGAT CGGCCTGTTC 180
 CTCTCGTGCC TCTACACCAT CTTCTCTCTC CCCATCGGCT TTGTGGGCAA CATCCTGATC 240
 CTGGTGGTGA ACATCAGCTT CCGCGAGAAG ATGACCATEC CCGACCTGTA CTTTCATCAAC 300
 CTGGCGGTGG CGGACCTCAT CCTGGTGGCC GACTCCCTCA TTGAGGTGTI CAACCTGCAC 360
 5 GAGCGGTACT ACGACATCGC CGTCTGTGC ACCTTCATBT CGCTCTTCCT GCAGGTCAAC 420
 ATGTACAGCA GCSTCTTCTT CCTCACCTGG ATGAGCTTGG ACCGCTACAT CGCCCTGGCC 480
 AGGGCCATGC GCTGCAGCCT GTTCCGCACC AAGCACCAGG CCGCCTGAG CTGTGGCCTC 540
 ATCTGGATGG CATCCGTGTC AGCCACGCTG GTGCCCTTCA CCGCCGTGCA CCTGCAGCAC 600
 ACCGACGAGG CCTGCTTCTG TTTCCGGGAT GTCCGGGAGG TGCAGTGGCT CGAGGTACG 660
 10 CTGGGCTTCA TCGTGCCCTT CGGCATCATC GGCCTGTGCT ACTCCCTCAT TGTCGGGGTG 720
 CTGGTCAGGG CGCACC GGCA CCGTGGGCTG CGGCCCGGC GGCAGAAAGC SAAACGCATG 780
 ATCCTCGCGG TGGTGCTGGT CTTCTTCGTC TGCTGGCTGC CGGAGAAAGT CTTTCATCAGC 840
 GTGCACCTCC TGCAGCGGAC GCAGCCTGGG GCCGCTCCCT GCAAGCAGTC TTTCCGCCAT 900
 GCCCACCCCC TCACGGGGCA CATTGTCAAC CTCGCCGCTT TCTCCAACAG CTGCCTAAAC 960
 15 CCCCTCATCT ACAGCTTCTT CCGGGAGACC TTCAGGGACA AGCTGAGGCT GTACATTGAG 1020
 CAGAAAACAA ATTTGCCGGC CCTGAACCGC TTCTGTCAGC CTGCCCTGAA GGCCGTCATT 1080
 CCAGACAGCA CCGACAGTC GGATGTGAGG TTCAGCAGTG CCGTGTGA 1128

(195) INFORMATION FOR SEQ ID NO:194:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 375 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

 (ii) MOLECULE TYPE: protein

 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

 Met Asp Val Thr Ser Gln Ala Arg Gly Val Gly Leu Glu Met Tyr Pro
 1 5 10 15

 Gly Thr Ala His Ala Ala Ala Pro Asn Thr Thr Ser Pro Glu Leu Asn
 20 25 30

 30 Leu Ser His Pro Leu Leu Gly Thr Ala Leu Ala Asn Gly Thr Gly Glu
 35 40 45

148

Leu Ser Glu His Gln Gln Tyr Val Ile Gly Leu Phe Leu Ser Cys Leu
 50 55 60

Tyr Thr Ile Phe Leu Phe Pro Ile Gly Phe Val Gly Asn Ile Leu Ile
 65 70 75 80

5 Leu Val Val Asn Ile Ser Phe Arg Glu Lys Met Thr Ile Pro Asp Leu
 85 90 95

Tyr Phe Ile Asn Leu Ala Val Ala Asp Leu Ile Leu Val Ala Asp Ser
 100 105 110

10 Leu Ile Glu Val Phe Asn Leu His Glu Arg Tyr Tyr Asp Ile Ala Val
 115 120 125

Leu Cys Thr Phe Met Ser Leu Phe Leu Gln Val Asn Met Tyr Ser Ser
 130 135 140

Val Phe Phe Leu Thr Trp Met Ser Phe Asp Arg Tyr Ile Ala Leu Ala
 145 150 155 160

15 Arg Ala Met Arg Cys Ser Leu Phe Arg Thr Lys His His Ala Arg Leu
 165 170 175

Ser Cys Gly Leu Ile Trp Met Ala Ser Val Ser Ala Thr Leu Val Pro
 180 185 190

20 Phe Thr Ala Val His Leu Gln His Thr Asp Glu Ala Cys Phe Cys Phe
 195 200 205

Ala Asp Val Arg Glu Val Gln Trp Leu Glu Val Thr Leu Gly Phe Ile
 210 215 220

Val Pro Phe Ala Ile Ile Gly Leu Cys Tyr Ser Leu Ile Val Arg Val
 225 230 235 240

25 Leu Val Arg Ala His Arg His Arg Gly Leu Arg Pro Arg Arg Gln Lys
 245 250 255

Ala Lys Arg Met Ile Leu Ala Val Val Leu Val Phe Phe Val Cys Trp
 260 265 270

30 Leu Pro Glu Asn Val Phe Ile Ser Val His Leu Leu Gln Arg Thr Gln
 275 280 285

Pro Gly Ala Ala Pro Cys Lys Gln Ser Phe Arg His Ala His Pro Leu
 290 295 300

Thr Gly His Ile Val Asn Leu Ala Ala Phe Ser Asn Ser Cys Leu Asn
 305 310 315 320

35 Pro Leu Ile Tyr Ser Phe Leu Gly Glu Thr Phe Arg Asp Lys Leu Arg
 325 330 335

Leu Tyr Ile Glu Gln Lys Thr Asn Leu Pro Ala Leu Asn Arg Phe Cys

149

	340		345		350
	His Ala Ala Leu Lys Ala Val	Ile Pro Asp Ser Thr Glu Gln Ser Asp			
	355	360		365	
5	Val Arg Phe Ser Ser Ala Val				
	370	375			

(196) INFORMATION FOR SEQ ID NO:195:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 960 base pairs
- (B) TYPE: nucleic acid
- 10 (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

	ATGCCATTCC CAAACTGCTC AGCCCCCAGC ACTGTGGTGG CCACAGCTGT GGGTGTCTTG	60
15	CTGGGGCTGG AGTGTGGGCT GGGTGTGCTG GGCAACGGCG TGGGGTGTG GACCTTCCTG	120
	TTCCGGGTCA GGGTGTGGAA GCCGTACGCT GTCTACCTGC TCAAGCTGEC CCTGGCTGAC	180
	CTGCTGTTGG CTGCGTGCCT GCCTTTCCTG GCCGCCTTCT ACCGAGGCT CCAGGCTTGG	240
	CATCTGGGCC GTGTGGGCTG CTGGGCCCTG CGCTTCCTTC TGAATCTEAG CCGCAGCGTG	300
	GGGATGGCCT TCCTGGCCGC CGTGGCTTTG GACCGGTACC TCGGTGTGCT CCACCTTCGS	360
20	CTTAAGGTCA ACCTGTGTG TCCTCAGGCG GCCCTGGGGG TCTCGGGGCT CGTCTGGCTC	420
	CTGATGGTCG CCCTCACCTG CCCGGGCTTG CTCATCTCTG AGGCCGCCCA GAACTCCACC	480
	AGGTGCCACA GTTCTACTC CAGGGCAGAC GGCTCCTTCA GCATCATCTG GCAGGAAGCA	540
	CTCTCCTGCC TTCAGTTTGT CCTCCCCTTT GGCTCATCG TGTTCGTCAA TGCAGGCATC	600
	ATCAGGGCTC TCCAGAAAAG ACTCCGGGAG CCTGAGAAAC AGCCCAAGCT TCAGCGGGCC	660
25	AAGGCACTGG TCACCTTGGT GGTGGTGCTG TTGCTCTGT GCTTTCTGCC CTGCTTCCTG	720
	GCCAGAGTCC TGATGCACAT CTTCCAGAAI CTGGGGAGCT GCAGGSCCCT TTGTGCAGTG	780
	GCTCATACCT CGGATGTCAC GGGCAGCCTC ACCTACCTGC ACASTGTGCT CAACCCCGTG	840
	GTATACTGCT TCTCCAGCCC CACCTTCAGG AGCTCCTATC GGAGGGTCTT CCACACCCTC	900
	CGAGGCAAAG GGCAGGCAGC AGAGCCCCCA GATTTCAACC CCAGAGACTC CTATTCTTGA	960

30 (197) INFORMATION FOR SEQ ID NO:196:

(i) SEQUENCE CHARACTERISTICS:

150

(A) LENGTH: 319 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

5

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

Met Pro Phe Pro Asn Cys Ser Ala Pro Ser Thr Val Val Ala Thr Ala
 1 5 10 15

10

Val Gly Val Leu Leu Gly Leu Glu Cys Gly Leu Gly Leu Leu Gly Asn
 20 25 30

Ala Val Ala Leu Trp Thr Phe Leu Phe Arg Val Arg Val Trp Lys Pro
 35 40 45

Tyr Ala Val Tyr Leu Leu Asn Leu Ala Leu Ala Asp Leu Leu Leu Ala
 50 55 60

15

Ala Cys Leu Pro Phe Leu Ala Ala Phe Tyr Leu Ser Leu Gln Ala Trp
 65 70 75 80

His Leu Gly Arg Val Gly Cys Trp Ala Leu Arg Phe Leu Leu Asp Leu
 85 90 95

20

Ser Arg Ser Val Gly Met Ala Phe Leu Ala Ala Val Ala Leu Asp Arg
 100 105 110

Tyr Leu Arg Val Val His Pro Arg Leu Lys Val Asn Leu Leu Ser Pro
 115 120 125

Gln Ala Ala Leu Gly Val Ser Gly Leu Val Trp Leu Leu Met Val Ala
 130 135 140

25

Leu Thr Cys Pro Gly Leu Leu Ile Ser Glu Ala Ala Gln Asn Ser Thr
 145 150 155 160

Arg Cys His Ser Phe Tyr Ser Arg Ala Asp Gly Ser Phe Ser Ile Ile
 165 170 175

30

Trp Gln Glu Ala Leu Ser Cys Leu Gln Phe Val Leu Pro Phe Gly Leu
 180 185 190

Ile Val Phe Cys Asn Ala Gly Ile Ile Arg Ala Leu Gln Lys Arg Leu
 195 200 205

Arg Glu Pro Glu Lys Gln Pro Lys Leu Gln Arg Ala Lys Ala Leu Val
 210 215 220

35

Thr Leu Val Val Val Leu Phe Ala Leu Cys Phe Leu Pro Cys Phe Leu
 225 230 235 240

Ala Arg Val Leu Met His Ile Phe Gln Asn Leu Gly Ser Cys Arg Ala

151

245										250					255				
Leu	Cys	Ala	Val	Ala	His	Thr	Ser	Asp	Val	Thr	Gly	Ser	Leu	Thr	Tyr				
260								265				270							
Leu	His	Ser	Val	Val	Asn	Pro	Val	Val	Tyr	Cys	Phe	Ser	Ser	Pro	Thr				
275							280				285								
Phe	Arg	Ser	Ser	Tyr	Arg	Arg	Val	Phe	His	Thr	Leu	Arg	Gly	Lys	Gly				
290						295				300									
Gln	Ala	Ala	Glu	Pro	Pro	Asp	Phe	Asn	Pro	Arg	Asp	Ser	Tyr	Ser					
305			310				315												

10 (198) INFORMATION FOR SEQ ID NO:197;

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1143 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

	ATGGAGGAAG	GTGGTGATTT	TGACAACTAC	TATGGGGCAG	ACAACCACTG	TGAGTGTGAG	60
	TACACAGACT	GGAAATCCTC	GGGGGCCCTC	ATCCCTGCCA	TCTACATGTT	GGTCTTCCTC	120
20	CTGGGCACCA	CGGGAAACGG	TCTGGTGCTC	TGGACCGTGT	TTCGAGCAG	CCGGGAGAAG	180
	AGGCGCTCAG	CTGATATCTT	CATTGCTAGC	CTGGCGGTGG	CTGACCTGAC	CTTCGTGGTG	240
	ACGCTGCCCC	TGTGGGCTAC	CTACACGTAC	CGGGACTATG	ACTGGCCCTT	TGGGACCTTC	300
	TTCTGCAAGC	TCAGCAGCTA	CCTCATCTTC	GTCAACATGT	ACGCCAGCGT	CTTCTGCCTC	360
	ACCGGCCCTCA	GCTTCGACCG	CTACCTGGCC	ATCGTGAGGC	CAGTGGCCAA	TGCTCGGCTG	420
25	AGGCTGCGGG	TCAGCGGGGC	CGTGCCACG	GCAGTTCTTT	GGGTGCTGGC	CGCCCTCCTG	480
	GCCATGCCTG	TCATGGTGTT	ACGCACCACC	GGGGACTTGG	AGAACACCAC	TAAGGTGCAG	540
	TGCTACATGG	ACTACTCCAT	GGTGCCCACT	GTGAGCTCAC	AGTGGGCCTG	GGAGGTGGGC	600
	CTTGGGGTCT	CGTCCACCAC	CGTGGGCTTT	GTGGTGCCCT	TCACCATCAT	GCTGACCTGT	660
	TACTTCTTCA	TCGCCCCAAC	CATCGCTGGC	CACCTCCGCA	AGGAACGCAT	CGAGGGCCTG	720
30	CGGAAGCGGC	GCCGGCTTAA	GAGCATCATC	GTGGTGCTGG	TGGTGACCTT	TGCCCTGTGC	780
	TGGATGCCCT	ACCACCTGGT	GAAGACGCTG	TACATGCTGG	GCAGCCTGCT	GCACTGGCCC	840
	TGTGACTTTG	ACCTCTCTCT	CATGAACATC	TTCCCCCTACT	GCACCTGCAT	CAGCTACGTC	900

152

AACAGCTGCC TCAACCCCTT CCTCTATGCC TTTTTCGACC CCCGCTTCGG CCAGGCCTGC 960
 ACCTCCATGC TCTGCTGTGG CCAGAGCAGG TGCGCAGGCA CCTCCCACAG CAGCAGTGGG 1020
 GAGAAGTCAG CCAGCTACTC TTCGGGGCAC AGCCAGGGGC CCGGCCCCAA CATCGGCAAG 1080
 GGTGGAGAAC AGATGCACGA GAAATCCATC CCCTACAGCC AGGAGACCCT TGTGGTTGAC 1140
 5 TAG 1143

(199) INFORMATION FOR SEQ ID NO:198:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 380 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

15 Met Glu Glu Gly Gly Asp Phe Asp Asn Tyr Tyr Gly Ala Asp Asn Gln
 1 5 10 15
 Ser Glu Cys Glu Tyr Thr Asp Trp Lys Ser Ser Gly Ala Leu Ile Pro
 20 20 25 30
 Ala Ile Tyr Met Leu Val Phe Leu Leu Gly Thr Thr Gly Asn Gly Leu
 35 40 45
 20 Val Leu Trp Thr Val Phe Arg Ser Ser Arg Glu Lys Arg Arg Ser Ala
 50 55 60
 Asp Ile Phe Ile Ala Ser Leu Ala Val Ala Asp Leu Thr Phe Val Val
 65 70 75 80
 25 Thr Leu Pro Leu Trp Ala Thr Tyr Thr Tyr Arg Asp Tyr Asp Trp Pro
 85 90 95
 Phe Gly Thr Phe Phe Cys Lys Leu Ser Ser Tyr Leu Ile Phe Val Asn
 100 105 110
 Met Tyr Ala Ser Val Phe Cys Leu Thr Gly Leu Ser Phe Asp Arg Tyr
 115 120 125
 30 Leu Ala Ile Val Arg Pro Val Ala Asn Ala Arg Leu Arg Leu Arg Val
 130 135 140
 Ser Gly Ala Val Ala Thr Ala Val Leu Trp Val Leu Ala Ala Leu Leu
 145 150 155 160
 35 Ala Met Pro Val Met Val Leu Arg Thr Thr Gly Asp Leu Glu Asn Thr
 165 170 175

153

Thr Lys Val Gln Cys Tyr Met Asp Tyr Ser Met Val Ala Thr Val Ser
 180 185 190
 Ser Glu Trp Ala Trp Glu Val Gly Leu Gly Val Ser Ser Thr Thr Val
 195 200 205
 5 Gly Phe Val Val Pro Phe Thr Ile Met Leu Thr Cys Tyr Phe Phe Ile
 210 215 220
 Ala Gln Thr Ile Ala Gly His Phe Arg Lys Glu Arg Ile Glu Gly Leu
 225 230 235 240
 10 Arg Lys Arg Arg Arg Leu Lys Ser Ile Ile Val Val Leu Val Val Thr
 245 250 255
 Phe Ala Leu Cys Trp Met Pro Tyr His Leu Val Lys Thr Leu Tyr Met
 260 265 270
 Leu Gly Ser Leu Leu His Trp Pro Cys Asp Phe Asp Leu Phe Leu Met
 275 280 285
 15 Asn Ile Phe Pro Tyr Cys Thr Cys Ile Ser Tyr Val Asn Ser Cys Leu
 290 295 300
 Asn Pro Phe Leu Tyr Ala Phe Phe Asp Pro Arg Phe Arg Gln Ala Cys
 305 310 315 320
 20 Thr Ser Met Leu Cys Cys Gly Gln Ser Arg Cys Ala Gly Thr Ser His
 325 330 335
 Ser Ser Ser Gly Glu Lys Ser Ala Ser Tyr Ser Ser Gly His Ser Gln
 340 345 350
 Gly Pro Gly Pro Asn Met Gly Lys Gly Gly Glu Gln Met His Glu Lys
 355 360 365
 25 Ser Ile Pro Tyr Ser Gln Glu Thr Leu Val Val Asp
 370 375 380

(200) INFORMATION FOR SEQ ID NO:199:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1119 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: DNA (genomic)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:
 35 ATGAACTACC CGCTAACGCT GGAAATGGAC CTCGAGAACC TGGAGGACCT GTTCTGGGAA 60
 CTGGACAGAT TGGACAATA TAACGACACC TCCCTGGTGG AAAATCATCT CTGCCCTGCC 120

154

ACAGAGGGTC CCCTCATGGC CTCCTTCAAG GCCGTGTTTCG TGCCCGTGGC CTACAGCCTC 180
 ATCTTCCTCC TGGGCGTGAT CGGCAACGTC CTGGTGCTGG TGATCCTGGA GCGGCACCGG 240
 CAGACACGCA GTTCCACGGA GACCTTCCTG TTCCACCTGG CCGTGGCCGA CCTCCTGCTG 300
 GTCTTCATCT TGCCCTTTGC CGTGGCCGAG GGCTCTGTGG GCTGGGTCTT GGGGACCTTC 360
 5 CTCTGCAAAA CTGTGATTGC CCTGCACAAA GTCAACTTCT ACTGCAGCAG CTTGCTCCTG 420
 GCCTGCATCG CCGTGGACCG CTACCTGGCC ATTGTCCACG CCGTCCATGC CTACCGCCAC 480
 CGCCGCCTCC TCTCCATCCA CATCACCTGT GGGACCATCT GGCTGGTGGG CTTCCTCCTT 540
 GCCTTGCCAG AGATTCTCTT CGCCAAAGTC AGCCAAGGCC ATCACAACAA CTCCCTGCCA 600
 CGTTGCACCT TCTCCCAAGA GAACCAAGCA GAAACGCATG CCTGGTTCAC CTCCCGATTC 660
 10 CTCTACCATG TGGCGGGATT CCTGCTGCCC ATGCTGGTGA TGGGCTGGTG CTACGTGGGG 720
 GTAGTGACA GGTGCGCCA GGGCCAGCGG CGCCCTCAGC GGCAGAAGGC AAAAAGGGTG 780
 GCCATCCTGG TGACAAGCAT CTCTTCCTC TGCTGGTCAC CCTACCACAT CGTCATCTTC 840
 CTGGACACCC TGGCGAGGCT GAAGGCGGTG GACAATACCT GCAAGCTGAA TGGCTCTCTC 900
 CCGTGGCCA TCACCATGTG TGAGTTCCTG GGCTGGCCC ACTGCTGCCT CAACCCCATG 960
 15 CTCTACACTT TCGCCGGCCT GAAGTCCGC AGTGACCTGT CGCGGCTCCT GACCAAGCTG 1020
 GGCTGTACCG GCCCTGCCTC CCTGTGCCAG CTCTCCCTA GCTGGCGCAG GAGCAGTCTC 1080
 TCTGAGTCAG AGAATGCCAC CTCTCTCACC ACCTTCTAG 1119

(201) INFORMATION FOR SEQ ID NO:200:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 372 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant
 (ii) MOLECULE TYPE: protein
- 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:
 Met Asn Tyr Pro Leu Thr Leu Glu Met Asp Leu Glu Asn Leu Glu Asp
 1 5 10 15
 Leu Phe Trp Glu Leu Asp Arg Leu Asp Asn Tyr Asn Asp Thr Ser Leu
 20 25 30
 30 Val Glu Asn His Leu Cys Pro Ala Thr Glu Gly Pro Leu Met Ala Ser
 35 40 45
 Phe Lys Ala Val Phe Val Pro Val Ala Tyr Ser Leu Ile Phe Leu Leu

155

	50	55	60
	Gly Val Ile Gly Asn Val Leu Val Leu Val Ile Leu Glu Arg His Arg 65 70 75 80		
5	Gln Thr Arg Ser Ser Thr Glu Thr Phe Leu Phe His Leu Ala Val Ala 85 90 95		
	Asp Leu Leu Leu Val Phe Ile Leu Pro Phe Ala Val Ala Glu Gly Ser 100 105 110		
	Val Gly Trp Val Leu Gly Thr Phe Leu Cys Lys Thr Val Ile Ala Leu 115 120 125		
10	His Lys Val Asn Phe Tyr Cys Ser Ser Leu Leu Leu Ala Cys Ile Ala 130 135 140		
	Val Asp Arg Tyr Leu Ala Ile Val His Ala Val His Ala Tyr Arg His 145 150 155 160		
15	Arg Arg Leu Leu Ser Ile His Ile Thr Cys Gly Thr Ile Trp Leu Val 165 170 175		
	Gly Phe Leu Leu Ala Leu Pro Glu Ile Leu Phe Ala Lys Val Ser Gln 180 185 190		
	Gly His His Asn Asn Ser Leu Pro Arg Cys Thr Phe Ser Gln Glu Asn 195 200 205		
20	Gln Ala Glu Thr His Ala Trp Phe Thr Ser Arg Phe Leu Tyr His Val 210 215 220		
	Ala Gly Phe Leu Leu Pro Met Leu Val Met Gly Trp Cys Tyr Val Gly 225 230 235 240		
25	Val Val His Arg Leu Arg Gln Ala Gln Arg Arg Pro Gln Arg Gln Lys 245 250 255		
	Ala Lys Arg Val Ala Ile Leu Val Thr Ser Ile Phe Phe Leu Cys Trp 260 265 270		
	Ser Pro Tyr His Ile Val Ile Phe Leu Asp Thr Leu Ala Arg Leu Lys 275 280 285		
30	Ala Val Asp Asn Thr Cys Lys Leu Asn Gly Ser Leu Pro Val Ala Ile 290 295 300		
	Thr Met Cys Glu Phe Leu Gly Leu Ala His Cys Cys Leu Asn Pro Met 305 310 315 320		
35	Leu Tyr Thr Phe Ala Gly Val Lys Phe Arg Ser Asp Leu Ser Arg Leu 325 330 335		
	Leu Thr Lys Leu Gly Cys Thr Gly Pro Ala Ser Leu Cys Gln Leu Phe 340 345 350		

156

Pro Ser Trp Arg Arg Ser Ser Leu Ser Glu Ser Glu Asn Ala Thr Ser
 355 360 365

Leu Thr Thr Phe
 370

5 (202) INFORMATION FOR SEQ ID NO:201:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1128 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

ATGGATGTGA CTTCCCAAGC CCGGGGCGTG GGCCTGGAGA TGTACCCAGG CACCGCGCAG 60
 CCTGCGGCCC CCAACACCAC CTCCTCCGAG CTCAACCTGT CCCACCCGCT CCTGGGCACC 120
 15 GGCCTGGCCA ATGGGACAGG TGAGCTCTCG GAGCACCAGC AGTACGTGAT CGGCCTGTTC 180
 CTCTCGTGCC TCTACACCAT CTTCCTCTTC CCCATCGGCT TTGTGGGCAA CATCCTGATC 240
 CTGGTGGTGA ACATCAGCTT CCGCGAGAAG ATGACCATCC CCGACCTGTA CTTTCATCAAC 300
 CTGGCGGTGG CGGACCTCAT CCTGGTGGCC GACTCCCTCA TTGAGGTGTT CAACCTGCAC 360
 GAGCGTACT ACGACATCGC CGTCCTGTGC ACCTTCATGT CGCTCTTCCT GCAGGTCAAC 420
 20 ATGTACAGCA GCGTCTTCTT CCTCACCTGG ATGAGCTTCG ACCGCTACAT CGCCCTGGCC 480
 AGGGCCATGC GCTGCAGCCT GTTCGCGACC AAGCACCACG CCCGGCTGAG CTGTGGCCTC 540
 ATCTGGATGG CATCCGTGTC AGCCACGCTG GTGCCCTTCA CCGCCGTGCA CCTGCAGCAC 600
 ACCGACGAGG CCTGCTTCTG TTTCGCGGAT GTCCGGGAGG TGCAGTGGCT CGAGGTCACG 660
 CTGGGCTTCA TCGTGCCCTT CGCCATCATC GGCCTGTGCT ACTCCCTCAT TGTCCGGGTG 720
 25 CTGGTCAGGG CGCACCAGCA CCGTGGGCTG CGGCCCCGGC GGCAGAAGGC GAAGCGCATG 780
 ATCCTCGCGG TGGTGCTGGT CTTCTTCGTC TGCTGGCTGC CGGAGAACGT CTTTCATCAGC 840
 GTGCACCTCC TGCAGCGGAC GCAGCCTGGG GCCGCTCCCT GCAAGCAGTC TTTCCGCCAT 900
 GCCCACCCCC TCACGGGCCA CATTGTCAAC CTCACCGCCT TCTCCAACAG CTGCCTAAAC 960
 CCCCTCATCT ACAGCTTCTT CGGGGAGACC TTCAGGGACA AGCTGAGGCT GTACATTGAG 1020
 30 CAGAAAACAA ATTTGCCGGC CCTGAACCGC TTCTGTCACG CTGCCCTGAA GGCCGTCATT 1080
 CCAGACAGCA CCGAGCAGTC GGATGTGAGG TTCAGCAGTG CCGTGTAG 1128

157

(203) INFORMATION FOR SEQ ID NO:202:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 375 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

10 Met Asp Val Thr Ser Gln Ala Arg Gly Val Gly Leu Glu Met Tyr Pro
 1 5 10 15
 Gly Thr Ala Gln Pro Ala Ala Pro Asn Thr Thr Ser Pro Glu Leu Asn
 20 25 30
 Leu Ser His Pro Leu Leu Gly Thr Ala Leu Ala Asn Gly Thr Gly Glu
 35 40 45
 15 Leu Ser Glu His Gln Gln Tyr Val Ile Gly Leu Phe Leu Ser Cys Leu
 50 55 60
 Tyr Thr Ile Phe Leu Phe Pro Ile Gly Phe Val Gly Asn Ile Leu Ile
 65 70 75 80
 20 Leu Val Val Asn Ile Ser Phe Arg Glu Lys Met Thr Ile Pro Asp Leu
 85 90 95
 Tyr Phe Ile Asn Leu Ala Val Ala Asp Leu Ile Leu Val Ala Asp Ser
 100 105 110
 Leu Ile Glu Val Phe Asn Leu His Glu Arg Tyr Tyr Asp Ile Ala Val
 115 120 125
 25 Leu Cys Thr Phe Met Ser Leu Phe Leu Gln Val Asn Met Tyr Ser Ser
 130 135 140
 Val Phe Phe Leu Thr Trp Met Ser Phe Asp Arg Tyr Ile Ala Leu Ala
 145 150 155 160
 30 Arg Ala Met Arg Cys Ser Leu Phe Arg Thr Lys His His Ala Arg Leu
 165 170 175
 Ser Cys Gly Leu Ile Trp Met Ala Ser Val Ser Ala Thr Leu Val Pro
 180 185 190
 Phe Thr Ala Val His Leu Gln His Thr Asp Glu Ala Cys Phe Cys Phe
 195 200 205
 35 Ala Asp Val Arg Glu Val Gln Trp Leu Glu Val Thr Leu Gly Phe Ile
 210 215 220
 Val Pro Phe Ala Ile Ile Gly Leu Cys Tyr Ser Leu Ile Val Arg Val

158

225 230 235 240
 Leu Val Arg Ala His Arg His Arg Gly Leu Arg Pro Arg Arg Gln Lys
 245 250 255
 5 Ala Lys Arg Met Ile Leu Ala Val Val Leu Val Phe Phe Val Cys Trp
 260 265 270
 Leu Pro Glu Asn Val Phe Ile Ser Val His Leu Leu Gln Arg Thr Gln
 275 280 285
 Pro Gly Ala Ala Pro Cys Lys Gln Ser Phe Arg His Ala His Pro Leu
 290 295 300
 10 Thr Gly His Ile Val Asn Leu Thr Ala Phe Ser Asn Ser Cys Leu Asn
 305 310 315 320
 Pro Leu Ile Tyr Ser Phe Leu Gly Glu Thr Phe Arg Asp Lys Leu Arg
 325 330 335
 15 Leu Tyr Ile Glu Gln Lys Thr Asn Leu Pro Ala Leu Asn Arg Phe Cys
 340 345 350
 His Ala Ala Leu Lys Ala Val Ile Pro Asp Ser Thr Glu Gln Ser Asp
 355 360 365
 Val Arg Phe Ser Ser Ala Val
 370 375

20 (204) INFORMATION FOR SEQ ID NO:203:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1137 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

ATGGACCTGG GGAAACCAAT GAAAAGCGTG CTGGTGGTGG CTCTCCTTGT CATTTTCCAG 60
 GTATGCCTGT GTCAAGATGA GGTCACGGAC GATTACATCG GAGACAACAC CACAGTGGAC 120
 30 TACACTTTGT TCGAGTCTTT GTGCTCCAAG AAGGACGTGC GGAACCTTAA AGCCTGGTTC 180
 CTCCTATCA TGTA CTCCAT CATTTGTTTC GTGGGCCTAC TGGGCAATGG GCTGGTCGTG 240
 TTGACCTATA TCTATTTCAA GAGGCTCAAG ACCATGACCG ATACCTACCT GCTCAACCTG 300
 GCGGTGGCAG ACATCCTCTT CCTCCTGACC CTTCCCTTCT GGGCCTACAG CGCGGCCAAG 360
 TCCTGGGTCT TCGGTGTCCA CTTTGTGCAAG CTCATCTTTG CCATCTACAA GATGAGCTTC 420

159

TTCAGTGGCA TGCTCCTACT TCTTTGCATC AGCATTGACC GCTACGTGGC CATCGTCCAG 480
 GCTGTCTCAG CTCACCGCCA CCGTGCCCGC GTCCTTCTCA TCAGCAAGCT GTCTGTGTG 540
 GGCATCTGGA TACTAGCCAC AGTGCTCTCC ATCCCAGAGC TCCTGTACAG TGACCTCCAG 600
 AGGAGCAGCA GTGAGCAAGC GATGCGATGC TCTCTCATCA CAGAGCATGT GGAGGCCTTT 660
 5 ATCACCATCC AGGTGGCCCA GATGGTGATC GGCTTTCTGG TCCCCTGCT GGCCATGAGC 720
 TTCTGTTACC TTGTCATCAT CCGCACCCTG CTCAGGCAC GCAACTTTGA GCGCAACAAG 780
 GCCAAAAGG TGATCATCGC TGTGGTCGTG GTCTTCATAG TCTTCCAGCT GCCCTACAAT 840
 GGGGTGGTCC TGGCCAGAC GGTGGCCAAC TTCAACATCA CCACTAGCAC CTGTGAGCTC 900
 AGTAAGCAAC TCAACATCGC CTACGACGTC ACCTACAGCC TGGCCTGCGT CCGCTGCTGC 960
 10 GTCAACCTT TCTGTACGC CTTCATCGG GTCAAGTTCC GCAACGATCT CTCAAGCTC 1020
 TTCAAGGACC TGGGCTGCCT CAGCCAGGAG CAGCTCCGGC AGTGGTCTTC CTGTCGGCAC 1080
 ATCCGGCGCT CCTCCATGAG TGTGGAGGCC GAGACCACCA CCACCTTCTC CCCATAG 1137

(205) INFORMATION FOR SEQ ID NO:204:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 378 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

Met Asp Leu Gly Lys Pro Met Lys Ser Val Leu Val Val Ala Leu Leu
1 5 10 15

Val Ile Phe Gln Val Cys Leu Cys Gln Asp Glu Val Thr Asp Asp Tyr
20 25 30

- 25 Ile Gly Asp Asn Thr Thr Val Asp Tyr Thr Leu Phe Glu Ser Leu Cys
35 40 45

Ser Lys Lys Asp Val Arg Asn Phe Lys Ala Trp Phe Leu Pro Ile Met
50 55 60

- 30 Tyr Ser Ile Ile Cys Phe Val Gly Leu Leu Gly Asn Gly Leu Val Val
65 70 75 80

Leu Thr Tyr Ile Tyr Phe Lys Arg Leu Lys Thr Met Thr Asp Thr Tyr
85 90 95

Leu Leu Asn Leu Ala Val Ala Asp Ile Leu Phe Leu Leu Thr Leu Pro

160

	100	105	110
	Phe Trp Ala Tyr Ser Ala Ala Lys Ser Trp Val Phe Gly Val His Phe 115 120 125		
5	Cys Lys Leu Ile Phe Ala Ile Tyr Lys Met Ser Phe Phe Ser Gly Met 130 135 140		
	Leu Leu Leu Leu Cys Ile Ser Ile Asp Arg Tyr Val Ala Ile Val Gln 145 150 155 160		
	Ala Val Ser Ala His Arg His Arg Ala Arg Val Leu Leu Ile Ser Lys 165 170 175		
10	Leu Ser Cys Val Gly Ile Trp Ile Leu Ala Thr Val Leu Ser Ile Pro 180 185 190		
	Glu Leu Leu Tyr Ser Asp Leu Gln Arg Ser Ser Ser Glu Gln Ala Met 195 200 205		
15	Arg Cys Ser Leu Ile Thr Glu His Val Glu Ala Phe Ile Thr Ile Gln 210 215 220		
	Val Ala Gln Met Val Ile Gly Phe Leu Val Pro Leu Leu Ala Met Ser 225 230 235 240		
	Phe Cys Tyr Leu Val Ile Ile Arg Thr Leu Leu Gln Ala Arg Asn Phe 245 250 255		
20	Glu Arg Asn Lys Ala Lys Lys Val Ile Ile Ala Val Val Val Val Phe 260 265 270		
	Ile Val Phe Gln Leu Pro Tyr Asn Gly Val Val Leu Ala Gln Thr Val 275 280 285		
25	Ala Asn Phe Asn Ile Thr Ser Ser Thr Cys Glu Leu Ser Lys Gln Leu 290 295 300		
	Asn Ile Ala Tyr Asp Val Thr Tyr Ser Leu Ala Cys Val Arg Cys Cys 305 310 315 320		
	Val Asn Pro Phe Leu Tyr Ala Phe Ile Gly Val Lys Phe Arg Asn Asp 325 330 335		
30	Leu Phe Lys Leu Phe Lys Asp Leu Gly Cys Leu Ser Gln Glu Gln Leu 340 345 350		
	Arg Gln Trp Ser Ser Cys Arg His Ile Arg Arg Ser Ser Met Ser Val 355 360 365		
35	Glu Ala Glu Thr Thr Thr Thr Phe Ser Pro 370 375		

(206) INFORMATION FOR SEQ ID NO:205:

161

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1086 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

ATGGATATAC AAATGGCAAA CAATTTTACT CCGCCCTCTG CAACTCCTCA GGGAAATGAC 60
TGTGACCTCT ATGCACATCA CAGCACGGCC AGGATAGTAA TGCCTCTGCA TTACAGCCTC 120
10 GTCTTCATCA TTGGGCTCGT GGGAAACTTA CTAGCCTTGG TCGTCATTGT TCAAACAGG 180
AAAAAATCA ACTCTACCAC CCTCTATTCA ACAAATTTGG TGATTCTGA TATACTTTTT 240
ACCACGGCTT TGCCTACACG AATAGCCTAC TATGCAATGG CCTTTGACTG GAGAATCGGA 300
GATGCCTTGT GTAGGATAAC TGCCTAGTG TTTTACATCA ACACATATGC AGGTGTGAAC 360
TTTATGACCT GCCTGAGTAT TGACCGCTTC ATTGCTGTGG TGCACCTCT ACCTACAAC 420
15 AAGATAAAAA GGATTGAACA TGCAAAGGC GTGTGCATAT TTGTCTGGAT TCTAGTATTT 480
GCTCAGACAC TCCCACTCCT CATCAACCTT ATGTCAAAGC AAGAGGCTGA AAGGATTACA 540
TGATGGAGT ATCCAAACTT TGAAGAACT AAATCTCTTC CTTGGATTCT GCTTGGGGCA 600
TGTTTCATAG GATATGTACT TCCACTTATA ATCATCTCA TCTCTATTC TCAGATCTGC 660
TGCAAACCTT TCAGAACTGC CAAACAAAAC CCACTCACTG AGAAATCTGG TGTAACAAA 720
20 AAGGCTAAAA ACACAATTAT TCTTATTATT GTTGTGTTTG TTCTCTGTTT CACACCTTAC 780
CATGTTGCAA TTATTCAACA TATGATTAAG AAGCTTCGTT TCTCTAATTT CTTGGAATGT 840
AGCCAAAGAC ATTCGTTCCA GATTTCTCTG CACTTTACAG TATGCCTGAT GAACTTCAAT 900
TGCTGCATGG ACCCTTTTAT CTAATTCTTT GCATGTAAAG GGTATAAGAG AAAGGTTATG 960
AGGATGCTGA AACGGCAAGT CAGTGTATCG ATTTCTAGTG CTGTGAAGTC AGCCCTTGAA 1020
25 GAAAATTCAC GTGAAATGAC AGAAACGCAG ATGATGATAC ATTCCAAGTC TTCAAATGGA 1080
AAGTGA 1086

(207) INFORMATION FOR SEQ ID NO:206:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 361 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: not relevant

30

162

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

	Met	Asp	Ile	Gln	Met	Ala	Asn	Asn	Phe	Thr	Pro	Pro	Ser	Ala	Thr	Pro	
	1				5					10					15		
5	Gln	Gly	Asn	Asp	Cys	Asp	Leu	Tyr	Ala	His	His	Ser	Thr	Ala	Arg	Ile	
			20						25					30			
	Val	Met	Pro	Leu	His	Tyr	Ser	Leu	Val	Phe	Ile	Ile	Gly	Leu	Val	Gly	
		35						40					45				
10	Asn	Leu	Leu	Ala	Leu	Val	Val	Ile	Val	Gln	Asn	Arg	Lys	Lys	Ile	Asn	
		50					55					60					
	Ser	Thr	Thr	Leu	Tyr	Ser	Thr	Asn	Leu	Val	Ile	Ser	Asp	Ile	Leu	Phe	
	65					70					75				80		
	Thr	Thr	Ala	Leu	Pro	Thr	Arg	Ile	Ala	Tyr	Tyr	Ala	Met	Gly	Phe	Asp	
					85					90					95		
15	Trp	Arg	Ile	Gly	Asp	Ala	Leu	Cys	Arg	Ile	Thr	Ala	Leu	Val	Phe	Tyr	
				100					105					110			
	Ile	Asn	Thr	Tyr	Ala	Gly	Val	Asn	Phe	Met	Thr	Cys	Leu	Ser	Ile	Asp	
				115				120					125				
20	Arg	Phe	Ile	Ala	Val	Val	His	Pro	Leu	Arg	Tyr	Asn	Lys	Ile	Lys	Arg	
		130					135					140					
	Ile	Glu	His	Ala	Lys	Gly	Val	Cys	Ile	Phe	Val	Trp	Ile	Leu	Val	Phe	
	145					150					155				160		
	Ala	Gln	Thr	Leu	Pro	Leu	Leu	Ile	Asn	Pro	Met	Ser	Lys	Gln	Glu	Ala	
					165					170					175		
25	Glu	Arg	Ile	Thr	Cys	Met	Glu	Tyr	Pro	Asn	Phe	Glu	Glu	Thr	Lys	Ser	
				180					185					190			
	Leu	Pro	Trp	Ile	Leu	Leu	Gly	Ala	Cys	Phe	Ile	Gly	Tyr	Val	Leu	Pro	
			195				200						205				
30	Leu	Ile	Ile	Ile	Leu	Ile	Cys	Tyr	Ser	Gln	Ile	Cys	Cys	Lys	Leu	Phe	
		210				215						220					
	Arg	Thr	Ala	Lys	Gln	Asn	Pro	Leu	Thr	Glu	Lys	Ser	Gly	Val	Asn	Lys	
	225					230					235				240		
	Lys	Ala	Lys	Asn	Thr	Ile	Ile	Leu	Ile	Ile	Val	Val	Phe	Val	Leu	Cys	
				245					250					255			
35	Phe	Thr	Pro	Tyr	His	Val	Ala	Ile	Ile	Gln	His	Met	Ile	Lys	Lys	Leu	
				260				265						270			

163

Arg Phe Ser Asn Phe Leu Glu Cys Ser Gln Arg His Ser Phe Gln Ile
 275 280 285

Ser Leu His Phe Thr Val Cys Leu Met Asn Phe Asn Cys Cys Met Asp
 290 295 300

5 Pro Phe Ile Tyr Phe Phe Ala Cys Lys Gly Tyr Lys Arg Lys Val Met
 305 310 315 320

Arg Met Leu Lys Arg Gln Val Ser Val Ser Ile Ser Ser Ala Val Lys
 325 330 335

10 Ser Ala Pro Glu Glu Asn Ser Arg Glu Met Thr Glu Thr Gln Met Met
 340 345 350

Ile His Ser Lys Ser Ser Asn Gly Lys
 355 360

(208) INFORMATION FOR SEQ ID NO:207:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1446 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:

ATGCGGTGGC TGTGGCCCCCT GGCTGTCTCT CTTGCTGTGA TTTTGGCTGT GGGGCTAAGC 60

AGGGTCTCTG GGGGTGCCCC CTTGCACCTG GGCAGGCACA GAGCCGAGAC CCAGGAGCAG 120

CAGAGCCGAT CCAAGAGGGG CACCGAGGAT GAGGAGGCCA AGGGCGTGCA GCAGTATGTG 180

CCTGAGGAGT GGGCGGAGTA CCCCCGCCCC ATTCACCTG CTGGCCTGCA GCCAACCAAG 240

25 CCCTTGGTGG CCACCAGCCC TAACCCCGAC AAGGATGGGG GCACCCGAGA CAGTGGGCAG 300

GAACTGAGGG GCAATCTGAC AGGGGCACCA GGGCAGAGGC TACAGATCCA GAACCCCTG 360

TATCCGGTGA CCGAGAGCTC CTACAGTGCC TATGCCATCA TGCTTCTGGC GCTGGTGGTG 420

TTTGCGGTGG GCATTGTGGG CAACCTGTCG GTCATGTGCA TCGTGTGGCA CAGCTACTAC 480

CTGAAGAGCG CCTGGAATC CATCCTTGCC AGCCTGGCCC TCTGGGATT TCTGGTCCTC 540

30 TTTTCTGCC TCCCTATTGT CATCTTCAAC GAGATCACCA AGCAGAGGCT ACTGGGTGAC 600

GTTTCTTGTC GTGCCGTGCC CTTCTGGAG GTCTCCTCTC TGGGAGTCAC GACTTTCAGC 660

CTCTGTGCCC TGGGCATTGA CCGCTTCCAC GTGGCCACCA GCACCCTGCC CAAGGTGAGG 720

CCCATCGAGC GGTGCCAATC CATCCTGGCC AAGTTGGCTG TCATCTGGGT GGGCTCCATG 780

164

ACGCTGGCTG TGCCTGAGCT CCTGCTGTGG CAGCTGGCAC AGGAGCCTGC CCCCACCATG 840
 GGCACCCTGG ACTCATGCAT CATGAAACCC TCAGCCAGCC TGCCCGAGTC CCTGTATTCA 900
 CTGGTGATGA CCTACCAGAA CGCCCGCATG TGSTGGTACT TTGGCTGCTA CTTCTGCCTG 960
 CCCATCCTCT TCACAGTCAC CTGCCAGCTG GTGACATGGC GGGTGCGAGG CCCTCCAGGG 1020
 5 AGGAAGTCAG AGTGCAGGGC CAGCAAGCAC GAGCAGTGTG AGAGCCAGCT CAAGAGCACC 1080
 GTGGTGGGCC TGACCGTGGT CTACGCCTTC TGCACCCTCC CAGAGAACGT CTGCAACATC 1140
 GTGGTGGCCT ACCTCTCCAC CGAGCTGACC CGCCAGACCC TGGACCTCCT GGGCCTCATC 1200
 AACCAGTTCT CCACCTTCTT CAAGGGCGCC ATCACCCAG TGCTGCTCCT TTGCATCTGC 1260
 AGGCCGCTGG GCCAGGCCTT CCTGGACTGC TGCTGCTGCT GCTGCTGTGA GGAGTGCGGC 1320
 10 GGGCCTTCGG AGGCCTCTGC TGCCAATGGG TCGGACAACA AGCTCAAGAC CGAGGTGTCC 1380
 TCTTCCATCT ACTTCCACAA GCCCAGGGAG TCACCCCCAC TCCTGCCCTT GGGCACACCT 1440
 TGCTGA 1446

(209) INFORMATION FOR SEQ ID NO:208:

- (i) SEQUENCE CHARACTERISTICS:
 15 (A) LENGTH: 481 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: protein
- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:
- | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Arg | Trp | Leu | Trp | Pro | Leu | Ala | Val | Ser | Leu | Ala | Val | Ile | Leu | Ala |
| 1 | | | 5 | | | | | | 10 | | | | 15 | | |
| Val | Gly | Leu | Ser | Arg | Val | Ser | Gly | Gly | Ala | Pro | Leu | His | Leu | Gly | Arg |
| | | 20 | | | | | 25 | | | | | 30 | | | |
| His | Arg | Ala | Glu | Thr | Gln | Glu | Gln | Gln | Ser | Arg | Ser | Lys | Arg | Gly | Thr |
| | | 35 | | | | 40 | | | | | | 45 | | | |
| Glu | Asp | Glu | Glu | Ala | Lys | Gly | Val | Gln | Gln | Tyr | Val | Pro | Glu | Glu | Trp |
| | 50 | | | | 55 | | | | | | 60 | | | | |
| Ala | Glu | Tyr | Pro | Arg | Pro | Ile | His | Pro | Ala | Gly | Leu | Gln | Pro | Thr | Lys |
| 65 | | | | | 70 | | | | 75 | | | | 80 | | |
| Pro | Leu | Val | Ala | Thr | Ser | Pro | Asn | Pro | Asp | Lys | Asp | Gly | Gly | Thr | Pro |
| | | | | 85 | | | | | 90 | | | | 95 | | |
| Asp | Ser | Gly | Gln | Glu | Leu | Arg | Gly | Asn | Leu | Thr | Gly | Ala | Pro | Gly | Gln |

165

	100	105	110
	Arg Leu Gln Ile Gln Asn Pro	Leu Tyr Pro Val Thr	Glu Ser Ser Tyr
	115	120	125
5	Ser Ala Tyr Ala Ile Met Leu	Leu Ala Leu Val Val	Phe Ala Val Gly
	130	135	140
	Ile Val Gly Asn Leu Ser Val Met Cys	Ile Val Trp His Ser Tyr Tyr	
	145	150	155 160
	Leu Lys Ser Ala Trp Asn Ser Ile Leu	Ala Ser Leu Ala Leu Trp Asp	
	165	170	175
10	Phe Leu Val Leu Phe Phe Cys Leu	Pro Ile Val Ile Phe Asn Glu Ile	
	180	185	190
	Thr Lys Gln Arg Leu Leu Gly Asp	Val Ser Cys Arg Ala Val Pro Phe	
	195	200	205
15	Met Glu Val Ser Ser Leu Gly Val Thr	Thr Phe Ser Leu Cys Ala Leu	
	210	215	220
	Gly Ile Asp Arg Phe His Val Ala Thr	Ser Thr Leu Pro Lys Val Arg	
	225	230	235 240
	Pro Ile Glu Arg Cys Gln Ser Ile Leu	Ala Lys Leu Ala Val Ile Trp	
	245	250	255
20	Val Gly Ser Met Thr Leu Ala Val	Pro Glu Leu Leu Leu Trp Gln Leu	
	260	265	270
	Ala Gln Glu Pro Ala Pro Thr Met Gly	Thr Leu Asp Ser Cys Ile Met	
	275	280	285
25	Lys Pro Ser Ala Ser Leu Pro Glu Ser	Leu Tyr Ser Leu Val Met Thr	
	290	295	300
	Tyr Gln Asn Ala Arg Met Trp Trp Tyr	Phe Gly Cys Tyr Phe Cys Leu	
	305	310	315 320
	Pro Ile Leu Phe Thr Val Thr Cys Gln	Leu Val Thr Trp Arg Val Arg	
	325	330	335
30	Gly Pro Pro Gly Arg Lys Ser Glu Cys	Arg Ala Ser Lys His Glu Gln	
	340	345	350
	Cys Glu Ser Gln Leu Lys Ser Thr Val	Val Gly Leu Thr Val Val Tyr	
	355	360	365
35	Ala Phe Cys Thr Leu Pro Glu Asn Val	Cys Asn Ile Val Val Ala Tyr	
	370	375	380
	Leu Ser Thr Glu Leu Thr Arg Gln Thr	Leu Asp Leu Leu Gly Leu Ile	
	385	390	395 400

166

Asn Gln Phe Ser Thr Phe Phe Lys Gly Ala Ile Thr Pro Val Leu Leu
 405 410 415
 Leu Cys Ile Cys Arg Pro Leu Gly Gln Ala Phe Leu Asp Cys Cys Cys
 420 425 430
 5 Cys Cys Cys Cys Glu Glu Cys Gly Gly Ala Ser Glu Ala Ser Ala Ala
 435 440 445
 Asn Gly Ser Asp Asn Lys Leu Lys Thr Glu Val Ser Ser Ser Ile Tyr
 450 455 460
 10 Phe His Lys Pro Arg Glu Ser Pro Pro Leu Leu Pro Leu Gly Thr Pro
 465 470 475 480
 Cys

(210) INFORMATION FOR SEQ ID NO:209:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1101 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

ATGTGGAACG CGACGCCAG CGAAGAGCCG GGGTTCAACC TCACACTGGC CGACCTGGAC 60
 TGGGATGCTT CCCCCGGCAA CGACTCGCTG GCGCAGAGC TGCTGCAGCT CTCCCCGCG 120
 CCGCTGCTGG CCGGCGTCAC AGCCACCTGC GTGGCACTCT TCGTGGTGGG TATCGCTGGC 180
 AACCTGCTCA CCATGCTGGT GGTGTCGCGC TTCCGCGAGC TCGCACCAC CACCAACCTC 240
 25 TACCTGTCCA GCATGGCCTT CTCCGATCTG CTCATCTTCC TCTGCATGCC CCTGGACCTC 300
 GTTCGCCTCT GGCAGTACCG GCCCTGGAAC TTCGGCGACC TCCTCTGCAA ACTCTTCCAA 360
 TTCGTCAAGT AGAGCTGCAC CTACGCCACG GTGCTCACCA TCACAGCGCT GAGCGTCGAG 420
 CGCTACTTCG CCATCTGCTT CCCACTCCGG GCCAAGGTGG TGGTCACCAA GGGGCGGGTG 480
 AAGCTGGTCA TCTTCGTCAT CTGGGCCGTG GCCTTCTGCA GCGCCGGGCC CATCTTCGTG 540
 30 CTAGTCGGGG TGGAGCACGA GAACGGCACC GACCCTTGGG ACACCAACGA GTGCCGCCCC 600
 ACCGAGTTTG CGGTGCGCTC TGGACTGCTC ACGGTCATGG TGTGGGTGTC CAGCATCTTC 660
 TTCTTCCTTC CTGTCTTCTG TCTCAGGTC CTCTACAGTC TCATCGGCAG GAAGCTGTGG 720
 CGGAGGAGGC GCGGCGATGC TGTCGTGGGT GCCTCGCTCA GGGACCAGAA CCACAAGCAA 780

167

ACCAAGAAAA TGCTGGGTGT AGTGGTGTTC GCCTTCATCC TCTGCTGGCT CCCCTTCCAC 840
 GTAGGGCGAT ATTTATTTTC CAAATCCTTT GAGCCTGGCT CCTTGGAGAT TGCTCAGATC 900
 AGCCAGTACT GCAACCTCGT GTCCTTTGTC CTCTTCTACC TCAGTGCTGC CATCAACCCC 960
 ATTCTGTACA ACATCATGTC CAAGAAGTAC CGGGTGGCAG TGTTCAGACT TCTGGGATTC 1020
 5 GAACCCCTTCT CCCAGAGAAA GCTCTCCACT CTGAAAGATG AAAGTTCTCG GGCCTGGACA 1080
 GAATCTAGTA TTAATACATG A 1101

(211) INFORMATION FOR SEQ ID NO:210:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 366 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

15 Met Trp Asn Ala Thr Pro Ser Glu Glu Pro Gly Phe Asn Leu Thr Leu
 1 5 10 15
 Ala Asp Leu Asp Trp Asp Ala Ser Pro Gly Asn Asp Ser Leu Gly Asp
 20 25 30
 Glu Leu Leu Gln Leu Phe Pro Ala Pro Leu Leu Ala Gly Val Thr Ala
 20 35 40 45
 Thr Cys Val Ala Leu Phe Val Val Gly Ile Ala Gly Asn Leu Leu Thr
 50 55 60
 Met Leu Val Val Ser Arg Phe Arg Glu Leu Arg Thr Thr Thr Asn Leu
 65 70 75 80
 25 Tyr Leu Ser Ser Met Ala Phe Ser Asp Leu Leu Ile Phe Leu Cys Met
 85 90 95
 Pro Leu Asp Leu Val Arg Leu Trp Gln Tyr Arg Pro Trp Asn Phe Gly
 100 105 110
 30 Asp Leu Leu Cys Lys Leu Phe Gln Phe Val Ser Glu Ser Cys Thr Tyr
 115 120 125
 Ala Thr Val Leu Thr Ile Thr Ala Leu Ser Val Glu Arg Tyr Phe Ala
 130 135 140
 Ile Cys Phe Pro Leu Arg Ala Lys Val Val Val Thr Lys Gly Arg Val
 145 150 155 160
 35 Lys Leu Val Ile Phe Val Ile Trp Ala Val Ala Phe Cys Ser Ala Gly

168

	165	170	175
	Pro Ile Phe Val Leu Val Gly Val Glu His Glu Asn Gly Thr Asp Pro		
	180	185	190
5	Trp Asp Thr Asn Glu Cys Arg Pro Thr Glu Phe Ala Val Arg Ser Gly		
	195	200	205
	Leu Leu Thr Val Met Val Trp Val Ser Ser Ile Phe Phe Phe Leu Pro		
	210	215	220
	Val Phe Cys Leu Thr Val Leu Tyr Ser Leu Ile Gly Arg Lys Leu Trp		
	225	230	235
10	Arg Arg Arg Arg Gly Asp Ala Val Val Gly Ala Ser Leu Arg Asp Gln		
	245	250	255
	Asn His Lys Gln Thr Lys Lys Met Leu Ala Val Val Val Phe Ala Phe		
	260	265	270
15	Ile Leu Cys Trp Leu Pro Phe His Val Gly Arg Tyr Leu Phe Ser Lys		
	275	280	285
	Ser Phe Glu Pro Gly Ser Leu Glu Ile Ala Gln Ile Ser Gln Tyr Cys		
	290	295	300
	Asn Leu Val Ser Phe Val Leu Phe Tyr Leu Ser Ala Ala Ile Asn Pro		
	305	310	315
20	Ile Leu Tyr Asn Ile Met Ser Lys Lys Tyr Arg Val Ala Val Phe Arg		
	325	330	335
	Leu Leu Gly Phe Glu Pro Phe Ser Gln Arg Lys Leu Ser Thr Leu Lys		
	340	345	350
25	Asp Glu Ser Ser Arg Ala Trp Thr Glu Ser Ser Ile Asn Thr		
	355	360	365

(212) INFORMATION FOR SEQ ID NO:211:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1842 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:

	ATGCGAGCCC CGGGCGCGCT TCTCGCCCCG ATGTCGCGGC TACTGCTTCT GCTACTGCTC	60
35	AAGGTGTCTG CCTCTTCTGC CCTCGGGGTC GCCCCTGCGT CCAGAAACGA AACTTGTCTG	120
	GGGGAGAGCT GTGCACCTAC AGTGATCCAG CGCCGCGGCA GGGACGCTG GGGACCGGGA	180

AATTCTGCAA GAGACGTTCT GCGAGCCCGA GCACCCAGGG AGGAGCAGGG GGCAGCGTTT 240
 CTTGCGGGAC CCTCTGGGA CCTGCCGGG GCCCCGGGG GTGACCCGSC TGCAGGCAGA 300
 GGGGCGGAGG CGTCGGCAGC CGGACCCCGG GGACCTCCAA CCAGGCCACC TGSCCCCTGG 360
 AGGTGGAAAG GTGCTCGGGG TCAGGAGCCT TCTGAAACTT TGGGAGAGG GAACCCACG 420
 5 GGCCTCCAGC TCTTCTTCA GATCTCAGAG GAGGAAGAGA AGGGTCCCAG AGGCGCTGGC 480
 ATTTCCGGGC GTAGCCAGGA GCAGAGTGTG AAGACAGTCC CCGGAGCCAG CGATCTTTT 540
 TACTGGCCAA GGAGAGCCGG GAAACTCCAG GGTTCACAC ACAAGCCCTT GTCCAAGACG 600
 CCCAATGGAC TGGCGGGGCA CGAAGGGTGG ACAATTGCAC TCCCGGGCCG GGGCTGGCC 660
 CAGAATGGAT CCTTGGGTGA AGGAATCCAT GAGCCTGGGG GTGCTCCCGG GGGAAACAGC 720
 10 ACGAACCGGC GTGTGAGACT GAAGAACCCG TTCTACCCCG TGAGCCAGGA GTCTATGGA 780
 GCCTACGCGG TCATGTGTCT GTCCGTGJTG ATCTTCGGGA CCGGCATCAT TGGCAACCTG 840
 CCGGTGATGT GCATCGTGTG CCACAACAC TACATGCGJA GATATCCAA CTCCTCTTG 900
 GCCAACCTGG CCTTCTGGGA CTTTCTCATC ATCTTCTTTT GCTTTCGGT GGTATCTTC 960
 CACGAGCTGA CCAAGAGTG GCTGCTGJAG GACTTCTCTT GCAAGATCGT GGCCTATATA 1020
 15 GAGGTGCGCT CTCTGGGAGT CACCACTTTC ACCTTATGAG CTCTGTGCAT AGACCGCTTC 1080
 CGTGCTGCCA CCAACGTACA GATGTACTAC GAAATGATG AAAATGTTC CTCACAACT 1140
 GCCAACTTG CTGTATATG GGTGGGAGCT CTATTGTTAG CACTTCAGA AGTGTCTTC 1200
 CGCCAGCTGA GCAAGGAGGA TTTGGGGTTT AGTGGCCGAG CTCCGGCAGA AAGGTGCATT 1260
 ATTAAGATCT CTCTGATTT ACCAGACACC ATCTATGTTC TAGCCCTCAC CTACGACAGT 1320
 20 GCGAGACTGT GGTGTATTT TGGCTGTAC TTTGTTTTC CCAAGCTTTT CACCATCACC 1380
 TGCTCTCTAG TGA CTGCGAG GAAATCCGC AAAGCAGAGA AAGCCTGTAC CCGAGGGAAT 1440
 AAACGGCAGA TTCAACTAGA GATCAGATG AAGGTACAG TAGTGGCATT GACCATTITA 1500
 TATGGATTTT GCATTATTCC TGAAATATC TGCAACATTG TTA CTGCTA CATGGCTACA 1560
 GGGGTTTCAC AGCAGACAAT GGACCTCCTT AATATCATCA GCGAGTTCCT TTTGTTCTTT 1620
 25 AAGTCCTGTG TCACCCAGT CCTCCTTTTC TGTCTCTGCA AACCTTCAG TCGGGCCTTC 1680
 ATGGAGTGCT GCTGCTGTTG CTGTGAGGAA TGCATTCAGA AGTCTTCAAC GGTGACCAGT 1740
 GATGACAATG ACAACGAGTA CACCACGGAA CTCGAACCTT CGCCTTTCAG TACCATACGC 1800
 CGTGAAATGT CCACTTTTGC TTCTGTGGA ACTCATTECT GA 1842

170

(213) INFORMATION FOR SEQ ID NO:212:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 613 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

10 Met Arg Ala Pro Gly Ala Leu Leu Ala Arg Met Ser Arg Leu Leu Leu
 1 5 10 15

Leu Leu Leu Leu Lys Val Ser Ala Ser Ser Ala Leu Gly Val Ala Pro
 20 25 30

Ala Ser Arg Asn Glu Thr Cys Leu Gly Glu Ser Cys Ala Pro Thr Val
 35 40 45

15 Ile Gln Arg Arg Gly Arg Asp Ala Trp Gly Pro Gly Asn Ser Ala Arg
 50 55 60

Asp Val Leu Arg Ala Arg Ala Pro Arg Glu Glu Gln Gly Ala Ala Phe
 65 70 75 80

20 Leu Ala Gly Pro Ser Trp Asp Leu Pro Ala Ala Pro Gly Arg Asp Pro
 85 90 95

Ala Ala Gly Arg Gly Ala Glu Ala Ser Ala Ala Gly Pro Pro Gly Pro
 100 105 110

Pro Thr Arg Pro Pro Gly Pro Trp Arg Trp Lys Gly Ala Arg Gly Gln
 115 120 125

25 Glu Pro Ser Glu Thr Leu Gly Arg Gly Asn Pro Thr Ala Leu Gln Leu
 130 135 140

Phe Leu Gln Ile Ser Glu Glu Glu Glu Lys Gly Pro Arg Gly Ala Gly
 145 150 155 160

30 Ile Ser Gly Arg Ser Gln Glu Gln Ser Val Lys Thr Val Pro Gly Ala
 165 170 175

Ser Asp Leu Phe Tyr Trp Pro Arg Arg Ala Gly Lys Leu Gln Gly Ser
 180 185 190

His His Lys Pro Leu Ser Lys Thr Ala Asn Gly Leu Ala Gly His Glu
 195 200 205

35 Gly Trp Thr Ile Ala Leu Pro Gly Arg Ala Leu Ala Gln Asn Gly Ser
 210 215 220

Leu Gly Glu Gly Ile His Glu Pro Gly Gly Pro Arg Arg Gly Asn Ser

171

	225		230		235		240
	Thr	Asn	Arg	Arg	Val	Arg	Leu
				245			250
							255
5	Glu	Ser	Tyr	Gly	Ala	Tyr	Ala
				260			265
							270
	Gly	Thr	Gly	Ile	Ile	Gly	Asn
				275			280
							285
	Asn	Tyr	Tyr	Met	Arg	Ser	Ile
				290			295
							300
10	Phe	Trp	Asp	Phe	Leu	Ile	Ile
	305				310		
							315
							320
	His	Glu	Leu	Thr	Lys	Lys	Trp
					325		
							330
							335
15	Val	Pro	Tyr	Ile	Glu	Val	Ala
				340			345
							350
	Cys	Ala	Leu	Cys	Ile	Asp	Arg
				355			360
							365
	Tyr	Tyr	Glu	Met	Ile	Glu	Asn
				370			375
							380
20	Val	Ile	Trp	Val	Gly	Ala	Leu
	385				390		
							395
							400
	Arg	Gln	Leu	Ser	Lys	Glu	Asp
					405		
							410
							415
25	Glu	Arg	Cys	Ile	Ile	Lys	Ile
				420			
							425
							430
	Val	Leu	Ala	Leu	Thr	Tyr	Asp
				435			440
							445
	Cys	Tyr	Phe	Cys	Leu	Pro	Thr
				450			455
							460
30	Thr	Ala	Arg	Lys	Ile	Arg	Lys
	465				470		
							475
							480
	Lys	Arg	Gln	Ile	Gln	Leu	Glu
				485			
							490
							495
35	Leu	Thr	Ile	Leu	Tyr	Gly	Phe
				500			
							505
							510
	Ile	Val	Thr	Ala	Tyr	Met	Ala
				515			
							520
							525

172

Leu Leu Asn Ile Ile Ser Gln Phe Leu Leu Phe Phe Lys Ser Cys Val
 530 535 540
 Thr Pro Val Leu Leu Phe Cys Leu Cys Lys Pro Phe Ser Arg Ala Phe
 545 550 555 560
 5 Met Glu Cys Cys Cys Cys Cys Glu Glu Cys Ile Gln Lys Ser Ser
 565 570 575
 Thr Val Thr Ser Asp Asp Asn Asp Asn Glu Tyr Thr Thr Glu Leu Glu
 580 585 590
 10 Leu Ser Pro Phe Ser Thr Ile Arg Arg Glu Met Ser Thr Phe Ala Ser
 595 600 605
 Val Gly Thr His Cys
 610

(214) INFORMATION FOR SEQ ID NO:213:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1248 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

ATGGTTTTTC CTCACAGAAT GGATAACAGC AAGCCACATT TGATTATTCC TACACTTCTG 60
 GTGCCCTCC AAAACCGCAG CTGCACTGAA ACAGCCACAC CTCTGCCAAG CCAATACCTG 120
 ATGGAATTAA GTGAGGAGCA CAGTTGGATG AGCAACCAAA CAGACCTTCA CTATGTGCTG 180
 AAACCCGGGG AAGTGGCCAC AGCCAGCATC TTCTTTGGGA TTCTGTGCTT GTTTTCTATC 240
 25 TTCGGCAATT CCCTGGTTTG TTTGGTCATC CATAGGAGTA GGAGGACTCA GTCTACCACC 300
 AACTACTTTG TGGTCTCCAT GGCATGTGCT GACCTTCTCA TCAGCGTTGC CAGCACGCCT 360
 TTCGTCTGTC TCCAGTTCAC CACTGGAAGG TGGACGCTGG GTAGTCAAC GTGCAAGGTT 420
 GTGCGATATT TTCAATATCT CACTCCAGGT GTCCAGATCT ACGTTCTCCT CTCCATCTGC 480
 ATAGACCGGT TCTACACCAT CGTCTATCCT CTGAGCTTCA AGGTGTCCAG AGAAAAAGCC 540
 30 AAGAAATGA TTGCGGCATC GTGGATCTTT GATGCAGGCT TTGTGACCCC TGTGCTCTTT 600
 TTCTATGGCT CCAACTGGGA CAGTCATTGT AACTATTTCC TCCCCTCCTC TTGGGAAGGC 660
 ACTGCCTACA CTGTCATCCA CTCTTTGGTG GGCTTTGTGA TTCCATCTGT CCTCATAATT 720
 TTATTTTACC AAAAGGTCAT AAAATATATT TGGAGAATAG GCACAGATGG CCGAACGGTG 780

173

AGGAGGACAA TGAACATTGT CCCTGGGACA AAAGTGAAAA CTAAAAAGAT GTTCCTCATT 840
 TTAAATCTGT TGTTTTGTCT CTCCTGGCTG CCTTTTCAIG TAGCTCAGCT ATGGCACCCC 900
 CATGAACAAG ACTATAAGAA AAGTCCCTT GTTTTCACAG CTATCACATG GATATCCTTT 960
 AGTTCTTCAG CCTCTAAACC TACTCTGTAT TCAATTTATA ATGCCAATTT TGGGAGAGGG 1020
 5 ATGAAAGAGA CTTTTTGTAT GTCCTCTATG AAATGTTACC GAAGCAATGC CTATACTATC 1080
 ACAACAAGTT CAAGGATGSC CAAAAAAAC TACGTTGGCA TTTCAGAAAT CCCTTCCATG 1140
 GCCAAAATA TTACCAAAGA CTCGATCTAT GACTCATTG ACAGAGAAGC CAAGGAAAAA 1200
 AAGCTTGCTT GGCCCATTA CTCAATCCA CCAAATACTT TTGTCTAA 1248

(215) INFORMATION FOR SEQ ID NO:214:

10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 415 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

15 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

Met	Val	Phe	Ala	His	Arg	Met	Asp	Asn	Ser	Lys	Pro	His	Leu	Ile	Ile
1				5				10					15		
Pro	Thr	Leu	Leu	Val	Pro	Leu	Gln	Asn	Arg	Ser	Cys	Thr	Glu	Thr	Ala
20			20					25					30		
Thr	Pro	Leu	Pro	Ser	Gln	Tyr	Leu	Met	Glu	Leu	Ser	Glu	Glu	His	Ser
			35					40					45		
Trp	Met	Ser	Asn	Gln	Thr	Asp	Leu	His	Tyr	Val	Leu	Lys	Pro	Gly	Glu
			50			55						60			
Val	Ala	Thr	Ala	Ser	Ile	Phe	Phe	Gly	Ile	Leu	Trp	Leu	Phe	Ser	Ile
25					70					75				80	
Phe	Gly	Asn	Ser	Leu	Val	Cys	Leu	Val	Ile	His	Arg	Ser	Arg	Arg	Thr
				85					90					95	
Gln	Ser	Thr	Thr	Asn	Tyr	Phe	Val	Val	Ser	Met	Ala	Cys	Ala	Asp	Leu
				100				105					110		
Leu	Ile	Ser	Val	Ala	Ser	Thr	Pro	Phe	Val	Leu	Leu	Gln	Phe	Thr	Thr
				115				120					125		
Gly	Arg	Trp	Thr	Leu	Gly	Ser	Ala	Thr	Cys	Lys	Val	Val	Arg	Tyr	Phe
				130			135						140		

174

Gln Tyr Leu Thr Pro Gly Val Gln Ile Tyr Val Leu Leu Ser Ile Cys
 145 150 155 160
 Ile Asp Arg Phe Tyr Thr Ile Val Tyr Pro Leu Ser Phe Lys Val Ser
 165 170 175
 5 Arg Glu Lys Ala Lys Lys Met Ile Ala Ala Ser Trp Ile Phe Asp Ala
 180 185 190
 Gly Phe Val Thr Pro Val Leu Phe Phe Tyr Gly Ser Asn Trp Asp Ser
 195 200 205
 10 His Cys Asn Tyr Phe Leu Pro Ser Ser Trp Glu Gly Thr Ala Tyr Thr
 210 215 220
 Val Ile His Phe Leu Val Gly Phe Val Ile Pro Ser Val Leu Ile Ile
 225 230 235 240
 Leu Phe Tyr Gln Lys Val Ile Lys Tyr Ile Trp Arg Ile Gly Thr Asp
 245 250 255
 15 Gly Arg Thr Val Arg Arg Thr Met Asn Ile Val Pro Arg Thr Lys Val
 260 265 270
 Lys Thr Lys Lys Met Phe Leu Ile Leu Asn Leu Leu Phe Leu Leu Ser
 275 280 285
 20 Trp Leu Pro Phe His Val Ala Gln Leu Trp His Pro His Glu Gln Asp
 290 295 300
 Tyr Lys Lys Ser Ser Leu Val Phe Thr Ala Ile Thr Trp Ile Ser Phe
 305 310 315 320
 Ser Ser Ser Ala Ser Lys Pro Thr Leu Tyr Ser Ile Tyr Asn Ala Asn
 325 330 335
 25 Phe Arg Arg Gly Met Lys Glu Thr Phe Cys Met Ser Ser Met Lys Cys
 340 345 350
 Tyr Arg Ser Asn Ala Tyr Thr Ile Thr Thr Ser Ser Arg Met Ala Lys
 355 360 365
 30 Lys Asn Tyr Val Gly Ile Ser Glu Ile Pro Ser Met Ala Lys Thr Ile
 370 375 380
 Thr Lys Asp Ser Ile Tyr Asp Ser Phe Asp Arg Glu Ala Lys Glu Lys
 385 390 395 400
 Lys Leu Ala Trp Pro Ile Asn Ser Asn Pro Pro Asn Thr Phe Val
 405 410 415

35 (216) INFORMATION FOR SEQ ID NO:215:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1842 base pairs

175

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

	ATGGGGCCCA CCTAGCGGT TCCCACCCC TATGGCTGTA TTGGCTGTAA CTACCCCAG	60
	CCAGAATACC CACCGGCTCT AATCATCTTT ATGTICTGCG CGATGGTTAT TACCATCGTT	120
	GTAGACCTAA TCGGCAATC CATGGTCATT TTGGCTGTGA CGAAGAACAA GAAGCTCCGG	180
	AATTCTGGCA ACATCTTCGT GGTCAGTCTC TCTGTGGCCG ATATGCTGCT GGCATCTAC	240
10	CCATACCCCT TGATGCTGCA TGCCATGTCC ATTGGGGGCT GGGATCTGAG CCAGTTACAG	300
	TGCCAGATGG TCGGGTTCAT CACAGGGCTG AGTGTGCTCG GTCCATCTT CAACATCGT	360
	GCAATCGCTA TCAACCTTA CTGCTACATC TCCACAGCC TCACTACGA ACGGATCTT	420
	AGTGTGCGCA ATACCTGCAT CTACCTGCTC ATCACCCTGA TCATGACCGT CTTGGCTGTC	480
	CTGCCCAACA TGTACATTGG CACCATCGAG TACGATCCTC GCACCTACAC CTGCATCTTC	540
15	AACIATCTGA ACAACCTGT CTTCCTGTT ACCATCGTCT GCATCCACTT CGTCCTCCCT	600
	CTCCTCATCG TGGCTTCTG CTACGTGAGG ATCTGGACCA AAGTGTGTC GGGCCGTGAC	660
	CCTGCAGGGC AGAATCCTGA CAACCAACTT GGTGAGGTTC GCAATAAAAT AACCATGTTT	720
	GTGATCTTCC TCCTCTTTGC AGTGTGCTGG TCCCTATCA AGTGTCTAC TGTCTTGGTG	780
	GCTGTCACTC CGAAGGAGAT GGCAGTCAAG ATCCCAACT GGCTTTATCT TGCAGCCTAC	840
20	TTCATAGCCT ACTTCAACAG CTGCCTCAAC GGTGTGATCT ACGGGCTCCT CAATGAGAAT	900
	TTCCGAAGAG AATACTGGAC CATCTTCCAT GCTATGCGGC ACCCTATCAT ATTCTTCTCT	960
	GGCCTCATCA GTGATATTGG TGAGATGCAG GAGGCCCGTA CCTGGCCCG CGCCCGTGCC	1020
	CATGCTCGCG ACCAAGCTCG TGAACAAGAC CGTGCCCATG CCTGTCTGCT TGTGGAGGAA	1080
	ACCCCGATGA ATGTCCGSA TGTTCATTA CCTGGTGATG CTGCAGCTGG CCACCCGAC	1140
25	CGTGCCTCTG GCCACCCTAA GCGCCATTCC AGATCCTCT CTGCCTATCG CAAATCTGCC	1200
	TCTACCCACC ACAAGTCTGT CTTTATCCAC TCCAAGGCTG CCTCTGGTCA CCTCAAGCCT	1260
	GTCTCTGGCC ACTCCAAGCC TGCCTCTGGT CACCCCAACT CTGCCACTGT CTACCTAAG	1320
	CCTGCCTCTG TCCATTTCAA GGCTGACTCT GTCCATTTC AAGGTGACTC TGTCCATTTC	1380
	AAGCCTGACT CTGTTTATTT CAAGCCTGCT TCCAGCAACC CCAAGCCCAT CACTGGCCAC	1440

176

CATGTCTCTG CTGGCAGCCA CTCCAAGTCT GCCTTCAATG CTGCCACCAG CCACCCATAA 1500
 CCCATCAAGC CAGCTACCAG CCATGCTGAG CCCACCACTG CTGACTATCC CAAGCCTGCC 1560
 ACTACCAGCC ACCCTAAGCC CGCTGCTGCT GACAACCCTG AGCTTCTCTG CTCCCATTGC 1620
 CCCGAGATCC CTGCCATTGC CCACCCCTGTG TCTGACGACA GTGACCTCCC TGAGTCGGCC 1680
 5 TCTAGCCCTG CCGCTGGGCC CACCAAGCCT GCTGCCAGCC AGCTGGAGTC TGACACCATC 1740
 GCTGACCTTC CTGACCTAC TGTAGTCACT ACCAGTACCA ATGATTACCA TGATGTCGTG 1800
 GTTGTGTATG TTGAAGATGA TCCTGATGAA ATGGCTGTGT GA 1842

(217) INFORMATION FOR SEQ ID NO:216:

- 10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 613 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

 (ii) MOLECULE TYPE: protein
- 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

 Met Gly Pro Thr Leu Ala Val Pro Thr Pro Tyr Gly Cys Ile Gly Cys
 1 5 10 15
 Lys Leu Pro Gln Pro Glu Tyr Pro Pro Ala Leu Ile Ile Phe Met Phe
 20 25 30
 Cys Ala Met Val Ile Thr Ile Val Val Asp Leu Ile Gly Asn Ser Met
 35 40 45
 Val Ile Leu Ala Val Thr Lys Asn Lys Lys Leu Arg Asn Ser Gly Asn
 50 55 60
 Ile Phe Val Val Ser Leu Ser Val Ala Asp Met Leu Val Ala Ile Tyr
 25 65 70 75 80
 Pro Tyr Pro Leu Met Leu His Ala Met Ser Ile Gly Gly Trp Asp Leu
 85 90 95
 Ser Gln Leu Gln Cys Gln Met Val Gly Phe Ile Thr Gly Leu Ser Val
 100 105 110
 Val Gly Ser Ile Phe Asn Ile Val Ala Ile Ala Ile Asn Arg Tyr Cys
 30 115 120 125
 Tyr Ile Cys His Ser Leu Gln Tyr Glu Arg Ile Phe Ser Val Arg Asn
 130 135 140
 Thr Cys Ile Tyr Leu Val Ile Thr Trp Ile Met Thr Val Leu Ala Val
 35 145 150 155 160

177

Leu Pro Asn Met Tyr Ile Gly Thr Ile Glu Tyr Asp Pro Arg Thr Tyr
 165 170 175
 Thr Cys Ile Phe Asn Tyr Leu Asn Asn Pro Val Phe Thr Val Thr Ile
 180 185 190
 5 Val Cys Ile His Phe Val Leu Pro Leu Leu Ile Val Gly Phe Cys Tyr
 195 200 205
 Val Arg Ile Trp Thr Lys Val Leu Ala Ala Arg Asp Pro Ala Gly Gln
 210 215 220
 10 Asn Pro Asp Asn Gln Leu Ala Glu Val Arg Asn Lys Leu Thr Met Phe
 225 230 235 240
 Val Ile Phe Leu Leu Phe Ala Val Cys Trp Cys Pro Ile Asn Val Leu
 245 250 255
 Thr Val Leu Val Ala Val Ser Pro Lys Glu Met Ala Gly Lys Ile Pro
 260 265 270
 15 Asn Trp Leu Tyr Leu Ala Ala Tyr Phe Ile Ala Tyr Phe Asn Ser Cys
 275 280 285
 Leu Asn Ala Val Ile Tyr Gly Leu Leu Asn Glu Asn Phe Arg Arg Glu
 290 295 300
 20 Tyr Trp Thr Ile Phe His Ala Met Arg His Pro Ile Ile Phe Phe Ser
 305 310 315 320
 Gly Leu Ile Ser Asp Ile Arg Glu Met Gln Glu Ala Arg Thr Leu Ala
 325 330 335
 Arg Ala Arg Ala His Ala Arg Asp Gln Ala Arg Glu Gln Asp Arg Ala
 340 345 350
 25 His Ala Cys Pro Ala Val Glu Glu Thr Pro Met Asn Val Arg Asn Val
 355 360 365
 Pro Leu Pro Gly Asp Ala Ala Ala Gly His Pro Asp Arg Ala Ser Gly
 370 375 380
 30 His Pro Lys Pro His Ser Arg Ser Ser Ser Ala Tyr Arg Lys Ser Ala
 385 390 395 400
 Ser Thr His His Lys Ser Val Phe Ser His Ser Lys Ala Ala Ser Gly
 405 410 415
 His Leu Lys Pro Val Ser Gly His Ser Lys Pro Ala Ser Gly His Pro
 420 425 430
 35 Lys Ser Ala Thr Val Tyr Pro Lys Pro Ala Ser Val His Phe Lys Ala
 435 440 445
 Asp Ser Val His Phe Lys Gly Asp Ser Val His Phe Lys Pro Asp Ser

178

450 455 460

Val His Phe Lys Pro Ala Ser Ser Asn Pro Lys Pro Ile Thr Gly His
465 470 475 480

5 His Val Ser Ala Gly Ser His Ser Lys Ser Ala Phe Asn Ala Ala Thr
485 490 495

Ser His Pro Lys Pro Ile Lys Pro Ala Thr Ser His Ala Glu Pro Thr
500 505 510

Thr Ala Asp Tyr Pro Lys Pro Ala Thr Thr Ser His Pro Lys Pro Ala
515 520 525

10 Ala Ala Asp Asn Pro Glu Leu Ser Ala Ser His Cys Pro Glu Ile Pro
530 535 540

Ala Ile Ala His Pro Val Ser Asp Asp Ser Asp Leu Pro Glu Ser Ala
545 550 555 560

15 Ser Ser Pro Ala Ala Gly Pro Thr Lys Pro Ala Ala Ser Gln Leu Glu
565 570 575

Ser Asp Thr Ile Ala Asp Leu Pro Asp Pro Thr Val Val Thr Thr Ser
580 585 590

Thr Asn Asp Tyr His Asp Val Val Val Val Asp Val Glu Asp Asp Pro
595 600 605

20 Asp Glu Met Ala Val
610

(218) INFORMATION FOR SEQ ID NO:217:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1884 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

30 ATGGGGCCCA CCCTAGCGGT TCCCACCCCC TATGGCTGTA TTGGCTGTAA GCTACCCCA3 60

CCAGAATACC CACCGGCTCT AATCATCTTT ATGTTCTGCG CGATGGTTAT CACCATCGTT 120

GTAGACCTAA TCGGCAACTC CATGGTCATT TTGGCTGTGA CGAAGAACAA GAAGCTCCG3 180

AATTCTGGCA ACATCTTCGT GGTCACTCTC TCTGTGGCCG ATATGCTGGT GGCCATCTAC 240

CCATACCCTT TGATGCTGCA TCCCATGTCC ATTGGGGGCT GGGATCTGAG CCAGTTACAG 300

35 TGCCAGATGG TCGGGTTCAT CACAGGGCTG AGTGTGGTCTG GCTCCATCTT CAACATCCTG 360

GCAATCGCTA TCAACCGTTA CTGCTACATC TGCCACAGCC TCCAGTACGA ACGGATCTTC 120
 AGTGTGCGCA ATACCTGCAT CTACCTGGTC ATCACCTGGA TCATGACCGT CCTGGCTGTC 480
 CTGCCCCACA TGTACATTGG CACCATCGAG TACGATCCTC GCACCTACAC CTGCATCTTC 540
 AACTATCTGA ACAACCGTGT CTTCACGTGT ACCATCGTCT GCATCCACTT CGTCCTCCCT 600
 5 CTCTCATCCT TGGGTTTCTG CTACGTGAGG ATCTGGACCA AAGTGCTGGC GGCCCGTGAC 660
 CCTGCAGGGC AGAATCCTGA CAACCAACTT GCTGAGGTTT GCAATAAACT AACCATGTTT 720
 GTGATCTTCT TCCTCTTTGC AGTGTGCTGG TGCCCTATCA ACGTGCTCAC TGTCTTGGTG 780
 GCTGTCACTC CGAAGGAGAT GGCAGGCAAG ATCCCCAACT GGCTTTATCT TGCAGCCTAC 840
 TTCATAGCCT ACTTCAACAG CTGCCTCAAC GCTGTGATCT ACGGGCTCCT CAATGAGAAT 900
 10 TTCCGAAGAG AATACTGGAC CATCTTCCAT GCTATGCGGC ACCCTATCAT ATTCTTCTCT 960
 GGCCTCATCA GTGATATTCT TGAGATGCAG GAGGCCCGTA CCTGGGCCCG CGCCCGTGCC 1020
 CATGCTCGCG ACCAAGCTCG TGAACAAGAC CGTGCCCATG CCTCTCCTGC TGTGGAGGAA 1080
 ACCCCGATGA ATGTCCGGAA TGTTCATTA CCTGGTGATG CTGTAGCTGG CCACCCCGAC 1140
 CGTGCCCTCTG GCCACCCTAA GCCCCATTCC AGATCCTCCT CTGCTCTATG CAAATCTGCC 1200
 15 TCTACCCACC ACAAGTCTGT CTTTAGCCAC TCCAAGGCTG CCTGTGGTCA CCTCAAGCCT 1260
 GTCTCTGGCC ACTCCAAGCC TGCCCTGGGT CACCCCAAGT CTGCCACTGT CTACCCTAAG 1320
 CCTGCCTCTG TCCATTTCAA GGCTGACTCT GTCCATTTCA AGGGTGACTC TGTCCATTTT 1380
 AAGCCTGACT CTGTTTATTT CAAGCCTGCT TCCAGCAACC CCAAGCCCAT CACTGGCCAC 1440
 CATGTCTCTG CTGGCAGCCA CTCCAAGTCT GCCTTCAGTG CTGCCACCAG CCACCCCTAA 1500
 20 CCCACCACTG GCCACATCAA GCCAGCTACC AGCCATGCTG AGCCCAACCAC TGCTGACTAT 1560
 CCCAAGCCTG CCACTACCAG CCACCTAAG CCCACTGCTG CTGACAACCC TGAGCTCTCT 1620
 GCCTCCCATC GCCCCGAGAT CCCTGCCATT GCCCACCCTG TGTCTGACGA CAGTGACCTC 1680
 CCTGAGTCGG CCTCTAGCCC TGCCGCTGGG CCCACCAAGC CTGCTGCCAG CCAGCTGGAG 1740
 TCTGACACCA TCGCTGACCT TCCTGACCCT ACTGTAGTCA CTACCACTAC CAATGATTAC 1800
 25 CATGATGTCG TGGTTGTTGA TGTGAAGAT GATCCTGATG AAATGGCTGT GTGA 1864

(219) INFORMATION FOR SEQ ID NO:218:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 617 amino acids
 - (B) TYPE: amino acid

180

(C) STRANDEDNESS:

(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

5	Met Gly Pro Thr Leu Ala Val Pro Thr Pro Tyr Gly Cys Ile Gly Cys	1	5	10	15
	Lys Leu Pro Gln Pro Glu Tyr Pro Pro Ala Leu Ile Ile Phe Met Phe	20	25	30	
10	Cys Ala Met Val Ile Thr Ile Val Val Asp Leu Ile Gly Asn Ser Met	35	40	45	
	Val Ile Leu Ala Val Thr Lys Asn Lys Lys Leu Arg Asn Ser Gly Asn	50	55	60	
	Ile Phe Val Val Ser Leu Ser Val Ala Asp Met Leu Val Ala Ile Tyr	65	70	75	80
15	Pro Tyr Pro Leu Met Leu His Ala Met Ser Ile Gly Gly Trp Asp Leu	85	90	95	
	Ser Gln Leu Gln Cys Gln Met Val Gly Phe Ile Thr Gly Leu Ser Val	100	105	110	
20	Val Gly Ser Ile Phe Asn Ile Val Ala Ile Ala Ile Asn Arg Tyr Cys	115	120	125	
	Tyr Ile Cys His Ser Leu Gln Tyr Glu Arg Ile Phe Ser Val Arg Asn	130	135	140	
	Thr Cys Ile Tyr Leu Val Ile Thr Trp Ile Met Thr Val Leu Ala Val	145	150	155	160
25	Leu Pro Asn Met Tyr Ile Gly Thr Ile Glu Tyr Asp Pro Arg Thr Tyr	165	170	175	
	Thr Cys Ile Phe Asn Tyr Leu Asn Asn Pro Val Phe Thr Val Thr Ile	180	185	190	
30	Val Cys Ile His Phe Val Leu Pro Leu Leu Ile Val Gly Phe Cys Tyr	195	200	205	
	Val Arg Ile Trp Thr Lys Val Leu Ala Ala Arg Asp Pro Ala Gly Gln	210	215	220	
	Asn Pro Asp Asn Gln Leu Ala Glu Val Arg Asn Lys Leu Thr Met Phe	225	230	235	240
35	Val Ile Phe Leu Leu Phe Ala Val Cys Trp Cys Pro Ile Asn Val Leu	245	250	255	

181

	Thr Val Leu Val Ala Val Ser Pro Lys Glu Met Ala Gly Lys Ile Pro	
	260	265 270
	Asn Trp Leu Tyr Leu Ala Ala Tyr Phe Ile Ala Tyr Phe Asn Ser Cys	
	275	280 285
5	Leu Asn Ala Val Ile Tyr Gly Leu Leu Asn Glu Asn Phe Arg Arg Glu	
	290	295 300
	Tyr Trp Thr Ile Phe His Ala Met Arg His Pro Ile Ile Phe Phe Ser	
	305	310 315 320
10	Gly Leu Ile Ser Asp Ile Arg Glu Met Gln Glu Ala Arg Thr Leu Ala	
		325 330 335
	Arg Ala Arg Ala His Ala Arg Asp Gln Ala Arg Glu Gln Asp Arg Ala	
		340 345 350
	His Ala Cys Pro Ala Val Glu Glu Thr Pro Met Asn Val Arg Asn Val	
		355 360 365
15	Pro Leu Pro Gly Asp Ala Ala Ala Gly His Pro Asp Arg Ala Ser Gly	
		370 375 380
	His Pro Lys Pro His Ser Arg Ser Ser Ser Ala Tyr Arg Lys Ser Ala	
		385 390 395 400
20	Ser Thr His His Lys Ser Val Phe Ser His Ser Lys Ala Ala Ser Gly	
		405 410 415
	His Leu Lys Pro Val Ser Gly His Ser Lys Pro Ala Ser Gly His Pro	
		420 425 430
	Lys Ser Ala Thr Val Tyr Pro Lys Pro Ala Ser Val His Phe Lys Ala	
		435 440 445
25	Asp Ser Val His Phe Lys Gly Asp Ser Val His Phe Lys Pro Asp Ser	
		450 455 460
	Val His Phe Lys Pro Ala Ser Ser Asn Pro Lys Pro Ile Thr Gly His	
		465 470 475 480
30	His Val Ser Ala Gly Ser His Ser Lys Ser Ala Phe Ser Ala Ala Thr	
		485 490 495
	Ser His Pro Lys Pro Thr Thr Gly His Ile Lys Pro Ala Thr Ser His	
		500 505 510
	Ala Glu Pro Thr Thr Ala Asp Tyr Pro Lys Pro Ala Thr Thr Ser His	
		515 520 525
35	Pro Lys Pro Thr Ala Ala Asp Asn Pro Glu Leu Ser Ala Ser His Cys	
		530 535 540
	Pro Glu Ile Pro Ala Ile Ala His Pro Val Ser Asp Asp Ser Asp Leu	

182

545 550 555 560
 Pro Glu Ser Ala Ser Ser Pro Ala Ala Gly Pro Thr Lys Pro Ala Ala
 565 570 575
 Ser Gln Leu Glu Ser Asp Thr Ile Ala Asp Leu Pro Asp Pro Thr Val
 5 580 585 590
 Val Thr Thr Ser Thr Asn Asp Tyr His Asp Val Val Val Val Asp Val
 595 600 605
 Glu Asp Asp Pro Asp Glu Met Ala Val
 610 615

10 (220) INFORMATION FOR SEQ ID NO:219:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1548 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

ATGGGACATA ACGGGAGCTG GATCTCTCCA AATGCCAGCG AGCCGCACAA CGCGTCCGGC 60
 GCCGAGGCTG CGGGTGTGAA CCGCAGCGCG CTCGGGGAGT TCGGCGAGGC GCAGCTGTAC 120
 20 CGCCAGTTCA CCACCACCGT GCAGGTCGTC ATCTTCATAG GCTCGCTGCT CGGAAACTTC 180
 ATGGTGTAT GGTCAACTTG CCGCACAAACC GTGTTCAAAAT CTGTACACAA CAGGTTTCATT 240
 AAAAACCTGG CCTGCTCGGG GATTTGTGCC AGCCTGGTCT GTGTGCCCTT CGACATCATC 300
 CTCAGCACCA GTCCTCACTG TTGCTGGTGG ATCTACACCA TGCTCTTCTG CAAGGTCGTC 360
 AAATTTTTC ACAAAGTATT CTGCTCTGTG ACCATCCTCA GCTTCCCTGC TATTGCTTTG 420
 25 GACAGGTACT ACTCAGTCCT CTATCCACTG GAGAGGAAAA TATCTGATGC CAAGTCCCGT 480
 GAACTGGTGA TGTACATCTG GGCCCATGCA GTGGTGGCCA GTGTCCCTGT GTTTGCAGTA 540
 ACCAATGTGG CTGACATCTA TGCCACGTCC ACCTGCACGG AAGTCTGGAG CAACTCCTTG 600
 GGCCACCTGG TGTACGTTCT GGTGTATAAC ATCACCACGG TCATTGTGCC TGTGGTGGTG 660
 GTGTTCTCT TCTTGATACT GATCCGACGG GCCCTGAGTG CCAGCCAGAA GAAGAAGGTC 720
 30 ATCATAGCAG CGCTCCGGAC CCCACAGAAC ACCATCTCTA TTCCCTATGC CTCCCAGCGG 780
 GAGGCCGAGC TGAAAGCCAC CCTGCTCTCC ATGGTGATGG TCTTCATCTT GTGTAGCGTG 840
 CCCTATGCCA CCCTGGTCGT CTACCAGACT GTGCTCAATG TCCCTGACAC TTCCGTCTTC 900

TTGCTGCTCA CTGCTGTTTG GCTGCCCAAA GTCTCCCTGC TGGCAAACCC TGTCTCTTT 960
 CTTACTGTGA ACAAATCTGT CCGCAAGTGC TTGATAGGGA CCCTGGTGCA ACTACACCAC 1020
 CGGTACAGTC GCCGTAATGT' GGTCAGTACA GGGAGTGGCA TGGCTGAGGC CAGCCTGGAA 1080
 CCCAGCATAC GCTCGGGTAG CCAGCTCCTG GAGATGTTCC ACATTGGGCA GCAGCAGATC 1140
 5 TTTAAGCCCA CAGAGGATGA GGAAGAGAGT GAGGCCAAGT ACATTGGGCTC AGCTGACTTC 1200
 CAGGCCAAGG AGATATTTAG CACCTGCCTG GAGGGAGAGC AGGGGCCACA GTTTCGCCCC 1260
 TCTGCCCCAC CCCTGAGCAC AGTGGACTCT GTATCCAGG TGGCACCGGC AGCCCTGTG 1320
 GAACCTGAAA CATTCCCTGA TAAGTATTCC CTGCAGTTTG GCTTTGGGCC TTTTGAGTTG 1380
 CCTCTCAGT GGCTCTCAGA GACCCGAAAC AGCAAGAAGC GGCTGCTTCC CCCCTTGGGC 1440
 10 AACACCCAG AAGAGCTGAT CCAGACAAAG GTGCCCAAGG TAGGCAGGCT GGAGCGGAAG 1500
 ATGAGCAGAA ACAATAAAGT GAGCATTTTT CCAAGGTGG ATTCCTAG 1548

(221) INFORMATION FOR SEQ ID NO:220:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 515 amino acids
 15 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

 (ii) MOLECULE TYPE: protein

 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:
 20 Met Gly His Asn Gly Ser Trp Ile Ser Pro Asn Ala Ser Glu Pro His
 1 5 10 15
 Asn Ala Ser Gly Ala Glu Ala Ala Gly Val Asn Arg Ser Ala Leu Gly
 20 25 30
 25 Glu Phe Gly Glu Ala Gln Leu Tyr Arg Gln Phe Thr Thr Thr Val Gln
 35 40 45
 Val Val Ile Phe Ile Gly Ser Leu Leu Gly Asn Phe Met Val Leu Trp
 50 55 60
 Ser Thr Cys Arg Thr Thr Val Phe Lys Ser Val Thr Asn Arg Phe Ile
 65 70 75 80
 30 Lys Asn Leu Ala Cys Ser Gly Ile Cys Ala Ser Leu Val Cys Val Pro
 85 90 95
 Phe Asp Ile Ile Leu Ser Thr Ser Pro His Cys Cys Trp Trp Ile Tyr
 100 105 110

184

Thr Met Leu Phe Cys Lys Val Val Lys Phe Leu His Lys Val Phe Cys
 115 120 125
 Ser Val Thr Ile Leu Ser Phe Pro Ala Ile Ala Leu Asp Arg Tyr Tyr
 130 135 140
 5 Ser Val Leu Tyr Pro Leu Glu Arg Lys Ile Ser Asp Ala Lys Ser Arg
 145 150 155 160
 Glu Leu Val Met Tyr Ile Trp Ala His Ala Val Val Ala Ser Val Pro
 165 170 175
 10 Val Phe Ala Val Thr Asn Val Ala Asp Ile Tyr Ala Thr Ser Thr Cys
 180 185 190
 Thr Glu Val Trp Ser Asn Ser Leu Gly His Leu Val Tyr Val Leu Val
 195 200 205
 Tyr Asn Ile Thr Thr Val Ile Val Pro Val Val Val Val Phe Leu Phe
 210 215 220
 15 Leu Ile Leu Ile Arg Arg Ala Leu Ser Ala Ser Gln Lys Lys Lys Val
 225 230 235 240
 Ile Ile Ala Ala Leu Arg Thr Pro Gln Asn Thr Ile Ser Ile Pro Tyr
 245 250 255
 20 Ala Ser Gln Arg Glu Ala Glu Leu Lys Ala Thr Leu Leu Ser Met Val
 260 265 270
 Met Val Phe Ile Leu Cys Ser Val Pro Tyr Ala Thr Leu Val Val Tyr
 275 280 285
 Gln Thr Val Leu Asn Val Pro Asp Thr Ser Val Phe Leu Leu Leu Thr
 290 295 300
 25 Ala Val Trp Leu Pro Lys Val Ser Leu Leu Ala Asn Pro Val Leu Phe
 305 310 315 320
 Leu Thr Val Asn Lys Ser Val Arg Lys Cys Leu Ile Gly Thr Leu Val
 325 330 335
 30 Gln Leu His His Arg Tyr Ser Arg Arg Asn Val Val Ser Thr Gly Ser
 340 345 350
 Gly Met Ala Glu Ala Ser Leu Glu Pro Ser Ile Arg Ser Gly Ser Gln
 355 360 365
 Leu Leu Glu Met Phe His Ile Gly Gln Gln Gln Ile Phe Lys Pro Thr
 370 375 380
 35 Glu Asp Glu Glu Glu Ser Glu Ala Lys Tyr Ile Gly Ser Ala Asp Phe
 385 390 395 400
 Gln Ala Lys Glu Ile Phe Ser Thr Cys Leu Glu Gly Glu Gln Gly Pro

185

405 410 415
 Gln Phe Ala Pro Ser Ala Pro Pro Leu Ser Thr Val Asp Ser Val Ser
 420 425 430
 5 Gln Val Ala Pro Ala Ala Pro Val Glu Pro Glu Thr Phe Pro Asp Lys
 435 440 445
 Tyr Ser Leu Gln Phe Gly Phe Gly Pro Phe Glu Leu Pro Pro Gln Trp
 450 455 460
 Leu Ser Glu Thr Arg Asn Ser Lys Lys Arg Leu Leu Pro Pro Leu Gly
 465 470 475 480
 10 Asn Thr Pro Glu Glu Leu Ile Gln Thr Lys Val Pro Lys Val Gly Arg
 485 490 495
 Val Glu Arg Lys Met Ser Arg Asn Asn Lys Val Ser Ile Phe Pro Lys
 500 505 510
 15 Val Asp Ser
 515

(222) INFORMATION FOR SEQ ID NO:221:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1164 base pairs
 (B) TYPE: nucleic acid
 20 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:

ATGAATCGGC ACCATCTGCA GGATCACTTT CTGGAAATAG ACAAGAAGAA CTGCTGTGTG 60
 25 TTCCGAGATG ACTTCATTGC CAAGGTGTTG CCGCCGGTGT TGGGGCTGGA GTTTATCTTT 120
 GGGCTTCTGG GCAATGGCCT TGCCCTGTGG ATTTTCTGTT TCCACCTCAA GTCCTGGAAA 180
 TCCAGCCGGA TTTTCCTGTT CAACCTGGCA GTAGCTGACT TTCTACTGAT CATCTGCCTG 240
 CCGTTCGTGA TGGACTACTA TGTGCGGCGT TCAGACTGGA AGTTTGGGGA CATCCCTTGC 300
 CGGCTGGTGC TCTTCATGTT TGCCATGAAC CGCCAGGGCA GCATCATCTT CCTCACGGTG 360
 30 GTGGCGGTAG ACAGGTATTT CCGGGTGGTC CATCCCCACC ACCCCCTGAA CAAGATCTCC 420
 AATTGGACAG CAGCCATCAT CTCTTGCCCT CTGTGGGGCA TCACTGTGG CCTAACAGTC 480
 CACCTCCTGA AGAAGAAGTT GCTGATCCAG AATGGCCCTG CAAATGTGTG CATCAGCTTC 540
 AGCATCTGCC ATACCTTCCG GTGGCAGGAA GCTATGTTCC TCCTGGAGTT CCTCCTGCCC 600

CTGGGCATCA TCCTGTTCTG CTCAGCCAGA ATTATCTGGA GCCTGCGGCA GAGACAAATG 660
 GACCGGCATG CCAAGATCAA GAGAGCCAAA ACCTTCATCA TGGTGGTGGC CATCGTCTTT 720
 GTCATCTGCT TCCTTCCCAG CGTGGTTGTG CGGATCCGCA TCTTCTGGCT CCTGCACACT 780
 TCGGGCAGCG AGAATTGTGA AGTGTACCGC TCGGTGGACC TGGCGTTCTT TATCACTCTC 840
 5 AGCTTCACCT ACATGAACAG CATGCTGGAC CCCGTGGTGT ACTACTTCTC CAGCCCATCC 900
 TTTCCCAACT TCTTCTCCAC TTGATCAAC CGCTGCCTCC AGAGGAAGAT GACAGGTGAG 960
 CCAGATAATA ACCGCAGCAC GAGCGTCGAG CTCACAGGGG ACCCAACAA AACCAGAGGC 1020
 GCTCCAGAGG CGTTAATGGC CAACTCCGGT GAGCCATGGA GCGCTCTCTA TCTGGGCCCA 1080
 ACCTCAAATA ACCATTCCAA GAAGGGACAT TGTCACCAAG AACCAGCATC TCTGGAGAAA 1140
 10 CAGTTGGGCT GTTGCATCGA GTAA 1164

(223) INFORMATION FOR SEQ ID NO:222:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 387 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:

20 Met Asn Arg His His Leu Gln Asp His Phe Leu Glu Ile Asp Lys Lys
 1 5 10 15
 Asn Cys Cys Val Phe Arg Asp Asp Phe Ile Ala Lys Val Leu Pro Pro
 20 25 30
 Val Leu Gly Leu Glu Phe Ile Phe Gly Leu Leu Gly Asn Gly Leu Ala
 35 40 45
 25 Leu Trp Ile Phe Cys Phe His Leu Lys Ser Trp Lys Ser Ser Arg Ile
 50 55 60
 Phe Leu Phe Asn Leu Ala Val Ala Asp Phe Leu Leu Ile Ile Cys Leu
 65 70 75 80
 30 Pro Phe Val Met Asp Tyr Tyr Val Arg Arg Ser Asp Trp Lys Phe Gly
 85 90 95
 Asp Ile Pro Cys Arg Leu Val Leu Phe Met Phe Ala Met Asn Arg Gln
 100 105 110
 Gly Ser Ile Ile Phe Leu Thr Val Val Ala Val Asp Arg Tyr Phe Arg
 115 120 125

187

Val Val His Pro His His Ala Leu Asn Lys Ile Ser Asn Trp Thr Ala
130 135 140

Ala Ile Ile Ser Cys Leu Leu Trp Gly Ile Thr Val Gly Leu Thr Val
145 150 155 160

5 His Leu Leu Lys Lys Lys Leu Leu Ile Gln Asn Gly Pro Ala Asn Val
165 170 175

Cys Ile Ser Phe Ser Ile Cys His Thr Phe Arg Trp His Glu Ala Met
180 185 190

10 Phe Leu Leu Glu Phe Leu Leu Pro Leu Gly Ile Ile Leu Phe Cys Ser
195 200 205

Ala Arg Ile Ile Trp Ser Leu Arg Gln Arg Gln Met Asp Arg His Ala
210 215 220

Lys Ile Lys Arg Ala Lys Thr Phe Ile Met Val Val Ala Ile Val Phe
225 230 235 240

15 Val Ile Cys Phe Leu Pro Ser Val Val Val Arg Ile Arg Ile Phe Trp
245 250 255

Leu Leu His Thr Ser Gly Thr Gln Asn Cys Glu Val Tyr Arg Ser Val
260 265 270

20 Asp Leu Ala Phe Phe Ile Thr Leu Ser Phe Thr Tyr Met Asn Ser Met
275 280 285

Leu Asp Pro Val Val Tyr Tyr Phe Ser Ser Pro Ser Phe Pro Asn Phe
290 295 300

Phe Ser Thr Leu Ile Asn Arg Cys Leu Gln Arg Lys Met Thr Gly Glu
305 310 315 320

25 Pro Asp Asn Asn Arg Ser Thr Ser Val Glu Leu Thr Gly Asp Pro Asn
325 330 335

Lys Thr Arg Gly Ala Pro Glu Ala Leu Met Ala Asn Ser Gly Glu Pro
340 345 350

30 Trp Ser Pro Ser Tyr Leu Gly Pro Thr Ser Asn Asn His Ser Lys Lys
355 360 365

Gly His Cys His Gln Glu Pro Ala Ser Leu Glu Lys Gln Leu Gly Cys
370 375 380

Cys Ile Glu
385

35 (224) INFORMATION FOR SEQ ID NO:223:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1212 base pairs

188

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: DNA (genomic)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:

ATGGCTTGCA ATGGCAGTGC GGGCAGGGGG CACTTTGACC CTGAGGACTT GAACCTGACT 60
 GACGAGGCAC TGAGACTCAA GTACCTGGGG CCCGAGCABA CAGAGTGTT CATGCCCATC 120
 TGTGCCACAT ACCTGCTGAT TTTCGTGGTG GCGCTGTGG GCAATGGGCT GACCTGTCTG 180
 GTCATCCTGC GCCACAAGGC CATGCGCAGC CTTACCAATT ACTAGCTCTT CAGCCTGGCC 240
 10 GTGTCGGACC TGCTGCTGCT GCTGGTGGGC CTGCCCCCTGG AGCTCTATGA GATGTGGCAC 300
 AACTACCCCT TCTGCTGGG CGTTGGTGGC TGCTATTTTC GCACGCTACT GTTGAGATG 360
 GTGTGCCTGG CCTCAGTCTT CAACGTCCTT GCCCTGAGCG TGGAACGCTA TGTGGCCGTG 420
 GTGCACCCAC TCCAGGCCAG GTCCATGGTG ACGCGGGCCC ATGTGEGCGG AGTGCTTGGG 480
 GCCGTCTGGG GTCTTGCCAT GCTCTGTCC CTGCCCCAACA CCAGCCTGCA CGGCATCCGG 540
 15 CAGCTGCACG TGCCCTGCCC GGGCCCAGTG CCAGACTCAG CTGTTTGCA TCTGGTCCGC 600
 CCACGGGCCC TCTACAACAT GGTAGTGCAG ACCACCGGC TGTTCTTCTT CTGCCTGCCC 660
 ATGGCCATCA TGAGCTGCTT CTACCTGCTC ATTGGCTGC GACTGCGGCG GGAGAGGCTG 720
 CTGCTCATGC AGGAGGCCAA GGGCAGGGGC TCTGCAGCAG CCAGGTCCAG ATACACCTGC 780
 AGGCTCCAGC AGCAGGATCG GGGCCGAGA CAAGTGAAAG AGATCCTGTT TGTCTTGGTC 840
 20 GTGGTGTGTT GCATCTGCTG GGGCCGTTT CACGTCGACC GCTCATGTG GAGCGTCGTG 900
 TCACAGTGGG CAGATGGCTT GCACCTGGCC TTCCAGCAGG TGCACGTCAT CTCCGGCATC 960
 TTCTTCTACC TGGGCTCGGC GGCCAACCCC GTGCTCTATA GCCTCATGTC CAGCCGCTTC 1020
 CGAGAGACCT TCCAGGAGGC CTGTGCCTC GGGGCTGCT GCCATGCGCT CAGACCCCGC 1080
 CACAGCTCCC ACAGCCTCAG CAGGATGACC ACAGGCAGCA CCTGTGTGA TGTGGGCTCC 1140
 25 CTGGGCAGCT GGGTCCACCC CTTGGCTGGG AACGATGGCC CAGAGGCGCA GCAAGAGACC 1200
 GATCCATCCT GA 1212

(225) INFORMATION FOR SEQ ID NO:224:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 403 amino acids
 (B) TYPE: amino acid

30

189

(C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:224:

```

5  Met Ala Cys Asn Gly Ser Ala Ala Arg Gly His Phe Asp Pro Glu Asp
   1              5              10              15

   Leu Asn Leu Thr Asp Glu Ala Leu Arg Leu Lys Tyr Leu Gly Pro Gln
           20              25              30

10  Gln Thr Glu Leu Phe Met Pro Ile Cys Ala Thr Tyr Leu Leu Ile Phe
           35              40              45

   Val Val Gly Ala Val Gly Asn Gly Leu Thr Cys Leu Val Ile Leu Arg
           50              55              60

   His Lys Ala Met Arg Thr Pro Thr Asn Tyr Tyr Leu Phe Ser Leu Ala
           65              70              75              80

15  Val Ser Asp Leu Leu Val Leu Leu Val Gly Leu Pro Leu Glu Leu Tyr
           85              90              95

   Glu Met Trp His Asn Tyr Pro Phe Leu Leu Gly Val Gly Gly Cys Tyr
           100             105             110

20  Phe Arg Thr Leu Leu Phe Glu Met Val Cys Leu Ala Ser Val Leu Asn
           115             120             125

   Val Thr Ala Leu Ser Val Glu Arg Tyr Val Ala Val Val His Pro Leu
           130             135             140

   Gln Ala Arg Ser Met Val Thr Arg Ala His Val Arg Arg Val Leu Gly
           145             150             155             160

25  Ala Val Trp Gly Leu Ala Met Leu Cys Ser Leu Pro Asn Thr Ser Leu
           165             170             175

   His Gly Ile Arg Gln Leu His Val Pro Cys Arg Gly Pro Val Pro Asp
           180             185             190

30  Ser Ala Val Cys Met Leu Val Arg Pro Arg Ala Leu Tyr Asn Met Val
           195             200             205

   Val Gln Thr Thr Ala Leu Leu Phe Phe Cys Leu Pro Met Ala Ile Met
           210             215             220

   Ser Val Leu Tyr Leu Leu Ile Gly Leu Arg Leu Arg Arg Glu Arg Leu
           225             230             235             240

35  Leu Leu Met Gln Glu Ala Lys Gly Arg Gly Ser Ala Ala Ala Arg Ser
           245             250             255

```

190

Arg Tyr Thr Cys Arg Leu Gln Gln His Asp Arg Gly Arg Arg Gln Val
 260 265 270
 Lys Lys Met Leu Phe Val Leu Val Val Val Phe Gly Ile Cys Trp Ala
 275 280 285
 5 Pro Phe His Ala Asp Arg Val Met Trp Ser Val Val Ser Gln Trp Thr
 290 295 300
 Asp Gly Leu His Leu Ala Phe Gln His Val His Val Ile Ser Gly Ile
 305 310 315 320
 10 Phe Phe Tyr Leu Gly Ser Ala Ala Asn Pro Val Leu Tyr Ser Leu Met
 325 330 335
 Ser Ser Arg Phe Arg Glu Thr Phe Gln Glu Ala Leu Cys Leu Gly Ala
 340 345 350
 Cys Cys His Arg Leu Arg Pro Arg His Ser Ser His Ser Leu Ser Arg
 355 360 365
 15 Met Thr Thr Gly Ser Thr Leu Cys Asp Val Gly Ser Leu Gly Ser Trp
 370 375 380
 Val His Pro Leu Ala Gly Asn Asp Gly Pro Glu Ala Gln Gln Glu Thr
 385 390 395 400
 20 Asp Pro Ser

(226) INFORMATION FOR SEQ ID NO:225:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1098 base pairs
 (B) TYPE: nucleic acid
 25 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

 (ii) MOLECULE TYPE: DNA (genomic)

 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:

ATGGGGAACA TCACTGCAGA CAACTCCTCG ATGAGCTGTA CCATCGACCA TACCATCCAC 60
 30 CAGACGCTGG CCCCGGTGGT CTATGTTACC GTGCTGGTGG TGGGCTTCCC GGCCTACTGC 120
 CTGTCCCTCT ACTTCGGCTA CCTGCAGATC AAGGCCCGGA ACGAGCTGGG CGTGTACCTG 180
 TGCAACCTGA CGGTGGCCGA CCTCTTCTAC ATCTGCTCGC TGCCCTTCTG GCTGCAGTAC 240
 GTGCTGCAGC ACGACAACCTG GTCTCACGGC GACCTGTCCT GCCAGGTGTG CCGCATCCTC 300
 CTGTACGAGA ACATCTACAT CAGCGTGGGC TTCCTCTGCT GCATCTCCGT GGACCGCTAC 360
 35 CTGGCTGTGG CCCATCCCTT CCGCTTCCAC CAGTCCCGA CCCTGAAGGC GCGCGTGGG 420

191

CTCAGCGTGG TCATCTGGGC CAAGGAGCTG CTGACCAGCA TCTACTTCCT GATGCACGAG 480
 GAGGTGATCG AGGACGAGAA CCAGCACCGC GTGTGCTTTG AGCACTACCC CATCCAGGCA 540
 TGGCAGCGCG CCATCAACTA CTACCGCTTC CTGGTGGGCT TCCTCTTCCC CATCTGCCTG 600
 CTGCTGGGCT CCTACCAGGG CATCCTGCGC GCCGTGCGCC GGAGCCACGG TACCCAGAAG 660
 5 AGCCGCAAGG ACCAGATCAA GCGGCTGGTG CTCAGCACCG TGATCATCTT CTTGGCCTGC 720
 TTCTGCGCTT ACCACGTGTT GCTGCTGGTG CGCAGCGTCT GGAGGCCAG CTGCGACTTC 780
 GCCAAGGGCG TTTTCAACGC CTACCACTTC TCCCTCCTGC TCACCAGCTT CAACTGCGTC 840
 GCCGACCCCG TGCTCTACTG CTTCGTCAGC GAGACCACCC ACCGGGACCT GGCCCGCCTC 900
 CGCGGGGGCT GCCTGGCCTT CTCACCTGC TCCAGGACCG GCGGGGCCAG GGAGGCCTAC 960
 10 CCGCTGGGTG CCCCCGAGGC CTCCGGGAAA AGCGGGGCCC AGGCTGAGGA GCCCGAGCTC 1020
 TTGACCAAGG TCCACCCGGC CTTCAGACC CTTAACTCGC CAGGGTCGGG CGGGTTCCCC 1080
 ACGGGCAGGT TGGCCTAG 1098

(227) INFORMATION FOR SEQ ID NO:226:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 365 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:226.

Met	Gly	Asn	Ile	Thr	Ala	Asp	Asn	Ser	Ser	Met	Ser	Cys	Thr	Ile	Asp
1				5					10					15	
His	Thr	Ile	His	Gln	Thr	Leu	Ala	Pro	Val	Val	Tyr	Val	Thr	Val	Leu
			20					25					30		
Val	Val	Gly	Phe	Pro	Ala	Asn	Cys	Leu	Ser	Leu	Tyr	Phe	Gly	Tyr	Leu
		35					40					45			
Gln	Ile	Lys	Ala	Arg	Asn	Glu	Leu	Gly	Val	Tyr	Leu	Cys	Asn	Leu	Thr
		50				55					60				
Val	Ala	Asp	Leu	Phe	Tyr	Ile	Cys	Ser	Leu	Pro	Phe	Trp	Leu	Gln	Tyr
65					70					75				80	
Val	Leu	Gln	His	Asp	Asn	Trp	Ser	His	Gly	Asp	Leu	Ser	Cys	Gln	Val
			85					90					95		
Cys	Gly	Ile	Leu	Leu	Tyr	Glu	Asn	Ile	Tyr	Ile	Ser	Val	Gly	Phe	Leu

192

	100	105	110
	Cys Cys Ile Ser Val Asp Arg Tyr Leu Ala Val Ala His Pro Phe Arg		
	115	120	125
5	Phe His Gln Phe Arg Thr Leu Lys Ala Ala Val Gly Val Ser Val Val		
	130	135	140
	Ile Trp Ala Lys Glu Leu Leu Thr Ser Ile Tyr Phe Leu Met His Glu		
	145	150	155 160
	Glu Val Ile Glu Asp Glu Asn Gln His Arg Val Cys Phe Glu His Tyr		
	165	170	175
10	Pro Ile Gln Ala Trp Gln Arg Ala Ile Asn Tyr Tyr Arg Phe Leu Val		
	180	185	190
	Gly Phe Leu Phe Pro Ile Cys Leu Leu Leu Ala Ser Tyr Gln Gly Ile		
	195	200	205
15	Leu Arg Ala Val Arg Arg Ser His Gly Thr Gln Lys Ser Arg Lys Asp		
	210	215	220
	Gln Ile Lys Arg Leu Val Leu Ser Thr Val Val Ile Phe Leu Ala Cys		
	225	230	235 240
	Phe Leu Pro Tyr His Val Leu Leu Leu Val Arg Ser Val Trp Glu Ala		
	245	250	255
20	Ser Cys Asp Phe Ala Lys Gly Val Phe Asn Ala Tyr His Phe Ser Leu		
	260	265	270
	Leu Leu Thr Ser Phe Asn Cys Val Ala Asp Pro Val Leu Tyr Cys Phe		
	275	280	285
25	Val Ser Glu Thr Thr His Arg Asp Leu Ala Arg Leu Arg Gly Ala Cys		
	290	295	300
	Leu Ala Phe Leu Thr Cys Ser Arg Thr Gly Arg Ala Arg Glu Ala Tyr		
	305	310	315 320
	Pro Leu Gly Ala Pro Glu Ala Ser Gly Lys Ser Gly Ala Gln Gly Glu		
	325	330	335
30	Glu Pro Glu Leu Leu Thr Lys Leu His Pro Ala Phe Gln Thr Pro Asn		
	340	345	350
	Ser Pro Gly Ser Gly Gly Phe Pro Thr Gly Arg Leu Ala		
	355	360	365

(228) INFORMATION FOR SEQ ID NO:227:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1416 base pairs
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(E) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:

```
5  ATGGATATTC TTTGTGAAGA AAATACTTCT TTGAGCTCAA CTACGAACTC CCTAATGCAA   60
    TTAAATGATG ACAACAGGCT CTACAGTAAT GACTTTAACT CCGGAGAAGC TAACACTTCT   120
    GATGCATTTA ACTGGACAGT CGACTCTGAA AATCGAACCA ACCTTTCCTG TGAAGGGTGC   180
    CTCTACCGT CGTGTCTCTC CTTACTTCAT CTCCAGGAAA AAAACTGGTC TGCTTTACTG   240
    ACAGCCGTAG TGATTATTCT AACTATTGCT GGAAACATAC TCGTCATCAT GGCAGTGTCC   300
10  CTAGAGAAAA AGCTGCAGAA TGCCACCAAC TATTTCTTGA TGCACTTGC CATAGCTGAT   360
    ATGCTGCTGG GTTTCCTTGT CATGCCCGTG TCCATGT1AA CCATCCTGTA TGGGTACCGG   420
    TGGCCTCTGC CGAGCAAGCT TTGTGCAGTC TGGATTTACC TGGACGTGCT CTTCCTCCACG   480
    GCCTCCATCA TGCACCTCTG CGCCATCTCG CTGGACCGCT ACGTC3CCAT CCAGAATCCC   540
    ATCCACCACA GCCGCTTCAA CTCCAGAACT AAGGCATTTG TGAAAATCAT TGCTGTTTGG   600
15  ACCATATCAG TAGGTATATC CATGCCAATA CCAGTCTTTG GGTACAGGA CGATTGGAAG   660
    GTCTTTAAGG AGGGGAGTTG CTTACTCGCC GATGATAACT TTGTCTGAT CGGCTCTTTT   720
    GTGTCATTTT TCATTCCCTT AACCATCATG GTGATCACCT ACTTTCTAAC TATCAAGTCA   780
    CTCCAGAAAG AAGCTACTTT GTGTGTAAGT GATCTTGGCA CACGGGCCAA ATTAGCTTCT   840
    TTCAGCTTCC TCCCTCAGAG TTCTTTGTCT TCAGAAAAGC TCTTCCAGCG GTCGATCCAT   900
20  AGGGAGCCAG GGTCTACAC AGGCAGGAGG ACTATGCAGT CCATCAGCAA TGAGCAAAAG   960
    GCAAAGAAGG TGCTGGGCAT CGTCTTCTTC CTGTTTGTGG TGATGTGGTG CCCTTTCTTC  1020
    ATCACAACA TCATGGCCGT CATCTGCAA GAGTCTTGCA ATGAGGATGT CATTGGGGCC  1080
    CTGCTCAATG TGTTTGTTTG GATCGGTTAT CTCTCTCAG CAGTCAACCC ACTAGTCTAC  1140
    ACACTGTTC ACAAAGACCTA TAGGTCAGCC TTTTCACGGT ATATTCAGTG TCAGTACAAG  1200
25  GAAAACAAAA AACCATTGCA GTTAATTTTA GTGAACACAA TACCGGCTTT GGCCTACAAG  1260
    TCTAGCCAAC TTCAAATGGG ACAAAAAAAG AATTCAAAGC AAGATGCCAA GACAACAGAT  1320
    AATGACTGCT CAATGGTTGC TCTAGGAAAG CAGTATTCTG AAGAGGCTTC TAAAGACAAT  1380
    AGCGACGGAG TGAATGAAAA GGTGAGCTGT GTGTGA   1416
```

(229) INFORMATION FOR SEQ ID NO:228:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 470 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

5

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:

10	1	Met Asp Ile Leu Cys Glu Glu Asn Thr Ser Leu Ser Ser Thr Thr Asn	5	10	15
		Ser Leu Met Gln Leu Asn Asp Asp Asn Arg Leu Tyr Ser Asn Asp Phe	20	25	30
		Asn Ser Gly Glu Ala Asn Thr Ser Asp Ala Phe Asn Trp Thr Val Asp	35	40	45
15		Ser Glu Asn Arg Thr Asn Leu Ser Cys Glu Gly Cys Leu Ser Pro Ser	50	55	60
		Cys Leu Ser Leu Leu His Leu Gln Glu Lys Asn Trp Ser Ala Leu Leu	65	70	75
		Thr Ala Val Val Ile Ile Leu Thr Ile Ala Gly Asn Ile Leu Val Ile	85	90	95
20		Met Ala Val Ser Leu Glu Lys Lys Leu Gln Asn Ala Thr Asn Tyr Phe	100	105	110
		Leu Met Ser Leu Ala Ile Ala Asp Met Leu Leu Gly Phe Leu Val Met	115	120	125
25		Pro Val Ser Met Leu Thr Ile Leu Tyr Gly Tyr Arg Trp Pro Leu Pro	130	135	140
		Ser Lys Leu Cys Ala Val Trp Ile Tyr Leu Asp Val Leu Phe Ser Thr	145	150	155
		Ala Ser Ile Met His Leu Cys Ala Ile Ser Leu Asp Arg Tyr Val Ala	165	170	175
30		Ile Gln Asn Pro Ile His His Ser Arg Phe Asn Ser Arg Thr Lys Ala	180	185	190
		Phe Leu Lys Ile Ile Ala Val Trp Thr Ile Ser Val Gly Ile Ser Met	195	200	205
35		Pro Ile Pro Val Phe Gly Leu Gln Asp Asp Ser Lys Val Phe Lys Glu	210	215	220
		Gly Ser Cys Leu Leu Ala Asp Asp Asn Phe Val Leu Ile Gly Ser Phe	225	230	235
					240

195

Val Ser Phe Phe Ile Pro Leu Thr Ile Met Val Ile Thr Tyr Phe Leu
 245 250 255

Thr Ile Lys Ser Leu Gln Lys Glu Ala Thr Leu Cys Val Ser Asp Leu
 260 265 270

5 Gly Thr Arg Ala Lys Leu Ala Ser Phe Ser Phe Leu Pro Gln Ser Ser
 275 280 285

Leu Ser Ser Glu Lys Leu Phe Gln Arg Ser Ile His Arg Glu Pro Gly
 290 295 300

10 Ser Tyr Thr Gly Arg Arg Thr Met Gln Ser Ile Ser Asn Glu Gln Lys
 305 310 315 320

Ala Lys Lys Val Leu Gly Ile Val Phe Phe Leu Phe Val Val Met Trp
 325 330 335

Cys Pro Phe Phe Ile Thr Asn Ile Met Ala Val Ile Cys Lys Glu Ser
 340 345 350

15 Cys Asn Glu Asp Val Ile Gly Ala Leu Leu Asn Val Phe Val Trp Ile
 355 360 365

Gly Tyr Leu Ser Ser Ala Val Asn Pro Leu Val Tyr Thr Leu Phe Asn
 370 375 380

20 Lys Thr Tyr Arg Ser Ala Phe Ser Arg Tyr Ile Gln Cys Gln Tyr Lys
 385 390 395 400

Glu Asn Lys Lys Pro Leu Gln Leu Ile Leu Val Asn Thr Ile Pro Ala
 405 410 415

Leu Ala Tyr Lys Ser Ser Gln Leu Gln Met Gly Gln Lys Lys Asn Ser
 420 425 430

25 Lys Gln Asp Ala Lys Thr Thr Asp Asn Asp Cys Ser Met Val Ala Leu
 435 440 445

Gly Lys Gln Tyr Ser Glu Glu Ala Ser Lys Asp Asn Ser Asp Gly Val
 450 455 460

30 Asn Glu Lys Val Ser Cys Val
 465 470

(230) INFORMATION FOR SEQ ID NO:229:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1377 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- 35
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:

```

ATGGTGAACC TGAGGAATGC GGTGCATTCA TTCCTTGTGC ACCTAATTGG CCTATTGGTT 60
TGGCAATGTG ATATTCTCTG GAGCCCAGTA GCAGCTATAG TAACTGACAT TTTCAATACC 120
TCCGATGGTG GACGCTTCAA ATTCCCAGAC GGGGTACAAA ACTGCCAGC ACTTTCAATC 180
5  GTCATCATAA TAATCATGAC AATAGGTGGC AACATCCTTG TGATCATGGC AGTAAGCATG 240
GAAAAGAAAC TGCACAATGC CACCAATTAC TTCTTAATGT CCCTAGCCAT TGCTGATATG 300
CTAGTGGGAC TACTTGTCTAT GCCCCTGTCT CTCCTGGCAA TCCTTTATGA TTATGTCTGG 360
CCACTACCTA GATATTTGTG CCCCGTCTGG ATTTCTTTAG ATGTTTATT TTCAACAGCG 420
TCCATCATGC ACCTCTGCGC TATATCGCTG GATCGGTATG TAGCAATACG TAATCCTATT 480
10 GAGCATAGCC GTTCAATTC GCGGACTAAG GCCATCATGA AGATTGCTAT TGTITGGGCA 540
ATTTCTATAG GTGTATCACT TCCTATCCCT GTGATTGGAC TGAGGGACGA AGAAAAGGTG 600
TTCGTGAACA ACACGACGTG CGTGCTCAAC GACCCAAAT TCCTTCTTAT TGGGTCCTTC 660
GTAGCTTTCT TCATACCGCT GACGATTATG GTGATTACGT ATTGCTGAC CATCTACGTT 720
CTGCGCCGAC AAGCTTTGAT GTTACTGCAC GGCACACCG AGGAACCGCC TGGACTAAGT 780
15 CTGGATTTC TGAAGTGCTG CAAGAGGAAT ACGGCCGAGG AAGAGAACTC TGCAAAACCT 840
AACCAAGACC AGAACGCACG CCGAAGAAAG AAGAAGGAGA GACGTCCTAG GGGCACCATG 900
CAGGCTATCA ACAATGAAAG AAAAGCTAAG AAAGTCCTTG GGATTGTTTT CTTTGTGTTT 960
CTGATCATGT GGTGCCCAIT TTTCATTACC AATATCTCTG CTGTTCTTTG TGAGAAGTCC 1020
TGTAACCAAA AGCTCATGGA AAAGCTTCTG AATGTGTTTG TTGGATGG CTATGTTGT 1080
20 TCAGGAATCA ATCCTCTGGT GTATACTCTG TTCAACAAAA TTTACCGAAG GGCATTCTCC 1140
AACTATTTGC GTTGCAATTA TAAGGTAGAG AAAAAGCCTC CTGTCAGGCA GATTCCAAGA 1200
GTTGCCGCCA CTGCTTTGTC TGGGAGGGAG CTTAATGTTA ACATTTATCG GCATACCAAT 1260
GAACCGGTGA TCGAGAAAGC CAGTGACAAAT GAGCCCGGTA TAGAGATGCA ACTTGAGAAT 1320
TTAGAGTTAC CAGTAAATCC CTCCAGTGTG GTTAGCGAAA GGATTAGCAG TGTGTGA 1377

```

25 (231) INFORMATION FOR SEQ ID NO:230:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 458 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:

197

(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

```

5 Met Val Asn Leu Arg Asn Ala Val His Ser Phe Leu Val His Leu Ile
  1           5           10           15

  Gly Leu Leu Val Trp Gln Cys Asp Ile Ser Val Ser Pro Val Ala Ala
    20           25           30

  Ile Val Thr Asp Ile Phe Asn Thr Ser Asp Gly Gly Arg Phe Lys Phe
    35           40           45

10 Pro Asp Gly Val Gln Asn Trp Pro Ala Leu Ser Ile Val Ile Ile Ile
   50           55           60

  Ile Met Thr Ile Gly Gly Asn Ile Leu Val Ile Met Ala Val Ser Met
  65           70           75           80

15 Glu Lys Lys Leu His Asn Ala Thr Asn Tyr Phe Leu Met Ser Leu Ala
    85           90           95

  Ile Ala Asp Met Leu Val Gly Leu Leu Val Met Pro Leu Ser Leu Leu
   100          105          110

  Ala Ile Leu Tyr Asp Tyr Val Trp Pro Leu Pro Arg Tyr Leu Cys Pro
   115          120          125

20 Val Trp Ile Ser Leu Asp Val Leu Phe Ser Thr Ala Ser Ile Met His
   130          135          140

  Leu Cys Ala Ile Ser Leu Asp Arg Tyr Val Ala Ile Arg Asn Pro Ile
  145          150          155          160

25 Glu His Ser Arg Phe Asn Ser Arg Thr Lys Ala Ile Met Lys Ile Ala
   165          170          175

  Ile Val Trp Ala Ile Ser Ile Gly Val Ser Val Pro Ile Pro Val Ile
   180          185          190

  Gly Leu Arg Asp Glu Glu Lys Val Phe Val Asn Asn Thr Thr Cys Val
   195          200          205

30 Leu Asn Asp Pro Asn Phe Val Leu Ile Gly Ser Phe Val Ala Phe Phe
   210          215          220

  Ile Pro Leu Thr Ile Met Val Ile Thr Tyr Cys Leu Thr Ile Tyr Val
  225          230          235          240

35 Leu Arg Arg Gln Ala Leu Met Leu Leu His Gly His Thr Glu Glu Pro
   245          250          255

  Pro Gly Leu Ser Leu Asp Phe Leu Lys Cys Cys Lys Arg Asn Thr Ala

```

198

	260	265	270
	Glu Glu Glu Asn Ser Ala Asn Pro Asn Gln Asp Gln Asn Ala Arg Arg		
	275	280	285
5	Arg Lys Lys Lys Glu Arg Arg Pro Arg Gly Thr Met Gln Ala Ile Asn		
	290	295	300
	Asn Glu Arg Lys Ala Lys Lys Val Leu Gly Ile Val Phe Phe Val Phe		
	305	310	315 320
	Leu Ile Met Trp Cys Pro Phe Phe Ile Thr Asn Ile Leu Ser Val Leu		
	325	330	335
10	Cys Glu Lys Ser Cys Asn Gln Lys Leu Met Glu Lys Leu Leu Asn Val		
	340	345	350
	Phe Val Trp Ile Gly Tyr Val Cys Ser Gly Ile Asn Pro Leu Val Tyr		
	355	360	365
15	Thr Leu Phe Asn Lys Ile Tyr Arg Arg Ala Phe Ser Asn Tyr Leu Arg		
	370	375	380
	Cys Asn Tyr Lys Val Glu Lys Lys Pro Pro Val Arg Gln Ile Pro Arg		
	385	390	395 400
	Val Ala Ala Thr Ala Leu Ser Gly Arg Glu Leu Asn Val Asn Ile Tyr		
	405	410	415
20	Arg His Thr Asn Glu Pro Val Ile Glu Lys Ala Ser Asp Asn Glu Pro		
	420	425	430
	Gly Ile Glu Met Gln Val Glu Asn Leu Glu Leu Pro Val Asn Pro Ser		
	435	440	445
25	Ser Val Val Ser Glu Arg Ile Ser Ser Val		
	450	455	

(232) INFORMATION FOR SEQ ID NO:231:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1068 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:

	ATGGATCAGT TCCCTGAATC AGTGACAGAA AACTTTGAGT ACGATGATTT GGCTGAGGCC	60
35	TGTTATATTG GGGACATCGT GGTCTTTGGG ACTGTGTTCC TGTCCATATT CTACTCCGTC	120
	ATCTTTGCCA TTGGCCTGGT GGGAAATTG TTGAGTAGTGT TTGCCCTCAC CAACAGCAAG	180

AAGCCCAAGA GTGTCACCGA CATTACCTC CTGAACCTGG CCTGTCTGA TCTGCTGTTT 240
 GTAGCCACTT TGCCCTTCTG GACTCACTAT TTGATAAATG AAAAGGGCCT CCACAATGCC 300
 ATGTGCAAAT TCACTACCGC CTTCTTCTTC ATCGGCTTTT TTGAAGCAT ATTCTTCATC 360
 ACCGTCATCA GCATTGATAG GTACCTGGCC ATCGTCTGG CCGCCAACTC CATGAACAAC 420
 5 CGGACCGTGC AGCATGGCGT CACCATCAGC CTAGGCGTCT GGGCAGCAGC CATTTTGGTG 480
 GCAGCACCCC AGTTCATGTT CACAAAGCAG AAAGAAAATG AATGCCTTGG TGACTACCCC 540
 GAGGTCTCTC AGGAAATCTG GCCCGTGCTC CGCAATGTGG AAACAAATTT TCTTGGCTTC 600
 CTACTCCCCC TGCTCATTAT GAGTTATTGC TACTTCAGAA TCATCCAGAC GCTGTTTTC 660
 TGCAAGAACC ACAAGAAAGC CAAAGCCAAG AACTGATCC TTCTGGTGGT CATCGTGTTT 720
 10 TTCCTCTTCT GGACACCCTA CAACGTTATG ATTTTCCTGG AGACGCTAA GCTCTATGAC 780
 TTCTTTCCCA GTTGTGACAT GAGGAAGGAT CTGAGGCTGG CCCTCAGTGT GACTGAGACG 840
 GTTGCAATTA GCCATTGTTG CCTGAATCCT CTCATCTATG CATTTGCTGG GGAGAAGTTC 900
 AGAAGATACC TTTACCACCT GTATGGGAAA TGCCTGGCTG TCCTGTGTGG GCGCTCAGTC 960
 CACGTTGATT TCTCTCATC TGAATCACAA AGGAGCAGGC ATGGAAGTGT TCTGAGCAGC 1020
 15 AATTTTACTT ACCACACGAG TGATGGAGAT GCATTGCTCC TTCTCTGA 1068

(233) INFORMATION FOR SEQ ID NO:232:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 355 amino acids
 (B) TYPE: amino acid
 20 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:

25 Met Asp Gln Phe Pro Glu Ser Val Thr Glu Asn Phe Glu Tyr Asp Asp
 1 5 10 15
 Leu Ala Glu Ala Cys Tyr Ile Gly Asp Ile Val Val Phe Gly Thr Val
 20 25 30
 Phe Leu Ser Ile Phe Tyr Ser Val Ile Phe Ala Ile Gly Leu Val Gly
 35 40 45
 30 Asn Leu Leu Val Val Phe Ala Leu Thr Asn Ser Lys Lys Pro Lys Ser
 50 55 60
 Val Thr Asp Ile Tyr Leu Leu Asn Leu Ala Leu Ser Asp Leu Leu Phe

200

	65	70	75	80
	Val Ala Thr Leu Pro Phe Trp Thr His Tyr Leu Ile Asn Glu Lys Gly	85	90	95
5	Leu His Asn Ala Met Cys Lys Phe Thr Thr Ala Phe Phe Phe Ile Gly	100	105	110
	Phe Phe Gly Ser Ile Phe Phe Ile Thr Val Ile Ser Ile Asp Arg Tyr	115	120	125
	Leu Ala Ile Val Leu Ala Ala Asn Ser Met Asn Asn Arg Thr Val Gln	130	135	140
10	His Gly Val Thr Ile Ser Leu Gly Val Trp Ala Ala Ala Ile Leu Val	145	150	155
	Ala Ala Pro Gln Phe Met Phe Thr Lys Gln Lys Glu Asn Glu Cys Leu	165	170	175
15	Gly Asp Tyr Pro Glu Val Leu Gln Glu Ile Trp Pro Val Leu Arg Asn	180	185	190
	Val Glu Thr Asn Phe Leu Gly Phe Leu Leu Pro Leu Leu Ile Met Ser	195	200	205
	Tyr Cys Tyr Phe Arg Ile Ile Gln Thr Leu Phe Ser Cys Lys Asn His	210	215	220
20	Lys Lys Ala Lys Ala Lys Lys Leu Ile Leu Leu Val Val Ile Val Phe	225	230	235
	Phe Leu Phe Trp Thr Pro Tyr Asn Val Met Ile Phe Leu Glu Thr Leu	245	250	255
25	Lys Leu Tyr Asp Phe Phe Pro Ser Cys Asp Met Arg Lys Asp Leu Arg	260	265	270
	Leu Ala Leu Ser Val Thr Glu Thr Val Ala Phe Ser His Cys Cys Leu	275	280	285
	Asn Pro Leu Ile Tyr Ala Phe Ala Gly Glu Lys Phe Arg Arg Tyr Leu	290	295	300
30	Tyr His Leu Tyr Gly Lys Cys Leu Ala Val Leu Cys Gly Arg Ser Val	305	310	315
	His Val Asp Phe Ser Ser Ser Glu Ser Gln Arg Ser Arg His Gly Ser	325	330	335
35	Val Leu Ser Ser Asn Phe Thr Tyr His Thr Ser Asp Gly Asp Ala Leu	340	345	350
	Leu Leu Leu	355		

201

(234) INFORMATION FOR SEQ ID NO:233:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:

10 GGCTTAAGAG CATCATCGTG GTGCTGGTG

29

(235) INFORMATION FOR SEQ ID NO:234:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iv) ANTI-SENSE: YES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:

20 GTCACCACCA GCACCACGAT GATGCTCTTA AGCC

34

(236) INFORMATION FOR SEQ ID NO:235:

- 25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:235:

CAAAGAAAGT ACTGGGCATC GTCTTCTTCC T

31

30 (237) INFORMATION FOR SEQ ID NO:236:

- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:

TGCTCTAGAT TCCAGATAGG TGAAAACTTG

30

(238) INFORMATION FOR SEQ ID NO:237:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

10 (iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:

CTAGGGGCAC CATGCAGGCT ATCAACAATG AAAGAAAAGC TAAGAAAGTC

50

(239) INFORMATION FOR SEQ ID NO:238:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:

CAAGGACTTT CTTAGCTTTT CTTTCATTGT TGATAGCCTG CATGGTGCCC

50

(240) INFORMATION FOR SEQ ID NO:239:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:

CGGCGGCAGA AGGCGAAACG CATGATCCTC GCGGT

35

(241) INFORMATION FOR SEQ ID NO:240:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid

203

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:240:

5 ACCGCGAGGA TCATGCGTTT CGCCTTCTGC CGCCG

35

(242) INFORMATION FOR SEQ ID NO:241:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:241:

GAGACATATT ATCTGCCACG GAGG

24

15 (243) INFORMATION FOR SEQ ID NO:242:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:

TTGGCATAGA AACCGGACCC AAGG

24

(244) INFORMATION FOR SEQ ID NO:243:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:243:

TAAGAATTCC ATAAAAATTA TGGAATGG

28

(245) INFORMATION FOR SEQ ID NO:244:

(i) SEQUENCE CHARACTERISTICS:

204

(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:244:

CCAGGATCCA GCTGAAGTCT TCCATCATTG

30

(246) INFORMATION FOR SEQ ID NO:245:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1071 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:245:

ATGAATGGGG TCTCGGAGGG GACCAGAGGC TGCAGTGACA GGCAACCTGG GGTCTTGACA 60

CGTGATCGCT CTTGTTCAG GAAGATGAAC TCTCCGGAT GCCTGTCTGA GGAGGTGGGG 120

TCCCTCCGCC CACTGACTGT GGTATCCTG TCTGCGTCCA TTGTCTCGG AGTGCTGGGC 180

AATGGGCTGG TGCTGTGGAT GACTGTCTTC CGTATGGCAC GCACGGTCTC CACCGTCTGC 240

20 TTCTTCACAC TGGCCCTTGC CGATTTATG CTCTCACTGT CTCTGCCCAT TGCCATGTAC 300

TATATTGTCT CCAGGCAGTG GTCCTCGGA GAGTGGGCCT GCAAACCTCA CATCACCTTT 360

GTGTTCTCTA GCTACTTTGC CAGTAACTGC CTCCTTGTCT TCATCTCTGT GGACCGTTGC 420

ATCTCTGTCC TCTACCCCGT CTGGGCCCTG AACCACCGCA CTGTGCAGCG GGCGAGCTGG 480

CTGGCCTTTG GGGTGTGGCT CCTGGCCGCC GCCTTGTGCT CTGCGCACCT GAAATTCGGG 540

25 ACAACCAGAA AATGGAATGG CTGTACGCAC TGCTACTTGG CGTTCAACTC TGACAATGAG 600

ACTGCCCAGA TTTGGATTGA AGGGGTCGTG GAGGGACACA TTATAGGGAC CATTGGCCAC 660

TTCTGTCTGG GCTTCCTGGG GCCCTTAGCA ATCATAGGCA CCTGCGCCCA CCTCATCCGG 720

GCCAAGCTCT TGCGGGAGGG CTGGGTCCAT GCCAACCAGC CCGCGAGGCT GCTGCTGGTG 780

CTGGTGAGCG CTTTCTTTAT CTCTGGTCC CCGTTTAACG TGGTGCTGTT GGTCCATCTG 840

30 TGGCGACGGG TGATGCTCAA GGAAATCTAC CACCCCGGA TGCTGCTCAT CCTCCAGGCT 900

AGCTTTGCCT TGGGCTGTGT CAACAGCAGC CTCAACCCCT TCCTCTACGT CTTCGTTGGC 960

205

AGAGATTTCC AAGAAAAGTT TTTCCAGTCT TTGACTTCTG CCTGGCGAG GCGGTTTGA 1020

GAGGAGGAGT TTCTGTCATC CTGTCCCCGT GGCAACGCCC CCCGGAATG A 1071

(247) INFORMATION FOR SEQ ID NO:246:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 356 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

- 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:246:

Met	Asn	Gly	Val	Ser	Glu	Gly	Thr	Arg	Gly	Cys	Ser	Asp	Arg	Gln	Pro	
1				5					10					15		
Gly	Val	Leu	Thr	Arg	Asp	Arg	Ser	Cys	Ser	Arg	Lys	Met	Asn	Ser	Ser	
			20					25					30			
Gly	Cys	Leu	Ser	Glu	Glu	Val	Gly	Ser	Leu	Arg	Pro	Leu	Thr	Val	Val	
		35					40					45				
Ile	Leu	Ser	Ala	Ser	Ile	Val	Val	Gly	Val	Leu	Gly	Asn	Gly	Leu	Val	
		50				55					60					
Leu	Trp	Met	Thr	Val	Phe	Arg	Met	Ala	Arg	Thr	Val	Ser	Thr	Val	Cys	
65				70					75					80		
Phe	Phe	His	Leu	Ala	Leu	Ala	Asp	Phe	Met	Leu	Ser	Leu	Ser	Leu	Pro	
			85					90					95			
Ile	Ala	Met	Tyr	Tyr	Ile	Val	Ser	Arg	Gln	Trp	Leu	Leu	Gly	Glu	Trp	
			100				105					110				
Ala	Cys	Lys	Leu	Tyr	Ile	Thr	Phe	Val	Phe	Leu	Ser	Tyr	Phe	Ala	Ser	
		115				120						125				
Asn	Cys	Leu	Leu	Val	Phe	Ile	Ser	Val	Asp	Arg	Cys	Ile	Ser	Val	Leu	
		130				135					140					
Tyr	Pro	Val	Trp	Ala	Leu	Asn	His	Arg	Thr	Val	Gln	Arg	Ala	Ser	Trp	
145				150					155				160			
Leu	Ala	Phe	Gly	Val	Trp	Leu	Leu	Ala	Ala	Ala	Leu	Cys	Ser	Ala	His	
			165					170				175				
Leu	Lys	Phe	Arg	Thr	Thr	Arg	Lys	Trp	Asn	Gly	Cys	Thr	His	Cys	Tyr	
			180				185					190				
Leu	Ala	Phe	Asn	Ser	Asp	Asn	Glu	Thr	Ala	Gln	Ile	Trp	Ile	Glu	Gly	
		195				200						205				

206

Val Val Glu Gly His Ile Ile Gly Thr Ile Gly His Phe Leu Leu Gly
 210 215 220

Phe Leu Gly Pro Leu Ala Ile Ile Gly Thr Cys Ala His Leu Ile Arg
 225 230 235 240

5 Ala Lys Leu Leu Arg Glu Gly Trp Val His Ala Asn Arg Pro Ala Arg
 245 250 255

Leu Leu Leu Val Leu Val Ser Ala Phe Phe Ile Phe Trp Ser Pro Phe
 260 265 270

10 Asn Val Val Leu Leu Val His Leu Trp Arg Arg Val Met Leu Lys Glu
 275 280 285

Ile Tyr His Pro Arg Met Leu Leu Ile Leu Gln Ala Ser Phe Ala Leu
 290 295 300

Gly Cys Val Asn Ser Ser Leu Asn Pro Phe Leu Tyr Val Phe Val Gly
 305 310 315 320

15 Arg Asp Phe Gln Glu Lys Phe Phe Gln Ser Leu Thr Ser Ala Leu Ala
 325 330 335

Arg Ala Phe Gly Glu Glu Glu Phe Leu Ser Ser Cys Pro Arg Gly Asn
 340 345 350

20 Ala Pro Arg Glu
 355

(248) INFORMATION FOR SEQ ID NO:247:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 32 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:247:

GCAGAAATTCG GCGGCCCAT GGACCTGCCC CC

32

30 (249) INFORMATION FOR SEQ ID NO:248:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:248:

GCTGGATCCC CCGAGCAGTG GCGTTACTTC

30

(250) INFORMATION FOR SEQ ID NO:249:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:249:

10 ATGGACCTGC CCCCGCAGCT CTCCTTCGGC CTCTATGTGG CCGCCTTTGC GCTGGGCTTC 60
CCGCTCAACG TCCTGGCCAT CCGAGGCGCG ACGGCCACG CCCGGCTCCG TCTCACCCTT 120
AGCCTGGTCT ACGCCCTGAA CCTGGGCTGC TCCGACCTGC TGCTGACAGT CTCTCTGCCC 180
CTGAAGGCGG TGGAGGCGCT AGCCTCCGGG GCCTGGCCTC TGCCGGCCTC GCTGTGCCCC 240
GTCTTCGCGG TGGCCCACTT CTTCCTACTC TATGCCGCGG GGGGCTTCCT GGCCGCCCTG 300
15 AGTGCAGGCC GCTACCTGGG AGCAGCCTTC CCCTTGGGCT ACCAAGCCTT CCGGAGGCCG 360
TGCTATTCCCT GGGGGGTGTG CGCGGCCATC TGGGCCCTCG TCCTGTGTCA CCTGGGTCTG 420
GTCTTTGGGT TGGAGGCTCC AGGAGGCTGG CTGGACCACA GCAACACCTC CCTGGGCATC 480
AACACACCGG TCAACGGCTC TCCGGTCTGC CTGGAGGCCT GGGACCCGGC CTCTGCCGGC 540
CCGGCCCCGT TCAGCCTCTC TCTCCTGCTC TTTTCTTGC CCTTGGCCAT CACAGCCTTC 600
20 TGCTACGTGG GCTGCCTCCG GGCCTGGCC CGCTCCGGCC TGACGCACAG GCGGAAGCTG 660
CGGGCCGCCT GGGTGGCCGG CGGGGCCCTC CTCACGCTGC TGCTCTGCGT AGGACCCTAC 720
AACGCCTCCA ACGTGGCCAG CTTCCTGTAC CCCAATCTAG GAGGCTCCTG GCGGAAGCTG 780
GGGCTCATCA CGGTGCCTG GAGTGTGGTG CTTAATCCGC TGGTGACCGG TTACTTGGGA 840
AGGGGTCTTG GCCTGAAGAC AGTGTGTGCG GCAAGAACGC AAGGGGGCAA GTCCCAGAAG 900
25 TAA 903

(251) INFORMATION FOR SEQ ID NO:250:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 300 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: not relevant

208

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:250:

	Met	Asp	Leu	Pro	Pro	Gln	Leu	Ser	Phe	Gly	Leu	Tyr	Val	Ala	Ala	Phe	
	1				5					10					15		
5	Ala	Leu	Gly	Phe	Pro	Leu	Asn	Val	Leu	Ala	Ile	Arg	Gly	Ala	Thr	Ala	
			20					25						30			
	His	Ala	Arg	Leu	Arg	Leu	Thr	Pro	Ser	Leu	Val	Tyr	Ala	Leu	Asn	Leu	
		35					40					45					
10	Gly	Cys	Ser	Asp	Leu	Leu	Leu	Thr	Val	Ser	Leu	Pro	Leu	Lys	Ala	Val	
		50					55					60					
	Glu	Ala	Leu	Ala	Ser	Gly	Ala	Trp	Pro	Leu	Pro	Ala	Ser	Leu	Cys	Pro	
		65				70					75				80		
	Val	Phe	Ala	Val	Ala	His	Phe	Phe	Pro	Leu	Tyr	Ala	Gly	Gly	Gly	Phe	
				85					90					95			
15	Leu	Ala	Ala	Leu	Ser	Ala	Gly	Arg	Tyr	Leu	Gly	Ala	Ala	Phe	Pro	Leu	
				100					105					110			
	Gly	Tyr	Gln	Ala	Phe	Arg	Arg	Pro	Cys	Tyr	Ser	Trp	Gly	Val	Cys	Ala	
			115					120					125				
20	Ala	Ile	Trp	Ala	Leu	Val	Leu	Cys	His	Leu	Gly	Leu	Val	Phe	Gly	Leu	
		130					135					140					
	Glu	Ala	Pro	Gly	Gly	Trp	Leu	Asp	His	Ser	Asn	Thr	Ser	Leu	Gly	Ile	
		145				150					155				160		
	Asn	Thr	Pro	Val	Asn	Gly	Ser	Pro	Val	Cys	Leu	Glu	Ala	Trp	Asp	Pro	
				165					170					175			
25	Ala	Ser	Ala	Gly	Pro	Ala	Arg	Phe	Ser	Leu	Ser	Leu	Leu	Leu	Phe	Phe	
				180				185						190			
	Leu	Pro	Leu	Ala	Ile	Thr	Ala	Phe	Cys	Tyr	Val	Gly	Cys	Leu	Arg	Ala	
		195					200						205				
30	Leu	Ala	Arg	Ser	Gly	Leu	Thr	His	Arg	Arg	Lys	Leu	Arg	Ala	Ala	Trp	
		210					215					220					
	Val	Ala	Gly	Gly	Ala	Leu	Leu	Thr	Leu	Leu	Leu	Cys	Val	Gly	Pro	Tyr	
		225				230					235				240		
	Asn	Ala	Ser	Asn	Val	Ala	Ser	Phe	Leu	Tyr	Pro	Asn	Leu	Gly	Gly	Ser	
				245					250					255			
35	Trp	Arg	Lys	Leu	Gly	Leu	Ile	Thr	Gly	Ala	Trp	Ser	Val	Val	Leu	Asn	
			260					265					270				
	Pro	Leu	Val	Thr	Gly	Tyr	Leu	Gly	Arg	Gly	Pro	Gly	Leu	Lys	Thr	Val	

209

275

280

285

Cys Ala Ala Arg Thr Gln Gly Gly Lys Ser Gln Lys
 290 295 300

(252) INFORMATION FOR SEQ ID NO:251:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 31 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:251:

CTCAAGCTTA CTCTCTCTCA CCAGTGGCCA C 31

(253) INFORMATION FOR SEQ ID NO:252:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:252:

CCCTCCTCCC CCGGAGGACC TAGC 24

(254) INFORMATION FOR SEQ ID NO:253:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1041 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:253:

30 ATGGATACAG GCCCCGACCA GTCCTACTTC TCCGGCAATC ACTGGTTCGT CTTCTCGGTG 60
 TACCTTCTCA CTTTCTGGT GGGGCTCCCC CTCAACCTGC TGGCCCTGGT GGTCTTCGTG 120
 GGCAAGCTGC AGCGCCGCCC GGTGGCCGTG GACGTGCTCC TGCTCAACCT GACCGCCTCG 180
 GACCTGCTCC TGCTGCTGTT CCTGCCTTTC CGCATGGTGG AGGCAGCCAA TGGCATGCAC 240
 TGGCCCCCTGC CCTTCATCCT CTGCCCCACTC TCTGGATTCA TCTTCTTCAC CACCATCTAT 300

210

CTCACCGCCC TCTTCCTGGC AGCTGTGAGC ATTGAACGCT TCCTGAGTGT GGGCCACCCA 360
 CTGTGGTACA AGACCCGGCC GAGGCTGGGG CAGGCAGGTC TGGTGAGTGT GGCTGTCTG 420
 CTGTTGGCCT CTGCTCACTG CAGCGTGGTC TACGTCATAG AATTCTCAGG GGACATCTCC 480
 CACAGCCAGG GCACCAATGG GACCTGCTAC CTGGAGTTCC GGAAGGACCA GCTAGCCATC 540
 5 CTCCTGCCCC TGCGGCTGGA GATGGCTGTG GTCCTCTTTG TGGTCCCGCT GATCATCACC 600
 AGCTACTGCT ACAGCCGCCT GGTGTGGATC CTCGGCAGAG GGGGCAGCCA CCGCCGGCAG 660
 AGGAGGGTGG CGGGGCTGTT GCGGCCACG CTGCTCAACT TCCTTGCTCTG CTTTGGGCCC 720
 TACAACGTGT CCCATGTCTG GGGCTATATC TCGGTGAAA GCGCGCATG GAGGATCTAC 780
 GTGACGCTTC TCAGCACCCCT GAACTCCTGT GTCGACCCCT TTGTCTACTA CTTCCTCTCC 840
 10 TCCGGGTTC AAGCCGACTT TCATGAGCTG CTGAGGAGGT TGTGTGGGCT CTGGGGCCAG 900
 TGGCAGCAGG AGAGCAGCAT GGAGCTGAAG GAGCAGAAGG GAGGGGAGGA GCAGAGAGCG 960
 GACCCACCAG CTGAAAGAAA GACCACTGAA CACTCACAGG GCTGTGGAAC TGGTGGCCAG 1020
 GTGGCCTGTG CTGAAAGCTA G 1041

(255) INFORMATION FOR SEQ ID NO:254:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 346 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

20 (ii) MOLECULE TYPE: protein

(x) SEQUENCE DESCRIPTION: SEQ ID NO:254:

Met	Asp	Thr	Gly	Pro	Asp	Gln	Ser	Tyr	Phe	Ser	Gly	Asn	His	Trp	Phe
1				5					10					15	
Val	Phe	Ser	Val	Tyr	Leu	Leu	Thr	Phe	Leu	Val	Gly	Leu	Pro	Leu	Asn
			20					25					30		
Leu	Leu	Ala	Leu	Val	Val	Phe	Val	Gly	Lys	Leu	Gln	Arg	Arg	Pro	Val
		35					40				45				
Ala	Val	Asp	Val	Leu	Leu	Leu	Asn	Leu	Thr	Ala	Ser	Asp	Leu	Leu	Leu
		50				55					60				
Leu	Leu	Phe	Leu	Pro	Phe	Arg	Met	Val	Glu	Ala	Ala	Asn	Gly	Met	His
65					70					75				80	
Trp	Pro	Leu	Pro	Phe	Ile	Leu	Cys	Pro	Leu	Ser	Gly	Phe	Ile	Phe	Phe
				85					90					95	

211

Thr Thr Ile Tyr Leu Thr Ala Leu Phe Leu Ala Ala Val Ser Ile Glu
 100 105 110
 Arg Phe Leu Ser Val Ala His Pro Leu Trp Tyr Lys Thr Arg Pro Arg
 115 120 125
 5 Leu Gly Gln Ala Gly Leu Val Ser Val Ala Cys Trp Leu Leu Ala Ser
 130 135 140
 Ala His Cys Ser Val Val Tyr Val Ile Glu Phe Ser Gly Asp Ile Ser
 145 150 155 160
 10 His Ser Gln Gly Thr Asn Gly Thr Cys Tyr Leu Glu Phe Arg Lys Asp
 165 170 175
 Gln Leu Ala Ile Leu Leu Pro Val Arg Leu Glu Met Ala Val Val Leu
 180 185 190
 Phe Val Val Pro Leu Ile Ile Thr Ser Tyr Cys Tyr Ser Arg Leu Val
 195 200 205
 15 Trp Ile Leu Gly Arg Gly Gly Ser His Arg Arg Gln Arg Arg Val Ala
 210 215 220
 Gly Leu Leu Ala Ala Thr Leu Leu Asn Phe Leu Val Cys Phe Gly Pro
 225 230 235 240
 20 Tyr Asn Val Ser His Val Val Gly Tyr Ile Cys Gly Glu Ser Pro Ala
 245 250 255
 Trp Arg Ile Tyr Val Thr Leu Leu Ser Thr Leu Asn Ser Cys Val Asp
 260 265 270
 Pro Phe Val Tyr Tyr Phe Ser Ser Ser Gly Phe Gln Ala Asp Phe His
 275 280 285
 25 Glu Leu Leu Arg Arg Leu Cys Gly Leu Trp Gly Gln Trp Gln Gln Glu
 290 295 300
 Ser Ser Met Glu Leu Lys Glu Gln Lys Gly Gly Glu Glu Gln Arg Ala
 305 310 315 320
 30 Asp Arg Pro Ala Glu Arg Lys Thr Ser Glu His Ser Gln Gly Cys Gly
 325 330 335
 Thr Gly Gly Gln Val Ala Cys Ala Glu Ser
 340 345

(256) INFORMATION FOR SEQ ID NO:255:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 31 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

212

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:255:

TTTAAGCTTC CCCTCCAGGA TGCTGCCGGA C

31

(257) INFORMATION FOR SEQ ID NO:256:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: not relevant

10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:256:

GGCGAATTCT GAAGGTCCAG GGAAACTGCT A

31

(258) INFORMATION FOR SEQ ID NO:257:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 993 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:257:

ATGCTGCCGG ACTGGAAGAG CTCCTTGATC CTCATGGCTT ACATCATCAT CTCCTCACT 60
GGCCTCCCTG CCAACCTCCT GGCCCTGCGG GCCTTTGTGG GTCGGATCCG CCAGCCCCAG 120
CCTGCACCTG TGCACATCCT CCTGCTGAGC CTGACGCTGG CCGACCTCCT CCTGCTGCTG 180
CTGCTGCCCT TCAAGATCAT CGAGGCTGCG TCGAACTTCC GCTGGTACCT GCCCAAGGTC 240
25 GTCTGCGCCC TCACGAGTTT TGGCTTCTAC AGCAGCATCT ACTGCAGCAC GTGGCTCCTG 300
GCGGGCATCA GCATCGAGCG CTACCTGGGA GTGGCTTTCC CCGTGCAGTA CAAGCTCTCC 360
CGCCGGCCTC TGTATGGAGT GATTGCAGCT CTGGTGGCCT GGGTTATGTC CTTTGGTCAC 420
TGCACCATCG TGATCATCGT TCAATACTTG AACACGACTG AGCAGGTCAG AAGTGGCAAT 480
GAAATTACCT GCTACGAGAA CTTACCGAT AACAGTTGG ACGTGGTGCT GCCCGTGGCG 540
30 CTGGAGCTGT GCCTGGTGCT CTTCTTCAIC CCCATGGCAG TCACCATCTT CTGCTACTGG 600
CGTTTTGTGT GGATCATGCT CTCCCAGCCC CTTGTGGGGG CCCAGAGGCG GCGCCGAGCC 660
GTGGGGCTGG CTGTGGTGAC GCTGCTCAAT TTCCTGGTGT GCTTCGGACC TTACAACGTG 720

TCCCACCTGG TGGGGTATCA CCAGAGAAAA AGCCCCTGGT GGCGGTCAAT AGCCGTGGTG 780
 TTCAGTTCAC TCAACGCCAG TCTGGACCCC CTGCTCTTCT ATTTCTCTTC TTCAGTGGTG 840
 CGCAGGGCAT TTGGGAGAGG GCTGCAGGTG CTGCCGAATC AGGGCTCCTC CCTGTTGGGA 900
 CGCAGAGGCA AAGACACAGC AGAGGGGACA AATGAGGACA GGGGTGTGGG TCAAGGAGAA 960
 5 GGGATGCCAA GTTCGGACTT CACTACAGAG TAG 993

(259) INFORMATION FOR SEQ ID NO:258:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 362 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:258:

15 Met Leu Pro Asp Trp Lys Ser Ser Leu Ile Leu Met Ala Tyr Ile Ile
 1 5 10 15
 Ile Phe Leu Thr Gly Leu Pro Ala Asn Leu Leu Ala Leu Arg Ala Phe
 20 20 25 30
 Val Gly Arg Ile Arg Gln Pro Gln Pro Ala Pro Val His Ile Leu Leu
 35 40 45
 20 Leu Ser Leu Thr Leu Ala Asp Leu Leu Leu Leu Leu Leu Pro Phe
 50 55 60
 Lys Ile Ile Glu Ala Ala Ser Asn Phe Arg Trp Tyr Leu Pro Lys Val
 65 70 75 80
 25 Val Cys Ala Leu Thr Ser Phe Gly Phe Tyr Ser Ser Ile Tyr Cys Ser
 85 90 95
 Thr Trp Leu Leu Ala Gly Ile Ser Ile Glu Arg Tyr Leu Gly Val Ala
 100 105 110
 Phe Pro Val Gln Tyr Lys Leu Ser Arg Arg Pro Leu Tyr Gly Val Ile
 115 120 125
 30 Ala Ala Leu Val Ala Trp Val Met Ser Phe Gly His Cys Thr Ile Val
 130 135 140
 Ile Ile Val Gln Tyr Leu Asn Thr Thr Glu Gln Val Arg Ser Gly Asn
 145 150 155 160
 35 Glu Ile Thr Cys Tyr Glu Asn Phe Thr Asp Asn Gln Leu Asp Val Val
 165 170 175

214

Leu Pro Val Arg Leu Glu Leu Cys Leu Val Leu Phe Phe Ile Pro Met
 180 185 190
 Ala Val Thr Ile Phe Cys Tyr Trp Arg Phe Val Trp Ile Met Leu Ser
 195 200 205
 5 Gln Pro Leu Val Gly Ala Gln Arg Arg Arg Arg Ala Val Gly Leu Ala
 210 215 220
 Val Val Thr Leu Leu Asn Phe Leu Val Cys Phe Gly Pro Tyr Asn Val
 225 230 235 240
 10 Ser His Leu Val Gly Tyr His Gln Arg Lys Ser Pro Trp Trp Arg Ser
 245 250 255
 Ile Ala Val Val Phe Ser Ser Leu Asn Ala Ser Leu Asp Pro Leu Leu
 260 265 270
 Phe Tyr Phe Ser Ser Ser Val Val Arg Arg Ala Phe Gly Arg Gly Leu
 275 280 285
 15 Gln Val Leu Arg Asn Gln Gly Ser Ser Leu Leu Gly Arg Arg Gly Lys
 290 295 300
 Asp Thr Ala Glu Gly Thr Asn Glu Asp Arg Gly Val Gly Gln Gly Glu
 305 310 315 320
 20 Gly Met Pro Ser Ser Asp Phe Thr Thr Glu
 325 330

(260) INFORMATION FOR SEQ ID NO:259:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 25 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

 (ii) MOLECULE TYPE: DNA (genomic)

 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:259:

CCCAAGCTTC GGGCACCATG GACACCTCCC

30

30 (261) INFORMATION FOR SEQ ID NO:260:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 35 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

 (ii) MOLECULE TYPE: DNA (genomic)

 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:260:

ACAGGATCCA AATGCACAGC ACTGGTAAGC

30

(262) INFORMATION FOR SEQ ID NO:261:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:261:

10 CTATAACTGG GTTACATGGT TTAAC

25

(263) INFORMATION FOR SEQ ID NO:262:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:262:

TTTGAATTCA CATATTAATT AGAGACATGG

30

20 (264) INFORMATION FOR SEQ ID NO:263:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2724 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:263:

ATGGACACCT CCCGGCTCGG TGTGCTCCTG TCCTTGCCTG TGCTGCTGCA GCTGGCGACC 60
GGGGGCAGCT CTCCCAGGTC TGGTGTGTTG CTGAGGGGCT GCCCACACA CTGTCATTGC 120
30 GAGCCCCGACG GCAGGATGTT GCTCAGGGIG GACTGCTCCG ACCTGGGGCT CTCGGAGCTG 180
CCTTCCAACC TCAGCGTCTT CACCTCCTAC CTAGACCTCA GTATGAACAA CATCAGTCAG 240
CTGCTCCCGA ATCCCCTGCC CAGTCTCCGC TTCCTGGAGG AGTTACGTCT TGCGGGAAAC 300
GCTCTGACAT ACATTCCCAA GGGAGCATTC ACTGGCCTTT ACAGTCTTAA AGTTCTTATG 360

	CTGCAGAATA ATCAGCTAAG ACACGTACCC ACAGAAGCTC TGCAGAATTT GCGAAGCCTT	420
	CAATCCCTGC GTCTGGATGC TAACCACATC AGCTATGTGC CCCCAGCTG TTTCAAGTGGC	480
	CTGCATTCCC TGAGGCACCT GTGGCTGGAT GACAATGCGT TAACAGAAAT CCCCGTCCAG	540
	GCTTTTAGAA GTTTATCGGC ATTGCAAGCC ATGACCTTGG CCCTGAACAA AATACACCAC	600
5	ATACCAGACT ATGCCTTTGG AAACCTCTCC AGCTTGGTAG TTCTACATCT CCATAACAAT	660
	AGAATCCACT CCCTGGGAAA GAAATGCTTT GATGGGCTCC ACAGCCTAGA GACTTTAGAT	720
	TTAAATTACA ATAACCTTGA TGAATTCCCC ACTGCAATTA GGACACTCTC CAACCTTAAA	780
	GAAC TAGGAT TTCATAGCAA CAATATCAGG TCGATACCTG AGAAAGCATT TGTAGGCAAC	840
	CCTTCTCTTA TTACAATACA TTTCTATGAC AATCCCATCC AATTGTTGG GAGATCTGCT	900
10	TTTCAACATT TACCTGAACT AAGAACACTG ACTCTGAATG GTGCCTCACA AATAACTGAA	960
	TTTCTGATT TAACTGGAAC TGCAAACCTG GAGAGTCTGA CTTTAACTGG AGCACAGATC	1020
	TCATCTCTTC CTCAAACCGT CTGCAATCAG TTACCTAATC TCCAAGTGCT AGATCTGTCT	1080
	TACAACCTAT TAGAAGATTT ACCCAGTTTT TCAGTCTGCC AAAAGCTTCA GAAAATTGAC	1140
	CTAAGACATA ATGAAATCTA CGAAATTAAA GTTGACACTT TCCAGCAGTT GCTTAGCCTC	1200
15	CGATCGCTGA ATTTGGCTTG GAACAAAATT GCTATTATTC ACCCCAATGC ATTTTCCACT	1260
	TTGCCATCCC TAATAAAGCT GGACCTATCG TCCAACCTCC TGTCGTCTTT TCCTATAACT	1320
	GGGTACATG GTTTAACTCA CTTAAAATTA ACAGGAAATC ATGCCTTACA GAGCTTGATA	1380
	TCATCTGAAA ACTTTCCAGA ACTCAAGGTT ATAGAAATGC CTTATGCTTA CCAGTGCTGT	1440
	GCATTTGGAG TGTGTGAGAA TGCCTATAAG ATTTCTAATC AATGGAATAA AGGTGACAAC	1500
20	AGCAGTATGG ACGACCTTCA TAAGAAAGAT GCTGGAATGT TTCAGGCTCA AGATGAACGT	1560
	GACCTTGAAG ATTTCTGTCT TGACTTTGAG GAAGACCTGA AAGCCCTTCA TTCAGTGCAG	1620
	TGTTACCTT CCCCAGGCCC CTTCAAACCC TGTGAACACC TGCTTGATGG CTGGCTGATC	1680
	AGAATTGGAG TGTGGACCAT AGCAGTTCTG GCACCTACTT GTAATGCTTT GGTGACTTCA	1740
	ACAGTTTTCA GATCCCCCTCT GTACATTTCC CCCATTAAAC TGTTAATTGG GGTCAATCGCA	1800
25	GCAGTGAACA TGCTCACGGG AGTCTCCAGT GCCGTGCTGG CTGGTGTGGA TCGTTTCACT	1860
	TTTGGCAGCT TTGCACGACA TGGTGCCTGG TGGGAGAATG GGGTTGGTTG CCATGTCAAT	1920
	GGTTTTTGT CCATTTTGC TTCAGAATCA TCTGTTTTCC TGCTTACTCT GGCAGCCCTG	1980
	GAGCGTGGGT TCTCTGTGAA ATATTCTGCA AAATTTGAAA CGAAAGCTCC ATTTTCTAGC	2040

CTGAAAGTAA TCATTTTGCT CTGTGCCCTG CTGGCCTTGA CCATGGCCGC AGTCCCCTG 2100
 CTGGGTGGCA GCAAGTATGG CGCCTCCCTT CTCTGCCTGC CTTTGCCTTT TGGGGAGCCC 2160
 AGCACCATGG GCTACATGGT CGCTCTCATC TTGCTCAATT CCCTTTGCTT CCTCATGATG 2220
 ACCATTGCCT ACACCAAGCT CTA CTGCAAT TTGACAAGG GAGACCTGGA GAATATTTGG 2280
 5 GACTGCTCTA TGGTAAACA CATTGCCCTG TTGCTCTTCA CCAACTGCAT CCTAAACTGC 2340
 CCTGTGGCTT TCTTGTCTT CTCTCTTTA ATAAACCTTA CATTTATCAG TCCTGAAGTA 2400
 ATTAAGTTTA TCCTTCTGGT GGTAGTCCCA CTCTCTGCAT GTCTCAATCC CCTTCTCTAC 2460
 ATCTTGITCA ATCCTCACTT TAAGGAGGAT CTGGTGAGCC TGAGAAAGCA AACCTACGTC 2520
 TGGACAAGAT CAAAACACCC AAGCTTGATG TCAATTA ACT CTGATGATGT CGAAAAACAG 2580
 10 TCCTGTGACT CAACTCAAGC CTTGGTAACC TTTACCAGCT CCAGCATCAC TTATGACCTG 2640
 CCTCCAGTT CCGTGCCATC ACCAGCTTAT CCAGTGACTG AGAGCTGCCA TCTTTCCTCT 2700
 GTGGCATTG TCCCATGTCT CTAA 2724

(265) INFORMATION FOR SEQ ID NO:264:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 907 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:264:

Met Asp Thr Ser Arg Leu Gly Val Leu Leu Ser Leu Pro Val Leu Leu
 1 5 10 15
 Gln Leu Ala Thr Gly Gly Ser Ser Pro Arg Ser Gly Val Leu Leu Arg
 20 25 30
 25 Gly Cys Pro Thr His Cys His Cys Glu Pro Asp Gly Arg Met Leu Leu
 35 40 45
 Arg Val Asp Cys Ser Asp Leu Gly Leu Ser Glu Leu Pro Ser Asn Leu
 50 55 60
 30 Ser Val Phe Thr Ser Tyr Leu Asp Leu Ser Met Asn Asn Ile Ser Gln
 65 70 75 80
 Leu Leu Pro Asn Pro Leu Pro Ser Leu Arg Phe Leu Glu Glu Leu Arg
 85 90 95
 Leu Ala Gly Asn Ala Leu Thr Tyr Ile Pro Lys Gly Ala Phe Thr Gly

218

	100	105	110
	Leu Tyr Ser Leu Lys Val	Leu Met Leu Gln Asn Asn Gln	Leu Arg His
	115	120	125
5	Val Pro Thr Glu Ala Leu Gln Asn Leu Arg Ser Leu Gln Ser Leu Arg		
	130	135	140
	Leu Asp Ala Asn His Ile Ser Tyr Val Pro Pro Ser Cys Phe Ser Gly		
	145	150	155 160
	Leu His Ser Leu Arg His Leu Trp Leu Asp Asp Asn Ala Leu Thr Glu		
	165	170	175
10	Ile Pro Val Gln Ala Phe Arg Ser Leu Ser Ala Leu Gln Ala Met Thr		
	180	185	190
	Leu Ala Leu Asn Lys Ile His His Ile Pro Asp Tyr Ala Phe Gly Asn		
	195	200	205
15	Leu Ser Ser Leu Val Val Leu His Leu His Asn Asn Arg Ile His Ser		
	210	215	220
	Leu Gly Lys Lys Cys Phe Asp Gly Leu His Ser Leu Glu Thr Leu Asp		
	225	230	235 240
	Leu Asn Tyr Asn Asn Leu Asp Glu Phe Pro Thr Ala Ile Arg Thr Leu		
	245	250	255
20	Ser Asn Leu Lys Glu Leu Gly Phe His Ser Asn Asn Ile Arg Ser Ile		
	260	265	270
	Pro Glu Lys Ala Phe Val Gly Asn Pro Ser Leu Ile Thr Ile His Phe		
	275	280	285
25	Tyr Asp Asn Pro Ile Gln Phe Val Gly Arg Ser Ala Phe Gln His Leu		
	290	295	300
	Pro Glu Leu Arg Thr Leu Thr Leu Asn Gly Ala Ser Gln Ile Thr Glu		
	305	310	315 320
	Phe Pro Asp Leu Thr Gly Thr Ala Asn Leu Glu Ser Leu Thr Leu Thr		
	325	330	335
30	Gly Ala Gln Ile Ser Ser Leu Pro Gln Thr Val Cys Asn Gln Leu Pro		
	340	345	350
	Asn Leu Gln Val Leu Asp Leu Ser Tyr Asn Leu Leu Glu Asp Leu Pro		
	355	360	365
35	Ser Phe Ser Val Cys Gln Lys Leu Gln Lys Ile Asp Leu Arg His Asn		
	370	375	380
	Glu Ile Tyr Glu Ile Lys Val Asp Thr Phe Gln Gln Leu Leu Ser Leu		
	385	390	395 400

219

Arg Ser Leu Asn Leu Ala Trp Asn Lys Ile Ala Ile Ile His Pro Asn
 405 410 415
 Ala Phe Ser Thr Leu Pro Ser Leu Ile Lys Leu Asp Leu Ser Ser Asn
 420 425 430
 5 Leu Leu Ser Ser Phe Pro Ile Thr Gly Leu His Gly Leu Thr His Leu
 435 440 445
 Lys Leu Thr Gly Asn His Ala Leu Gln Ser Leu Ile Ser Ser Glu Asn
 450 455 460
 10 Phe Pro Glu Leu Lys Val Ile Glu Met Pro Tyr Ala Tyr Gln Cys Cys
 465 470 475 480
 Ala Phe Gly Val Cys Glu Asn Ala Tyr Lys Ile Ser Asn Gln Trp Asn
 485 490 495
 Lys Gly Asp Asn Ser Ser Met Asp Asp Leu His Lys Lys Asp Ala Gly
 500 505 510
 15 Met Phe Gln Ala Gln Asp Glu Arg Asp Leu Glu Asp Phe Leu Leu Asp
 515 520 525
 Phe Glu Glu Asp Leu Lys Ala Leu His Ser Val Gln Cys Ser Pro Ser
 530 535 540
 20 Pro Gly Pro Phe Lys Pro Cys Glu His Leu Leu Asp Gly Trp Leu Ile
 545 550 555 560
 Arg Ile Gly Val Trp Thr Ile Ala Val Leu Ala Leu Thr Cys Asn Ala
 565 570 575
 Leu Val Thr Ser Thr Val Phe Arg Ser Pro Leu Tyr Ile Ser Pro Ile
 580 585 590
 25 Lys Leu Leu Ile Gly Val Ile Ala Ala Val Asn Met Leu Thr Gly Val
 595 600 605
 Ser Ser Ala Val Leu Ala Gly Val Asp Ala Phe Thr Phe Gly Ser Phe
 610 615 620
 30 Ala Arg His Gly Ala Trp Trp Glu Asn Gly Val Gly Cys His Val Ile
 625 630 635 640
 Gly Phe Leu Ser Ile Phe Ala Ser Glu Ser Ser Val Phe Leu Leu Thr
 645 650 655
 Leu Ala Ala Leu Glu Arg Gly Phe Ser Val Lys Tyr Ser Ala Lys Phe
 660 665 670
 35 Glu Thr Lys Ala Pro Phe Ser Ser Leu Lys Val Ile Ile Leu Leu Cys
 675 680 685
 Ala Leu Leu Ala Leu Thr Met Ala Ala Val Pro Leu Leu Gly Gly Ser

220

	690	695	700
	Lys Tyr Gly Ala Ser Pro Leu Cys Leu Pro Leu Pro Phe Gly Glu Pro		
	705	710	715 720
5	Ser Thr Met Gly Tyr Met Val Ala Leu Ile Leu Leu Asn Ser Leu Cys		
		725	730 735
	Phe Leu Met Met Thr Ile Ala Tyr Thr Lys Leu Tyr Cys Asn Leu Asp		
		740	745 750
	Lys Gly Asp Leu Glu Asn Ile Trp Asp Cys Ser Met Val Lys His Ile		
		755	760 765
10	Ala Leu Leu Leu Phe Thr Asn Cys Ile Leu Asn Cys Pro Val Ala Phe		
		770	775 780
	Leu Ser Phe Ser Ser Leu Ile Asn Leu Thr Phe Ile Ser Pro Glu Val		
		785	790 795 800
15	Ile Lys Phe Ile Leu Leu Val Val Val Pro Leu Pro Ala Cys Leu Asn		
		805	810 815
	Pro Leu Leu Tyr Ile Leu Phe Asn Pro His Phe Lys Glu Asp Leu Val		
		820	825 830
	Ser Leu Arg Lys Gln Thr Tyr Val Trp Thr Arg Ser Lys His Pro Ser		
		835	840 845
20	Leu Met Ser Ile Asn Ser Asp Asp Val Glu Lys Gln Ser Cys Asp Ser		
		850	855 860
	Thr Gln Ala Leu Val Thr Phe Thr Ser Ser Ser Ile Thr Tyr Asp Leu		
		865	870 875 880
25	Pro Pro Ser Ser Val Pro Ser Pro Ala Tyr Pro Val Thr Glu Ser Cys		
		885	890 895
	His Leu Ser Ser Val Ala Phe Val Pro Cys Leu		
		900	905

(266) INFORMATION FOR SEQ ID NO:265:

- 30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:265:

CGGAAGCTGC GGGCCAAATG GGTGGCCGGC

221

(267) INFORMATION FOR SEQ ID NO:266:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:266:

CAGAGGAGGG TGAAGGGGCT GTTGGCG

27

10 (268) INFORMATION FOR SEQ ID NO:267:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:267:

GGCGGCGCCG AGCCAAGGGG CTGGCTGTGG

30

(269) INFORMATION FOR SEQ ID NO:268:

- 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- 25 (ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:268:

GGGACTGCTC TATGAAAAAA CACATTGCCC TG

32

(270) INFORMATION FOR SEQ ID NO:269:

- 30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1071 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:269:

ATGAATGGGG TCTCGGAGGG GACCAGAGGC TGCAGTGACA GGCAACCTGG GGTCTGACA

60

222

CGTGATCGCT CTTGTTCCAG GAAGATGAAC TCTTCCGGAT GCCTGTCTGA GGAGGTGGGG 120
 TCCCTCCGCC CACTGACTGT GGTATCCTG TCTGCGTCCA TTGTCGTGG AGTGTGGGC 180
 AATGGGCTGG TGCTGTGGAT GACTGTCTTC CGTATGGCAC GCACGGTCTC CACCGTCTGC 240
 TTCTTCCACC TGGCCCTTGC CGATTTCATG CTCTCACTGT CTCTGCCCAT TGCCATGTAC 300
 5 TATATTGTCT CCAGGCAGTG GCTCCTCGGA GAGTGGGCCT GCAAACCTCTA CATCACCTTT 360
 GTGTTCCCTCA GCTACTTTGC CAGTAACTGC CTCCTTGTCT TCATCTCTGT GGACCGTTGC 420
 ATCTCTGTCC TCTACCCCGT CTGGGCCCTG AACCACCGCA CTGTGCAGCG GGCAGCTGG 480
 CTGGCCTTTG GGGTGTGGCT CCTGGCCGCC GCCTTGTGCT CTGCGCACCT GAAATTCCGG 540
 ACAACCAGAA AATGGAATGG CTGTACGCAC TGCTACTTGG CGTTCAACTC TGACAATGAG 600
 10 ACTGCCCAGA TTTGGATTGA AGGGGTCGTG GAGGGACACA TTATAGGGAC CATTTGGCCAC 660
 TTCCTGTCTG GCTTCTTGGG GCCCTTAGCA ATCATAGGCA CCTGCGCCCA CCTCATCCGG 720
 GCCAAGCTCT TCGGGGAGGG CTGGGTCCAT GCCAACCGGC CCAAGAGGCT GCTGCTGGTG 780
 CTGGTGAGCG CTTCCTTTAT CTTCTGGTCC CCGTTTAACG TGGTGTGTT GGTCCATCTG 840
 TGGCGACGGG TGATGCTCAA GGAAATCTAC CACCCCGGA TGCTGCTCAT CTTCCAGGCT 900
 15 AGCTTTGCCT TGGGCTGTGT CAACAGCAGC CTCACCCCT TCCTCTACGT CTTGTTGGC 960
 AGAGATTTCC AAGAAAAGTT TTCCAGTCT TTGACTTCTG CCCTGGCGAG GCGTTTGA 1020
 GAGGAGGAGT TTCTGTCATC CTGTCCCGT GGCAACGCCC CCCGGGAATG A 1071

(271) INFORMATION FOR SEQ ID NO:270:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 356 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

- 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:270:

Met Asn Gly Val Ser Glu Gly Thr Arg Gly Cys Ser Asp Arg Gln Pro
 1 5 10 15

Gly Val Leu Thr Arg Asp Arg Ser Cys Ser Arg Lys Met Asn Ser Ser
 20 25 30

- 30 Gly Cys Leu Ser Glu Glu Val Gly Ser Leu Arg Pro Leu Thr Val Val
 35 40 45

223

Ile Leu Ser Ala Ser Ile Val Val Gly Val Leu Gly Asn Gly Leu Val
 50 55 60

Leu Trp Met Thr Val Phe Arg Met Ala Arg Thr Val Ser Thr Val Cys
 65 70 75 80

5 Phe Phe His Leu Ala Leu Ala Asp Phe Met Leu Ser Leu Ser Leu Pro
 85 90 95

Ile Ala Met Tyr Tyr Ile Val Ser Arg Gln Trp Leu Leu Gly Glu Trp
 100 105 110

10 Ala Cys Lys Leu Tyr Ile Thr Phe Val Phe Leu Ser Tyr Phe Ala Ser
 115 120 125

Asn Cys Leu Leu Val Phe Ile Ser Val Asp Arg Cys Ile Ser Val Leu
 130 135 140

Tyr Pro Val Trp Ala Leu Asn His Arg Thr Val Gln Arg Ala Ser Trp
 145 150 155 160

15 Leu Ala Phe Gly Val Trp Leu Leu Ala Ala Ala Leu Cys Ser Ala His
 165 170 175

Leu Lys Phe Arg Thr Thr Arg Lys Trp Asn Gly Cys Thr His Cys Tyr
 180 185 190

20 Leu Ala Phe Asn Ser Asp Asn Glu Thr Ala Gln Ile Trp Ile Glu Gly
 195 200 205

Val Val Glu Gly His Ile Ile Gly Thr Ile Gly His Phe Leu Leu Gly
 210 215 220

Phe Leu Gly Pro Leu Ala Ile Ile Gly Thr Cys Ala His Leu Ile Arg
 225 230 235 240

25 Ala Lys Leu Leu Arg Glu Gly Trp Val His Ala Asn Arg Pro Lys Arg
 245 250 255

Leu Leu Leu Val Leu Val Ser Ala Phe Phe Ile Phe Trp Ser Pro Phe
 260 265 270

30 Asn Val Val Leu Leu Val His Leu Trp Arg Arg Val Met Leu Lys Glu
 275 280 285

Ile Tyr His Pro Arg Met Leu Leu Ile Leu Gln Ala Ser Phe Ala Leu
 290 295 300

Gly Cys Val Asn Ser Ser Leu Asn Pro Phe Leu Tyr Val Phe Val Gly
 305 310 315 320

35 Arg Asp Phe Gln Glu Lys Phe Phe Gln Ser Leu Thr Ser Ala Leu Ala
 325 330 335

Arg Ala Phe Gly Glu Glu Glu Phe Leu Ser Ser Cys Pro Arg Gly Asn

224

340

345

350

Ala Pro Arg Glu
355

(272) INFORMATION FOR SEQ ID NO:271:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 903 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:271:

ATGGACCTGC CCCCGCAGCT CTCCTTCGGC CTCTATGTGG CCGCCTTTGC GCTGGGCTTC 60
CCGCTCAACG TCCTGGCCAT CCGAGGCGCG ACGGCCACG CCGGGCTCCG TCTCACCCCT 120
15 AGCCTGGTCT ACCCCCTGAA CCTGGGCTGC TCCGACCTGC TGCTGACAGT CTCTCTGCCC 180
CTGAAGGCGG TGGAGGCGCT AGCCTCCGGG GCCTGGCCTC TCCCGGCCTC GCTGTGCCCC 240
GTCTTCGCGG TGGCCCACTT CTTCCCACTC TATGCCGGCG GGGGCTTCCT GGCCGCCCTG 300
AGTGCAGGCC GCTACCTGGG AGCAGCCTTC CCCTTGGGCT ATCAAGCCTT CCGGAGGCCG 360
TGCTATTCTT GGGGGGTGTG CGCGGCCATC TGGGCCCTCG TCTGTGTCA CCTGGGTCTG 420
20 GTCTTTGGGT TGGAGGCTCC AGGAGGCTGG CTGGACCACA GCAACACCTC CCTGGGCATC 480
AACACACCGG TCAACGGCTC TCCGGTCTGC CTGGAGGCCT GGGACCCGGC CTCTGCCGGC 540
CCGGCCCCGT TCAGCCTCTC TCTCCTGCTC TTTTCTCTGC CCTTGGCCAT CACAGCCTTC 600
TGCTACGTGG GCTGCCTCCG GGCACCTGGC CGCTCCGGCC TGACGCACAG GCGGAAGCTG 660
CGGGCCAAAT GGGTGGCCGG CGGGGCCCTC CTCACGCTGC TGCTCTGCGT AGGACCTTAC 720
25 AACGCCTCCA ACGTGGCCAG CTTCTGTAC CCAATCTAG GAGGCTCCTG GCGGAAGCTG 780
GGGCTCATCA CGGTGCCTG GAGTGTGGTG CTTAATCCGC TGGTGACCGG TTAATTGGGA 840
AGGGGTCTCT GCCTGAAGAC AGTGTGTGCG GCAAGAACCC AAGGGGGCAA GTCCCAGAAG 900
TAA 903

(273) INFORMATION FOR SEQ ID NO:272:

- 30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 300 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:

225

(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:272:

5 Met Asp Leu Pro Pro Gln Leu Ser Phe Gly Leu Tyr Val Ala Ala Phe
 1 5 10 15
 Ala Leu Gly Phe Pro Leu Asn Val Leu Ala Ile Arg Gly Ala Thr Ala
 20 25 30
 His Ala Arg Leu Arg Leu Thr Pro Ser Leu Val Tyr Ala Leu Asn Leu
 35 40 45
 10 Gly Cys Ser Asp Leu Leu Leu Thr Val Ser Leu Pro Leu Lys Ala Val
 50 55 60
 Glu Ala Leu Ala Ser Gly Ala Trp Pro Leu Pro Ala Ser Leu Cys Pro
 65 70 75 80
 15 Val Phe Ala Val Ala His Phe Phe Pro Leu Tyr Ala Gly Gly Gly Phe
 85 90 95
 Leu Ala Ala Leu Ser Ala Gly Arg Tyr Leu Gly Ala Ala Phe Pro Leu
 100 105 110
 Gly Tyr Gln Ala Phe Arg Arg Pro Cys Tyr Ser Trp Gly Val Cys Ala
 115 120 125
 20 Ala Ile Trp Ala Leu Val Leu Cys His Leu Gly Leu Val Phe Gly Leu
 130 135 140
 Glu Ala Pro Gly Gly Trp Leu Asp His Ser Asn Thr Ser Leu Gly Ile
 145 150 155 160
 25 Asn Thr Pro Val Asn Gly Ser Pro Val Cys Leu Glu Ala Trp Asp Pro
 165 170 175
 Ala Ser Ala Gly Pro Ala Arg Phe Ser Leu Ser Leu Leu Leu Phe Phe
 180 185 190
 Leu Pro Leu Ala Ile Thr Ala Phe Cys Tyr Val Gly Cys Leu Arg Ala
 195 200 205
 30 Leu Ala Arg Ser Gly Leu Thr His Arg Arg Lys Leu Arg Ala Lys Trp
 210 215 220
 Val Ala Gly Gly Ala Leu Leu Thr Leu Leu Leu Cys Val Gly Pro Tyr
 225 230 235 240
 35 Asn Ala Ser Asn Val Ala Ser Phe Leu Tyr Pro Asn Leu Gly Gly Ser
 245 250 255
 Trp Arg Lys Leu Gly Leu Ile Thr Gly Ala Trp Ser Val Val Leu Asn

226

260 265 270

Pro Leu Val Thr Gly Tyr Leu Gly Arg Gly Pro Gly Leu Lys Thr Val
275 280 285

5 Cys Ala Ala Arg Thr Gln Gly Gly Lys Ser Gln Lys
290 295 300

(274) INFORMATION FOR SEQ ID NO:273:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1041 base pairs
(B) TYPE: nucleic acid
10 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:273:

ATGGATACAG GCCCGACCA GTCCTACTTC TCCGGCAATC ACTGGTTCGT CTTCTCGGTG 60

15 TACCTTCTCA CTTTCTGGT GGGGCTCCCC CTCAACCTGC TGGCCCTGGT GGTCTTCGTG 120

GGCAAGCTGC AGCGCCGCC GGTGGCCGTG GACGTGCTCC TGCTCAACCT GACCGCCTCG 180

GACCTGCTCC TGCTGCTGTT CCTGCCTTTC CGCATGGTGG AGGCAGCCAA TGGCATGCAC 240

TGGCCCCTGC CCTTCATCCT CTGCCCCATC TCTGGATTCA TCTTCTTCAC CACCATCTAT 300

CTCACGCCCC TCTTCTGGC AGCTGTGAGC ATTGAACGCT TCCTGAGTGT GGCCACCCCA 360

20 CTGTGGTACA AGACCCGCC GAGGCTGGG CAGGCAGGTC TGGTGAGTGT GGCCCTGCTGG 420

CTGTGGCCT CTGCTCACTG CAGCGTGGTC TACGTCATAG AATTCTCAGG GGACATCTCC 480

CACAGCCAGG GCACCAATGG GACCTGCTAC CTGGAGTTCC GGAAGGACCA GCTAGCCATC 540

CTCCTGCCCC TGCGGCTGGA GATGGCTGTG GTCCTCTTTG TGGTCCCGCT GATCATCACC 600

AGCTACTGCT ACAGCCGCCT GGTGTGGATC CTCGGCAGAG GGGGCAGCCA CCGCCGGCAG 660

25 AGGAGGGTGA AGGGGCTGTT GGCGGCCACG CTGCTCAACT TCCTTGCTCG CTTTGGGCCC 720

TACAACGTGT CCCATGTCGT GGGCTATATC TCGGTGAAA GCCCGGCATG GAGGATCTAC 780

GTGACGCTTC TCAGCACCTT GAACTCCTGT GTCGACCCCT TTGTCTACTA CTTCTCCTCC 840

TCCGGGTTC AAGCCGACTT TCATGAGCTG CTGAGGAGGT TGTGTGGGCT CTGGGGCCAG 900

TGGCAGCAGG AGAGCAGCAT GGAGCTGAAG GAGCAGAAGG GAGGGGAGGA GCAGAGAGCG 960

30 GACCGACCAG CTGAAAGAAA GACCAGTGAA CACTCACAGG GCTGTGGAAC TGGTGGCCAG 1020

GTGGCCTGTG CTGAAAGCTA G 1041

(275) INFORMATION FOR SEQ ID NO:274:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 346 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:274:

10 Met Asp Thr Gly Pro Asp Gln Ser Tyr Phe Ser Gly Asn His Trp Phe
 1 5 10 15
 Val Phe Ser Val Tyr Leu Leu Thr Phe Leu Val Gly Leu Pro Leu Asn
 20 25 30
 Leu Leu Ala Leu Val Val Phe Val Gly Lys Leu Gln Arg Arg Pro Val
 35 40 45
 15 Ala Val Asp Val Leu Leu Leu Asn Leu Thr Ala Ser Asp Leu Leu Leu
 50 55 60
 Leu Leu Phe Leu Pro Phe Arg Met Val Glu Ala Ala Asn Gly Met His
 65 70 75 80
 20 Trp Pro Leu Pro Phe Ile Leu Cys Pro Leu Ser Gly Phe Ile Phe Phe
 85 90 95
 Thr Thr Ile Tyr Leu Thr Ala Leu Phe Leu Ala Ala Val Ser Ile Glu
 100 105 110
 Arg Phe Leu Ser Val Ala His Pro Leu Trp Tyr Lys Thr Arg Pro Arg
 115 120 125
 25 Leu Gly Gln Ala Gly Leu Val Ser Val Ala Cys Trp Leu Leu Ala Ser
 130 135 140
 Ala His Cys Ser Val Val Tyr Val Ile Glu Phe Ser Gly Asp Ile Ser
 145 150 155 160
 30 His Ser Gln Gly Thr Asn Gly Thr Cys Tyr Leu Glu Phe Arg Lys Asp
 165 170 175
 Gln Leu Ala Ile Leu Leu Pro Val Arg Leu Glu Met Ala Val Val Leu
 180 185 190
 Phe Val Val Pro Leu Ile Ile Thr Ser Tyr Cys Tyr Ser Arg Leu Val
 195 200 205
 35 Trp Ile Leu Gly Arg Gly Gly Ser His Arg Arg Gln Arg Arg Val Lys
 210 215 220
 Gly Leu Leu Ala Ala Thr Leu Leu Asn Phe Leu Val Cys Phe Gly Pro

228

225 230 235 240
 Tyr Asn Val Ser His Val Val Gly Tyr Ile Cys Gly Glu Ser Pro Ala
 245 250 255
 5 Trp Arg Ile Tyr Val Thr Leu Leu Ser Thr Leu Asn Ser Cys Val Asp
 260 265 270
 Pro Phe Val Tyr Tyr Phe Ser Ser Ser Gly Phe Gln Ala Asp Phe His
 275 280 285
 Glu Leu Leu Arg Arg Leu Cys Gly Leu Trp Gly Gln Trp Gln Gln Glu
 290 295 300
 10 Ser Ser Met Glu Leu Lys Glu Gln Lys Gly Gly Glu Glu Gln Arg Ala
 305 310 315 320
 Asp Arg Pro Ala Glu Arg Lys Thr Ser Glu His Ser Gln Gly Cys Gly
 325 330 335
 15 Thr Gly Gly Gln Val Ala Cys Ala Glu Ser
 340 345

(276) INFORMATION FOR SEQ ID NO:275:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 993 base pairs
 (B) TYPE: nucleic acid
 20 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:275:

ATGCTGCCGG ACTGGAAGAG CTCCTTGATC CTCATGGCTT ACATCATCAT CTTCCTCACT 60
 25 GGCTCCCTG CCAACCTCCT GGCCCTGCGG GCCTTTGTGG GGCGGATCCG CCAGCCCCAG 120
 CCTGCACCTG TGCACATCCT CTGCTGAGC CTGACGCTGG CCGACCTCCT CCTGCTGCTG 180
 CTGCTGCCCT TCAAGATCAT CGAGGCTGCG TCGAACTTCC GCTGGTACCT GCCCAAGGTC 240
 GTCTGCGCCC TCACGAGTTT TGGCTTCTAC AGCAGCATCT ACTGCAGCAC GTGGCTCCTG 300
 GCGGGCATCA GCATCGAGCG CTACCTGGGA GTGGCTTTCC CCGTGCACTA CAAGCTCTCC 360
 30 CGCCGGCCTC TGTATGGAGT GATTGCAGCT CTGGTGGCCT GGGTTATGTC CTTTGGTCAC 420
 TGCACCATCG TGATCATCGT TCAATACTTG AACACGACTG AGCAGGTCAG AAGTGGCAAT 480
 GAAATTACCT GCTACGAGAA CTTACCGAT AACCAGTTGG ACGTGGTGCT GCCCGTGGG 540
 CTGGAGCTGT GCCTGGTGCT CTTCTTCATC CCCATGGCAG TCACCATCTT CTGCTACTGG 600

229

CGTTTTGTGT GGATCATGCT CTCCCAGCCC CTTGTGGGGG CCCAGAGGCG GCGCCGAGCC 660
 AAGGGGCTGG CTGTGGTGAC GCTGCTCAAT TTCCTGGTGT GCTTCGGACC TTACAACGTG 720
 TCCCACCTGG TGGGGTATCA CCAGAGAAAA AGCCCCTGGT GGCGGTCAAT AGCCGTGGTG 780
 TTCAGTTTAC TCAACGCCAG TCTGGACCCC CTGCTCTTCT ATTCTCTTC TTCAGTGGTG 840
 5 CGCAGGGCAT TTGGGAGAGG GCTGCAGGTG CTGCGGAATC AGGGCTCCTC CCTGTTGGGA 900
 CGCAGAGGCA AAGACACAGC AGAGGGGACA AATGAGGACA GGGGTGTGGG TCAAGGAGAA 960
 GGGATGCCAA GTTCGGACTT CACTACAGAG TAG 993

(277) INFORMATION FOR SEQ ID NO:276:

(i) SEQUENCE CHARACTERISTICS:
 10 (A) LENGTH: 330 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant
 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:276:

Met Leu Pro Asp Trp Lys Ser Ser Leu Ile Leu Met Ala Tyr Ile Ile
 1 5 10 15
 Ile Phe Leu Thr Gly Leu Pro Ala Asn Leu Leu Ala Leu Arg Ala Phe
 20 25 30
 Val Gly Arg Ile Arg Gln Pro Gln Pro Ala Pro Val His Ile Leu Leu
 35 40 45
 Leu Ser Leu Thr Leu Ala Asp Leu Leu Leu Leu Leu Leu Pro Phe
 50 55 60
 Lys Ile Ile Glu Ala Ala Ser Asn Phe Arg Trp Tyr Leu Pro Lys Val
 25 65 70 75 80
 Val Cys Ala Leu Thr Ser Phe Gly Phe Tyr Ser Ser Ile Tyr Cys Ser
 85 90 95
 Thr Trp Leu Leu Ala Gly Ile Ser Ile Glu Arg Tyr Leu Gly Val Ala
 100 105 110
 Phe Pro Val Gln Tyr Lys Leu Ser Arg Arg Pro Leu Tyr Gly Val Ile
 30 115 120 125
 Ala Ala Leu Val Ala Trp Val Met Ser Phe Gly His Cys Thr Ile Val
 130 135 140
 Ile Ile Val Gln Tyr Leu Asn Thr Thr Glu Gln Val Arg Ser Gly Asn
 35 145 150 155 160

230

Glu Ile Thr Cys Tyr Glu Asn Phe Thr Asp Asn Gln Leu Asp Val Val
 165 170 175
 Leu Pro Val Arg Leu Glu Leu Cys Leu Val Leu Phe Phe Ile Pro Met
 180 185 190
 5 Ala Val Thr Ile Phe Cys Tyr Trp Arg Phe Val Trp Ile Met Leu Ser
 195 200 205
 Gln Pro Leu Val Gly Ala Gln Arg Arg Arg Arg Ala Lys Gly Leu Ala
 210 215 220
 10 Val Val Thr Leu Leu Asn Phe Leu Val Cys Phe Gly Pro Tyr Asn Val
 225 230 235 240
 Ser His Leu Val Gly Tyr His Gln Arg Lys Ser Pro Trp Trp Arg Ser
 245 250 255
 Ile Ala Val Val Phe Ser Ser Leu Asn Ala Ser Leu Asp Pro Leu Leu
 260 265 270
 15 Phe Tyr Phe Ser Ser Ser Val Val Arg Arg Ala Phe Gly Arg Gly Leu
 275 280 285
 Gln Val Leu Arg Asn Gln Gly Ser Ser Leu Leu Gly Arg Arg Gly Lys
 290 295 300
 20 Asp Thr Ala Glu Gly Thr Asn Glu Asp Arg Gly Val Gly Gln Gly Glu
 305 310 315 320
 Gly Met Pro Ser Ser Asp Phe Thr Thr Glu
 325 330

(278) INFORMATION FOR SEQ ID NO:277:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2724 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:277:

ATGGACACCT CCCGGCTCGG TGTGCTCCTG TCCTTGCCCTG TGCTGCTGCA GCTGGCGACC 60
 GGGGGCAGCT CTCCCAGGTC TGGTGTGTTG CTGAGGGGCT GCGCCACACA CTGTCATTGC 120
 GAGCCCGACG GCAGGATGTT GCTCAGGGTG GACTGCTCCG ACCTGGGGCT CTCGGAGCTG 180
 CCTTCCAACC TCAGCGTCTT CACCTCCTAC CTAGACCTCA GTATGAACAA CATCAGTCAG 240
 35 CTGCTCCCGA ATCCCCTGCC CAGTCTCCGC TTCCTGGAGG AGTTACGTCT TGCGGGAAAC 300

	GCTCTGACAT ACATTCCCAA GGGAGCATTC ACTGGCCTTT ACAGTCTTAA AGTTCTTATG	360
	CTGCAGAATA ATCAGCTAAG ACACGTACCC ACAGAAGCTC TGCAGAATTT GCGAAGCCTT	420
	CAATCCCTGC GTCTGGATGC TAACCACATC AGCTATGTGC CCCCAGCTG TTTCAGTGGC	480
	CTGCATTCCC TGAGGCACCT GTGGCTGGAT GACAATGCGT TAACAGAAAAT CCCCCTCCAG	540
5	GCTTTTAGAA GTTTATCGGC ATTGCAAGCC ATGACCTTGG CCCTGAACAA AATACACCAC	600
	ATACCAGACT ATGCCTTTGG AAACCTCTCC AGCTTGGTAG TTCTACATCT CCATAACAAT	660
	AGAATCCACT CCCTGGGAAA GAAATGCTTT GATGGGCTCC ACAGCCTAGA GACTTTAGAT	720
	TTAAATTACA ATAACCTTGA TGAATTCCCC ACTGCAATTA GGACACTCTC CAACCTTAAA	780
	GAAGTAGGAT TTCATAGCAA CAATATCAGG TCGATACCTG AGAAAGCATT TGTAGGCAAC	840
10	CCTTCTCTTA TTACAATACA TTTCTATGAC AATCCCATCC AATTGTGG GAGATCTGCT	900
	TTTCAACATT TACCTGAACT AAGAACACTG ACTCTGAATG GTGCCTCACA AATAACTGAA	960
	TTTCCTGATT TAACTGGAAC TGCAAACTG GAGAGTCTGA CTTTAACTGG AGCACAGATC	1020
	TCATCTCTTC CTCAAACCGT CTGCAATCAG TTACCTAATC TCCAAGTGCT AGATCTGTCT	1080
	TACAACTAT TAGAAGATTT ACCCAGTTTT TCAGTCTGCC AAAAGCTTCA GAAAATTGAC	1140
15	CTAAGACATA ATGAAATCTA CGAAATTAAA GTTGACACTT TCCAGCAGTT GCTTAGCCTC	1200
	CGATCGCTGA ATTTGGCTTG GAACAAAATT GCTATTATTC ACCCCAATGC ATTTTCCACT	1260
	TTGCCATCCC TAATAAAGCT GGACCTATCG TCCAACCTCC TGTCGTCTTT TCCTATAACT	1320
	GGGTTACATG GTTTAACTCA CTTAAATTA ACAGGAAATC ATGCCTTACA GAGCTTGATA	1380
	TCATCTGAAA ACTTTCAGA ACTCAAGGTT ATAGAAATGC CTTATGCTTA CCAAGTGCTGT	1440
20	GCATTTGGAG TGTGTGAGAA TGCCTATAAG ATTTCTAATC AATGGAATAA AGGTGACAAC	1500
	AGCAGTATGG ACGACCTTCA TAAGAAAGAT GCTGGAATGT TTCAGGCTCA AGATGAACGT	1560
	GACCTTGAAG ATTTCTGCT TGACTTTGAG GAAGACCTGA AAGCCCTTCA TTCAGTGCAG	1620
	TGTTACACCT CCCCAGGCC CTTCAAACCC TGTGAACACC TGCTTGATGG CTGGCTGATC	1680
	AGAATTGGAG TGTGGACCAT AGCAGTTCTG GCACTTACTT GTAATGCTTT GGTGACTTCA	1740
25	ACAGTTTTCA GATCCCTCT GTACATTTCC CCCATTAAAC TGTTAATTGG GGTGATCGCA	1800
	GCAGTGAACA TGCTCACGGG AGTCTCCAGT GCCGTGCTGG CTGGTGTGGA TCGCTTCACT	1860
	TTTGGCAGCT TTGCACGACA TGGTGCCTGG TGGGAGAATG GGGTTGGTTG CCATGTCATT	1920
	GGTTTTTGT CCATTTTGC TTCAGAATCA TCTGTTTTCC TGCTTACTCT GGCAGCCCTG	1980

GAGCGTGGGT TCTCTGTGAA ATATTCTGCA AAATTTGAAA CGAAAGCTCC ATTTTCTAGC 2040
 CTGAAAGTAA TCATTTTGCT CTGTGCCCTG CTGGCCTTGA CCATGGCCGC AGTTCCCTCTG 2100
 CTGGGTGGCA GCAAGTATGG CGCCTCCCCT CTCTGCCTGC CTTTGCCTTT TGGGGAGCCC 2160
 AGCACCATGG GCTACATGGT CGCTCTCATC TTGCTCAATT CCCTTTGCTT CCTCATGATG 2220
 5 ACCATTGCCT ACACCAAGCT CTACTGCAAT TTGGACAAGG GAGACCTGGA GAATATTTGG 2280
 GACTGCTCTA TGAAAAACA CATTGCCCTG TTGCTCTTCA CCAACTGCAT CCTAAACTGC 2340
 CCTGTGGCTT TCTTGTCTT CTCCTCTTTA ATAAACCTTA CATTTATCAG TCCTGAAGTA 2400
 ATTAAGTTTA TCCTTCTGGT GGTAGTCCCA CTTCTGTCAT GTCTCAATCC CCTTCTCTAC 2460
 ATCTTGTTC ATCCTCACTT TAAGGAGGAT CTGGTGAGCC TGAGAAAGCA AACCTACGTC 2520
 10 TGGACAAGAT CAAAACACCC AAGCTTGATG TCAATTAACCT CTGATGATGT CGAAAAACAG 2580
 TCCTGTGACT CAACTCAAGC CTTGGTAACC TTTACCAGCT CCAGCATCAC TTATGACCTG 2640
 CCTCCAGTT CCGTGCCATC ACCAGCTTAT CCAGTGACTG AGAGCTGCCA TCTTCTCTCT 2700
 GTGGCATTG TCCCATGTCT CTAA 2724

(279) INFORMATION FOR SEQ ID NO:278:

- 15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 907 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: not relevant
- 20 (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:278:
- | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asp | Thr | Ser | Arg | Leu | Gly | Val | Leu | Leu | Ser | Leu | Pro | Val | Leu | Leu |
| 1 | | | | 5 | | | | 10 | | | | | | 15 | |
| Gln | Leu | Ala | Thr | Gly | Gly | Ser | Ser | Pro | Arg | Ser | Gly | Val | Leu | Leu | Arg |
| 25 | | | 20 | | | | | 25 | | | | | 30 | | |
| Gly | Cys | Pro | Thr | His | Cys | His | Cys | Glu | Pro | Asp | Gly | Arg | Met | Leu | Leu |
| | 35 | | | | | | 40 | | | | | 45 | | | |
| Arg | Val | Asp | Cys | Ser | Asp | Leu | Gly | Leu | Ser | Glu | Leu | Pro | Ser | Asn | Leu |
| | 50 | | | | | 55 | | | | 60 | | | | | |
| Ser | Val | Phe | Thr | Ser | Tyr | Leu | Asp | Leu | Ser | Met | Asn | Asn | Ile | Ser | Gln |
| 65 | | | | | 70 | | | | | 75 | | | | 80 | |
| Leu | Leu | Pro | Asn | Pro | Leu | Pro | Ser | Leu | Arg | Phe | Leu | Glu | Glu | Leu | Arg |
| | | | | 85 | | | | | 90 | | | | | 95 | |

233

Leu Ala Gly Asn Ala Leu Thr Tyr Ile Pro Lys Gly Ala Phe Thr Gly
 100 105 110
 Leu Tyr Ser Leu Lys Val Leu Met Leu Gln Asn Asn Gln Leu Arg His
 115 120 125
 5 Val Pro Thr Glu Ala Leu Gln Asn Leu Arg Ser Leu Gln Ser Leu Arg
 130 135 140
 Leu Asp Ala Asn His Ile Ser Tyr Val Pro Pro Ser Cys Phe Ser Gly
 145 150 155 160
 10 Leu His Ser Leu Arg His Leu Trp Leu Asp Asp Asn Ala Leu Thr Glu
 165 170 175
 Ile Pro Val Gln Ala Phe Arg Ser Leu Ser Ala Leu Gln Ala Met Thr
 180 185 190
 Leu Ala Leu Asn Lys Ile His His Ile Pro Asp Tyr Ala Phe Gly Asn
 195 200 205
 15 Leu Ser Ser Leu Val Val Leu His Leu His Asn Asn Arg Ile His Ser
 210 215 220
 Leu Gly Lys Lys Cys Phe Asp Gly Leu His Ser Leu Glu Thr Leu Asp
 225 230 235 240
 20 Leu Asn Tyr Asn Asn Leu Asp Glu Phe Pro Thr Ala Ile Arg Thr Leu
 245 250 255
 Ser Asn Leu Lys Glu Leu Gly Phe His Ser Asn Asn Ile Arg Ser Ile
 260 265 270
 Pro Glu Lys Ala Phe Val Gly Asn Pro Ser Leu Ile Thr Ile His Phe
 275 280 285
 25 Tyr Asp Asn Pro Ile Gln Phe Val Gly Arg Ser Ala Phe Gln His Leu
 290 295 300
 Pro Glu Leu Arg Thr Leu Thr Leu Asn Gly Ala Ser Gln Ile Thr Glu
 305 310 315 320
 30 Phe Pro Asp Leu Thr Gly Thr Ala Asn Leu Glu Ser Leu Thr Leu Thr
 325 330 335
 Gly Ala Gln Ile Ser Ser Leu Pro Gln Thr Val Cys Asn Gln Leu Pro
 340 345 350
 Asn Leu Gln Val Leu Asp Leu Ser Tyr Asn Leu Leu Glu Asp Leu Pro
 355 360 365
 35 Ser Phe Ser Val Cys Gln Lys Leu Gln Lys Ile Asp Leu Arg His Asn
 370 375 380
 Glu Ile Tyr Glu Ile Lys Val Asp Thr Phe Gln Gln Leu Leu Ser Leu

	385		390		395		400
	Arg Ser Leu Asn	Leu Ala Trp Asn Lys Ile	Ala Ile Ile His Pro Asn				
	405		410			415	
5	Ala Phe Ser Thr	Leu Pro Ser Leu Ile Lys Leu Asp Leu Ser Ser Asn					
	420		425			430	
	Leu Leu Ser Ser Phe Pro Ile Thr Gly Leu His Gly Leu Thr His Leu						
	435		440			445	
	Lys Leu Thr Gly Asn His Ala Leu Gln Ser Leu Ile Ser Ser Glu Asn						
	450		455			460	
10	Phe Pro Glu Leu Lys Val Ile Glu Met Pro Tyr Ala Tyr Gln Cys Cys						
	465		470			475	480
	Ala Phe Gly Val Cys Glu Asn Ala Tyr Lys Ile Ser Asn Gln Trp Asn						
		485		490			495
15	Lys Gly Asp Asn Ser Ser Met Asp Asp Leu His Lys Lys Asp Ala Gly						
	500		505			510	
	Met Phe Gln Ala Gln Asp Glu Arg Asp Leu Glu Asp Phe Leu Leu Asp						
	515		520			525	
	Phe Glu Glu Asp Leu Lys Ala Leu His Ser Val Gln Cys Ser Pro Ser						
	530		535			540	
20	Pro Gly Pro Phe Lys Pro Cys Glu His Leu Leu Asp Gly Trp Leu Ile						
	545		550			555	560
	Arg Ile Gly Val Trp Thr Ile Ala Val Leu Ala Leu Thr Cys Asn Ala						
		565		570			575
25	Leu Val Thr Ser Thr Val Phe Arg Ser Pro Leu Tyr Ile Ser Pro Ile						
	580		585			590	
	Lys Leu Leu Ile Gly Val Ile Ala Ala Val Asn Met Leu Thr Gly Val						
	595		600			605	
	Ser Ser Ala Val Leu Ala Gly Val Asp Ala Phe Thr Phe Gly Ser Phe						
	610		615			620	
30	Ala Arg His Gly Ala Trp Trp Glu Asn Gly Val Gly Cys His Val Ile						
	625		630			635	640
	Gly Phe Leu Ser Ile Phe Ala Ser Glu Ser Ser Val Phe Leu Leu Thr						
		645		650			655
35	Leu Ala Ala Leu Glu Arg Gly Phe Ser Val Lys Tyr Ser Ala Lys Phe						
	660		665			670	
	Glu Thr Lys Ala Pro Phe Ser Ser Leu Lys Val Ile Ile Leu Leu Cys						
	675		680			685	

235

Ala Leu Leu Ala Leu Thr Met Ala Ala Val Pro Leu Leu Gly Gly Ser
690 695 700

Lys Tyr Gly Ala Ser Pro Leu Cys Leu Pro Leu Pro Phe Gly Glu Pro
705 710 715 720

5 Ser Thr Met Gly Tyr Met Val Ala Leu Ile Leu Leu Asn Ser Leu Cys
725 730 735

Phe Leu Met Met Thr Ile Ala Tyr Thr Lys Leu Tyr Cys Asn Leu Asp
740 745 750

10 Lys Gly Asp Leu Glu Asn Ile Trp Asp Cys Ser Met Lys Lys His Ile
755 760 765

Ala Leu Leu Leu Phe Thr Asn Cys Ile Leu Asn Cys Pro Val Ala Phe
770 775 780

Leu Ser Phe Ser Ser Leu Ile Asn Leu Thr Phe Ile Ser Pro Glu Val
785 790 795 800

15 Ile Lys Phe Ile Leu Leu Val Val Val Pro Leu Pro Ala Cys Leu Asn
805 810 815

Pro Leu Leu Tyr Ile Leu Phe Asn Pro His Phe Lys Glu Asp Leu Val
820 825 830

20 Ser Leu Arg Lys Gln Thr Tyr Val Trp Thr Arg Ser Lys His Pro Ser
835 840 845

Leu Met Ser Ile Asn Ser Asp Asp Val Glu Lys Gln Ser Cys Asp Ser
850 855 860

Thr Gln Ala Leu Val Thr Phe Thr Ser Ser Ser Ile Thr Tyr Asp Leu
865 870 875 880

25 Pro Pro Ser Ser Val Pro Ser Pro Ala Tyr Pro Val Thr Glu Ser Cys
885 890 895

His Leu Ser Ser Val Ala Phe Val Pro Cys Leu
900 905

(280) INFORMATION FOR SEQ ID NO:279:

- 30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 32 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- 35 (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:279:

CATGCCAACC GGCCCGCGAG GCTGCTGCTG GT

236

(281) INFORMATION FOR SEQ ID NO:280:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:280:

ACCAGCAGCA GCCTCGCGGG CCGGTTGGCA TG

32

INTERNATIONAL SEARCH REPORT

Int. Appl. No.
PCT/US 99/23938

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C07K14/72 G01N33/50 G01N33/566

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	KJELSBERG M. A. ET AL.: "CONSTITUTIVE ACTIVATION OF THE ALPHA1B-ADRENERGIC RECEPTOR BY ALL AMINO ACID SUBSTITUTIONS AT A SINGLE SITE" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 3, 25 January 1992 (1992-01-25), pages 1430-1433, XP002911764 ISSN: 0021-9258 the whole document --- -/--	1,2, 4-13, 15-33, 35-37,41

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "S" document member of the same patent family

Date of the actual completion of the international search

2 March 2000

Date of mailing of the international search report

09/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx: 31 651 eponi,
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 99/23938

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	SCHEER A. ET AL.: "CONSTITUTIVELY ACTIVE G PROTEIN-COUPLED RECEPTORS: POTENTIAL MECHANISMS OF RECEPTOR ACTIVATION" JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, vol. 17, no. 1/03, 1997, pages 57-73, XP000867531 ISSN: 1079-9893 the whole document ---	1,2, 4-13, 15-33, 35-37,41
X	WO 97 21731 A (NEW ENGLAND MEDICAL CENTER INC) 19 June 1997 (1997-06-19) the whole document, especially Fig. 2-3 ---	1,2,4, 9-13, 20-32, 35-37,41
X	WO 98 38217 A (HERRICK DAVIS KATHARINE ;TEITLER MILT (US); EGAN CHRISTINA C (US)) 3 September 1998 (1998-09-03) the whole document, especially page 7, lines 24-27, and figure 4 ---	1,2, 4-13, 15-33, 35-37,41
P,X	PAUWELS P. J. ET AL.: "REVIEW: AMINO ACID DOMAINS INVOLVED IN CONSTITUTIVE ACTIVATION OF G-PROTEIN-COUPLED RECEPTORS" MOLECULAR NEUROBIOLOGY, vol. 17, no. 1/03, 1998, pages 109-135, XP000866477 ISSN: 0893-7648 the whole document -----	1,2, 4-13, 15-33, 35-37,41

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/23938

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 34, 38-40, 42, 43
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 23938

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 34,38-40,42,43

Claims 34, 38-40, 42 and 43 refer to compounds with an agonistic effect on a GPCR without giving a true technical characterization. Moreover, no such specific compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/23938

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9721731 A	19-06-1997	US 5750353 A	12-05-1998
		AU 1334397 A	03-07-1997
		CA 2239293 A	19-06-1997
		EP 0869975 A	14-10-1998
WO 9838217 A	03-09-1998	AU 6343998 A	18-09-1998